

SCIENTIFIC PROGRAM

33rd ICPE

*International Conference on Pharmacoepidemiology
& Therapeutic Risk Management*

AUGUST 26-30, 2017

PALAIS DES CONGRÈS DE MONTRÉAL

MONTRÉAL, CANADA

**Access ICPE Abstracts
on your Mobile Device**

www.abstractsonline.com/pp8/#!/4385/



- ◆ Online only Abstract Supplement
- ◆ Free WiFi is provided for you to access this tool

Join the conversation #ICPEmontreal

JOINTLY SPONSORED BY:



**DALHOUSIE
UNIVERSITY**



Faculté de pharmacie

Université 
de Montréal

33rd ICPE

AUGUST 26-30, 2017

PALAIS DES CONGRÈS DE MONTRÉAL
MONTRÉAL, CANADAInternational Conference on
Pharmacoepidemiology &
Therapeutic Risk Management

ISPE OFFICERS & BOARD OF DIRECTORS

OFFICERS

Kiyoshi Kubota, FISPE, *President*
 Jesper Hallas, FISPE, *President-Elect*
 Sonia Hernández-Díaz, FISPE, *Immediate Past President*
 Tobias Gerhard, FISPE, *Vice President Finance*
 Mark H Epstein, *Executive Secretary*

DIRECTORS

Morten Andersen	Malcolm Maclure
Dorothee Bartels	Lisa Pont, FISPE
Andrew Bate	June Raine
Stanley A Edlavitch, <i>Lifetime Emeritus</i>	Jennita Reefhius
Helga Gardarsdottir	Rachel Sobel, FISPE
Wan-Ting Huang	Sabine Straus
Marie Lindquist	Almut G Winterstein, FISPE
Vincent Lo Re III, FISPE	Wei Zhou, FISPE

2017 ICPE SCIENTIFIC PROGRAM COMMITTEE

Adrian Levy, Chair

CORE PROGRAM COMMITTEE

Quazi Ataher	Deborah Layton
Kristen Bibeau	Charles Leonard
Suzanne Cadarette	Geoffrey Liu, FISPE
Melissa Castan	Vin Lo Re III, FISPE
Colin Dormuth	Frank May, FISPE
Mark H Epstein	Yola Moride, FISPE
Tobias Gerhard, FISPE	Suzanne Perez-Gutthann, FISPE
Jesper Hallas, FISPE	Nicole Pratt
Christian Hampp	Mary E Ritchey
Robert Hay	Harry Seifert, FISPE
Juan Hincapie-Castillo	Soko Setuguchi Iwata, FISPE
Krista Huybrechts, FISPE	Ingrid Sketis
Seoyoung C Kim	Montse Soriano Gabarro
Olaf Klungel	Edward W. ThommesKiyoshi
Kubota, FISPE	Darren Toh
Bradley Layton	Almut Winterstein, FISPE

CHAIRS/CO-CHAIRS & LIAISONS

COMMITTEES

Archives & History Hugh Tilson, FISPE
Bylaws & Policies Stella Blackburn, FISPE
 Frank May, FISPE
Development Kirk Midkiff
 Dimitri Bennett, FISPE
Education Darren Toh
 Anton Pottegard
 Joshua Gagne
Fellowship & Awards Sonia Hernandez-Diaz, FISPE
Finance Tobias Gerhard, FISPE
Global Development K. Arnold Chan, FISPE
 Wei Zhou, FISPE
Management Oversight Sonia Hernandez-Diaz, FISPE
Membership Jonathan Schelfhout
 Alicia Gilseman
Nominating Sonia Hernandez-Diaz, FISPE
Public Policy & Ethics Yola Moride, FISPE
 Corinne S de Vries, FISPE
Publications & Communications Mina Tadrous
 Rhonda Bohn, FISPE
Scholarship Kiyoshi Kubota, FISPE
 David Miller
Scientific Program Adrian Levy
Strategic Planning Jesper Hallas, FISPE

COUNCILS

Academic Vera Ehrenstein
 Deborah Layton
Government/Regulatory Sabine Straus
 Gianpiero Mazzaglia
Industry/Service Providers Susan Oliveria, FISPE
 John Acquavella, FISPE
Student Juan Hincapie Castillo
 Amelia Smith

SPECIAL INTEREST GROUPS

Adherence Robert Gross, FISPE
AsPEN Nicole Pratt
 Edward Chia-Cheng Lai
Biologics & Biosimilars Amanda Keatley Golembesky
BRACE Rachel Sobel, FISPE
 Meredith Smith
 Alicia Gilseman
Comparative Effectiveness Research (Cer) Emily Brouwer
 Michelle Johnson-Funk
 Hongo Yuan
Databases Bing Cai
 Rachael Williams



VOLUNTEER LEADERS & COMMITTEES

Drug Utilization	Katja Taxis Veronika Wirtz
Medical Device	Chantal Holy Katherine Etter
Medicines In Pregnancy	Leyla Sahin Deborah Covington, FISPE
Molecular Epi/Biomarkers/ Pharmacogenetics	Amalia Issa Kelly Filipski Geoffrey Liu, FISPE
Oncology	Al Artaman Wei Zhou, FISPE
Pediatrics	Jon Slaughter Susan DosReis Lina Titievsky
Rare Diseases	Jasmanda Wu, FISPE
Vaccines	Harry Seifert, FISPE

LIAISONS

CIOMS	Sabine Straus
ENCePP	Yola Moride, FISPE
FDA	Christian Hampf
International Joint Policy Committee of the Societies of Epidemiology	Yola Moride, FISPE

REGIONAL CHAPTERS

FarmacoEpiEnRed-Spanish Chapter	Elisa Martín-Merino Daniel Prieto-Alhambra
Gulf Region	Hisham Aljadhey Thamir Alshammary Tariq Alhawassi
Latin America	Rene Soria-Saucedo

WORKING GROUP

Patient Engagement in Pharmacoepidemiology Studies	Suzanne L West, FISPE
---	-----------------------

STUDENT CHAPTERS

- ◆ Basel Pharmacoepidemiology Unit, University of Basel, Switzerland & the Boston Collaborative Drug Surveillance Program, Boston University, USA
- ◆ Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health, USA
- ◆ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy, USA
- ◆ Clinical and Population Health Research Program, Department of Quantitative Health Sciences, University of Massachusetts Medical School, USA

- ◆ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Canada
- ◆ College of Pharmacy, University of Cincinnati, USA
- ◆ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, USA
- ◆ Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, USA
- ◆ Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, India
- ◆ Harvard University School of Public Health, USA
- ◆ Health Outcomes and Pharmacy Practice, The University of Texas at Austin, USA
- ◆ Faculty of Pharmacy, JSS University, Mysore, India
- ◆ Graduate Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Canada
- ◆ Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island, USA
- ◆ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA
- ◆ Program for Clinical Pharmacy and Pharmaceutical Sciences, National Chen-Kung University, Taiwan
- ◆ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA
- ◆ University of Bordeaux, France

2017 ICPE LOCAL HOST COMMITTEE

Ingrid Sketris, Co-Chair	Karissa Johnston
Yola Moride, FISPE, Co-Chair	I Fan Kuo
Ariel Arias, FISPE	Adrian Levy
Martin Barbeau	Geoffrey Liu, FISPE
Leah Canning	Colleen Maxwell
Janet Crain	Robert Platt
Colin Dormuth	Marc Poitras
Judith Fisher	Scot Simpson
Judith Glennie	Shanna Trenaman
Jean-Pierre Gregoire, FISPE	

ISPE DEVELOPMENT COMMITTEE

Kirk Midkiff, Chair	Doug Kou
Dimitri Bennet, Co-Chair	Susan Oliveria, FISPE
Andrzej Czarnecki, FISPE	Syd Phillips
Mark Cziraky	Kate Saltus
Mark H Epstein	Nancy Santanello, FISPE
Nick Everage	Jasmanda Wu, FISPE
Robert Hay	





ABSTRACT REVIEWERS

ORGANIZATIONAL & INSTITUTIONAL MEMBERS

PHARMACEUTICALS

GlaxoSmithKline
Sanofi-Aventis

SERVICE PROVIDERS

RTI Health Solutions
Seattle Genetics

GOVERNMENT/REGULATORY AGENCY

Department of Epidemiology, Lazio Regional Health Service

ACADEMIC PROGRAMS

- ◆ Center for Drug Safety & Effectiveness, Department of Epidemiology, Johns Hopkins School of Public Health
- ◆ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- ◆ Center for Pharmacoepidemiology and Treatment Science(PETS), Rutgers, the State University of New Jersey
- ◆ Center for Pharmacoepidemiology Research and Training (CPeRT), Perelman School of Medicine at the University of Pennsylvania

- ◆ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- ◆ Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women’s Hospital & Harvard Medical School
- ◆ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- ◆ Harvard School of Public Health
- ◆ London School of Hygiene and Tropical Medicine
- ◆ McGill Pharmacoepidemiology Research Unit, McGill University
- ◆ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ◆ Russian National Society of Evidence-Based Pharmacotherapy
- ◆ University of Massachusetts Medical School – Clinical and Population Health Research
- ◆ University of Texas at Austin – College of Pharmacy

ANNUAL CAMPAIGN as of August 3

The Society extends its appreciation to the individuals listed below for their contributions in support of the 33rd Annual Meeting (ICPE).

- | | |
|--------------------------|--------------------------|
| Silvia Alessi-Severini | Monica Kobayashi |
| Thamir Alshammari | Chia-Hung Liu |
| Zachary Babcock | Lukas Lofling |
| Hsu-Chih Chien | Luciane Lopes |
| Nicolas Deltour | Pablo Lopez |
| Susan DosReis | Karine Marinier |
| Sara Ephross | Josiah Masuka |
| Daina Esposito | Frank May, FISPE |
| Tobias Gerhard, FISPE | Alfi Yasmina Noorsyahdy |
| Alicia Gilsenen | Hedvig Nordeng |
| Cynthia Girman, FISPE | Didier Nzolo Bomene |
| Christopher Gravel | Susan Oliveria, FISPE |
| Daniel Horton | Cynthia ‘Syd’ Phillips |
| Jacqueline Hugtenburg | Shih-Chieh Shao |
| Krista Huybrechts, FISPE | Suzanne West, FISPE |
| Michele Jonsson Funk | Yea-Huei Kao Yang, FISPE |
| Alan Kinlaw | Elvind Ystrom |

IN THIS PROGRAM

33RD ICPE AGENDA

Friday, August 25	12
Saturday, August 26	12
Sunday, August 27	20
Monday, August 28	12
Tuesday, August 29	41
Wednesday, August 30	52

33RD ICPE POSTERS

Poster Guidelines	61
Poster Session A	62
Poster Session B	74
Poster Session C	89

INDEXES

Abstract Index	101
Advertisers Index	117



Heshu Abdullah-Koolmees
John Acquavella, FISPE
Michael Adena
Fariba Ahmadizar
Edifon Akpan
Silvia Alessi-Severini
Myriam Alexander
Fawaz Alharbi
Tariq Alhawassi
M Sanni Ali
Alex Allepuz
Thamir Alshammari
Keith Altman
Carlos Alves
Klaus Andersen
Elizabeth Andrews, FISPE
Daniel Ankrah
Mary Anthony
Kwame Appenteng
Alejandro Arana, FISPE
Ariel Arias, FISPE
Al Artaman
Darren Ashcroft
Magdalene Assimon
Samina Aziz
Shahram Bahmanyar
Nicole Baker
Clare Barnett
Francesco Barone-Adesi
Dorothee Bartels
Gillian Bartlett-Esquillant
Andrew Bate
Brian Bateman
Marloes Bazelier
Daniel Beachler
Sigrid Behr
Dimitri Bennett, FISPE
Aurore Bergamasco
Tomas Bergvall
Jesse Berlin
Mondira Bhattacharya
Stella Blackburn, FISPE
Bianca Blanch
William Blumentals
Mariette Boerstael
Rhonda L Bohn, FISPE
Jaclyn Bosco
Naomi Boxall
Matthew Breitenstein
Kimberly Brodovicz
Mehmet Burcu
Greta Bushnell

Anne Butler
Aisling Caffrey
Caitriona Cahir
Miguel Cainzos
Gloria Caldwell
Gregory Calip
Wendy Camelo Castillo
Ying Cao
Wendy Carman
Thomas Cars
Deborah Casso
Ola Caster
Ruby Castilla-Puentes
Gillian Caughey
Lucia Cea Soriano
Edmore Chamapiwa
Christina Chambers
Rebecca Chandler
Chao Chen
Lei Chen
Yingkai Cheng
Victoria Chia
Hsu-Chih Chien
Zelma Chiesa Fuxench
Yoonyoung Choi
Carole Chrvala
Sze Ling Celine Chui
Cecilia Chung
Noelle Cocoros
Jacqueline Cohen
Catherine Cohet
Alexander Cole
John Connolly
Andrew Cooper
Paul Coplan
Priscila Corraini
Deborah Covington, FISPE
James Crispo
Josip Culig
Andrzej Czarnecki, FISPE
Benjamin Daniels
Nabarun Dasgupta
Marie Louise De Bruin
Hilda De Jong
Sieta De Vries
Kitaw Demissie
Maral DerSarkissian
Chinmay Deshpande
Rachael DiSantostefano
Paul Dolin
Katherine Donegan
Macarius Donneyong

Susan DosReis
Ian Douglas
Johanna Driessen
Milbhor D'Silva
Wei Du
Genevive Durrieu
Roar Dyrkorn
Sohela El Kebir
Soha Elmorsy
Monique Elseviers
Cheryl Enger
Irene Eriksson
Daina Esposito
Katherine Etter
Nicholas Everage
Jean-Luc Faillie
Gang Fang
Joel Farley
Soulmaz Fazeli Farsani
James Feinstein
Miriam Fenton
Kristian Fillion
Evelyn Flahavan
James Flory
Robert Flynn
Joan Forn
Michael Forstner
Joan Fortuny
Nadia Foskett
Annie Fourrier-Reglat
Jessica Franklin
Lourdes Frau, FISPE
Andrew Freedman
Jon Fryzek
Candace Fuller
Kari Furu
Joshua Gagne
David Gagnon
Arlene Gallagher
Helga Gardarsdottir
Nicolle Gatto, FISPE
Alicia Gayle
Madlen Gazarian
Stewart Geary
Tobias Gerhard, FISPE
David Gilbertson
Alicia Gilnsen
Rosa Gini
Cynthia Girman, FISPE
Natasa Gisev
Gunnar Gislason
Earl Goehring Jr.

Mugdha Gokhale
Inbal Goldshtein
Amanda Keatley Golembesky
Amandine Gouverneur
Carlos Grijalva
Robert Gross, FISPE
Qi Guan
Sandra Guedes
Jason Guertin
Ezgi Gulmez
Lia Gutierrez
Mendel Haag
Katrina Hagberg
Eelko Hak
Gillian Hall, FISPE
Jesper Hallas, FISPE
Christian Hampp
Janet Hardy
Raymond Harvey
Abdul Haseeb
A. Brett Hauber
Ulrike Haug
Jari Haukka
Samuel Hawley
Maja Hellfritsch
Sharon Hensley Alford
Sonia Hernandez-Diaz, FISPE
Ulrik Hesse, FISPE
Juan Hincapie Castillo
Veena Hoffman
Ken Hornbuckle, FISPE
Simon Horsburgh
Daniel Horton
Jason C. Hsu
Yujing Huang
Ting-Ying Huang
Li Ying Huang
Wan-Ting Huang
Consuelo Huerta
Jacqueline Hugtenburg
Krista Huybrechts, FISPE
Lynn Huynh
Luisa Ibanez
Takuya Imatoh
Lyna Irawati
Ireny Iskandar
Masao Iwagami
Jessica Jalbert
Meghna Jani
Joao Joaquim
Catherine Johannes
Karin Johnson



ABSTRACT REVIEWERS

Cynthia Jones
Hugh Kawabata
James Kaye
Judy Kelly
Michael Kelsh
Tomomi Kimura
Alan Kinlaw
Ursula Kirchmayer
Henry Kirchner
Victor Kiri
Olaf Klungel
Caitlin Knox
Monica Kobayashi
Oleksii Korzh
Tzuyung Douglas Kou
Whitney Krueger
Kiyoshi Kubota, FISPE
Veronique Kugener
Hiraku Kumamaru
Jennifer Kuntz
I Fan Kuo
Amanj Ismael Baker Kurdi
Natalia Kutishenko
Jean-Philippe Lafrance
Edward Lai
Pamela Landsman-Blumberg
Kate Lapane, FISPE
Sharon Larson
Tamar Lasky, FISPE
Julie Lauffenburger
Marcus Lawrance
Deborah Layton
Hristina Lebanova
Joongyub Lee
Sally Lee
Charles Leonard
Hubert Leufkens, FISPE
Michael Lewis, FISPE
Hu Li
Se Li
Fabio Lievano
Tzu-Chieh Lin
Dora Lin
Jennifer Hsiang-Ling Lin
Mei-Shu Lin
Zhen-Fang Lin
Marie Linder
Marie Lindquist
Shao-Hsien Liu
Yanfang Liu
Geoffrey Liu, FISPE

Longjian Liu
Vincent Lo Re III, FISPE
Feng-Hua Loh
Sandra Lopez Leon
Jennifer Lund
Angela Lupattelli
Theodore Lystig
Sonal Sekhar M
Isla Mackenzie
Anke-Hilse Maitland-van der Zee, FISPE
Kenneth Man
Zachary Marcum
Andrea Margulis
Danica Marinac-Dabic, FISPE
Diana Martins
Kayleigh Mason
Christopher Mast
Uday Venkat Mateti
Shinichi Matsuda
Géric Maura
Colleen Maxwell
Una Mc Menamin
Leah McGrath
Ann McMahon
Peter McMahon
Vinay Mehta
Hemalkumar Mehta
Cristiane Menezes
Kristin Meyers
Rajibul Mian
Kirk Midkiff
Katie Miller
Daniel Mines
Eileen Ming
Daniela Moga
Yola Moride, FISPE
Elaine Morrato
Julie Mouchet
Cristiano Moura
Christoph Mueller
Tanja Mueller
Jerald Mullersman
Dorian Murariu
Walter-Rodney Nagumo
Cassandra Nan
Juliet Ndikum
Michael Nguyen
Prasad Nishtala
Shimpei Niwa
Wim Noël

Alfi Yasmina Noorsyahdy
Hedvig Nordeng
Beth Nordstrom
Niklas Noren
Josephine Ocran
Rachel Odesanya
Maire O'Dwyer
Denise Oleske
Susan Oliveria, FISPE
Busuyi Olotu
Vicki Osborne
Osemeké Osokogu
Ellie Paige
Mary Panaccio
Georgios Papazisis
Rosa Parisi
Lianne Parkin
Laura Park-Wyllie
Sallie-Anne Pearson
Alma Pedersen
Susana Perez-Gutthann, FISPE
Paul Petraro
Hans Petri
Payam Peymani
Cynthia 'Syd' Phillips
Jeanne Pimenta
Federica Edith Pisa
Robert Platt
Marc Poitras
Lisa Pont, FISPE
Anton Pottgard
Chih-Ying Pratt
Nicole Pratt
Daniel Prieto-Alhambra
Scott Proestel
Dima Qato
Jennifer Quint
Smriti Raichand
Thiyagu Rajakannan
Sudha Raman
Darmendra Ramcharran
Cristina Rebordosa Garcia
Jennita Reefhuis
Mette Reilev
Adriano Max Reis
Stephanie Reisinger
Christel Renoux
Matthew Reynolds
Shannon Reynolds
Margaret Richards
Kathryn Richardson

Mary E Ritchey
Elena Rivero, FISPE
Andrew Roddam
Daniel Rosenberg
Kieran Rothnie
Kathryn Rough
Elizabeth Roughead, FISPE
Watcharee Rungapiromnan
Leo Russo
Jens Sondergaard
Patricia Saddier
Nuria Saigi-Morgui
Maribel Salas, FISPE
Nurrul Salwa Saleh
Claudia Salinas
Catherine Saltus
Francesco Salvo
John Sampalis
Gabriel Sanfelix-Gimeno
Thibaut Sanglier
Veronica Sansing-Foster
Yared Santa-Ana-Tellez
Tania Schink
Fred Schneiweiss
Martijn Schuemie
Renate Schulze-Rath
Frank Scott
Jodi Segal
Harry Seifert, FISPE
Randi Selmer
Soko Setoguchi, FISPE
Sumitra Shantakumar
Yu-Hsuan Joni Shao
Natalia Shcherbakova
Sophie Shen
Csaba Siffel
Edgar Simard
Jason Simeone
Scot Simpson
Sarah-Jo Sinnott
Eva Skovlund
Jim Slattery
Jonathan Slaughter
Janet Sluggett
Meredith Smith
Amelia Smith
Rachel Sobel, FISPE
Pooja Solanki
Henrik Toft Sorensen
Rene Soria-Saucedo
Patrick Souverein



J. Michael Sprafka
 Chalasani Sri Harsha
 Gayathri Sridhar
 Michael Steinbuch, FISPE
 Douglas Steinke
 Vanessa Stevens
 Elizabeth Suarez
 Katie Suda
 Richard Swain
 Geert 't Jong
 Mina Tadrous
 Yoshinori Takeuchi
 Varun Talla
 Janet Tate
 Katja Taxis
 Stephanie Tcherny-Lessenot
 Martina Teichert
 Dana Teltsch
 Bharat Thakrar
 Karen Thomson
 Tristan Timbrook
 Lina Titievsky
 Darren Toh
 Sylvie Tomczyk
 Massoud Toussi
 Gianluca Trifiro
 Ilse Truter
 Nicole Tsao
 Md Jamal Uddin
 Anan Udombhornprabha
 Christine Ulbricht
 Marianne Ulcickas Yood, FISPE
 Hisashi Urushihara
 Carla Van Bennekom
 Sascha Van Boemmel-
 Wegmann
 Patricia van den Bemt
 Helene van der Meer
 Angela van der Salm
 Florence van Hunsel
 Robert Vander Stichele
 Zdravko Vassilev
 Erica Velthuis
 Thomas Verstraeten
 David Vizcaya
 Scott Vouri
 Peter Wahl
 Florence Wang
 Shirley Wang
 Tongtong Wang
 Meng-Ting Wang

Grace Wangge
 Yu-Jung 'Jenny' Wei
 Daniala Weir
 Natalie Weir
 Sheila Weiss, FISPE
 Lisa Weiss
 Xuerong Wen
 Anna Westerlund
 Bjorn Wettermark
 Andrew Wiese
 Rachael Williams

Lesley Wise
 Robert Wise, FISPE
 Yun Sum Wong
 Mollie Wood
 Jasmanda Hsiao-Hui Wu,
 FISPE
 Richard Wyss
 Wai Ping Yau
 Zenas Yiu
 Mellissa Yong
 Jessica Young

Onchee Yu
 Zhong Yuan
 Huifeng Yun
 Salwa Zghebi
 Siyan Zhan
 Wei Zhou, FISPE
 Yanmin Zhu
 Julie Zito, FISPE
 Inge Zomerdijs

SAVE THE DATES!



**INTERNATIONAL CONFERENCE ON PHARMACOEPIDEMIOLOGY
 & THERAPEUTIC RISK MANAGEMENT**
AUGUST 22-26, 2018
PRAGUE CONGRESS CENTRE
PRAGUE, CZECH REPUBLIC





ICPE EXHIBITORS & SUPPORTERS



International Conference on
Pharmacoepidemiology &
Therapeutic Risk Management

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped the Society advance the scientific program content and increase attendance at ISPE's 33rd annual meeting (ICPE).

EXHIBITORS*

- ◆ Aarhus University
- ◆ Aetion
- ◆ Analysis Group
- ◆ Boehringer-Ingelheim
- ◆ Boston Health Economics
- ◆ Brown University School of Public Health
- ◆ Clinical Practice Research Datalink (CPRD)
- ◆ Commonwealth Informatics
- ◆ Dove Medical Press Ltd
- ◆ Drug Safety Research Unit
- ◆ EPID Research
- ◆ EU2P
- ◆ Evalytica
- ◆ Evidera
- ◆ HealthCore
- ◆ IBM Watson Health
- ◆ ICON
- ◆ INC Research
- ◆ Japan Medical Data Center
- ◆ Kantar Health
- ◆ Klein Hersh International
- ◆ Mapi
- ◆ Medical Data Vision Co. Ltd
- ◆ OM1
- ◆ Optum
- ◆ Oxon Epidemiology
- ◆ Pharmaceutical Health Services Research
- ◆ PHARMO Institute
- ◆ QuintilesIMS
- ◆ Reagan-Udall Foundation
- ◆ RTI Health Solutions
- ◆ STATinMED Research
- ◆ Takeda
- ◆ The Degge Group Ltd. & DGI LLC
- ◆ Truven Health Analytics, IBM Watson Health
- ◆ UBC: An Express Scripts Company
- ◆ Uppsala Monitoring Centre
- ◆ Vizient

BADGES

All attendees at the 2017 ICPE must wear their badges to all events and conference-related functions including the Welcome Reception/Academic Showcase, scientific sessions, exhibit/poster hall, and social event. Badges will be included in the registration material. In some cases, tickets for admission will be required; e.g., courses and guests.

ANNUAL MEETING SPONSORS*

PLATINUM

- ◆ HealthCore
- ◆ QuintilesIMS

GOLD

- ◆ Aetion
- ◆ Analysis Group
- ◆ Amgen
- ◆ Bayer
- ◆ Biogen
- ◆ Boehringer-Ingelheim
- ◆ Boston Health Economics
- ◆ Commonwealth Informatics
- ◆ Eli Lilly
- ◆ EPID Research
- ◆ Evalytica
- ◆ Evidera
- ◆ INC Research
- ◆ Kantar Health
- ◆ Optum
- ◆ RTI Health Solutions
- ◆ Pfizer Inc.
- ◆ Takeda
- ◆ The Degge Group Ltd. & DGI LLC
- ◆ UBC: An Express Scripts Company

SILVER

- ◆ Procter & Gamble

BRONZE

- ◆ Boston Collaborative Drug Surveillance Program
- ◆ Harvard Pilgrim Health Care Institute

*As of August 10, 2017



Expect More
with

Evidera

Evidence, Value & Access by PPD

When you need to stand apart from the crowd, choose the leading provider of evidence-based solutions to help you get there.

Our expert presentations during ICPE 2017 include:

Pre-Conference Course: *Comparative Effectiveness Research, Database Utilization Workshop*

Workshop: *Beyond Retrospective Studies, Using Electronic Health Records for Prospective Research*

Oral Presentation: *Study of Mirabegron & Cardiovascular Outcomes using the Publicly Available Mini-Sentinel Protocol*

Six Posters: See the entire list at: <http://www.evidera.com/events/icpe-2017/>

READY TO LEARN MORE?

evidera.com | info@evidera.com

30+ Years of Experience

Data Analytics • Epidemiology • Evalytica® • Health Economics • Interventional and Observational Studies
Market Access Consulting and Communications • Medical Writing • Meta Research • Modeling and Simulation
Outcomes Research • Real-World Evidence • Value and Evidence Planning

FRIDAY, AUGUST 25, 2017

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:30am-5:00pm Speaker Ready Room 523A						4:00pm-6:00pm Registration Foyer S17 East (Fifth Floor)						

SATURDAY, AUGUST 26, 2017

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
7:30am-5:00pm Speaker Ready Room 523A						7:30am-6:00pm Registration FOYER 517 EAST (Fifth Floor)						
8:30am-12:30pm Educational Sessions				12:30pm-2:00pm Lunch on Your Own		2:00pm-6:00pm Educational Sessions						
Adherence to Pharmacotherapy 518C Introduction to Pharmacoepidemiology 519 Introduction to Therapeutic Risk Management 521AB Pharmacogenomics I: Pharmacogenomics in the Real World 2.0 524AB Pragmatic Randomized Clinical Trials (pRCTs) 524C						Comparative Effectiveness Research 524C Newcomers/Early Stage Pharmacoepidemiology Workshop 518AB Pharmacogenomics II 524AB Practical Skills in Protocol Writing And Computer Programming 518C Using Pharmacoepidemiology Database Resources 519 Using Field Studies to Value-add in Pharmacoepi 521AB						
						1:00pm-5:00pm ISPE Board of Directors Meeting (Intercontinental Montreal)						

SUNDAY, AUGUST 27, 2017

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
Meet at 6:30am Fun Run	7:30am-5:00pm Speaker Ready Room 523A						7:30am-6:30pm Registration FOYER 517 EAST (Fifth Floor)					
8:30am-12:30pm Educational Sessions				12:30pm-2:00pm Lunch on Your Own		2:00pm-6:00pm Educational Sessions				6:00pm-7:30pm Welcome Reception/International Chapter & Academic Program Showcase 710		
Epidemiology of Vaccine Safety 518AB Intermediate Pharmacoepidemiology 519 Introduction to Drug Utilization Research 524AB Modern Pregnancy Pharmacoepidemiology 524C Pharmacovigilance & Signal Detection 520CF Propensity Scores in Pharmacoepidemiology 518C Registries & Prospective Cohort Studies 521AB				12:30pm-2:00pm New Member & Early Stage Investigator Luncheon (By Invitation) 725		Advanced Topics in Pharmacoepidemiology 519 Advanced Drug Utilization Research 524AB Weighing the Benefits & Risks 518AB Medical Devices Epidemiology 521AB Pediatric Pharmacoepidemiology 524C Pharmacoepidemiologic Considerations for Biologics and Biosimilars 518C Regulatory Pharmacoepidemiology 520CF				7:30pm-9:30pm Students/ Early Career Professionals Meet & Greet (Off-Site/TBA)		

MONDAY, AUGUST 28, 2017

7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm					
6:00am-7:00am Mindful Yoga 513F	7:00am-8:00am Poster Session A Set-Up 220BC						7:00am-5:00pm Speaker Ready Room 523A										
7:00am-8:00am Continental Breakfast 220BC						7:00am-6:00pm Registration Foyer 517 East (Fifth Floor)											
7:15am-8:00am International Chapter Meetings Pharmacoepidemiology 520BE, Gulf Region 520AD, Latin America 520CF						7:30am-6:00pm Exhibits/Posters 220BC											
8:15am-8:30am BIENVENUE 517AD		8:30am-10:00am Keynote Address: Benefits and Risks of Medical Products: A Systematic Approach to Continuous Evidence Generation 517CD		10:00am-10:30am Break/Posters/Exhibits 220BC		10:30am-Noon Symposia & Workshops Control Yourself 517CD Integrating Sentinel into Routine Regulatory Drug Review 520AD The Non-Pharmacological Basis of Regulatory Decision-Making 520BE Methodological Challenges and Opportunities of Conducting Pharmacoepidemiologic Research in Medically Complex Populations 520CF It Takes a Village 524AB		Noon-1:30pm Lunch/Poster Session/Exhibits 220BC Committee Meetings (open to all participants) Development/Membership 522BC Fellowship & Awards 522A Finance 525B Public Policy 525A Roundtable Discussion (Reserved table) 220BC		1:30pm-3:00pm Concurrent Sessions Opening Doors to Data 517CD The "ACE" of BRACE 520AD Opioids 520BE Quality of Care 520CF Vaccines 524AB Pediatrics 524C		3:00pm-3:30pm Break/Posters/Exhibits 220BC		3:30pm-5:00pm Symposia & Workshop Non-Traditional RCTs 517CD Improving Screening of Adverse Drug Events 520AD Therapeutic Monomania 520BE Medication Use and Criminality 520CF Impact of Pharmacoepidemiology on Public Health? 524AB		5:00pm-6:30pm Concurrent Sessions Design Tips for Observational and Final Data 517CD Natural Language Processing 520AD Is It Worth It? Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease (Cardio) Vascular Safety Outcomes 524AB Good & Bad of Diabetes Treatment 524C	
						6:45pm-7:45pm Special Interest Group Meetings Adherence 520AD AsPEN 520BE BRACE 520CF Biologics and Biosimilars 518AB CER 524AB Databases 525B DIR 525A Medical Devices 521C Medications in Pregnancy 522A Molecular Epi/ Biomarkers/ Pharmacogenetics 522BC Oncology 521B Pediatrics 518C Rare Disease 524C Vaccines 521A						7:30pm PDS Editorial Board (By Invitation) 514AB					



MEETING-AT-A-GLANCE

TUESDAY, AUGUST 29, 2017


	7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
Meet at 6:30am Fun Run	7:00am-8:00am Round Table Discussion (Reserved table) 220BC	7:00am-5:00pm Speaker Ready Room 523A											
6:00am-7:00am Mindful Yoga 513F	7:00am-8:00am Poster Session B Set-Up 220BC	7:00am-6:00pm Registration Foyer 517 East (Fifth Floor)											
	7:00am-8:00am Continental Breakfast 220BC	7:30am-6:00pm Exhibits/Posters 220BC											
	7:00am-8:00am Digital Epidemiology 525A	8:00am-9:30am Concurrent Sessions	9:30am-10:00am Break/ Posters/ Exhibits 220BC	10:00am-11:30am Plenary Session: Medical Product and Performance Evaluation Programs Using Distributed Data Sources 517CD	11:30am-1:00pm Lunch/Poster Session B/Exhibits 220BC	1:00pm-2:30pm Concurrent Sessions	2:35pm-3:30pm Annual Meeting of ISPE Members & Awards Ceremony 517CD	3:30pm-4:00pm Break/ Posters/ Exhibits 220BC	4:00pm-5:30pm Symposia & Workshop	5:30pm-6:30pm Council Meetings	7:30pm-11:30pm Social Evening at New City Gas (Buses will shuttle to New City Gas from the Convention Centre and back to the hotel from New City Gas.)		
	7:00am-8:00am Asian DURG Meeting 522BC	Indices 517CD Opioid Policy 520AD Un mélange d'idées 520BE Pregnancy General 520CF Cancer 1 524AB It's a Bloody Mess 524C			Education 522BC Global Development 525A Publications & Communications 525B	Outsmarting Bias 517CD Seeing Beyond the Data Horizon 520AD Adherences 520BE Vaccines - Use and Effectiveness 520CF Outcomes in Diabetes 524AB Cardiovascular Potpourri 524C			Comparative Safety and Effectiveness Evidence 517CD Evidence Generation in Multimorbidity 520AD TreeScan™: A Novel Data-Mining Tool for Medical Product Safety 520BE Surveillance: Real-World Battles with Real-World Data 520CF Implementing Sequence Symmetry Analysis 524AB Listening to the Patient Voice 524C	Academic Government/Regulatory 520CF Industry/Service Provider 518C Student 520BE 524C			
					11:45am-12:45pm Spotlight Poster Session 516BC								

WEDNESDAY, AUGUST 30, 2017

	7:00 am	8:00 am	9:00 am	10:00 am	11:00 am	12:00 pm	1:00 pm	2:00 pm	3:00 pm	4:00 pm	5:00 pm	6:00 pm	7:00 pm
6:00am-7:00am Mindful Yoga 513F	7:00am-8:00am Poster Session C Set-Up 220BC	7:00am-3:30pm Speaker Ready Room 523A											
		7:00am-4:30pm Registration Foyer 517 East (Fifth Floor)											
		7:30am-1:45pm Exhibits/Posters 220BC											
	7:00am-8:15am Continental Breakfast 220BC	8:30am-10:00am Concurrent Sessions	10:00am-10:30am Break/ Posters/ Exhibits 220BC	10:30am-Noon Symposia & Workshops	Noon-1:30pm Lunch/Poster Session B/Exhibits 220BC	1:30pm-3:00pm Concurrent Sessions	3:15pm-4:45pm Hot Topic Session: A Bitter Pill to Swallow, Smart or Inject: What have we learned about the impact of our opioid policies in North America? 517CD	4:45pm-5:15pm The Final Word 517CD					
	7:15am-8:15am 2018 ICPE Scientific Program Committee 518C	Pregnancy Methods 517CD Better, Worse, or the Same? 520AD It Is Nice to Know What You Are Talking About 520BE Patient Centered Care 520CF Evolution in Pharmacovigilance 524AB Remember Not to Forget 524C		Records for Prospective Research 517CD Real World Evidence and Precision Medicine in Cancer Research 520AD Practical Points to Address Uncertainties in Risk Management Planning 520BE Optimizing Design, Conduct and Interpretation of EHR-enabled Randomised Clinical Trials 520CF Promises and Perils of Machine Learning 524AB	ISPE Board of Directors luncheon 518C 12:15pm-1:15pm Spotlight Poster Session 516BC	Coping with Imperfection 517CD Drug Utilization Across the Board 520AD Pregnancy Nerves 520CF Cancer 2 520BE Psych/Mental Health 524AB Get the How Just Right 524C							

SAVE THE DATES!

APRIL 21-24, 2018
ISPE's 2018 Mid-Year Meeting
 Sheraton Centre Toronto Hotel
 Toronto, Canada





PRE-CONFERENCE | FRIDAY, AUGUST 25

7:30am-5:00pm

Speaker Ready Room

523A

4:00pm-6:00pm

Registration

Foyer 517 East (Fifth Floor)

**If you plan to attend a pre-conference course on Saturday, it is recommended that you register on Friday evening to avoid delays.*

PRE-CONFERENCE | SATURDAY, AUGUST 26

7:30am-5:00pm

Speaker Ready Room

523A

7:30am-6:00pm

Registration

Foyer 517 East
(Fifth Floor)

**Individuals attending a morning pre-conference course should arrive by 7:30am to register.*

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required)*

8:30am-12:30pm

Adherence to Pharmacotherapy

518C

Content

This course will provide an overview of measurement issues to be considered when designing and conducting an adherence study. The course will cover the following topics:

- ◆ Description of different constructs of unintentional and intentional adherence that can be measured: initiation (primary adherence), implementation and persistence.
- ◆ Selection of measurement techniques according to the construct being measured.
- ◆ Strengths and limitations of commonly used techniques: self-reports, medical/pharmacy electronic data and microelectronic monitoring data, among others.
- ◆ Discussion of analysis issues: choice of the duration of an adherence interval, taking multiple drug regimens and switches into account, various approaches to summarizing adherence data from the different techniques, and linking adherence data to relevant outcomes.

Course Faculty

Robert Gross FISPE, Associate Professor of Medicine and Epidemiology, University of Pennsylvania Perelman School of Medicine

Jacqueline Hugtenburg, Associate Professor, Department of Clinical Pharmacology and Pharmacy, VU University Medical Center

Niteesh Choudhry, Associate Professor, Harvard Medical School; Executive Director, Center for Healthcare Delivery Sciences, Brigham and Women's Hospital

Jean-Pierre Grégoire FISPE, Professor, Faculty of Pharmacy, and Scientist, Chair on Adherence to Treatments, Laval University

Petra Denig, Professor, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen

Introduction to Pharmacoepidemiology

519

Content

This course will provide participants with a short introduction to the basic principles and concepts of pharmacoepidemiology. The course includes lectures on cohort studies, case-control studies, and bias & confounding.

Course Faculty

Almut Winterstein, FISPE, University of Florida College of Pharmacy, *Cohort Studies*

Jennifer Lund, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, *Case-Control Studies*

Tobias Gerhard, FISPE, Ernest Mario School of Pharmacy, Rutgers University, *Bias & Confounding*



Real-World Insight into Drug Safety and Epidemiology

Proven epidemiology research expertise powered by the HealthCore Integrated Research Environment (HIRE®).

HealthCore is on the frontline of observational research aimed at uncovering vital evidence on the utilization, safety and effectiveness of biopharmaceuticals and devices in large, real-world patient populations.

Our multi-disciplinary team of pharmacoepidemiologists brings a broad range of scientific expertise and operational experience to the timely and accurate execution of safety and risk management studies in the post-marketing real-world setting.

The HIRE® incorporates one of the largest healthcare data repositories. This allows for the augmentation of automated claims with clinical data obtained from medical records, electronic health records, physicians, and patients – making it a rare and valuable resource for conducting medical product safety and risk management studies.

Our comprehensive integrated research solutions include:

- Drug and vaccine post authorization safety studies
- Risk management and REMS survey studies
- Active surveillance of new medical products and adverse events
- Development and validation of algorithms using predictive modeling with machine learning
- Multi-database study design, coordination, and execution
- Descriptive epidemiology (natural history of disease, burden of illness)
- Data linkage capability
- Systematic literature reviews
- Strategic consulting

Visit Booth #28 during ICPE to learn about our full-service research solutions or contact us at RWE@HealthCore.com.

HealthCore®

www.healthcore.com

Safety & Epidemiology Research | HEOR | Comparative Effectiveness Research | Late Phase Research
Medical Record & Survey-Based Research | Pragmatic Clinical Trials





EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required) (Continued)*

Introduction to Therapeutic Risk Management

521AB

Content

This course presents an overview global risk management principles, with a focus on methods and examples for consideration in the development and evaluation of risk minimization tools. The didactic section includes speakers from regulatory, industry and research communities to present background, trends in regulatory requirements, and examples of effective design and evaluation techniques. The interactive workshop section asks participants to actively engage in discussion relating to the development, selection and evaluation of risk minimization tools.

Course Faculty

Lesley Wise, Managing Director, Wise Pharmacovigilance and Risk Management Ltd - *Level-Setting – Defining And Assessing Risk In The Context Of Drug Safety?*

Meredith Smith, Global Risk Management Officer, Global Patient Safety at Amgen, *Designing Effective Risk Minimization Programs, From Global Sponsor Company Perspective*

Gerald Dal Pan, Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, *Real-World Example Of A Risk Evaluation And Mitigation Strategies (REMS) In The US And Future Directions From A US Regulatory Perspective*

Alicia Gilsean, Senior Director, Epidemiology, RTI Health Solutions - *Considerations For Evaluation Of Risk Minimization Tools*

Elaine Morrato, Associate Dean & Associate Professor, Colorado School of Public Health and **Rania Mouchantaf**, A/ Manager, Health Canada, Marketed Pharmaceuticals and Medical Devices; Facilitators for Workshop For Participants - *Considerations When Developing A Risk Minimization Plan And Tools*

Pharmacogenomics I: Pharmacogenomics in the Real World 2.0

524AB

Content

This course, sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics SIG, will focus on the essentials every pharmacoepidemiologist should know about real world applications of pharmacogenomics. This introduction to the field will include the use of recent and historical examples of precision medicine from research through to clinical application. There will be short pre-course orientating videos on the ISPE website that will cover basic definitions and concepts in preparation for the main course, allowing the main course to focus more on practical applications. A variety of instructional techniques (including didactic teaching, scenario-based discussions, and an interactive debate) will be used.

Course Faculty

Gillian Bartlett, McGill University

Bruce Carleton, University of British Columbia

Amalia M. Issa, University of the Sciences in Philadelphia

Geoffrey Liu, FISPE, University of Toronto

Leah Sansbury, GSK



EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required) (Continued)*

Let's Be Pragmatic – the Design, Implementation, and Analysis of Pragmatic Randomized Clinical Trials (pRCTs) 524C

Content

Pragmatic randomized clinical trials (pRCTs) require the expertise of pharmacoepidemiologists who understand considerations and methodologic challenges that arise with more “pragmatic” RCTs compared with traditional “explanatory” RCTs. These include real world site and patient identification, enrollment and retention, ethical review issues, approach to randomization, selection bias, and defining the appropriate comparator. In addition, choice of study design including cluster randomized or step wedge design, and associated analytic considerations will be highlighted. Handling of randomizing patients to “standard of care (SOC)”, and accounting for changes in therapies over time, or claims such as therapy switching, augmentation and discontinuation and analytic population (intention to treat vs as treated) will also be discussed. Distinction will be made between issues pertaining to primary data collection and studies conducted using electronic health records and claims data. The significant operational challenges of conducting pRCTs will be discussed at length.

Course Faculty

Jennifer Christian, FISPE, Vice President, Clinical Evidence, QuintilesIMS Real World Insight

Priscilla Velentgas, Senior Director of Epidemiology, QuintilesIMS Real World Insight

Cynthia Girman, FISPE, CERObS Consulting, LLC

It begins with a promise
 to discover medicines that make life better.

Since 1876, we have worked tirelessly to discover medicines that make life better, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/promise.
 2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.





12:30pm-2:00pm

Lunch on Your Own

1:00pm-5:00pm

ISPE Board of Directors Meeting (Intercontinental Montreal)

Open to ISPE members; members should contact info@pharmacoepi.org if they would like to attend.

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket required)

Comparative Effectiveness Research

524C

Content

Comparative effectiveness research (CER) is increasingly important for generating real-world evidence to inform clinicians, patients, regulators, and other decision makers. The recent Prescription Drug User Fee Act reauthorization (PDUFA VI) and the 21st Century Cures Act in the US and adaptive pathways in the EU all have implications for the use of real-world evidence to inform regulatory decision making. This year's course will start with an overview of these new initiatives, describe CER methods for generating evidence using real-world data, and will discuss how real-world evidence can be used in the changing regulatory landscape. Multiple case studies will be used to facilitate an interactive group discussion and will address how observational, real-world data can be used to evaluate clinical outcomes for drugs approved using biomarker endpoints and to generate evidence to support secondary indications.

Course faculty

H (Bert).G.M. Leufkens, FISPE, Utrecht University, Faculty of Science and Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology

Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School

Sebastian Schneeweiss, FISPE, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School

Newcomers/Early Stage Pharmacoepidemiology Workshop

518AB

Content

Workshop Session 1: The Pharmacoepidemiologist's Toolbox: Important Research Skills (2 hours)

Course Faculty

Almut Winterstein, FISPE, University of Florida. *Effective Research Grant Writing*

Tarek Hammad, FISPE, Merck Research Laboratories, *Preparing An Effective Oral Research Presentation*

Darren Toh, Harvard Medical School and Harvard Pilgrim Health Care Institute, *Tips For Successful Manuscript Writing*

Vincent Lo Re III, FISPE, University of Pennsylvania, *Managing Your Pharmacoepidemiology Research Team*

Content

Workshop Session 2: Developing a Successful Early Career in Pharmacoepidemiology

Course Faculty

Vincent Lo Re III, FISPE, University of Pennsylvania, *Establishing Productive Mentor-Mentee Relationships*

Sean Hennessy, FISPE, University of Pennsylvania, *Enhancing Creativity/Productivity In Pharmacoepidemiology*

Caitlin Knox, Vertex Pharmaceuticals, *Professional Networking In Pharmacoepidemiology*

TBA, *How To Get The Most Out Of The Early Stage Of Your Career In Pharmacoepidemiology*





EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES (Ticket required) (Continued)

Pharmacogenomics II: Cancer Pharmacoepidemiology and Genomics: What You Should Know in the World of Molecular Oncology, Targeted Therapies and Biomarkers

524AB

Content

This course, co-sponsored by the Molecular Epidemiology, Biomarkers, and Pharmacogenomics and the Oncology SIGS, will focus on the essentials every pharmacoepidemiologist should know about real world applications of cancer personalized medicine including precision medicine, companion diagnostics, biomarkers and the biomarker development pipeline, and linking databases with genomic information.

This course incorporates the broader definition of genomic and other biomarkers, including both germline and somatic changes. There will be short pre-course orientating videos on the ISPE website that will cover basic definitions and concepts in preparation for the main course.

Course Faculty

Bruce Carleton, University of British Columbia

Andrew Freedman, National Cancer Institute, National Institutes of Health

Geoffrey Liu, FISPE, University of Toronto

Wei Zhou, FISPE, Merck Research Laboratories

Rapid Cycle Analytics to Inform Value-Based Care Decisions

Visit us at ICPE Booth #36

The Aetion Evidence Platform™ combines best-of-breed science with patented computing technology to unlock risk adjusted evidence from real world data.

FASTER TIME-TO-RESULTS

BUILT-IN TRANSPARENCY AND REPRODUCIBILITY



Contact us to learn more:
844-8-AETION (844-823-8466)
sales@aetion.com www.aetion.com





EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket required) (Continued)*

Practical Skills In Protocol Writing And Computer Programming Relevant To Pharmacoepidemiology 518C

Content

Pharmacoepidemiologic studies that involve the use of electronic healthcare data have complex and unique characteristics that must be taken into consideration when planning and conducting these types of studies. This highly interactive course will engage participants in the following topics:

- ◆ Pre-specifying study components of a protocol, including design, analysis, and reporting of the study, along with a science-based rationale for the choices pertaining to these components; and
- ◆ Translating elements of the study protocol into SAS programming.

The first part of the class will start with the presentation of an example protocol for a hypothetical case. Using this example, we will walk through a study protocol with substantial inadequacies. A short lecture will follow to address how to write a clear and detailed protocol. Students will form groups to discuss and present their suggestions and approaches to improve the protocol example. The second part of the course includes hands-on session for programing using the previously discussed example protocol.

Course Faculty

Christian Hampp, Epidemiologist, U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Division of Epidemiology II

Jessica Jalbert, Director of Pharmacoepidemiology US, LASER Analytica, Assistant Professor of Healthcare Policy and Research, Weill Cornell Medical College

Chih-Ying (Natasha) Pratt, Epidemiologist, U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Division of Epidemiology II

Nicole Pratt, Associate Professor, Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia

Soko Setoguchi, FISPE, Adjunct Associate Professor, Department of Epidemiology, Rutgers School of Public Health, Institute for Health, Health Care Policy and Aging Research

Using Pharmacoepidemiology Database Resources To Address Drug Safety Research

519

Content

- ◆ Examine the use of database resources in pharmacoepidemiology research;
- ◆ Define the different types of data resources available for pharmacoepidemiology and the selection criteria to select the most appropriate resource, workshop will strengthen the concepts discussed through participant interaction;
- ◆ Assess the quality of electronic medical record data
- ◆ Conduct validation studies through a variety of approaches
- ◆ Examine characteristics of available resources for data linkage between pharmacoepidemiology resources particularly to patient registry data resources

Course Faculty

Gillian Hall, FISPE, Independent Consultant

Matthew Reynolds, Vice President, Scientific Development, Evidera

Steve Lanes, HealthCore, Inc.

Sudha Raman, Duke University

Using Field Studies to Value-add in Pharmacoepi

521AB

Content

This course provides basic theory and practical tips in conducting pharmacoepidemiologic studies when required information is not captured in databases or when large databases are not available. Common study designs used to collect data through observations, medical records or questionnaires will be presented and the strengths and limitations of working without large databases discussed.

Course Faculty

Annie Fourier- Reglat, University of Bordeaux

Lisa Pont, FISPE, Macquarie University

Veronika Wirtz, Boston University School of Public Health

Katja Taxis, University of Groningen





EVIDENCE *Unleashed*

**INNOVATIVE
TECHNOLOGY**

**METHODOLOGICAL
RIGOR**

**DIVERSE
REAL-WORLD DATA**

evalytica.com | evidera.com | ppdi.com



Meet at 6:30am

Fun Runs

Corner of Avenue Viger & Rue de Bleury (northwest corner of the Palais des Congres, near the main entrance)

- ◆ 10-miles (round trip to the top of Mount Royal)
- ◆ 5-miles in the Old Port of Montreal
- ◆ 3-miles in the Old Port

7:30am-5:00pm

Speaker Ready Room

523A

7:30am-6:30pm

Registration

Foyer 517 East (Fifth Floor)

8:30am-12:30pm

EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required)*

Epidemiology of Vaccine Safety

518AB

Content

This course aims to establish an understanding of some of the ways in which vaccine safety and effectiveness are monitored after licensure, including passive surveillance methods, common observational vaccine-safety study designs and methods, and data-mining. The course will involve lectures with a combination of presentations and examples, and opportunities for audience participation (questions and discussion).

Course Faculty

S. Rizwan Ahmad, FISPE
Robert T. Chen, FISPE
Robert Maroko
Patricia Saddier
Martin Kulldorff
W. Katherine Yih

Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders

519

Content

This course will introduce participants to multiple approaches to addressing unmeasured confounders, the requirements and assumptions of each, and an opportunity to compare these approaches through facilitated discussion of a case-study. The faculty will address different approaches to handling unmeasured covariates. Faculty will provide foundational knowledge about each approach illustrated through real-world examples in a lecture format with an opportunity for discussion and questions. The interactive case study will pose a hypothetical research question and engage the audience in thinking about the likely unmeasured covariates, considering how each of the approaches might be used in that setting, and weighing the pros/cons of each. This case-study will provide integration across the approaches and give audience members an opportunity to work through the selection of an appropriate strategy for addressing important unmeasured covariates in light of real-world constraints.

Course faculty

Jennifer Lund, Dept of Epidemiology, University of North Carolina at Chapel Hill
Sudha Raman, Center for Pragmatic Health Systems Research, Duke Clinical Research Institute, Duke University
Mugdha Gokhale, Epidemiology Manager, Real World Evidence & Epidemiology, GlaxoSmithKline
Til Stürmer, FISPE, Pharmacoepidemiology Program, Dept of Epidemiology, University of North Carolina at Chapel Hill
Michele Jonsson Funk, Dept of Epidemiology, University of North Carolina at Chapel Hill





EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required) (Continued)*

Introduction to Drug Utilization Research

524AB

Content

This educational session provides an overview of drug utilisation research and presents essential methods used. The session includes interaction with participants, question, and answer sessions and discussion during and at the end of each presentation. At the end of the session, the participant will be exposed to:

- ◆ Description of the theoretical framework and practical applications of different methods illustrated using selected examples
- ◆ Classification systems used in drug utilisation monitoring and research
- ◆ Limitations of data sources and methods
- ◆ Interpretation of aggregate and individual-based data, variation and change
- ◆ Using drug utilisation research for public health and implications for policy decisions

Course Faculty

Katja Taxis, University of Groningen

Bjorn Wettermark, Centre for Pharmacoepidemiology, Karolinska Institute

Christian Berg, WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health

Mina Thadrous, University of Toronto and Ontario Drug Policy Research Network

Powerful Data. High-Quality Research. More Choices. Truven Health Analytics.

When you need data for pharmacoepidemiological research, you also need expertise in prospective and retrospective analytics and data linkages working with you. We have both—data and experienced epidemiologists—plus many specialty data choices.

- MarketScan® Research Databases
- MarketScan® Explorys® Claims-EMR Data Set
- Treatment Pattern Analysis and Visualization Tool
- Micromedex® Complete Drug Interactions

Stop by **booth #19** to learn more about how our newest claims-EMR data set can give you even more choices to align your research questions with the data best suited to the analysis.



© Copyright 2017 Truven Health Analytics, part of the IBM Watson Health business. IBM, the IBM logo and ibm.com are trademarks of IBM Corporation in the United States, other countries or both. Truven Health Analytics and its respective logo are trademarks of Truven Health Analytics in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies. A current list of IBM trademarks is available on the web at "Copyright and trademark information" at ibm.com/legal/copytrade.shtml. LS 18218 0717

TRUVEN
HEALTH ANALYTICS
IBM Watson Health™



EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES (Ticket required) (Continued)

Modern Pregnancy Pharmacoepidemiology: Methodological Challenges in Outcome Definition and Ascertainment and Implications for Study Design and Analysis

524C

Content

In this course, we will discuss study design and analysis aspects related to outcomes in studies of drug safety in pregnancy. The course format will consist of short methods-focused presentations by faculty with Q&A along with two break-out sessions giving participants the opportunity to discuss and report back on the assigned readings, and a short faculty-moderated session wrap-up.

The content of this course has changed from last year's. While in 2015 the course provided an overview of issues that are particular to pregnancy safety research and in 2016 the course focused on challenges related to exposure measurement, this year the focus shifts to pregnancy, neonatal and long-term outcomes. Some of the topics to be covered may include selecting relevant outcomes for safety studies in pregnancy, binarization of birth weight, lumping versus splitting congenital malformations, non-live birth outcomes, outcome validation and sensitivity analyses, and defining the etiologically relevant time window for different outcomes.



Course Faculty

Brian Bateman, Brigham and Women's Hospital / Harvard Medical School

Krista Huybrechts, FISPE, Brigham and Women's Hospital / Harvard Medical School

Helle Kieler, Director CPE (Centre for Pharmacoepidemiology), Karolinska Institutet

Andrea Margulis, RTI Health Solutions



KANTAR HEALTH+



A KANTAR HEALTH COMPANY

MEET OUR DECISION
 SUPPORT AND
 SAFETY EXPERTS
 AT OUR BOOTH

- + Unrivaled global expertise in physician and patient centered study designs
- + World-class epidemiological data
- + Global patient-level datasets
- + Drug utilization studies, pass and safety registries
- + Data collection through our proprietary, validated EDC system

info.kantarhealth.com/icpe2017



EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required) (Continued)*

Pharmacovigilance & Signal Detection

520CF

Content

This course will introduce participants to the principles of surveillance in pharmacovigilance with a focus on quantitative aspects and recent advances in the field. The course will cover classical pharmacovigilance signal detection using spontaneous adverse event reports, quantitative signal detection methods for electronic medical record and claims data, and international initiatives, including the EU-ADR project and the US FDA's Sentinel program, aimed at using routinely collected electronic healthcare data to conduct signal detection and prospective medical product safety monitoring. The course will involve lectures with ample opportunities for questions and discussion. Use of social media for signal detection will also be discussed.

Course faculty

Andrew Bate, Worldwide Safety & Regulatory Epidemiology, Pfizer Ltd

Gianluca Trifirò, Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands & Department of Clinical and Experimental Medicine, University of Messina

Joshua Gagne, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, U

DEPARTMENT OF POPULATION MEDICINE



HARVARD
MEDICAL SCHOOL



Harvard Pilgrim
Health Care Institute

Come work with us!

**Pharmacoepidemiologists, Biostatisticians, Research Associates,
SAS Programmers, Analysts, Program Managers**

We are the home of the:

- FDA Sentinel Operations Center
- Reagan-Udall Foundation IMEDS Analytics Center
- PCORnet Query Fulfillment Center
- NIH Health Care Systems Research Collaboratory Distributed Research Network
- State of Massachusetts MDPHnet Coordinating Center

We look forward to meeting you here at ICPE – look for anyone with the 'Ask me about Sentinel' buttons or email us at info@sentinelssystem.org.

Please visit our website for information about our research programs, career, and training opportunities.

www.populationmedicine.org





EDUCATIONAL SESSIONS: HALF-DAY MORNING COURSES *(Ticket required) (Continued)*

Propensity Scores in Pharmacoepidemiology

518C

Content

Issues of bias and confounding relate to study design and analysis in the setting of non-random treatment assignment where compared subjects might differ substantially with respect to comorbidities. Failing to address a lack of balance in the covariates between treated and comparison groups can produce confounded estimates of treatment effect. Faculty will explain how propensity scores can be used to mitigate confounding through standard observational approaches (restriction, stratification, matching, regression, or weighting). The advantages and disadvantages of standard adjustment relative to propensity score-based methods will be discussed. Details of propensity score methodology (variable selection, use, and diagnostics) will also be discussed.

Course Faculty

John Seeger, FISPE, Chief Scientific Officer, Optum Epidemiology

Jeremy Rassen, Chief Scientific Officer, Aetion

Registries & Prospective Cohort Studies

521AB

Content

This course will provide an overview of the theory and practice for registries and prospective studies, with an emphasis on field practice including methods for the design, execution and interpretation. Topics include regulatory, methodological and logistical challenges, as well as fit-for-purpose evidence expectations in terms of regulators, payers, clinicians and patients. Methods for prospective data collection will include clinician-reported and patient-reported data, including emerging topics in using smartphones and wearable devices. Special applications relating to pregnancy registries will also be presented.


Course Faculty

Nancy A. Dreyer, FISPE, Global Chief of Scientific Affairs & Senior Vice President, Quintiles Real-world & Late Phase Research

Christina D. Mack, Director, Epidemiology and Health Outcomes, Quintiles Real-world & Late Phase Research

William Dixon, Professor of Digital Epidemiology, Director, Arthritis Research UK Centre for Epidemiology & Honorary Consultant Rheumatologist

Sonia Hernández-Díaz, FISPE, Professor of Epidemiology & Director Pharmacoepidemiology Program, Department of Epidemiology, Harvard T.H. Chan School of Public Health





**Consulting in Clinical Drug Safety,
Pharmacovigilance, and Medical Product
Epidemiology since 1988!**

+1 571.490.8020 info@deggegroup.com www.deggegroup.com

A ▶ PHARMALEX COMPANY

Visit Booth # 18 to learn more

**Identify databases by subscribing to our online compendium
of ~280 population database profiles from 38 countries**

Search, review, and compare database profiles
[Profiles are reviewed by respective database managers and frequently updated.]
Access specialized glossary and interactive maps of databases

+1 571.490.8400 info@bridgetodata.org www.bridgetodata.org

B.R.I.D.G.E. TO DATA® is an online service provided by DGI, LLC, a non-profit organization



RTI (h)(s)[™]
Health Solutions

Meet us at ICPE

The power of knowledge. The value of understanding.

Let us help you reduce the uncertainty of risks to patients by investigating disease epidemiology, drug-outcome associations, and product usage in routine clinical practice and by evaluating the effectiveness of your risk minimization strategies.

FIND US AT:
Booth #1

LEARN MORE:
rtihs.org/ICPEMontreal

Research Triangle Park - Ann Arbor - Barcelona - Belfast - Ljungskile - Manchester - Waltham



12:30pm-2:00pm

Lunch on Your Own

12:30pm-2:00pm

New Member & Early Stage Investigator Luncheon

725

(By Invitation, Ticket Required)

2:00pm-6:00pm

EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket required)*

Advanced Topics in Pharmacoepidemiology

519

Course Faculty

Sean Hennessy, FISPE, University of Pennsylvania, *Trend-In-Trend Research Design*

Irene Petersen, FISPE, University College London, *Regression Discontinuity Design*

Sammy Suissa, McGill University, *Prevalent New-User Cohort Designs For Comparative Drug Effect Studies By Time-Conditional Propensity Scores*

Richard Wyss, Brigham and Women's Hospital, *The "Dry-Run" Analysis: A Method For Evaluating Risk Scores For Confounding Control*

Advanced Drug Utilization Research

524AB

Content

This interactive educational program includes presentations, question and answer sessions and a final discussion with the faculty panel. The session will involve participants in the:

- ◆ Use of drug utilisation information from administrative health data to improve medicines use
- ◆ Use of prescribing quality indicators to assess prescribing
- ◆ Application of principles derived from Health Services and Implementation Research to the design of a clinical intervention
- ◆ Methods for evaluating the effect of clinical or policy interventions
- ◆ Interpretation of the evaluation data and dissemination of results

Course Faculty

Petra Denig, Faculty of Medical Sciences, University of Groningen, Groningen, Netherlands

Lisa Kalisch Ellett, NHMRC-ARC Dementia Research Development Fellow, Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia

Lisa Pont FISPE, Australian Institute of Health Innovation, Macquarie University





EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket required) (Continued)*

Weighing the Benefits & Risks: The Science and Methods of Benefit-Risk Assessment in Drug Development & Regulatory Decision-Making

518AB

Content

This course will help attendees develop an understanding of quantitative benefit-risk assessment methods; understand how to successfully structure and present benefit-risk information for decision-making and regulatory interactions; and develop an understanding of how pharmacoepidemiology intersects with patient engagement, by developing an understanding of the use of preference methods.

Course Faculty

Brett Hauber, RTI – Health Solutions
Tarek Hammad, FISPE, Merck Research Laboratories
Juhaeri Juhaeri, Sanofi
Rebecca Noel, Eli Lilly & Company

Medical Devices Epidemiology

521AB

Content:

Over the past few years, there has been increased focus on “real-world evidence.” Thus, epidemiology of therapeutic products is gaining visibility outside of ISPE. Medical device epidemiology uses methodologies similar to those seen with medicines. However, alternative strategies are often implemented due to the nature of the products, data sources, and situational use. With the changing regulatory and reimbursement environments, it is more important than ever for all pharmacoepidemiology researchers to better understand the world of medical device epidemiology. The nuances of methods may be applicable to other therapeutic products, the data sources may provide deeper understanding of benefits and risks in clinical context, and honestly, its exciting stuff.

Course Faculty

Jessica Jalbert, Director of Pharmacoepidemiology/Assistant Professor(courtesy), LA-SER Group & Weill Cornell Medical College
Daniel Prieto Alhambra, Associate Professor, University of Oxford
Christina Mack, Senior Director, Epidemiology and Clinical Evidence; Head, Sports Injury Surveillance and Analytics, Center for Advanced Evidence Generation, QuintilesIMS
Daniel Canos, Senior Epidemiologist, Centers for Medicare and Medicaid
Mary E Ritchey, Principal Epidemiologist for Medical Devices, RTI Health Solutions
Chantal Holy, Senior Director, Real World Analytics and Research, Johnson and Johnson
Kade Etter, Associate Director, Real World Analytics and Research, Johnson and Johnson

Pediatric Pharmacoepidemiology

524C

Content

The increasing use of medications by children and the history of excluding children from clinical trials have created the need for pediatric pharmacoepidemiology, a sub-specialty within pharmacoepidemiology. Unique challenges in studying children, accessing data, defining outcomes, and designing pediatric studies will be discussed. This half-day course will introduce participants who have a good understanding of pharmacoepidemiology to the specific methodologic issues arising in pediatric pharmacoepidemiology and operational approaches used to study medications in children.

Course Faculty

Tamar Lasky, FISPE, MIE Resources
Alan Kinlaw, Sheps Center for Health Services Research, University of North Carolina at Chapel Hill
Rachel E. Sobel, FISPE, Worldwide Research and Development / Pfizer Inc.
Timothy Beukelman, Division of Pediatric Rheumatology, Department of Pediatrics, University of Alabama at Birmingham
Daniel B. Horton, Rutgers University





EDUCATIONAL SESSIONS: HALF-DAY AFTERNOON COURSES *(Ticket required) (Continued)*

Pharmacoepidemiologic Considerations for Biologics and Biosimilars

518C

Content

This workshop will provide participants with information on the following topics:

- ◆ Background on biologics, biosimilars and differences from small molecules
- ◆ Naming and traceability issues for biologics and biosimilars
- ◆ Interchangeability, switching, and automatic substitution from a regulatory, methodological, and clinical perspective
- ◆ Review country-specific regulatory guidelines, particularly focused on postmarketing monitoring, pharmacovigilance, and risk management requirements for biologics and biosimilars
- ◆ Conducting observational studies of biologics and biosimilars, including primary data collection and secondary use of data sources for evaluating patterns of use as well as comparative safety and effectiveness of biologics and biosimilars

Course Faculty

Nancy A. Dreyer, FISPE, Head of Center for Advanced Evidence Generation; Global Chief of Scientific Affairs, QuintilesIMS Real-World Insights, Cambridge, MA; Adjunct Professor of Epidemiology, University of North Carolina, Chapel Hill

Thijs Giezen, Foundation Pharmacy for Hospitals in Haarlem, Expert at the Medicines Evaluation Board in the Netherlands; Member of the EMA Biosimilars Working Party.

Jaclyn L. F. Bosco, Real-World Evidence Solutions, QuintilesIMS Real-World Insights; Adjunct Assistant Professor of Epidemiology, Boston University School of Public Health

Gianluca Trifirò, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina; Department of Medical Informatics – Erasmus Medical Center

Brian D. Bradbury, Center for Observational Research at Amgen, Inc.; Adjunct Associate Professor of Epidemiology, University of California Los Angeles School of Public Health

Regulatory Pharmacoepidemiology

520CF

Content

- ◆ Understand the intent and structure of regulation to protect the public health
- ◆ Appreciate the challenges of decision making with weak data
- ◆ Know about practical approaches typically chosen by regulators
- ◆ Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- ◆ Gain an overview of worldwide challenges for drug regulatory agencies and variation in approaches
- ◆ Know about current strategies to strengthen regulation in the face of these challenges

Course Faculty

Gerald Dal Pan, Center for Drug Evaluation and Research, US Food and Drug Administration

June Raine, Medicines and Healthcare Regulatory Products Agency





6:00pm-7:30pm

Welcome Reception/International Chapter & Academic Program Showcase

710

Ingrid Sketris, Co-Chair, 2017 Local Host Committee
Yola Moride, FISPE, Co-Chair, 2017 Local Host Committee
Adrian Levy, Chair, 2017 Scientific Program Committee
Kiyoshi Kubota, FISPE, ISPE President

International Chapter & Academic Showcase Participants

- ◆ Center for Drug Safety & Pharmaceutical Health Services Research Graduate Program, University of Maryland School of Pharmacy
- ◆ Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- ◆ Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School
- ◆ Drug Safety Research Unit, Associated Department, School of Pharmacy, Portsmouth University
- ◆ Gulf Region Chapter
- ◆ ISPE Student Council
- ◆ Pharmacoepidemiology Program, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- ◆ Center for Pharmacoepidemiology and Treatment Science (PETS), Rutgers, the State University of New Jersey
- ◆ University of Rhode Island
- ◆ Graduate Studies in Pharmaceutical Sciences, Université de Montréal
- ◆ Department of Epidemiology, Biostatistics and Occupational Health, McGill University
- ◆ Pharmacoepidemiology and Pharmacovigilance, London School of Hygiene and Tropical Medicine
- ◆ Schutte Fellowship in Pharmaceutical Outcomes and Policy, University of Kentucky College of Pharmacy
- ◆ College of Pharmacy, Faculty of Health and Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

7:30pm-9:30pm

Students/Early Career Professionals Meet & Greet

(Off-Site/TBA)

- ◆ Open to all students, recent graduates and young professionals.
- ◆ Registration required – limited capacity.
- ◆ Organized by the ISPE Student Council (SISPE). Please contact SISPEchair@gmail.com for more information and to RSVP.



6:00am-7:00am

Mindful Yoga 513F

Start your day with balance, flexibility, strength and awareness!

Ideally bring your own sticky mat, but if you don't have one, some will be available. Miles Braun, FISPE, a former ISPE Board member, and registered teacher (Yoga Alliance) will lead the sessions.

7:00am-8:00am

Poster Session A Set-Up 220BC

7:00am-8:00am

Continental Breakfast 220BC

7:00am-5:00pm

Speaker Ready Room 523A

7:00am-6:00pm

Registration Foyer 517 East (Fifth Floor)

7:15am-8:00am

International Chapter Meetings

(open to all participants)

- ◆ FarmacoepiEnRed 520BE
- ◆ Gulf Region 520AD
- ◆ Latin America 520CF

7:30am-6:00pm

Exhibits/Posters 220BC

8:15am-8:30am

BIENVENUE 517CD

Yola Moride, FISPE, Co-Chair, 2017 Local Host Committee

Ingrid Sketris, Co-Chair, 2017 Local Host Committee

Adrian Levy, Chair, 2017 Scientific Program Committee

Kiyoshi Kubota, FISPE, ISPE President

8:30am-10:00am

Keynote Address 517CD

Robert Califf, Vice Chancellor for Health Data Science, Duke Health

Benefits and Risks of Medical Products: A Systematic Approach to Continuous Evidence Generation

A system in which the point of market entry for medical products could be carefully calibrated to assure patients and providers that the benefits of using the products as intended were likely to outweigh its risks would fairly balance the need for safety with the desire for access to effective technologies. Given the documented risk tolerance differences in different patient populations, an evidence generation system is needed that could be used to develop rational policies that would be specific for each clinical situation.

In order for this system to work, a comprehensive post-market environment is needed to constantly provide reliable surveillance for safety while also fostering the generation of new evidence about the risks and benefits for intended use; the comparative effectiveness relative to alternative approaches to therapy; and the cost effectiveness and value of the product. The past disaggregated approach in the US has left major holes in the information needed for rational policy and created a system that cannot generate information that is needed for a reasonable cost.

Major changes in computation, analysis and policy are putting the elements of a comprehensive system into place. Critically for our national philosophy, the system is federated, not centralized, and it is subject to controls at the individual, local and regional levels. The FDA's Sentinel System for drugs and biologics, PRISM for vaccines and the NeST for devices use various combinations of claims data, EHR data and registries to produce a tapestry of information. This is now bolstered by PCORI's PCORnet and the Clinical and Translational Science Awards to bring in the capability of prospective trials and observational studies linking these data sources to health systems and providers.

10:00am-10:30am

Break/Posters/Exhibits 220BC

10:30am-Noon

Symposia & Workshops

Control Yourself: Guidance for the Application and Reporting of Self-Controlled Study Designs in Pharmacoepidemiology [1] 517CD

Suzanne M Cadarette, Mina Tadrous, J AC Delaney, Joshua J Gagne, Shirley V Wang, Heather Whitaker, Jesper Hallas, Malcolm Maclure. (Canada)

Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year [2] 520AD

Michael D Nguyen, Steven Bird, Efe Eworuke, David Moeny, Lockwood Taylor, Judith Maro. (United States)

The Non-Pharmacological Basis of Regulatory Decision-Making [3] 520BE

Syed Rizwanuddin Ahmad, FISPE, FCP, Jerome Avorn, June M. Raine, Hubert Leufkens, Byung-Joo Park, Hisham S Aljadhey. (United States)

Methodological Challenges and Opportunities of Conducting Pharmacoepidemiologic Research in Medically Complex Populations: The Case of Nursing Homes [4] 520CF

Andrew R Zullo, Daniela C Moga, Danijela Gnjidic, Jenny Wei, Kate Lapane. (United States)
Moderators: CHAIR PENDING

It Takes a Village: Raising a Global Community of Pharmacoepidemiologists Through High Quality Education [5] 524AB

Soko Setoguchi, Yea-Huei Kayo-Yang, Brian Strom, Paul Stang, Daniel Horton, Tobias Gerhard, Susana Perez-Gutthann, Bert Leufkens, Simone Pinheiro. (United States)





Noon-1:30pm

Lunch/Poster Session A/Exhibits

220BC

Committee Meetings *(open to all participants, lunch available)*

- ◆ Development/Membership 522BC
- ◆ Fellowship & Awards 522A
- ◆ Finance 525B
- ◆ Public Policy 525A

Roundtable Discussion *(Reserved table)*

220BC

To foster the ability of more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting two roundtable discussions – a luncheon roundtable on Monday and a breakfast roundtable on Tuesday. There will be NO formal presentation made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

Hosts: **Jessica Franklin and Shirley Wang**

Topic: Evaluating the robustness of observational healthcare database studies via large-scale replication.

Robustness of observational findings requires that 1) the data and study design are sufficient to answer the question of interest and 2) reporting of specific study implementation parameters are transparent. We discuss strategies for evaluating these two criteria in ongoing projects that focus on replicating several randomized trials with observational healthcare databases and replicating a large sample of high-impact published database studies.

12:15pm-1:15pm

Spotlight Poster Session

516BC

- ◆ Asian Pharmacoepidemiology Network (AsPEN)
- ◆ Biologics & Biosimilars
- ◆ Databases
- ◆ Vaccines

1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Opening Doors to Data - Linkage or Comparison

517CD

Moderators: **Michelle Jonsson Funk & Olaf Klungel**

1:30 PM

Medicare Supplemental Data: Is Something Missing? [6]

Sarah R Hoffman, Jessica C Young, Virginia Pate, Michele Jonsson Funk. (United States)

1:45 PM

Using the CPRD and HES Linked Datasets to Derive the Burden of Medically Attended Norovirus-Attributable Acute Gastroenteritis in England [7]

Thomas Verstraeten, Tom Cattaert, John Harris, Ben Lopman, Clarence Tam, Germano Ferreira. (Belgium)

2:00 PM

Feasibility Analysis of Mortality Outcomes in the Sentinel Distributed Database [8]

Richard S Swain, Lockwood G. Taylor, Tiffany S Woodworth, Candace C Fuller, Andrew B Petrone, Talia J Menzin, Nicole R Haug, Darren Toh, Andrew D Mosholder. (United States)

2:15 PM

Curating Inpatient Medication Use Data from a Hospital Network Electronic Medication Administration Record (eMAR) System: Lessons from the Sentinel System about Expanding Drug Safety Surveillance Potential [9]

Jennifer R Popovic, Candace C Fuller, Caren Spencer-Smith, Jason Hickok, Karla M Miller, Russell Poland, Denise M Boudreau. (United States)

2:30 PM

Expansion of the US FDA Sentinel System to Inpatient Blood Transfusion Data from Hospital Corporation of America: New Surveillance Options [10]

Candace C Fuller, Meghan A Baker, Caren Spencer-Smith, Steven A Anderson, Carolyn Balsbaugh, Hayley Burgess, Howard Chazin, Pamela Clark, Lesley H Curtis, Richard Forshee, Jason Hickok, Mikhail Menis, Karla M Miller, Manette Niu, Joyce Obidi, Wendy Paul, Russell Poland, Jennifer Popovic, Robert Rosofsky, Craig Zinderman, Azadeh Shoabi. (United States)

2:45 PM

An Approach to Linkage of Registry Data to Medicare Claims Using Multiple Non-Unique Identifiers [11]

Fenglong Xie, Lang Chen, Hui Feng Yun, Jeffrey Greenberg, Jeffrey R Curtis. (United States)





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

The "ACE" of BRACE

520AD

Moderators: **Elaine Morrato & Terri Madison**

1:30 PM

Intervention to Increase Appropriate Anticoagulation in Patients with Atrial Fibrillation [12]

Shirley V Wang, James R Rogers, Yinzhu Jin, David Decicchi, Sara Z DeJene, Jean M Connors, David Bates, Michael A Fischer. (United States)

1:45 PM

Identification of Name Confusion Medication Errors in the Sentinel System [13]

Noelle M Cocoros, Kevin Haynes, Chi-Ming Tu, Jo Wyeth, Fang Tian, Yulan Ding, Elizabeth Dee, Michael Nguyen, Darren Toh. (United States)

2:00 PM

A Review of Cross-Sectional Survey Studies Evaluating Risk Minimisation Measures in European Union (EU) Using the EU Electronic Register of Post-Authorisation Studies [14]

Pareen Vora, Esther Artime, Montse Soriano-Gabarro, Nawab Qizilbash, Alex Asimwe. (Germany)

2:15 PM

Novel Method for Rapid Risk Minimization Evaluation in Electronic Health Data--Assessment of MHRA's 2012 Label Change for Proton Pump Inhibitors (PPIs) [15]

Rachel E Sobel, William Blackwell, David M. Fram, Andrew J. Bate. (United States)

2:30 PM

Determinants for Healthcare Professional to Take Action on Direct Healthcare Professional Communications (DHPCS) [16]

Peter Mol, Sieta de Vries, Petra Denig, on behalf of SCOPE work package 6. (Netherlands)

2:45 PM

Potential Pitfalls in Using the Beers Criteria to Identify Potentially Inappropriate Medications in the Context of an Index Event [17]

Jennifer L. Lund, Sharon Peacock Hinton, Til Sturmer. (United States)

ALMOST 1 IN 3 PEOPLE DIE FROM CARDIOVASCULAR DISEASE | OUR SCIENTISTS WON'T ACCEPT THAT

According to the World Health Organization (WHO), cardiovascular diseases are the number one cause of death throughout the world. That's why we're investigating treatments to manage heart failure, as well as prevent myocardial infarctions and strokes. Which heart patient wouldn't love to benefit from that? To find out how our innovations are helping to change lives for the better, visit www.bayer.com/cvd1902.

BAYER
Science For A Better Life





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Mapping the Epidemic of Opioids

520BE

Moderators: Tamar Lasky, FISPE, & Eileen E. Ming

1:30 PM

Trajectories of Buprenorphine Opioid Agonist Therapy During Pregnancy in a Large Medicaid Program [18]

Wei-Hsuan Lo-Ciganic, Julie M Donohue, Joo Yeon Kim, Elizabeth E Krans, David Kelley, Everette James, Marian Jarlenski. (United States)

1:45 PM

Risk Factors for Concurrent Non-Medical Opioid and Sedative Use in Youth: Results from a National Study in the US [19]

Vicki Osborne, Sadaf Milani, Catherine W Striley, Linda B Cottler. (United States)

2:00 PM

Resident and Facility-Level Correlations of Long-Term Opioid Use in United States Nursing Homes [20]

Jacob N Hunnicutt, Christine Ulbricht, Anne Hume, Kate Lapane. (United States)

2:15 PM

A Close Link Between Opioid Related Mortality and Medicines Commonly Used for Chronic Pain [21]

Teng-Chou Chen, Li-Chia Chen, Roger David Knaggs. (United Kingdom)

2:30 PM

Assessment of Prior Opioid Tolerance Among New Users of Fentanyl Transdermal System in the Sentinel System [22]

Noelle M Cocoros, Marc Robert Larochelle, Jennifer Popovic, Andrew Petrone, Cynthia Kornegay, Jing Ju, Judith A Racoosin. (United States)

2:45 PM

Concomitant Use of Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder and Benzodiazepines: Using the Prescription Behavior Surveillance System [23]

Yanmin Zhu, D. Tyler Coyle, Mohamed Mohamoud, Esther Zhou, Efe Eworuke, Catherine Dormitzer, Judy Staffa. (United States)

Pfizer
Working together for a healthier world

Committed to bringing therapies to people that extend and significantly improve their lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Pfizer Epidemiology is proud to support the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management in Montréal, Canada.





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Quality of Care: Provider and Policy Considerations

520CF

Moderators: **Ursula Kirchmayer & Sarah-Jo Sinnott**

1:30 PM

Medications Prescribed, Stopped and Modified at Hospital Discharge and Filled Medications in the Community: Impact of Failure to Follow In-Hospital Medication Changes on Adverse Health Outcomes 30-Days Post Hospital Discharge [24]

Daniala L. Weir, Aude Motulsky, Robyn Tamblin. (Canada)

1:45 PM

Quality of Pharmacologic Care by Physicians, Nurse Practitioners and Physician Assistants in the United States [25]

Irene B. Murimi, Shiyin Jiao, Randall S. Stafford, Ramin Mojtabei, G. Caleb Alexander. (United States)

2:00 PM

The Association Between Workarounds and Medication Administration Errors in Barcode-Assisted Medication Administration [26]

Katja Taxis, Willem VanderVeen, David Bates, Johannes DeGier, Patricia VanderBemt. (Netherlands)

2:15 PM

Did a Policy to Ease the Prescribing Restrictions for Lapatinib (L) as Second-Line HER2-Positive Metastatic Breast Cancer (HER2+MBC) Increase Initiation Rates? [27]

Benjamin Daniels, Nehmat Houssami, Sarah J Lord, Belinda E Kiely, Sallie-Anne Pearson. (Australia)

2:30 PM

Interrupted Time Series Evaluating the Impact of Regulatory Action on Nitrofurantoin Prescribing Rates [28]

Katherine Donegan, Tracy J Turc-Milloy, Arlene Gallagher, Anthony Matthews. (United Kingdom)

2:45 PM

Reimbursement Drug Policy Induced Denominator Selection Bias [29]

Anat Fisher, Ken Basset, Greg Carney, Malcolm Maclure, Colin R Dormuth. (Canada)

Vaccines

524AB

Moderators: **Robert Chen, FISPE, & Anne Butler**

1:30 PM

Developing a Mother-Infant Cohort in Sentinel's PRISM Program as a Resource to Monitor the Safety of Vaccine Use During Pregnancy [30]

Alison Tse Kawai, Susan Andrade, Robert Rosofsky, Lauren Zichittella, Katherine Haffenreffer, Cheryl Walraven, Kevin Haynes, Mano Selvan, Anita M. Loughlin, Azadeh Shoaibi, Steven Anderson, Grace Lee. (United States)

1:45 PM

Narcolepsy and Adjuvanted Pandemic A(H1N1) 2009 Vaccines: A Global Investigation [31]

Daniel Weibel, Miriam Sturkenboom, Steven Black, Maria de Ridder, Caitlin Dodd, Jan Bonhoeffer, Angela Gentile, Norberto Giglio, Vanesa Castellano, Jeffrey C. Kwong, Karen Cauch-Dudek, Diana Juhasz, Michael Campitelli, Wan-Ting Huang, Maria Giner-Soriano, Rosa Morros, Silvia Perez-Vilar, Javier Diez-Domingo, Lawrence W. Svenson, Salah Mahmud, Bruce Carleton, Lisen Arnheim-Dahlstroem, Lars Pedersen, Frank DeStefano, Tom T. Shimabukuro. (Netherlands)

2:00 PM

Enhanced Safety Surveillance for Influenza Vaccines in 2016/17: Second Year of Experience with a Passive Approach in EU [32]

Hélène Bricout, Anne Laure Chabanon, Sonja Banga, Tim Caroe, Karina Butler. (France)

2:15 PM

Implementing Near-Real Time Vaccine Safety Surveillance Using the Clinical Practice Research Datalink [33]

Andreia Leite, Nick Andrews, Sara Thomas. (United Kingdom)

2:30 PM

Timing and Predictors of Severe Rotavirus Gastroenteritis Among Unvaccinated Infants in Low- and Middle-Income Countries [34]

Joann F Gruber, Sylvia Becker-Dreps, Michael G Hudgens, M. Alan Brookhart, James C. Thomas, Michele Jonsson Funk. (United States)

2:45 PM

Methods for Evaluating the Safety of Concomitant Vaccines [35]

Shirley V Wang, Abdurrahman Abdurrob, Julia Spoendlin, Ned Lewis, Sophia R Newcomer, Bruce Fireman, Matthew F Daley, Jason M Glanz, Jonathan M Duffy, Eric Weintraub, Martin Kuldorff. (United States)





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Pediatrics

524C

Moderators: **Jonathan L. Slaughter & Stuart MacLeod**

1:30 PM

Antibiotic Prescribing During Infancy and Risk of Treated Airway Diseases Among Children Born in Denmark 2004-2012 [36]

Alan C Kinlaw, Henrik Toft Sørensen, Jennifer L Lund, Lars Pedersen, Julie L Daniels, Michael D Kappelman, Christina D Mack, Michael J Steiner, Trine Frøslev, Til Stürmer. (United States)

1:45 PM

Genome-Wide Association Study of Asthma Exacerbations in European Children Treated with Inhaled Corticosteroids [37]

Susanne J Vijverberg, Natalia Hernandez-Pacheco, Niloufar Farzan, Ben Francis, Carlos Flores, Maximilian Schieck, Patricia Soares, Leila Karimi, Roger Tavendale, Vojko Berce, Katja Repnik, Katia M Verhamme, Uros Potocnik, Somnath Mukhopadhyay, Munir Pirmohamed, Colin N Palmer, Steve W Turner, Daniel B Hawcutt, Michael Kabesch, Maria Pino-Yanes, Anke-Hilse Maitland-van der Zee. (Netherlands)

2:00 PM

17q21 Gene Variation Increases the Risk of Exacerbations in Asthmatic Children Treated with Inhaled Corticosteroids: A Meta-Analysis in the Multi-Ethnic Pica Consortium [38]

Niloufar Farzan, Susanne J Vijverberg, Anke-Hilse Maitland-van der Zee. (Netherlands)

2:15 PM

Risk of Incident Type 2 Diabetes Following Anticonvulsant-Mood Stabilizer Treatment Initiation in Publicly Insured U.S. Youth [39]

Mehmet Burcu, Julie M. Zito, Daniel J. Safer. (United States)

2:30 PM

Long-Term Adverse Drug Reactions in Pediatrics: Overview from MUSiC Project [40]

Carmen Ferrajolo, Gianluca Trifirò, Daniela Cimmaruta, Ugo Moretti, Laura Sottosanti, Francesco Rossi, Annalisa Capuano. (Italy)

2:45 PM

Oral Glucocorticoids and Incident Diabetes Mellitus and Hypertension in Children with Chronic Diseases [41]

Daniel B Horton, Fenglong Xie, Lang Chen, Melissa L Mannion, Brian L Strom, Jeffrey R Curtis, Timothy Beukelman. (United States)

3:00pm-3:30pm

Break/Posters/Exhibits

220BC

3:30pm-5:00pm

Symposia & Workshops

Fit-for-Purpose Non-Traditional RCTs. What Will It Take to Convince a Skeptical Community? [42]

517CD

Mary E Ritchey, Theodore C Lystig, Priscilla Valentgas, Emily S Brouwer, Daniel A Canos, Jennifer Lund, Bray Patrick-Lake, Jesse A Berlin, Nancy A Dreyer. (United States)

Sponsored by the Comparative Effectiveness Research (CER) Special Interest Group

Improving Screening of Adverse Drug Events in Large Electronic Healthcare Databases [43]

520AD

Anton Pottegård, Alec Walker, Solomon Iyasu, Martin Kulldorff, Michael Nguyen. (Denmark)

Therapeutic Monomania: Physician Preference-Based Instrumental Variables [44]

520BE

Jacques LeLorier, Sean Henessy, Sebastian Schneeweiss, Brian Potter. (Canada)

Medication Use and Criminality [45]

520CF

Bjorn Wettermark, Frank May, Bernice S Elger, Ameet Sarpatwari. (Sweden)

How to Measure the Impact of Pharmacovigilance Activities on Public Health? [46]

524AB

Helga Gardarsdottir, Agnes Kant, Marie Louise De Bruin, Christine E. Hallgren, Gerald Dal Pan, Dominic Way. (Netherlands)





5:00pm-6:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Design Tips for Observational and Final Data

517CD

Moderators: **Kourtney Davis & Helga Gardarsdottir**

5:00 PM

A Bias in the Evaluation of Bias Comparing Randomized Trials and Nonexperimental Studies [47]

Jessica M. Franklin, Sarah Dejene, Krista F. Huybrechts, Shirley V. Wang, Martin Kulldorff, Kenneth J. Rothman. (United States)

5:15 PM

Comparing Methods to Generalize Randomized Clinical Trials without Individual-Level Data for the Real-World Target Population [48]

Jin-Liern Hong, Michael Webster-Clark, Michele Jonsson Funk, Sara Dempster, Til Stürmer, Stephen R Cole, Robert LoCasale. (United States)

5:30 PM

Evaluation of Methods Estimating the Treatment Effect of a Clinical Trial in Comparison with an External Comparator [49]

Xiaofeng Zhou, Vera Frajzyngier, Ann Madsen, Rongjun Shen, Jamie Geier, Alexander M Walker. (United States)

5:45 PM

The Trend-in-Trend Research Design for Studying the Effects of Treatments with Prominent Trends in Use [50]

Sean Hennessy, Xinyao Ji, Charles E. Leonard, Dylan Small. (United States)

6:00 PM

Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors (SSRIs): A Comparison of Study Designs [51]

Katsiaryna Bykov, Sebastian Schneeweiss, Robert J Glynn, Murray A Mittleman, Joshua J Gagne. (United States)

6:15 PM

Validity of Strategies for Sampling Comparison Cohorts from General Population Registries in Matched Cohort Studies [52]

Uffe Heide-Joergensen, Johnny Kahlert, Henrik T Sørensen, Lars Pedersen. (Denmark)

Using Natural Language Processing

520AD

Moderators: **David Dore & Xiaojuan Li**

5:00 PM

Utilizing Natural Language Processing to Examine the Risk of Arthralgia Between Vedolizumab and Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease [53]

Tzu-Chieh Lin, Tianrun Cai, Gwendolyn Kane-Wanger, Andrew Cagan, Shawn N. Murphy, Ashwin Ananthakrishnan, Katherine P. Liao. (United States)

5:15 PM

Extraction of Breast Cancer Biomarker Data from Narrative Clinical Documents Using Natural Language Processing [54]

Jinghua He, Fangqian Ouyang, George Eckert, Joel Martin, Abby Church, Kristina Knapp, Paul Dexter. (United States)

5:30 PM

Detecting and Encoding Mentions of Suspected Adverse Events in Twitter Using Natural Language Processing [55]

Johan Ellenius, Lucie M. Gattepaille, Sara Vidlin, Carrie Pierce, Tomas Bergvall. (Sweden)

5:45 PM

Extraction of Adverse Event Severity Information from Clinical Narratives Using Natural Language Processing [56]

Rebecka Jacobsson, Tomas Bergvall, Lovisa Sandberg, Johan Ellenius. (Sweden)

6:00 PM

Characterization of Potential Serious Allergic Reactions Using Data from Natural Language Processing (NLP) within an Electronic Health Record (EHR) Based System [57]

Florence T Wang, Jennifer Song, Nancy D Lin. (United States)

6:15 PM

Using Natural Language Processing to Examine the Media Uptake of a Study on Isotretinoin Safety [58]

Hossein Mohammadhassanzadeh, Samuel A Stewart, Robyn Traynor, Susan Alexander, Ingrid S Sketris. (Canada)



5:00pm-6:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Is It Worth It: Cost Considerations in Medication Use

520BE

Moderators: **Silvia Alessi-Severini & Bjorn Wettermark**

5:00 PM

Reduced Out-of-Pocket Costs and Medication Adherence - A Population-Based Study [59]

Shenzhen Yao, Lisa Lix, Yvonne Shevchuk, Gary Teare, David F Blackburn. (Canada)

5:15 PM

Cost Predictors Among Hospitalized Pediatric Patients with Pneumonia [60]

Zachary R Babcock, Aisling R Caffrey. (United States)

5:30 PM

Examining the Health Care Utilization and Costs among Elderly Patients with Chronic Obstructive Pulmonary Disease in The United States [61]

Qisu Zhang, Lin Xie, Allison Keshishian, Yiyun Lin, Onur Baser. (United States)

5:45 PM

Impact of Generic Entry on Imatinib Prices in a Large Commercial Insurance Database [62]

Ashley L. Cole, Stacie B. Dusetzina. (United States)

6:00 PM

Effect of Direct-To-Customer Advertising (DTCA) on Statin Use in the United States [63]

Irene B. Murimi, Hsien-Yen Chang, Matthew Daubresse, Dima M. Qato, Sherry L. Emery, G. Caleb Alexander. (United States)

6:15 PM

Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second-Line Therapy [64]

Hossein Borghaei, Mayank Gandhi, Annie Guerin, Raluca Ionescu-Iltu, Irina Pivneva, Sherry Shi, Yeun Mi Yim. (Canada)



Better Health, Brighter Future



Takeda is proud to sponsor the 2017 ICPE.



For more than 230 years, we have been serving society with innovative medicines and helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

We continue to transform the future of healthcare by unifying our strengths around the world. We are a diverse organization committed to working with local communities to fully understand their needs and deliver industry-leading solutions with a sense of urgency, dedication and unparalleled efficiency.

Our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world.

Copyright 1995-2017 Takeda Pharmaceutical Company Limited. All rights reserved. [To learn more, visit us at Takeda.com.](http://Takeda.com)



5:00pm-6:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease

520CF

Moderators: **Vincent Lo Re III, FISPE, & Quazi Ataher**

5:00 PM

Incidence Rates of Neurotropic-Like and Viscerotropic-Like Diseases in Mexico, Brazil and Malaysia [65]

Carine Cohen, Edson Moreira, Homero Nañez, Nachi Jeyaseelan, Catherine Huoi, Joshua Nealon, Elsa Sarti, Esteban Puentes-Rosas, Annick Moureau, Alena Khromava, On behalf of the Study Team. (France)

5:15 PM

Determination of Days Since Last Active Medical Support for Chronic Lung Disease, Associated with Respiratory Syncytial Virus Hospitalizations in Infants [66]

Yoonyoung Choi, Cody Meissner, Haesuk Park, Babet Brumback, Almut G Winterstein. (United States)

5:30 PM

Income-Driven Food Insecurity Drives Treatment Non-Adherence and Virologic Failure in HIV/HCV-Coinfected Individuals [67]

Celline C Almeida-Brasil, Erica E Moodie, Marina B Klein, Joseph Cox. (Canada)

5:45 PM

Cumulative Viral Load and Incident Myocardial Infarction: Handling the Initiation of Antiretroviral Therapy [68]

Robin M Nance, Heidi M Crane, Susan R Heckbert, Daniel R Drozd, Matthew Budoff, Matthew Feinstein, Jessica Williams-Nguyen, Greer Burkholder, Michael J Mugavero, William C Mathews, Richard D Moore, Joseph J Eron, Peter W Hunt, Elvin Geng, Maria E Perez-Trejo, Michael S Saag, Mari M Kitahata, Joseph A Delaney. (United States)

6:00 PM

Respiratory Effect of Beta-Blockers in People with Asthma and Cardiovascular Disease: Population Based Nested Case Control Study [69]

Daniel R Morales, Brian J Lipworth, Peter T Donnan, Cathy Jackson, Bruce Guthrie. (United Kingdom)

6:15 PM

Severity of COPD in New Users of Acclidinium Bromide and Other COPD Medications: A Population-Based Study in the United Kingdom and Denmark [70]

Cristina Rebordosa, Jordi Castellsague, Nina Kristiansen, Anton Pottegård, Estel Plana, Jaume Aguado, Esther Garcia-Gil, Jesper Hallas, Susana Perez-Gutthann. (Spain)

(Cardio) Vascular Safety Outcomes

524AB

Moderators: **Soko Setoguchi, FISPE, & G. Caleb Alexander**

5:00 PM

Sulfonylureas and the Risk of Adverse Cardiovascular Events Among Patients with Type 2 Diabetes: A Population-Based Cohort Study [71]

Kristian B Filion, Laurent Azoulay, Hui Yin, Oriana H Yu, Samy Suissa. (Canada)

5:15 PM

Comparative Cardiovascular Safety of Strontium Ranelate and Bisphosphonates Amongst Patients with no Contraindications: a Multi-database Study in our European Countries by the EU-ADR Alliance [72]

M Sanni Ali, Klára Berencsi, Karine Marinier, Nicolas Deltour, Samuel Hawley, Lars Pedersen, Peter Rijnbeek, R G Duijnhoven, Johan Van der Lei, Francesco Lappi, Monica Simonetti, Cristina Reyes-Reyes, Miriam Sturkenboom, Daniel Prieto-Alhambra. (United Kingdom)

5:30 PM

Cardiovascular Safety of Vildagliptin: Pan-European Non-Interventional Safety Study [73]

Rachael Williams, Frank de Vries, Carmen Serban, Sandra Lopez, Wolfgang Kothny, Raymond Schlienger. (United Kingdom)

5:45 PM

Cardiovascular Safety in Users of Different Combined Oral Contraceptives - Final Results from the INAS-SCORE Study [74]

Klaas Heinemann, Jürgen Dinger, Thai Do Minh, Sabine Moehner, Christian Franke. (Germany)

6:00 PM

Cardiovascular Safety of OTC Strength Ibuprofen and Paracetamol in a Representative Sample of the French National Healthcare System Database [75]

Mai Duong, Régis Lassalle, Abdelilah Abouelfath, Cécile Droz, Nicholas Moore. (France)

6:15 PM

Azithromycin and Ventricular Arrhythmia: A National Claims-Based Cohort Study [76]

Yizhou Ye, E P Larrat, Aisling R Caffrey. (United States)





5:00pm-6:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Good & Bad of Diabetes Treatment

524C

Moderators: **Jodi Segal & Rosa Gini**

5:00 PM

HbA1c Response After Insulin Initiation in Patients with Type 2 Diabetes in Real-life: Identifying Distinct Subgroups [77]

Petra Denig, Job van Boven, Trynke Hoekstra, Giel Nijpels, Klaas Hoogenberg, Grigory Siderenkov. (Netherlands)

5:15 PM

How Much Does Persistence to Insulin Influence Glycemic Control? [78]

Julie C Lauffenburger, Wenhui Wei, Jennifer Lewey, Alan Chant, Saira Jan, Niteesh K Choudhry. (United States)

5:30 PM

Diabetic Ketoacidosis Risk After Initiating an SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitor: A Population-Based Cohort Study [79]

Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. (United States)

5:45 PM

Type of Beta-Blocker Use by Diabetes Status and Associated Outcomes in Older Nursing Home Residents After Acute Myocardial Infarction [80]

Andrew R Zullo, Michelle Hersey, Sadia Sharmin, Elliott Bosco, Lori A. Daiello, Yoojin Lee, W. John Boscardin, David Dore, Sei J Lee, Michael A Steinman. (United States)

6:00 PM

Comorbid Depression and All-Cause Mortality in Type 2 Diabetes: A 9-Year Cohort Study [81]

Carlotta Lunghi, Jean-Pierre Grégoire, Jocelyne Moisan, Line Guénette. (Canada)

6:15 PM

Pattern of Use of Incretin-Based Medicines in a Large Sample of the Italian General Population [82]

Giuseppe Roberto, Francesco Barone-Adesi, Francesco Giorgianni, Valeria Pizzimenti, Carmen Ferrajolo, Michele Tari, Roberto Da Cas, Marina Maggini, Stefania Spila Alegiani, Paolo Francesconi, Gianluca Trifirò, Elisabetta Poluzzi, Fabio Baccetti, Rosa Gini. (Italy)

12:15 PM

Australia's Herceptin Program (HP) for HER2+ metastatic breast cancer (HER2+MBC): Has it lived up to expectations? [94]

Benjamin Daniels, Belinda E Kiely, Nehmat Houssami, Sarah J Lord, Sallie-Anne Pearson. (Australia)

6:45pm-7:45pm

SPECIAL INTEREST GROUP MEETINGS (Open to all participants)

◆ Adherence	520AD	◆ Medical Devices	521C
◆ Asian Pharmacoepidemiology Network (AsPEN)	520BE	◆ Medications in Pregnancy	522A
◆ Benefit Risk Assessment, Communication and Evaluation (BRACE)	520CF	◆ Molecular Epi/Biomarkers/Pharmacogenetics	522BC
◆ Biologics and Biosimilars	518AB	◆ Oncology	521B
◆ Comparative Effectiveness Research (CER)	524AB	◆ Pediatrics	518C
◆ Drug Databases	525B	◆ Rare Disease	524C
◆ Utilization/Health Services Research	525A	◆ Vaccines	521B

7:30pm

PDS Editorial Board (By Invitation)

514AB





MAIN CONFERENCE | TUESDAY, AUGUST 29

6:00am-7:00am

Mindful Yoga

513F

Start your day with balance, flexibility, strength and awareness!

Ideally bring your own sticky mat, but if you don't have one, some will be available. Miles Braun, FISPE, a former ISPE Board member, and registered teacher (Yoga Alliance) will lead the sessions.

Meet at 6:30am

Fun Runs

Corner of Avenue Viger & Rue de Bleury (northwest corner of the Palais des Congrès, near the main entrance)

- ◆ 5-miles in the Old Port of Montreal
- ◆ 3-miles in the Old Port

7:00am-8:00am

Roundtable Discussion *(Reserved table)*

220BC

To foster the ability of more junior participants to network and first-timers to meet others attending the ICPE, ISPE is hosting two roundtable discussions – a luncheon roundtable on Monday and a breakfast roundtable on Tuesday. There will be NO formal presentation made at the roundtables. The objectives are discussion, information exchange, and networking. Seating is limited; first-come, first-served.

Host: **Eileen Ming**

Topic: Building a Consultancy in the Pharmacoepidemiology Industry

7:00am-8:00am

Poster Session B Set-up

220BC

Continental Breakfast

220BC

7:00am-8:00am *(open to all participants)*

Digital Epidemiology SIG

525A

Asian DURG Meeting

522BC

7:00am-5:00pm

Speaker Ready Room

523A

7:00am-6:00pm

Registration

FOYER 517 EAST (FIFTH FLOOR)

7:30am-6:00pm

Exhibits/Posters

220BC

DEPARTMENT OF CLINICAL EPIDEMIOLOGY IN AARHUS, DENMARK

Better clinical care through research

VISIT US AT BOOTH # 21





8:00am-9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Indices

517CD

Moderators: **Nicole Pratt & Anton Pottegard**

8:00 AM

A Dynamic Risk Prediction Model for Hospital Associated Hypokalemia: Model Development and Validation [344]

Yan Li, Benjamin Staley, Carl Henriksen, Dandan Xu, Gigi Lipori, Babette Brumback, Thomas E. Johns, Almut G. Winterstein. (United States)

8:15 AM

NORRISK 2: A Norwegian Risk Model for Acute Cerebral Stroke and Myocardial Infarction [345]

Randi Selmer, Jannicke Igland, Inger Ariansen, Aage Tverdal, Inger Njølstad, Kari Furu, Grethe S. Tell, Tor Ole Klemsdal. (Norway)

8:30 AM

Risk Adjustment in Total Knee Arthroplasty: Are We Using the Correct Index? [346]

Katherine Etter, Gary Chung, Andrew Yoo. (United States)

8:45 AM

Developing a Comorbidity Risk Prediction Model for Older Adults with Indolent Non-Hodgkin Lymphoma [347]

Laura Hester, M. Alan Brookhart, Til Stürmer, Jennifer Lund. (United States)

9:00 AM

Development and Validation of a Pediatric Asthma Control Index Using Administrative Data [348]

François Després, Francine M. Ducharme, Amélie Forget, Sze Man Tse, Fatima-Zohra Kettani, Lucie Blais. (Canada)

9:15 AM

Using Machine Learning to Develop a Prediction Model to Identify Patients with Hemophilia A in an Administrative Claims Database [349]

Jennifer L Lyons, Vibha Desai, Jamileh Jemison, Yaping Xu, Greg Ridgeway, William Finkle, Paul G Solari, Sean D Sullivan, Stephan Lanes. (United States)

Opioid Policy: Let's Put a Lid on It

520AD

Moderators: **Brian Bateman & Maire O'Dwyer**

8:00 AM

The Impact of Tamper-Deterrent Long-Acting Oxycodone on Long-Acting Opioid Prescribing Rates Across Canada [350]

Tara Gomes, Andrea Mastorakos, Michael Paterson, Ingrid Sketris, Patricia Caetano, David Henry. (Canada)

8:15 AM

Opioid Switching After Introduction of a Tamper-Resistant Oxycodone Formulation in Australia: A Population-Based Study [351]

Andrea L Schaffer, Nicholas A Buckley, Timothy A Dobbins, Louisa Degenhardt, Briony Larance, Sallie-Anne Pearson. (Australia)

8:30 AM

Tramadol Classification Had No Impact on Other Opioids Utilisation in England [352]

Teng-Chou Chen, Li-Chia Chen, Roger David Knaggs. (United Kingdom)

8:45 AM

Impact of Risk Reduction Initiatives on Rates of Opioid Overdose [353]

Sascha Dublin, Michael Von Korff, Kathleen Saunders, Rod L Walker, Manu Thakral, Karen J Sherman, Evette J Ludman, Ryan N Hansen, Michael Parchman, Susan M Shortreed. (United States)

9:00 AM

Financial Conflicts of Interest and the Centers for Disease Control and Prevention's 2016 Guideline for Prescribing Opioids for Chronic Pain [354]

Dora H Lin, Eleanor Lucas, Irene B. Murimi, Andrew Kolodny, G. Caleb Alexander. (United States)

9:15 AM

Evaluation of the Fentanyl Patch-for-Patch Program in Ontario, Canada [355]

Mina Tadrous, Simon Greaves, Diana Martins, Komail Nadeem, Samantha Singh, Chris Auger, Tara Gomes. (Canada)





8:00am-9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Un mélange d'idées (A Mixture of Good Ideas)

520BE

Moderators: **Kevin Haynes, FISPE & Jaclyn Bosco**

8:00 AM

Risk of Trauma-Related Hospitalisation and Use of H1 Antihistamines or Anticholinergic Drugs [356]

Julien Bezin, Yohann Mansiaux, Ana Jarne, Pernelle Noize, Antoine Pariente. (France)

8:15 AM

Pregabalin Use Early in Pregnancy and the Risk of Major Congenital Malformations [357]

Elisabetta Paterno, Brian T Bateman, Krista F. Huybrechts, Sarah C MacDonald, Jacqueline M Cohen, Rishi J Desai, Alice Panchaud, Helen Mogun, Page B Pennell, Sonia Hernandez-Diaz. (United States)

8:30 AM

Fate of Clinical Drug Trials [358]

Cornelis A van den Bogert, Patrick C. Souverein, Cecile T Brekermans, Susan W Janssen, Gerard Koëter, Hubert G Leufkens. (Netherlands)

8:45 AM

A Randomized Clinical Trial Using FDA's Sentinel Infrastructure: An Analysis Assessing Feasibility [359]

Crystal Garcia, Noelle Cocoros, Kevin Haynes, Sean Pokorney, Hussein Al-Khalidi, Sana Al-Khatib, Jeffrey Brown, Jennifer Goldsack, Thomas Harkins, Hannah Katcoff, Nancy Lin, Debbe McCall, Vinit Nair, Lauren Parlett, Ryan Saliga, Cheryl Walraven, Christopher Granger, Richard Platt. (United States)

9:00 AM

Study of Mirabegron and Cardiovascular Outcomes Using the Publicly Available Mini-Sentinel Protocol [360]

Jason Simeone, Beth L. Nordstrom, Kwame Appenteng, Samuel Huse, Milbhor D'Silva. (United States)

9:15 AM

Predictors of Medication Adherence Among Family Members: Identifying the Effect of Social Reinforcement Using Routinely-Collected Data [361]

Julie C Lauffenburger, Nazleen F Khan, Gregory Brill, Nitesh K Choudhry. (United States)

Pregnancy General

520CF

Moderators: **Mette Norgaard & Jennita Reefhuis**

8:00 AM

Birth Outcomes Following Pregnancy Exposure to Adalimumab: The OTIS Autoimmune Diseases in Pregnancy Project [362]

Christina D Chambers, Diana L Johnson, Ronghui Xu, Yunjun Luo, Margaret P Adam, Stephen R Braddock, Luther Robinson, Keith Vaux, Kenneth Lyons Jones. (United States)

8:15 AM

Periconceptional NSAID Use and the Risk of Spina Bifida [363]

Daina B Esposito, Samantha E Parker, Allen A Mitchell, Sarah C Tinker, Martha M Werler. (United States)

8:30 AM

Beta Blocker Use in Pregnancy and the Risk of Congenital Malformations: A Study from the International Pregnancy Safety Study (InPreSS) Consortium [364]

Brian T Bateman, Uffe Heide-Jørgensen, Kari Furu, Mika Gissler, Sonia Hernández-Díaz, Krista F Huybrechts, Helle Kieler, Mette Nørgaard, Johan Reutfors, Helga Zoega. (United States)

8:45 AM

Trends of Opioid Utilization During Pregnancy and Incidence of Neonatal Abstinence Syndrome [365]

Chintan Dave, Yanmin Zhu, Xi Wang, Almut Winterstein, Adel Alrwisan, Abraham Hartzema. (United States)

9:00 AM

Maternal Exposure to Levothyroxine and the Risk of Congenital Malformations [366]

Arendse Torp-Pedersen, Karin Gíden, Espen Jimenez-Solem, Henrik E. Poulsen, Jon T. Andersen. (Denmark)

9:15 AM

The Safety of Gabapentin in Pregnant Women with Regard to the Risk of Congenital Malformations [367]

Elisabetta Paterno, Sonia Hernandez-Diaz, Krista F Huybrechts, Jacqueline M Cohen, Rishi J Desai, Helen Mogun, Brian T Bateman. (United States)





8:00am-9:30am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Cancer 1

524AB

Moderators: **Andrew Roddam & Joshua Brown**

8:00 AM

The Risk of Malignancy Associated with Use of Tumor Necrosis Factor Inhibitors in Childhood [368]

Timothy Beukelman, Fenglong Xie, Lang Chen, Daniel B Horton, James D Lewis, Ronac Mamtani, Melissa Mannion, Kenneth G Saag, Jeffrey R Curtis. (United States)

8:15 AM

Does Proton-Pump Inhibitor Use Diminish Capecitabine Efficacy in Advanced Cancer Patients? [369]

Jeff Y. Yang, Hanna K. Sanoff, Robert S. Sandler, Til Stürmer, Michele Jonsson Funk, Jennifer L. Lund. (United States)

8:30 AM

Hypothyroidism and Breast Cancer Recurrence: A Danish Population-Based Cohort Study [370]

Anne Mette Falstie-Jensen, Anders Kjærsgaard, Ebbe L Lorenzen, Jeanette Dupont Jensen, Kristin Valborg Reinertsen, Olaf M Dekkers, Marianne Ewertz, Deirdre P Cronin-Fenton. (Denmark)

8:45 AM

The Impact of Hospital-Diagnosed Overweight or Obesity on Cancer Risk: A Nationwide Danish Cohort Study [371]

Sigrid B Gribsholt, Deidre C Fenton, Katalin Veres, Dóra K Farkas, Anne G Ording, Bjørn Richelsen, Henrik T Sørensen. (Denmark)

9:00 AM

Use of Low-Dose Aspirin and Mortality After Prostate Cancer: A Nationwide Cohort Study [372]

Charlotte Skriver, Christian Dehrendorff, Michael Borre, Klaus Brasso, Signe B Larsen, Susanne O Dalton, Mette Nørgaard, Anton Pottegård, Jesper Hallas, Henrik T Sørensen, Søren Friis. (Denmark)

9:15 AM

Statin Use and Survival After Ovarian Cancer [373]

Merete K Hansen, Freija Verdoodt, Susanne K Kjaer, Anton Pottegård, Søren Friis, Christian Dehrendorff. (Denmark)

It's a Bloody Mess

524C

Moderators: **Wei Zhou, FISPE, & Patricia van den Bemt**

8:00 AM

Self-Controlled Assessment of Thromboembolic Events (TEEs) Risk Following Intravenous Immune Globulin (IGIV) [374]

Eric M Ammann, Elizabeth A Chrischilles, Ryan M Carnahan, Bruce H Fireman, Candace C Fuller, Marin L Schweizer, Crystal Garcia, Madelyn Pimentel, Charles E Leonard, Meghan A Baker, Adam C Cuker, Enrique C Leira, Jennifer G Robinson, Scott K Winiecki. (United States)

8:15 AM

Nordic Country Patient Registry for Immune Thrombocytopenia (NCPRIPT): A Cohort of Patients with Chronic Immune Thrombocytopenia in Denmark, Sweden, and Norway [375]

Christian F Christiansen, Shahram Bahmanyar, Waleed Ghanima, Nickolaj R Kristensen, Scott Stryker, John Acquavella, Kara Cetin, Mette Nørgaard, Henrik Toft Sørensen. (Denmark)

8:30 AM

Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors (SSRI): Does Order Matter? [376]

Katsiaryna Bykov, Sebastian Schneeweiss, Robert J Glynn, Murray A Mittleman, Joshua J Gagne. (United States)

8:45 AM

Association of Antithrombotic Drug Use with Subdural Hematoma Risk [377]

Anton Anton Pottegård, Luis A. Rodríguez, Maja Hellfritsch, Frantz R. Poulsen, Bo Halle, Jesper Hallas, David Gaist. (Denmark)

9:00 AM

Factors Associated with Bleeding and Thrombotic Events in Anticoagulant Users During Hospitalization [378]

Albert R Dreijer, Marieke J Kruij, Jeroen Diepstraten, Rolf Brouwer, Frank W Leebeek, Patricia M van den Bemt. (Netherlands)

9:15 AM

Does Discontinuation of an Antihyperlipidemic Drug during Warfarin Therapy Increase the Risk of Venous Thromboembolism and Stroke? [379]

Charles E Leonard, Colleen M Brensinger, Warren B Bilker, Stephen E Kimmel, Heather J Whitaker, Sean Hennessy. (United States)

9:30am-10:00am

Break/Posters/Exhibits

220BC





10:00am-11:30am

Plenary Session: *Medical Product and Performance Evaluation Programs Using Distributed Data Sources*

517CD

Analyses of distributed data have played a significant role in a wide range of scientific disciplines. These developments in data science and in biostatistics, along with the need for rapid evaluation of safety and effectiveness, have led to real-world studies that have far greater power than individual center studies to detect unintended drug safety signals, by combining data from multiple repositories.

Two existing networks – the Canadian Network of Observational Drug Effect Studies (CNODES) and the US Sentinel System – analyze distributed data to respond to queries about drugs generated by Health Canada and the US Food and Drug Administration, respectively. In this Plenary Session, CNODES and Sentinel System investigators will compare and contrast the methods for distributed analyses of CNODES and the Sentinel System, and, regulators from Canada and the US will describe barriers and facilitators for generating queries and applying the study results to regulatory decision making.

Canadian CNODES and US FDA Sentinel System teams and representatives of the regulatory authorities will discuss the uses of distributed administrative, claims, and electronic health record data

to support medical product performance evaluation involving large segments of a nation’s population. They will focus on systems that leverage routinely collected administrative, claims, and electronic health record data from separate private organizations and/or government agencies. The experience of both countries will be used to illustrate the strengths and limitations of distributed systems, the pros and cons of standardizing on a common data model, the potential for developing reusable tools to analyze data, the efficiencies that reusable tools can enable, and opportunities for coordination between systems in different countries. Throughout the session, studies conducted by both teams will serve as illustrative examples.

Moderator: **Samy Suissa**, McGill University

Speakers:

Richard Platt, Harvard Medical School and Harvard Pilgrim Health Care Institute

Robert Platt, McGill University

Robert Ball, Deputy Director, Office of Surveillance and Epidemiology, CDER/FDA

Megan Beetle, Health Canada



Driving Innovation in Healthcare Analytics

BHE combines research expertise, powerful analytic solutions, and a variety of real-world datasets to provide actionable insights to the life science, provider, and payer communities

Visit us at booth #6 to learn about:

Instant Health Data (IHD)

- Generating Actionable Insights in Epidemiologic Studies
 - Analyses in Minutes Rather than Days or Weeks

Custom Research

- Observational Studies
- Statistical, Epidemiologic, and Economic Models

For more information contact Joseph Menzin or Jack Fuller
20 Fox Road / Waltham, MA, 02451 / (781) 290-0808

www.bhei.com





11:30am-1:00pm

Lunch/Poster Session B/ Exhibits

220BC

Committee Meetings

(Open to all participants, food available)

- ◆ Education 522BC
- ◆ Global Development 525A
- ◆ Publications & Communications 525B

11:45am-12:45pm

Spotlight Poster Session

516BC

- ◆ Adherence
- ◆ Molecular Epidemiology/
Biomarkers/Pharmacogenetics
- ◆ Oncology
- ◆ Pediatrics

1:00pm-2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Outsmarting Bias

517CD

Moderators: **Cynthia Girman, FISPE, & Krista Huybrechts, FISPE**

1:00 PM

Mitigating Bias Due to Measurement Error by Trimming [380]

Mitchell M Conover, Kenneth J Rothman, Til Stürmer, Michele Jonsson Funk. (United States)

1:15 PM

Instrumental Variables to Test for Unmeasured Confounding: *A Precautionary Note* [381]

M Sanni Ali, Sara Khalid, R H Groenwold, Gary S Collins, O H Klungel, Daniel Prieto-Alhambra. (United Kingdom)

1:30 PM

Finding Optimal Propensity Score Estimators Using a Modified Plasmode Simulation Framework [382]

Yuxi Tian, Martijn Schuemie, Marc A. Suchard. (United States)

1:45 PM

Using Causal Diagrams to Visualize Solutions for the Built-In Selection Bias of the HR in the Context of Time-Varying Exposures: An Example from Asthma Research [383]

Cristina Longo, Gillian Bartlett, Tracie A. Barnett, Tibor Schuster. (Canada)

2:00 PM

Quantifying the Impact of Differential Confounder Misclassification on the Choice of Lookback Period [384]

John G Connolly, Joshua J Gagne. (United States)

2:15 PM

Handling Missing Covariate Data and Changes in Exposure Status in Electronic Health Records: An Empirical Approach [385]

John R Tazare, Ian J Douglas, Elizabeth J Williamson. (United Kingdom)



1:00pm-2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Seeing Beyond the Data Horizon

520AD

Moderators: **Martin Kulldorff & Bradley Layton**

1:00 PM

Identifying Gastrointestinal Symptoms within an Electronic Health Record Database Among Patients with Type 2 Diabetes Treated with a GLP-1 Agonist [386]

Anthony P Nunes, John D Seeger, Stephen M Ezzy, Anita M Loughlin. (United States)

1:15 PM

Algorithms to Identify Pertussis in Four European Primary Care Databases - The ADVANCE Project [387]

Rosa Gini, Caitlin Dodd, Kaatje Bollaerts, Claudia Bartolini, Giuseppe Roberto, Consuelo Huerta, Elisa Martín-Merino, Talita Duarte Salles, Gino Picelli, Lara Tramontan, Giorgia Danieli, Benedikt Becker, Charlotte Switzer, Sonja Banga, Jorgen Bauwens, Daniel Weibel, Miriam Sturkenboom. (Italy)

1:30 PM

Identifying Patients with High Care-Continuity to Improve Validity of Comparative Effectiveness Research Using Electronic Health Records [388]

Kueiyu Joshua Lin, Daniel E Singer, Robert J Glynn, Sebastian Schneeweiss. (United States)

1:45 PM

Identifying Relapsing-Remitting Multiple Sclerosis (RRMS) in United States Integrated Delivery Network Healthcare Electronic Health Record Data [389]

Hoa V Le, Monica G Kobayashi, Aaron W Kamauu, John R Holmén, Christopher L Fillmore, Chi Thi Truong, Schiffo L Wong. (United States)

2:00 PM

Identifying Breast Cancer Stage and ER/HER2 Status in Claims Data Using Predictive Models [390]

Daniel C Beachler, Ruihua Yin, Philip T Cochetti, Jamileh Jemison, Kelsey Gangemi, Cynthia de Luise, Stephan Lanes. (United States)

2:15 PM

Practical Lessons Learned for Identification of Thromboembolic Events and Intravenous Immunoglobulin Exposure in the Sentinel Distributed Database [391]

Crystal J Garcia, Candace C Fuller, Elizabeth A Chrischilles, Madelyn Pimentel, Ryan M Carnahan, Bruce H Fireman, Marin L Schweizer, Charles E Leonard, Adam Cuker, Enrique C Leira, Jennifer G Robinson, Scott K Winiecki, Meghan A Baker, Eric M Ammann. (United States)

Adherence

520BE

Moderators: **Robert Gross, FISPE, & Julie Lauffenburger**

1:00 PM

Group-Based Trajectory Models: Assessing Adherence to Antihypertensive Medication in Older Adults in a Community Pharmacy Setting [392]

Paul Dillon, Susan M Smith, Paul Gallagher, Gráinne Cousins. (Ireland)

1:15 PM

Patterns of Adherence to Low-Dose Aspirin Treatment Using Group-Based Trajectory Modeling [393]

Aya Ajrouche, Candice Estellat, Yann De-Rycke, Florence Tubach. (France)

1:30 PM

Comparing Continuous and Binary Trajectory Modeling: An Example Using Real-World Statin Adherence Data [394]

Ryan P Hickson, Izabela E Annis, Ley A Killeja-Jones, Gang Fang. (United States)

1:45 PM

The Proportion of Patients Covered (PPC) Method [395]

Lotte Rasmussen, Morten Rix Hansen, Nicole Pratt, Libby Roughead, Jesper Hallas, Anton Pottegård. (Denmark)

2:00 PM

Determinants of Non-Adherence to Antidiabetic Drug Treatments: A Study Using a Psychosocial Theoretical Framework and Pharmacy-Based Adherence Measures [396]

Line Guénette, Arsène Zongo, Laurence Guillaumie, Sophie Lauzier, Lucie Blais, Jean-Pierre Grégoire, Jocelyne Moisan. (Canada)

2:15 PM

Examining Parental Adherence as a Predictor of Child SSRI Adherence in Pediatric Anxiety [397]

Greta A Bushnell, M Alan Brookhart, Bradley N Gaynes, Scott N Compton, Stacie B Dusetzina, Til Stürmer. (United States)





1:00pm-2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Vaccines - Use and Effectiveness

520CF

Moderators: **Patricia Saddier & Wan-Ting Huang**

1:00 PM

Building Capacity for Active Surveillance of Vaccine Adverse Events in Low and Middle-Income Countries [398]

Miriam Sturkenboom, Silvia Perez-Vilar, Daniel Weibel, Steven Black, Christine Maure, Jose Luis Castro, Pamela Bravo-Alcántara, Caitlin N Dodd, Silvana A Romio, Maria de Ridder, Swabra Nakato, Helvert F Molina, Varalakshmi Elango, Patrick L Zuber. (Netherlands)

1:15 PM

Multiyear Study on the Effect of Statins on the Effectiveness of Influenza Vaccines [399]

Hector S Izurieta, Yoganand Chillarige, Richard Forshee, Yandong Qiang, Yuqin Wei, Michael Wernecke, Douglas Pratt, Yun Lu, Wendy Xu, Michael Lu, Jeffrey A Kelman. (United States)

1:30 PM

Pneumococcal Vaccine Effectiveness and Its Interaction With Age: A UK Population Based Study in Older Adults [400]

Adam J Streeter, Jane A Masoli, Alessandro Blé, David Melzer, William E Henley. (United Kingdom)

1:45 PM

Patterns of Human Papillomavirus and Other Adolescent Vaccine Use in the United States [401]

Anne M. Butler, Nadja A Vielot, M. Alan Brookhart, Sylvia I Becker-Dreps, Jennifer S. Smith. (United States)

2:00 PM

Use of a Common Data Model Based Tool for Active Surveillance of Hepatic Decompensation in a Population Treated for Hepatitis C Infection [402]

Denise Oleske, Raghava Danwada. (United States)

2:15 PM

Geospatial Visualization of New Vaccine Adoption in the US, 2006-2015 [403]

Christopher Mast. (United States)

Macro- and Microvascular Outcomes in Diabetes...Mostly

524AB

Moderators: **Ken Hornbuckle, FISPE, & James Flory**

1:00 PM

Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events [404]

Dr. Antonios Douros, Oriana Hoi Yun Yu, Hui Yin, Kristian B. Filion, Laurent Azoulay, Samy Suissa. (Canada)

1:15 PM

Dose- and Drug-Specific Effects of Sulfonylureas on Hypoglycemia and Cardiovascular Events in Older Nursing Home Residents [405]

Andrew R Zullo, Sadia Sharmin, Lori A Daiello, Tingting Zhang, Theresa I Shireman. (United States)

1:30 PM

Cardiovascular Safety of Sodium Glucose Cotransporter-2 Inhibitors Versus Sulfonylureas in Patients with Type II Diabetes Mellitus [406]

Ghadeer Dawwas, Haesuk Park. (United States)

Student Award Recipient – Second Best Abstract Submitted by a Student/Post-Doc

1:45 PM

Greater and More Prolonged Exposure to Hyperglycaemia Is Associated with Increased Risk of Both Micro- and Macrovascular Complications [407]

Jetty A Overbeek, Rients P van Wijngaarden, Edith M Heintjes, Agata Schubert, Joris Diels, Huub Straatman, Ewout W Steyerberg, Ron M Herings. (Netherlands)

2:00 PM

Incretins and Diabetic Retinopathy: Real World Evidence for Safety [408]

Tiansheng Wang, Emily Gower, Seema Garg, Virginia Pate, Raquel Masegú, John Buse, Til Stürmer, Jin-liern Hong. (United States)

2:15 PM

Xanthine Oxidase Inhibitor Treatment and the Risk of Type 2 Diabetes in Patients with Gout [409]

Rishi J Desai, Daniel H Solomon, Jessica M Franklin, Julia Spöndlin, Goodarz Danaei, Seoyoung Kim. (United States)





1:00pm-2:30pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Strike Stroke Stricken -- Caridovascular Potpourri

524C

Moderators: **Zhen-Fang Lin & Dorothee Bartels**

1:00 PM

Antidepressants and the Risk of Hemorrhagic Stroke [410]

Wiebke Schaefer, Christina Princk, Nadine Schlie, Bianca Kollhorst, Tania Schink. (Germany)

1:15 PM

Resistant Hypertension and the Incidence of Myocardial Infarction, Stroke and Death: A UK Cohort Study 1995-2015 [411]

Sarah-Jo Sinnott, Liam Smeeth, Elizabeth Williamson, Ian J Douglas. (United Kingdom)

1:30 PM

Does Statin Exposure Prior to a Stroke Influence Survival and Institutionalization After Hospital Discharge? [412]

Matthew Alcusky, Anne L Hume, Kate L Lapane. (United States)

1:45 PM

Non-Steroidal Anti-Inflammatory Drugs and the Risk of Out-of-Hospital Cardiac Arrest: A Case Control Study in AmsteRdam REsuscitation STudies (ARREST) Registry [413]

Mohammad Bakhriansyah, Patrick C Souverin, Anthonius deBoer, Olaf H Klungel, Marieke T Blom, Hanno L Tan. (Netherlands)

2:00 PM

Effectiveness of Combinations of Drugs Recommended for Secondary Prevention After Acute Coronary Syndrome [414]

Julien Bezin, Olaf H Klungel, Régis Lassalle, Caroline Dureau-Pournin, Nicholas Moore, Antoine Pariente. (France)

2:15 PM

Cardiovascular Outcomes and Mortality in Patients with Concomitant Use of Bupropion and Risperidone [415]

Moa P Lee, Angela Y Tong, Joshua J Gagne. (United States)



In the right hands, the right data can make a world of difference. As a health services and innovation company, we believe researchers who have access to real-world data sets and analytics experts can uncover meaningful insights. Only then can evidence-based health care decisions be made. That's how well gets done.

Visit us at booth #25
optum.com/epidemiology





2:35pm-3:30pm

Annual Meeting of ISPE Members & Awards Ceremony

517CD

Annual Meeting

- ◆ Call to Order & Presidential Address
Kiyoshi Kubota, FISPE, President
- ◆ Financial Report
Tobias Gerhard, FISPE, Vice President, Finance
- ◆ New Business

Awards Ceremony

The Ronald D. Mann Best Paper Awards for Manuscripts Published in *Pharmacoepidemiology and Drug Safety* (PDS), 2016, Volume 25:

◆ Presenters

Brian L. Strom, FISPE, Editor-In-Chief
Sean Hennessy, FISPE, Regional Editor for the Americas
Hubert G M Leufkens, FISPE, Regional Editor for Europe
Byung Joo Park, FISPE, Regional Editor for Asia-Pacific and ROW

◆ First Prize

Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke. *Pharmacoepidemiol Drug Saf* 2016; 25; pages 151-160
James S. Floyd, Kerri L. Wiggins, Mark Christiansen, Sascha Dublin, William T. Longstreth, Nicholas L. Smith, Barbara McKnight, Susan R. Heckbert, Noel S. Weiss and Bruce M. Psaty

◆ Honorable Mentions

Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies. *Pharmacoepidemiol Drug Saf* 2016; 25; pages 170-178

Craig Hansen, Susan E. Andrade, Heather Freiman, Sascha Dublin, Katie Haffenreffer, William O. Cooper, T. Craig Cheetham, Sengwee Toh, De-Kun Li, Marsha A. Raebel, Jennifer L. Kuntz, Nancy Perrin, A. Gabriela Rosales, Shelley Carter, Pamala A. Pawloski, Elizabeth M. Maloney, David J. Graham, Leyla Sahin, Pamela E. Scott, John Yap and Robert Davis

Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study. *Pharmacoepidemiol Drug Saf* 2016; 25; pages 336-343

Maja Hellfritzsch, Jette Rathe, Tore Bjerregaard Stage, Steffen Thirstrup, Erik L. Grove, Per Damkier and Anton Pottegård

Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. *Pharmacoepidemiol Drug Saf* 2016; 25; pages 1186-1195

Ahmed S. Abdelmoneim, Dean T. Eurich, Ambikaipakan Senthilselvan, Weiyu Qiu and Scot H. Simpson

ISPE Awards

- ◆ Special Award for Public Health Promotion Through Pharmacoepidemiology
Bernard Bégaud
- ◆ Honorary Lifetime Fellow
Judith K. Jones, FISPE

ICPE 2017 Awards

- ◆ **The Andrew McAfee Award**
(Best abstract submitted by a researcher or student residing in a developing country)
Angel Yun Sum Wong, The University of Hong Kong
- ◆ **The John Snow Award**
(Best abstract submitted by a female researcher or student residing in a developing country)
A. Yasmina Noorsyahdy, Utrecht University
- ◆ **Student Awards**
 - ◆ **Best Methods Abstract**
Shao-Hsien Liu, University of Massachusetts Medical School
 - ◆ **Third Best Abstract**
Kathryn Rough, Harvard School of Public Health
 - ◆ **Second Best Abstract**
Ghadeer Khalid Dawwas, University of Florida
 - ◆ **The Stanley A. Edlavitch Award & Oral Presentation**
(Best abstract submitted by a student/post-doc)
Issa J. Dahabreh, Brown University
Emulating a Multi-Arm Randomized Controlled Trial of Antihypertensive Treatments for Chronic Kidney Disease Using Observational Data: How Do the Results Compare with Network Meta-Analysis? [416]
Issa J. Dahabreh, Jason Nelson, Andrew R. Zullo, William H. Crown, Nilay D. Shah, Lesley A. Inker. (United States)
- ◆ **Induction of ISPE Fellows**
 - ◆ Ariel Arias
 - ◆ Dimitri Bennett
 - ◆ Paul Coplan
 - ◆ Deborah Covington
 - ◆ Nicolle Gatto
 - ◆ Geoffrey Liu
 - ◆ Anke H. Maitland-van der Zee
 - ◆ Harry Seifert
 - ◆ Wei Zhou.

ISPE Board Transition

Retiring Board Members & Officers

- ◆ Andrew Bate
- ◆ Helga Gardarsdottir
- ◆ Marie Lindquist
- ◆ Almut G. Winterstein, FISPE
- ◆ Wei Zhou, FISPE
- ◆ Sonia Hernandez-Diaz, FISPE

Induction of New Board Members

- ◆ Montse Soriano Gabarro, Industry/Service Provider (Europe/Africa)
- ◆ Cynthia Girman, FISPE, Industry/Service Provider (Americas)
- ◆ Jasmanda Wu, FISPE, Industry/Service Provider (Asia/Pacific)
- ◆ Olaf Klungel, Academic (Europe/Africa)
- ◆ Michele Jonsson Funk, Academic (Americas)

Installation of 2017-2018 Officers

- ◆ Krista Huybrechts, FISPE, Vice President, Finance – Elect
- ◆ Alison Bourke, FISPE, President - Elect
- ◆ Tobias Gerhard, FISPE, Vice President, Finance
- ◆ Kiyoshi Kubota, FISPE, Immediate Past President
- ◆ Jesper Hallas, FISPE, President

Adjournment of Meeting



3:30pm-4:00pm

Break/Posters/Exhibits

220BC

4:00pm-5:30pm

Symposia & Workshops

4:00 PM

Comparative Safety and Effectiveness Evidence - What Do You Do When the Ideal Comparator is Not Obtainable? [417] 517CD

Jaclyn L. F. Bosco, Christina Mack, Krista F Huybrechts, Danica Marinac-Dabic. (United States)

4:00 PM

Evidence Generation in Multimorbidity: A New Frontier in Drug Utilization [418] 520AD

Gillian E Caughey, Katja Taxis, Lisa G Pont, Arsène Zongo, Björn Wettermark. (Australia)
Sponsored by the Drug Utilization Research (DUR) Special Interest Group

4:00 PM

TreeScan™: A Novel Data-Mining Tool for Medical Product Safety Surveillance [419] 520BE

Judith C. Maro, Rima Izem, Azadeh Shoaibi, Martin Kulldorff. (United States)

4:00 PM

Real-World Battles with Real-World Data [420] 520CF

Jeffrey Brown, Andrew Bate, Robert Platt, Marsha Raebel, Brian Sauer, Gianluca Trifiro. (United States)

4:00 PM

A Practical Guide to Implementing Sequence Symmetry Analysis; a Tool for Conducting Studies in the Asian Pharmacoepidemiology Network (AsPEN) [421] 524AB

Nicole Pratt, Edward Chia-Cheng Lai, Anton Pottegard, Elizabeth Roughead, Jesper Hallas. (Australia)

Sponsored by the Asian Pharmacoepidemiology Network (AsPEN) Special Interest Group

4:00 PM

Listening to the Patient Voice in Pharmacoepidemiological Research: Opportunities for Innovation and Inclusion [422] 524C

Wendy Camelo Castillo, Susan dosReis, Sascha Dublin, Brett Hauber, Irene Petersen, Nancy Santanello, Suzanne L West. (United States)

5:30pm-6:30pm

Council Meetings *(Open to all participants)*

- ◆ Academic 520CF
- ◆ Government/Regulatory 518C
- ◆ Industry/Service Provider 520BE
- ◆ Student 524C

7:30pm-11:30pm


Social Evening *(New City Gas)*

Join us for an evening of food, music, networking, and dancing to Montreal Rhapsody.

Full ICPE registration includes:

- ◆ Admission to New City Gas by badge or ticket (guests)
- ◆ Food
- ◆ Entertainment
- ◆ Transportation. Buses will shuttle between the convention centre and New City Gas, with the first bus departing at 7:00pm from the centre entrance located at 301 St. Antoine Street. Starting at 9:30pm buses will depart New City Gas.

A cash bar will be available.





6:00am-7:00am

Mindful Yoga 513F

Start your day with balance, flexibility, strength and awareness!

Ideally bring your own sticky mat, but if you don't have one, some will be available. Miles Braun, FISPE, a former ISPE Board member, and registered teacher (Yoga Alliance) will lead the sessions.

7:00am-8:00am

Poster Session C Set-up 220BC

7:00am-8:15am

Continental Breakfast 220BC

7:00am-3:30pm

Speaker Ready Room 523A

7:00am-4:30pm

Registration FOYER 517 EAST (FIFTH FLOOR)

7:15am-8:15am

2018 ICPE Scientific Program Committee (Breakfast available) 518C

7:30am-1:45am

Exhibits/Posters 220BC

8:30am-10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Pregnancy Methods

517CD

Moderators: **Sonia Hernandez-Diaz, FISPE, & Janet Hardy**

8:30 AM

The Antiretroviral Pregnancy Registry: 25 Years of Monitoring for Birth Defects [722]

Jessica D. Albano, Vani Vannappagari, Angela E. Scheuerle, D. Heather Watts, Karen Beckerman, Daniel Seekins, Susan Sinclair, Lynne Mofenson, Hugh Tilson. (United States)

8:45 AM

Birth Outcomes Associated with the Use of Smoking Cessation Pharmacotherapies in Pregnancy: Findings from the Smoking MUMS (Maternal Use of Medications and Safety) Study [723]

Duong T. Tran, Alys Havard, David B Preen, Kristjana Einarsdottir, Anna Kemp-Casey, Deborah Randall, Louisa R Jorm. (Australia)

9:00 AM

Detection Rates of Congenital Malformations Depend on Time of Follow-Up [724]

Pär Karlsson, Gabriella Bröms, Helle Kieler. (Sweden)

Better, Worse, or the Same?

520AD

Moderators: **Eva Skovlund & Edward Chia Cheng Lai**

8:30 AM

Effectiveness and Safety of Ticagrelor Compared to Clopidogrel and Prasugrel: Results from a Cohort Study in the Nationwide French Claims and Hospitalisation Database (SNIIRAM) [728]

Patrick Blin, Caroline Dureau-Pournin, Jérémy Jové, Régis Lassalle, Jacques Bénichou, Laurent Bonello, Jean Dallongeville, Nicolas Danchin, Bruno Falissard, Florence Thomas-Delecourt, Cécile Droz-Perroteau, Nicholas Moore. (France)

8:45 AM

Comparative Effectiveness of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome and Co-Morbid Diabetes Mellitus: A Cohort Study [729]

Julia Spoendlin, Joshua J Gagne, Jennifer Lewey, Rishi Desai. (United States)

9:00 AM

Comparative Effectiveness of Sitagliptin Compared to Sulphonylureas for Type 2 Diabetes Among Elderly Patients Inadequately Controlled on Metformin [730]

Manuj Sharma, Irwin Nazareth, Irene Petersen. (United Kingdom)

9:15 AM

Validation of Algorithms to Estimate Gestational Age in Medicaid Analytic eXtract Data [725]

Yanmin Zhu, Christian Hampp, Yu-Jung Wei, Dikea Roussos-Ross, Babette Brumback, Xi Wang, Yasser Albogami, Almut G. Winterstein. (United States)

9:30 AM

Women Treated for Epilepsy During Pregnancy: Outcomes from a Nationwide, Population-Based Cohort Study [726]

Miia Artama, Jemina Ahola, Jani Raitanen, Jukka Uotila, Mika Gissler, Jouko Isojärvi, Anssi Auvinen. (Finland)

9:45 AM

Use of Tumor Necrosis Factor- α Inhibitors During Pregnancy Among Women Who Delivered Liveborn Infants [727]

Efe Eworuke, Genna Panucci, Margie Goulding, Sengwee Toh. (United States)

9:15 AM

A Population Based Cohort Study on Comparative Effectiveness and Safety of Biologics in Inflammatory Bowel Disease [731]

Riccardo Di Domenicantonio, Francesco Trotta, Silvia Cascini, Nera Agabiti, Anna Kohn, Antonio Gasbarrini, Marina Davoli, Antonio Addis. (Italy)

9:30 AM

Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury [732]

Todd A Miano, Niels Martin, Adam Cuker, Brian Smith, Jason Christie, Wensheng Guo, Sean Hennessy. (United States)

9:45 AM

Effectiveness and Safety of Direct Oral Anticoagulants Versus VKA: A Cohort Study of About 100,000 Non-Valvular Atrial Fibrillation from the Nationwide French Claims and Hospitalisation Database [733]

Patrick Blin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Régis Lassalle, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Cécile Droz-Perroteau, Nicholas Moore. (France)





8:30am-10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

It Is Nice to Know What You Are Talking About

520BE

Moderators: **Jessica Franklin & Til Sturmer, FISPE**

8:30 AM

Analytical Interrelations Between Validity Indices for Validation of Case-Finding Algorithms in Healthcare Data Research: A Contribution from ADVANCE [734]

Kaatje Bollaerts, Alexandros Rekkas, Tom De Smedt, Caitlin Dodd, Nick Andrews, Rosa Gini. (Belgium)

8:45 AM

Impact of ICD-10-CM Transition on Selected Cardiovascular-Related Events in the Sentinel System [735]

Tiffany S Woodworth, Catherine A Panozzo, Emily C Welch, Ting-Ying Jane Huang, Qoua L Her, Catherine Rogers, Max Erhmann, Talia J Menzin, Nicole Haug, Katherine E Freitas, Darren Toh. (United States)

9:00 AM

Agreement Between Maternal Report and Medical Records During Pregnancy: Medications for Rheumatoid Arthritis [736]

Kristin Palmsten, Avanthi Hulugalle, Gretchen Bandoli, Grace M Kuo, Shayda Ansari, Ronghui Xu, Christina D Chambers. (United States)

9:15 AM

Refining Estimates of Prescription Durations by Incorporation of Observed Covariates in Pharmaco-Epidemiologic Databases. An Application of the Reverse Waiting Time Distribution [737]

Henrik Støvring, Anton Pottegård, Jesper Hallas. (Denmark)

9:30 AM

Improving Identification of Incident Colorectal (CRC) Cancer and Differentiation by Cancer Site Using Claims Data and a Multistage, Machine Learning, Classification and Regression Tree (CART) Approach [738]

Monica E D'Arcy, Til Sturmer, Jennifer L Lund. (United States)

9:45 AM

Validation of Systemic Lupus Erythematosus (SLE) Diagnosis in Claims Data Using Electronic Health Records (EHR) [739]

Edward Hammond, Helen Trenz, Xia Wang, Raj Tummala, Barnabas Desta, Rachel Halpern. (United States)

Patient Centered Care

520CF

Moderators: **Juhaeri Juhaeri & Judith Jones, FISPE**

8:30 AM

Developing Requirements for Incorporating Patient Preferences in Benefit-Risk Decision-Making: The IMI-PREFER Project [740]

Rachael DiSantostefano, Leo Russo, Bennett Levitan, Juhaeri Juhaeri. (United States)

8:45 AM

Influence of Medication Risks and Benefits on Patient and Clinician Preferences for Treatment in Multimorbidity: A Discrete-Choice Experiment [741]

Gillian E Caughey, Elisabeth Huynh, Sepehr Shakib, John M Rose, Joffre Swait. (Australia)

9:00 AM

Development and Validation of Patient-Reported Risk, Efficacy and Benefit Measures in the Context of DTC Prescription Drug Advertising [742]

Bridget J. Kelly, Douglas Rupert, Kathryn Aikin, Helen Sullivan, Mihaela Johnson, Suzanne West, Brian Southwell, Carla Bann, Nicole Mack, Sarah Parvanta, Susana Peinado, Alexander Rabre. (United States)

9:15 AM

Collection of Anti-Rheumatic Medication Data from Both Patients and Rheumatologists Shows Strong Agreement in a Real World Clinical Cohort: The Ontario Best Practices Research Initiative (OBRI) a Rheumatoid Arthritis Cohort [743]

Mohammad Movahedi, Angela Cesta, Xiuying Li, Claire Bombardier and Other OBRI Investigators. (Canada)

9:30 AM

Disparities in the Appropriateness of Medication Use: Analysis of the REGARDS Study [744]

Md Motiur Rahman, George Howard, Jingjing Qian, Chiahung Chou, Richard Hansen. (United States)

9:45 AM

Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR Study) - A Cluster Randomized Controlled Trial [745]

Katja Taxis, Jessica Scheper, Hedi Koning, Chris Brouwer, Jos Twisk, Helene Van der Meer, Froukje Boersma, Sytse Zuidema, Hans Wouters. (Netherlands)





8:30am-10:00am

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Evolution in Pharmacovigilance

524AB

Moderators: **Shirley Wang & Nabarun Dasgupta**

8:30 AM

Prospective Surveillance Pilot of Rivaroxaban Safety Within the US Food and Drug Administration Sentinel System [746]

Elizabeth A. Chrischilles, Joshua Gagne, Bruce Fireman, Jennifer C Nelson, Sengwee Toh, Azadeh Shoaibi, Marsha E Reichman, Shirley V Wang, Michael D Nguyen, Rongmei Zhang, Rima Izem, Margie R Goulding, Mary Ross Southworth, David J Graham, Candace C Fuller, Hannah Katcoff, Tiffany S Woodworth, Catherine Rogers, Ryan M Saliga, Nancy D Lin, Cheryl N McMahonill-Walraven, Vinit P Nair, Kevin Haynes, Ryan M Carnahan. (United States)

8:45 AM

Replicating a Clinical Trial Population to Estimate Background Event Rates: A Novel Method for Vaccine Pharmacovigilance [747]

Linda E Levesque, Meera Kumar, Sonja Banga, Alena Khromava. (Canada)

9:00 AM

Benefits of Combining Change-Point Analysis with Disproportionality Analysis in Pharmacovigilance Signal Detection [748]

Nhung Trinh, Elodie Sole, Mehdi Benkebil. (France)

9:15 AM

Association Rule Analysis to Evaluate Frequent Drug Combinations Associated with Fracture Risk in Older Adults [749]

Prasad S Nishtala, Danijela Gnjidic, Fabian Held, David Le Couteur, Te-yuan Chyou. (New Zealand)

9:30 AM

Implementation and Visualization of the Tree-Based Scan Statistic for Drug Safety Surveillance in Longitudinal Electronic Healthcare Data: A Pilot Study [750]

Stephen E. Schachterle, Sharon Hurley, Qing Liu, Kenneth R. Petronis, Andrew Bate. (United States)

9:45 AM

Does Patient Reporting Lead to Earlier Detection of Drug Safety Signals? A Retrospective Study in an International Database of Spontaneous Reports [751]

Leàn Rolfes, Florence van Hunsel, Ola Caster, Henric Taavola, Katja Taxis, Eugène van Puijenbroek. (Netherlands)

Remember Not to Forget

524C

Moderators: **Gianluca Trifiro & Margaret Richards**

8:30 AM

Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia [752]

Patrick Imfeld, Michael Bodmer, Susan S. Jick, Christoph R. Meier. (Switzerland)

8:45 AM

Proton Pump Inhibitor Use and Dementia Risk [753]

Sascha Dublin, Shelly L. Gray, Rod L. Walker, Onchee Yu, Erin J. Aiello Bowles, Melissa L. Anderson, Paul K. Crane, Eric B. Larson. (United States)

9:00 AM

Long-Term Risk of Dementia among Men with Benign Prostatic Hyperplasia [754]

Mette Nørgaard, Erzsébet Horváth-Puhó, Priscila Corraini, Victor W. Henderson, Henrik T Sørensen. (Denmark)

9:15 AM

Post-Traumatic Stress Disorder, Antipsychotic Use and Risk of Dementia in Veterans [755]

Elizabeth E Roughead, Nicole L Pratt, Lisa M Kalisch Ellett, Emmae N Ramsay, John D Barratt, Philip Morris, Graeme Killer. (Australia)

9:30 AM

Raised Blood Pressure as a Risk Factor For Vascular Dementia but Not Alzheimer's Disease: A Cohort Of 2.6 Million People Over Two Decades [756]

Nawab Qizilbash, John Gregson, Michelle E Johnson, Neil Pearce, Ian Douglas, Kevin Wing, Stuart S Pocock. (Spain)

9:45 AM

Frailty, Antipsychotics and Mortality Among Community-Based Older Adults with Impaired Cognition [757]

Colleen J Maxwell, Michael A Campitelli, David B Hogan, Christina Diong, Peter C Austin, Joseph E Amuah, Kate Lapane, Dallas P Seitz, Sudeep S Gill, Andrea Gruneir, Walter P Wodchis, Susan E Bronskill. (Canada)



MAIN CONFERENCE | WEDNESDAY, AUGUST 30

10:00am-10:30am

Break/Posters/Exhibits

220BC

10:30am-Noon

Symposia & Workshops

Beyond Retrospective Studies, Using Electronic Health Records for Prospective Research [758] 517CD

Carol E Koro, Sheila Weiss, Lesley Curtis, Sonia Hernandez-Diaz, Kourtney J Davis, June Raine. (United States)

Real World Evidence and

Precision Medicine in Cancer Research [759] 520AD

Wei Zhou, Ken Carson, Andy Freeman, Geoffrey Liu, Bruce Carleton. (United States)

Sponsored by the Cancer Special Interest Group

Practical Points to Address Uncertainties in Risk Management Planning [760] 520BE

Saad Shakir, Lourens Bloem, Marie L De Bruin, Jarno Hoekman, Hubert Leufkens, Patrick Ryan. (United Kingdom)

Optimizing Design, Conduct and Interpretation of EHR-enabled Randomised Clinical Trials: Case

Examples Demonstrate the Critical Role of Epidemiology and Future Challenges [761] 520CF

Kourtney J Davis, Matthew Sperrin, Jeanne Pimenta, David Webb, Rachael Williams, Lesley Curtis, Jeff Brown, Mark Wright, Tjeerd Van Staa. (United States)

Promises and Perils of Machine Learning: A Real-World Evidence Fable [762] 524AB

Mary E Ritchey, Michele Jonsson Funk, Mary Anthony, G Niklas Noren, Steven Thomas, Nabarun Dasgupta. (United States)

Noon-1:30pm

Lunch/Poster Session C/Exhibits

220BC

ISPE Board of Directors Luncheon

518C

Open to ISPE members; members should contact info@pharmacoepi.org if they would like to attend.

12:15pm-1:15pm

Spotlight Poster Session

516BC

- ◆ Benefit Risk Assessment, Communication & Evaluation (BRACE)
- ◆ Comparative Effectiveness Research (CER)
- ◆ Drug Utilization/Health Service Research

- ◆ Medical Devices
- ◆ Medications in Pregnancy

1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS

Coping with Imperfection

517CD

Moderators: Ian Douglas & Robert Glynn

1:30 PM

Using the Reverse Waiting Time Distribution to Estimate Medication Stopping Rates and Real-Time Prevalence of Drug Use in Pharmaco-Epidemiologic Databases [763]

Henrik Støvring, Anton Pottegård, Jesper Hallas. (Denmark)

1:45 PM

Using Inverse Probability Weighting to Correct for Outcome Misclassification [764]

Christopher A Gravel, Kristian B. Filion, Pauline M. Reynier, Robert W. Platt. (Canada)

2:00 PM

Missing Data in Marginal Structural Models: A Plasmode Simulation Study Comparing Multiple Imputation and Inverse Probability Weighting [765]

Shao-Hsien Liu, Stavroula A. Chrysanthopoulou, Qiuzhi Chang, Jacob N. Hunnicutt, Kate L. Lapane. (United States)

Student Award Recipient – Best Methods Abstract Submitted by a Student/Post-Doc

2:15 PM

Comparing Bayesian External and Internal Validation Approaches with the Multiple Imputation Approach to Correct Outcome Misclassification Bias in Logistic Regression [766]

Elham Rahme, Jiayi Ni, Kaberi Dasgupta, Denis Talbot, Geneviève Lefebvre, Lisa Lix, Lucie Blais. (Canada)

2:30 PM

Parametric Models for Evidence Synthesis of Overall Survival in Patients with Gastric Cancer [767]

Min-Hua Jen, Michael Sonksen. (United Kingdom)

2:45 PM

Power Considerations for Interrupted Time-Series Analysis: A Simulation Study [768]

Samuel Hawley, Sanni Ali, Andrew Judge, Daniel Prieto-Alhambra. (United Kingdom)





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Drug Utilization Across the Board

520AD

Moderators: **Annie Fourrier-Reglat & Lisa Pont, FISPE**

1:30 PM

Time Series Analysis of Emergency Room Consultations and Hospitalizations: Impact of Generic Clopidogrel Commercialization [769]

Jacinthe Leclerc, Claudia Blais, Louis Rochette, Denis Hamel, Line Guénette, Paul Poirier. (Canada)

1:45 PM

Does Ticagrelor Decrease the Risk of Recurrent Fatal or Non-Fatal Myocardial Infarction in Real-World Settings? The AREMIS (Antiplatelet agents and Recurrent Myocardial Infarction Study) Case-Cohort Study [770]

Lamia Grimaldi-Bensouda, Nicholas Danchin, Jean Dallongeville, Bruno Falissard, Alain Furber, Yves Cottin, Laurent Bonello, Olivier Morel, Florence Leclercq, Etienne Puymirat, Fahmi Ghanem, Jacques Bénichou, Lucien Abenham. (France)

2:00 PM

Off-Label Antidepressant Use [771]

Wiebke Schaefer, Bianca Kollhorst, Tammo Reinders, Oliver Riedel. (Germany)

2:15 PM

Temporal Patterns of Hypnotic Dose Dynamics Among Long-Term Hypnotic Users Aged 50 and Older [772]

Sébastien Cortaredona, Marie Tournier, Hélène Verdoux, Pierre Verger. (France)

2:30 PM

Prevalence of Antibiotic Prescription in Pediatric Outpatients in Italy: The Role of Local Health Districts and Primary Care Physicians in Determining Variation [773]

Mirko Di Martino, Adele Lallo, Ursula Kirchmayer, Marina Davoli, Danilo Fusco. (Italy)

2:45 PM

Trends for Prevalence and Incidence of Resistant Hypertension: A Population Based Study in the UK 1995-2015 [774]

Sarah-Jo Sinnott, Liam Smeeth, Elizabeth Williamson, Ian J Douglas. (United Kingdom)

Pregnancy Nerves

520CF

Moderators: **Sara Ephross & Andrea Margulis**

1:30 PM

Attention-Deficit Hyperactivity Disorder Medication Use During Pregnancy and Risk for Birth Defects in United States, 1997-2011 [775]

Jennita Reefhuis, Kayla N Anderson, Annelise Arth, Cheryl Broussard, Sherry Farr, Jennifer Lind, Susanna Visser, Sarah Tinker. (United States)

1:45 PM

ADHD Drugs During Pregnancy and the Risk of Congenital Malformations: A Study from the International Pregnancy Safety Study (InPreSS) Consortium [776]

Gabriella Bröms, Sonia Hernández-Díaz, Brian Bateman, Kristjana Einarsdóttir, Kari Furu, Krista Huybrechts, Pär Karlsson, Anna-Maria Lahesmaa-Korpinen, Mette Nørgaard, Johan Reutfors, Helga Zoega, Helle Kieler. (Sweden)

2:00 PM

Detecting the Etiologically Relevant Risk Window for Medications Used in Pregnancy [777]

Krista F Huybrechts, Helen Mogun, Brian T. Bateman, Sonia Hernández-Díaz, Jacqueline M. Cohen, Shirley Wang, Rishi Desai, Elisabetta Patorno, Kathryn Rough, Martin Kulldorff. (United States)

2:15 PM

Maternal Depression and Antidepressant Use During Pregnancy and Risk of Autism Spectrum Disorders in Offspring: Population-based Cohort and Bidirectional Case-Crossover Sibling Study [778]

Katrina Wilcox Hagberg, Annelies Robijn, Susan S Jick. (United States)

2:30 PM

Effect of Time-Dependent SSRI Exposure During Pregnancy on Child's Neurobehavioral Development by Age 5 [779]

Angela Lupattelli, Eivind Ystrom, Mollie Wood, Hedvig Nordeng. (Norway)

2:45 PM

Paternal Antidepressant Use as a Negative Control for Maternal Use [780]

Jacqueline M Cohen, Mollie E Wood, Sonia Hernandez-Diaz, Eivind Ystrom, Hedvig M Nordeng. (United States)



1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Cancer 2

520BE

Moderators: **John Acquavella, FISPE & Evelyn Flahavan**

1:30 PM

Oral Contraceptives and Breast Cancer Risk - A Sibling Comparison Study [781]

Klaus K Andersen, Søren Friis, Merete Hansen, Charlotte Skriver, Christian Dehlendorff. (Denmark)

1:45 PM

Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer [782]

Farzin Khosrow-Khavar, Hui Yin, Alan Barkun, Nathaniel Bouganim, Laurent Azoulay. (Canada)

2:00 PM

Use of Hydrochlorothiazide and Risk of Skin Cancer [783]

Anton Pottegård, Jesper Hallas, Sidsel Arnsparang, David Gaist, Morten Olesen, Mathias T Svendsen, Laurel A Habel, Gary D Friedman, Sigrun A Schmidt, Lisbet R Hölmich, Søren Friis. (Denmark)

2:15 PM

Metformin and the Incidence of Viral Associated Cancers in Patients with Type 2 Diabetes [784]

Blanaid Hicks. (United Kingdom)

2:30 PM

Pioglitazone and the Risk of Bladder Cancer in Older Adults with Type 2 Diabetes: A Comparison with a Clinically Meaningful Treatment Alternative [785]

Elizabeth M Garry, John B Buse, Jennifer L Lund, Virginia Pate, Til Stürmer. (United States)

2:45 PM

Risk of Pancreatitis and Pancreatic Cancer in Diabetics Treated with Incretin Mimetic Agents [786]

Daina B Esposito, Stephan F Lanes. (United States)

Psych/Mental Health

524AB

Moderators: **Alejandro Arana, FISPE, & Tobias Gerhard, FISPE**

1:30 PM

Suicide, Suicidal Behavior, and Mortality Rates in Patients with Psoriasis in England [787]

Mary Anthony, Brian Calingaert, Lisa J McQuay, Elizabeth Andrews, Leah McGrath, Kenneth J Rothman, Elena Rivero-Ferrer. (United States)

1:45 PM

Risk of Suicidal Event with Stimulant Treatment: A Self-Controlled Case Series Study [788]

Kenneth Man, David Coghill, Esther Chan, Wallis Lau, Chris Hollis, Elizabeth Liddle, Tobias Banaschewski, Suzanne McCarthy, Antje Neubert, Kapil Sayal, Patrick Ip, Martijn Schuemie, Miriam Sturkenboom, Edmund Sonuga-Barke, Jan Buitelaar, Sara Carucci, Alessandro Zuddas, Hanna Kovshoff, Peter Garas, Peter Nagy, Sarah Inglis, Kerstin Konrad, Alexander Häge, Eric Rosenthal, Ian Wong. (Hong Kong)

2:00 PM

Early Childhood Antibiotics Exposure and the Risk of Autism Spectrum Disorders [789]

Amani Hamad, I fan Kuo, Silvia Alessi-Severini, Salah Mahmud, Marni Brownell. (Canada)

2:15 PM

Current Use of Antipsychotics Is Associated with an Increased Risk of Urinary Tract Infections in the Elderly [790]

Patrick C Souverein, Astrid M van Strien, Carolina J Keijsers, Eibert R Heerdink, Hieronymus J Derijks, Rob J van Marum. (Netherlands)

2:30 PM

Use of Attention Deficit Hyperactivity Disorder Medication Amongst Adults in Quebec, Canada [791]

Jason R Guertin, Jacques LeLorier, Mitchell Levine. (Canada)

2:45 PM

Drug Burden Index and Physical and Cognitive Function in Older Adults with Intellectual Disabilities: A Cross-Sectional Study [792]

Maire O'Dwyer, Juliette O'Connell, Clare Donegan, Eilish Burke, Niamh Mulryan, Claire O'Dwyer, Philip McCallion, Mary McCarron, Martin Henman. (Ireland)





1:30pm-3:00pm

CONCURRENT SESSIONS: ORAL PRESENTATIONS (Continued)

Get the How Just Right

524C

Moderators: Susanna Perez-Gutthann, FISPE & David Gagnon

1:30 PM

Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Among Chronic Kidney Disease Patients [793]

Andrew R Zullo, Issa J Dahabreh, Jason Nelson, David M Kent, William H Crown, Nilay D Shah, Lesley A Inker. (United States)

1:45 PM

A Cohort Study to Assess Cardio-Renal Outcomes Among Users of Aliskiren in Routine Clinical Care [794]

John D Seeger, Katsiaryna Bykov, Jessica Franklin, Raymond Schlienger, Sebastian Schneeweiss. (United States)

2:00 PM

Comparative Safety of Intravenous Iron Dosing Protocols in Hemodialysis Patients [795]

Xiaojuan Li, Stephen Cole, Jason Fine, Til Stürmer, Abhijit Kshirsagar, M Alan Brookhart. (United States)

2:15 PM

Effectiveness and Safety of Switching from Epoetin alfa Originator to Other Epoetins in Nephrology: An Italian Population-Based Study [796]

Francesco Trotta, Valeria Belleudi, Gianluca Trifirò, Danilo Fusco, Francesco Giorgianni, Ylenia Ingrassiotta, Marina Davoli, Antonio Addis. (Italy)

2:30 PM

Acute Kidney Injury and Infections in Patients Taking Antihypertensive Drugs: A Self-Controlled Case Series Analysis [797]

Kathryn E Mansfield, Ian J Douglas, Dorothea Nitsch, Sara L Thomas, Liam Smeeth, Laurie A Tomlinson. (United Kingdom)

2:45 PM

Incidence of Chronic Kidney Disease and Progression of Kidney Dysfunction Among Patients With and Without Type 2 Diabetes [798]

Gregory A Nichols, Anouk Derauz-Luyet, Sibylle J Hauske, Kimberly G Brodovicz. (United States)

Raising the standard in pharmacoepidemiology

For more than 30 years, Analysis Group has worked with prominent clinicians, academics, and industry thought leaders to develop innovative solutions for our clients across North America, Europe, and emerging markets.

Drawing on our expertise in pharmacoepidemiology, we assist our clients with:

- Peri-approval safety studies for IND and NDA submissions and post-approval commitment
 - Observational pharmacoepidemiology studies (e.g., claims analysis and chart review, EMR data analysis)
 - Prospective drug safety surveillance
 - Patient Reporting
- Pharmacovigilance and spontaneous report analyses
- Clinical trial data analyses and meta-analyses for drug safety endpoints
- PMR/PMS and PASS studies
- Strategic responses to drug safety concerns raised by U.S. and ex-U.S. regulatory agencies
- Design and evaluation of the effectiveness of REMS programs
- Advanced methods in causal inference (e.g., marginal structural models, mediation analysis, high-dimensional propensity score matching)
- Comparative effectiveness research
- Quality of life instrument development and validation
- Mass tort pharmaceutical liability litigation
- Machine learning and big data analytics




ANALYSIS GROUP

ECONOMIC, FINANCIAL and STRATEGY CONSULTANTS

Drug Safety and Epidemiology

For more information, contact **Mei Sheng Duh**, Sc.D., M.P.H., Managing Principal and Chief Epidemiologist, at mei.duh@analysisgroup.com, 617-425-8131 or visit our website at www.analysisgroup.com/epidemiology





3:15pm-4:45pm

Hot Topic Session: A Bitter Pill to Swallow, Snort or Inject: What have we learned about the impact of our opioid policies in North America?

517CD

The increasing prevalence of opioid use and addiction is one of the largest public health issues currently facing North America. Over the past two decades, regulators and clinicians have been attempting to develop evidence-based policies and guidelines that adequately balance access to these drugs for pain management against a growing epidemic of opioid addiction. This has been met with varied success due to the complexity of this issue as it spans the fields of prescription drug regulation, access to pain management alternatives and addiction services, and illicit drug trafficking. Furthermore, many jurisdictions have been criticized for poor data collection and ability to actively monitor this issue as it evolves.

This hot topic presentation will include a panel of speakers from the US, Canada and Europe that will present various perspectives on the value and impact of different policies that have been introduced to address this problem. This will provide a forum for discussion and debate of past successes and failures in drug policy, and potential consequences as this problem extends globally.

Moderator:

Yola Moride, FISPE, Professor, Faculty of Pharmacy, Université de Montréal; Moderator

Speakers:

Judy A. Staffa, Associate Director for Public Health Initiatives, Office of Surveillance & Epidemiology, CDER/FDA

Tara Gomes, Ontario Drug Policy Research Network; Institute for Clinical Evaluative Sciences, St. Michael's Hospital

Richard C Dart, Director of the Rocky Mountain Poison and Drug Center; Executive Director of Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS® System); and Chairman, Denver Health Authority Pharmacy and Therapeutics Committee

Maryse Lapeyre-Mestre, Associate Professor of Clinical Pharmacology, Toulouse University Hospital, Head of the Addictovigilance Center of Toulouse

4:45pm-5:15pm

The Final Word

517CD

33rd ICPE Awards

Adrian Levy, Chair, 2017 Scientific Program Committee

- ◆ **Vincent Lo Re**, FISPE, Newcomer Track
- ◆ **Charles Leonard**, Newcomer Track
- ◆ **Kristen B Bibeau**, Roundtable Discussions
- ◆ **J. Bradley Layton**, Spotlight Poster Sessions

Spotlight Poster Awards

J. Bradley Layton, Chair, Spotlight Poster Sessions

2018 Meetings

Mid-Year Meeting – Toronto

- ◆ **Suzanne M Cadarette**, Co-Chair, Program Planning Committee
- ◆ **Geoff Liu**, FISPE, Co-Chair, Program Planning Committee

34th ICPE – Prague

- ◆ **Olaf Klungel**, Chair, 2018 Scientific Program Committee
- Drawing for complimentary registrations for ICPE 2018 (*must be present to win*)

Adjournment of ICPE 2017

Adrian Levy, Chair, 2017 Scientific Program Committee



Japanese Administrative Database



◀「MDV analyzer」

MDV

medical.data.vision



▶ Data Set Analysis
55 Year Old Male with Rectal Cancer
※This is a sample

Characteristics of Our Database

|| Vast Data Volume

Staggering around **20 million** patient data

|| Rich with Elderly Data

Around **34%** Over **65** Years Old.

|| Daily Medical Treatment Information

Medication, Examination, Treatment, Surgery, and So On.

Blood Test Result (Limited to Number of Hospitals)

Medical Data Vision Co., Ltd.

7 Kanda Mitoshicho, Chiyoda-ku
Tokyo, Japan 101-0053




<https://www.mdv.co.jp/solution/pharmaceutical/english/>



Email ebm_sales@mdv.co.jp

Value through Innovation



More than 130 years of experience, we remain intensely curious.

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Global Epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real world settings. Would you like to join our epidemiological research group? Please send an e-mail to epidemiology@boehringer-ingelheim.com indicating your interest.

www.boehringer-ingelheim.com



Overview

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

NOTE

Neither ISPE nor the Congress Centre will be responsible for any poster that is left on display overnight or is lost or damaged.

Poster Sessions

Spotlight Session Posters will be displayed in Room 516BC, while all other posters will be displayed in the Exhibit Hall (Room 220BC), August 28-30. Each day will have distinct Spotlight Session and poster session. All posters for a specific day's session must be removed at the end of that day.

- ◆ Monday, August 28 Poster Session A
- ◆ Tuesday, August 29 Poster Session B
- ◆ Wednesday, August 30 Poster Session C

1. Set Up

7:00am-8:00am daily; all posters must be in place by 8:00am. The poster area (including floor) must remain clear and clean of tubes.

2. Hours

Posters will be displayed from 8:00am-6:00pm on Monday & Tuesday, and 8:00am-1:45pm on Wednesday.

3. Discussion Time

General Poster Sessions: Presenters should be at their posters between 12:15-1:15pm on Monday (A) and Wednesday (C); and between 11:45-12:45pm on Tuesday (B) – **Exhibit Hall/Room 220BC**

Spotlight Poster Sessions: Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters between 12:15-1:15pm on Monday (A) and Wednesday (C); and between 11:45-12:45pm on Tuesday (B) – **Room 516BC**

The Spotlight Sessions offer pre-selected presenters the opportunity to share their work and to discuss the results with an audience. When the poster walk chair and audience stop at poster, presenters will give brief, 3-minute, presentations and answer questions.

- Monday**
- ◆ Asian Pharmacoeconomics Network (AsPEN)
 - ◆ Biologics & Biosimilars
 - ◆ Databases
 - ◆ Vaccines

- Tuesday**
- ◆ Adherence
 - ◆ Molecular Epidemiology/ Biomarkers/Pharmacogenetics
 - ◆ Oncology
 - ◆ Pediatrics

- Wednesday**
- ◆ Benefit Risk Assessment, Communication & Evaluation (BRACE)
 - ◆ Comparative Effectiveness Research (CER)
 - ◆ Drug Utilization Research
 - ◆ Medical Devices
 - ◆ Medications in Pregnancy

4. Take Down

All posters must be taken down by 6:30pm on Monday and Tuesday, and by 5:00pm on Wednesday.

Numbering System

Each poster board will be numbered. Presenters should attach their posters to the board that number corresponds to the number assigned to their poster on that day as listed in the Final Program. The **POSTER BOARD NUMBER** is the first number listed. The **PUBLICATION NUMBER**, for use in locating abstracts in the **Final Program**, is listed after the abstract title.

Example

97 Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]

Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

Key

97 POSTER BOARD Number
176 PUBLICATION Number

Call4Posters

Posters ordered through Call4Posters can be picked up in the Exhibit Hall (Room 220BC) at the times below.

Poster Pick Up Schedule

Sunday, August 27:	Noon-5:00pm
Monday, August 28:	7:00am-3:00pm
Tuesday, August 29:	7:00am-3:00pm
Wednesday, August 30:	7:00am-Noon

SPOTLIGHT SESSION PRIZES

A group of judges will select the best posters of each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced during The Final Word session on Wednesday afternoon, August 30.





Spotlight Session - Asian Pharmacoevidence Network (AsPEN)

- A. Comparative Cardio-Metabolic Risk of Antipsychotics in Psychiatric Children, Adolescents and Young Adults [83]**
Ying-Shan Chung, Shih-Chieh Shao, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- B. Comparative Effectiveness of Dementia Prevention Among Patients Receiving Angiotensin-Converting-Enzyme Inhibitors [84]**
Chien-Hsun Li, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- C. Comparison of the Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated with Ticagrelor Versus Clopidogrel in Taiwan: A Population Based Study [85]**
Ching-Lan Cheng, Cheng-Han Lee, Yea-Huei Kao Yang, Yi-Heng Li. (Taiwan)
- D. Use of Dipeptidyl Deptidase-4 (DPP-4) Inhibitors and Risk of Arthralgia: Population-Based Cohort and Nested Case-Control Studies [86]**
Chen-Yu Wang, Shǎu-Huǎi Fú, Chuan-Ching Huang, Chih-Chien Hung, Chen-Chiang Lin, Kai-Hsin Liao, Chih-Wan Lin, Rǒng-Şǎn Yǎng, Fei-Yuan Hsiao. (Taiwan)
- E. Patient and Provider Characteristics Related with Prescribing of ADHD Medication: Nationwide Health Insurance Claims Database Study in Korea [87]**
Ju-Young Shin, Inmyung Song. (Korea, Republic of)
- F. Variations in the Prescribing of Secondary Cardiovascular Preventative Therapies for Patients with Acute Coronary Syndrome in the Multi-Ethnic Malaysian Population [88]**
Dr. Nur Lisa Zaharan, Padmaa Venkatason, Ahmad Syadi Mahmood Zuhdi. (Malaysia)
- G. Determinants of Antipsychotic Use in Elderly Patients Following Ischemic Stroke [89]**
Chien Chou Su, Cheng-Yang Hsieh, Yea-Huei Kao Yang. (Taiwan)

- H. Validation Studies in the Asia-Pacific Region: A Comprehensive Review [90]**
Nana Koram, James Stark, Megan Delgado, Soko Setoguchi, Cynthia de Luise. (United States)

Spotlight Session - Biologics and Biosimilars

- I. Comparative Cardiovascular Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients With and Without Cardiovascular Disease: A Population-Based Cohort Study [91]**
Yinzhu Jin, Eun Ha Kang, Gregory Brill, Rishi J. Desai, Seoyoung C. Kim. (United States)
- J. Is Early Initiation of Biologic Therapy in Crohn's Disease Associated with Reduced Risk of Hospitalization? An Application of Group-Based Trajectory Modeling [92]**
Chao Chen, Hong Xiao, Yu-Jung Wei, Abraham Hartzema. (United States)
- K. Safety of Intravitreal Injections for the Treatment of Patients with Diabetic Retinopathy: A Population-Based Study [93]**
Marina A Machado, Cristiano Moura, Hassan Behloul, Robert Campbell, Sasha Bernatsky. (Canada)
- L. Abstract Withdrawn [94]**
- M. Examining the Risk of Serious Infection in Patients with Psoriasis on Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) [95]**
Zenas Z Yiu, Catherine H Smith, Darren M Ashcroft, Mark Lunt, Shernaz Walton, Ruth Murphy, Nick J Reynolds, Anthony D Ormerod, Christopher E Griffiths, Richard B Warren. (United Kingdom)
- N. Corticosteroid Utilization and Risk of Infections Among Rheumatoid Arthritis Patients Taking Biologic and Non-Biologic Disease Modifying Antirheumatic Drugs with and without Corticosteroids [96]**
Elham Rahme, Hacene Nedjar, Louis Bessette, Francisco de Assis Acurcio. (Canada)

- O. Safety of Anti-Vascular Endothelial Growth Factor (anti-VEGF) Intravitreal Injections for the Treatment of Patients with Age-Related Macular Degeneration (AMD) [97]**
Cristiano S Moura, Marina A Machado, Hassan Behloul, Robert Campbell, Sasha Bernatsky. (Canada)
- P. Transfusion-Related Acute Lung Injury Among the Inpatient U.S. Elderly During 2007-2016 [98]**
Mikhail Menis, Richard A Forshee, Hector S Izurieta, Zebulin Kessler, Stephen McKean, Rob Warnock, Sumit Verma, Bo Kim, Christopher M Worrall, Jeffrey A Kelman, Steven A Anderson. (United States)

Spotlight Session - Databases

- Q. The "Propensity Score Paradox": A Threat to Pharmaco-Epidemiological Studies? [99]**
M Sanni Ali, G S Collins, Daniel Prieto-Alhambra. (United Kingdom)
- R. Validity of Melanoma Diagnoses in the Danish Cancer Registry and the Danish Melanoma Database [100]**
Sidsel Arnspang, Sigrun Alba Schmidt, Siri Klausen, Anton Pottegaard, Søren Friis, Lisbet Rosenkrantz Holmich, David Gaist. (Denmark)
- S. The Impact of Care-Discontinuity on Recording of Patient Characteristics Critical for Comparative Effectiveness Research Using Electronic Health Records [101]**
Kueiyu Joshua Lin, Robert J Glynn, Daniel E Singer, Sebastian Schneeweiss. (United States)
- T. Area-Level Socioeconomic Status Indicators for Observational Studies of Medication Use [102]**
Chandrasekar Gopalakrishnan, Joshua J Gagne, Ameet Sarpatwari, Sara Z Dejene, Sarah Dutcher, Raisa Levin, Jessica M Franklin, Rishi J Desai. (United States)
- U. Can Valid Cases of Schizophrenia Be Identified in Administrative Claims Data? [103]**
Syd Phillips, Matthew Sidovar, Deb Casso, Jeremiah J Trudeau, Kimberley J Woodcroft, Susan A Oliveria. (United States)





- V. The Difference Between Asthma and COPD - A Distinction Based on Dispensing Data [104]**
Jetty A Overbeek, Marina Bakker, Berber T Snoeijer. (Netherlands)
- W. Linking Randomized Clinical Trials and Electronic Databases - Assessing Feasibility in 41 Countries [105]**
James Pierce, Mehdi Nejafzadeh, Emma Payne, Margaret Okobi. (United States)
- X. Changes in the Adoption of Claims Based Diagnosis Codes for Eosinophilic Esophagitis and Implications on Patient Identification Using Claims Data [106]**
Mugdha Gokhale, Chris Bell, Matthew Lau, Eric Bradford, Yunhao Liu, Ayush Patel, Melissa Van Dyke. (United States)

Spotlight Session - Vaccines

- Y. Rotavirus Vaccination and Risk of Short-Term Adverse Events in US Infants [107]**
J. Bradley Layton, Anne M Butler, Catherine A Panozzo, M. Alan Brookhart. (United States)
- Z. An Observational Cohort Study of Live, Oral, Human Rotavirus Vaccine Administered to Infants in US Health Insurance Plans [108]**
Veena Hoffman, Remon Abu-Elyazeed, Cheryl Enger, Daina B. Esposito, Michael Doherty, Scott C. Quinlan, Kathleen Skerry, Crystal N. Holick, Peter Basile, Leonard R. Friedland, Nicolas Praet, Stephanie Wery, Corinne Willame, David D. Dore, Dominique Rosillon. (United States)
- AA. Lack of Risk for Cranial Nerve III Palsy After Childhood Immunization: A Case Centered Analysis [109]**
Kristin S Goddard, Ned Lewis, Roger Baxter, Nicola P Klein. (United States)
- BB. Case-Control Analysis of Narcolepsy After 2009 H1N1 Pandemic Vaccination in Taiwan [110]**
Wan-Ting Huang, Yu-Shu Huang, Chung-Yao Hsu, Hsi-Chung Chen, Hsin-Chun Lee, Hui-Chen Lin, Cheng-Fang Hsieh, Meng-Ni Wu, Chin-Hui Yang. (Taiwan)

- CC. An Evaluation of Non-Vaccine Triggered Anaphylaxis Cases Identified Following Vaccination in the Vaccine Safety Datalink (VSD) [111]**
Michael M McNeil, Eric S Weintraub, Jonathan Duffy, Lakshmi Sukumaran, Steven J Jacobsen, Nicola P Klein, Simon J Hambidge, Grace M Lee, Lisa A Jackson, Stephanie A Irving, Jennifer P King, Elyse O Kharbanda, Robert A Bednarczyk, Frank DeStefano. (United States)
- DD. Paresthesia Following Pandemic H1N1 (PH1N1) Influenza Vaccine: Reports to the Vaccine Adverse Event Reporting System (VAERS) [112]**
Michael M McNeil, Paige Lewis, Maria V Cano. (United States)
- EE. Patterns of Use of High-Dose Influenza Vaccine in the U.S. Dialysis Population [113]**
Anne M. Butler, J. Bradley Layton, Leah J. McGrath. (United States)
- FF. Rotavirus Vaccination May Reduce Acute Gastroenteritis Rates Across All Age Groups in England [114]**
Margarita Riera-Montes, Tom Cattaert, Germano Ferreira, Thomas Verstraeten. (Belgium)

Burden of Disease - Cancer

- 1. Prevalence of Endocrine Therapy-NaÖve Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer in the US, an Extrapolation from Observations within an Electronic Health Record Database [115]**
Anthony P Nunes, Tapashi Dalvi, Jan Lewis, Nick Jones, Edward Green, William J Gradishar, John D Seeger. (United States)
- 2. Disease Burden and Clinical Characteristics of Multiple Myeloma A Population Based Database Study Utilizing the National Health Insurance Claims Database in Taiwan [116]**
Yanfang Liu, Chao-Hsiun Tang, Hsin-An Hou, Hung-Yi Liu, Hong Qiu, Lee Anne Rothwell. (Singapore)

- 3. Cancer Incidence in Patients with Rheumatoid Arthritis Based on a Claims Database [117]**
Chuntao Wu, Marie-Laure Kurzinger, Meera Kumar, Anju Garg, Stephen Lin, Juhaeri Juhaeri. (United States)
- 4. Age-and Gender-Specific Incidence of Malignant Neoplasms in Patients with Multiple Sclerosis Using a U.S. Claims Database [118]**
Sampada K Gandhi, Meera Kumar, Juhaeri Juhaeri. (United States)
- 5. Characteristics and Treatment of Prostate Cancer Patients with Bone Metastasis in Beijing: An Observational Study Using the Beijing Urban Employee Basic Medical Insurance Database [119]**
Yuting Pan, Yinchu Cheng, Shuangqing Gao, Wentao Sun, Lin Xu, Jihong Zong, Montse Soriano Gabarró, Siyan Zhan. (China)
- 6. Risk of Skin Cancer Among Patients with Myotonic Dystrophy Type 1: Data from the United Kingdom Clinical Practice Research Datalink [120]**
Youjin Wang, Ruth Pfeiffer, Rotana Alsaggaf, Wilhelmine Meeraus, Julia Gage, Lesley A Anderson, Nikoletta Nikolenko, Hanns Lochmuller, Mark H Greene, Shahinaz M Gadalla. (United States)
- 7. Mortality by Frailty Status as Defined by a Claims-Based Disability Status (DS) in Elderly Patients (Pts) Newly Diagnosed with Multiple Myeloma (MM) in the United States (US) [121]**
Shuling Li, Tanya Natwick, Jiannong Liu, Vicki A. Morrison, Sarah Vidito, Winifred Werther, Khalid Mezzi, Akeem Yusuf, Jatin Shah, Saad Usmani. (United States)
- 8. Use of Olmesartan and Enteropathy Outcomes: A Multi-Database Study [122]**
Yaa-Hui Dong, Yinzhu Jin, Theodore N. Tsacogianis, Mengdong He, Ping-Hsin Hsieh, Joshua J. Gagne. (Taiwan)

Burden of Disease - Diabetics

- 9. A Pragmatic Model to Predict Diabetes among Patients with Elevated Hemoglobin A1c Values: A Cohort Study [123]**
Eric S Johnson, Erin M Keast, Xiuhai Yang, Amanda F Petrik, David H Smith. (United States)



10. **Cataract in Patients with Diabetes Mellitus - Incidence Rates in the UK and Risk Factors Based on the Clinical Practice Research Datalink (CPRD) [124]**
 Claudia Becker, Cornelia Schneider, Samuel Aballéa, Clare Bailey, Rupert Bourne, Susan Jick, Christoph Meier. (Switzerland)
11. **Ethnic Differences in Type 2 Diabetes Mellitus and Coronary Heart Disease: A Prospective Cohort Study in the Clinical Practice Research Datalink [125]**
 Rohini Mathur, Krishnan Bhaskaran, Sophie V Eastwood, Nishi Chaturvedi, Liam Smeeth. (United Kingdom)
12. **Pregestational Diabetes Mellitus During Pregnancy and Its Adverse Effects [126]**
 Sonia J Coton, Irwin Nazareth, Irene Petersen. (United Kingdom)
13. **Prevalence of Depression Among Type 2 Diabetes Mellitus Patients in India: Evidence Based Systematic Review and Meta Analysis [127]**
 Salman Hussain, Anwar Habib, Ambrish Singh, Mohd Akhtar, Abul Kalam Najmi. (India)
14. **Incidence and Prevalence of Diabetes Mellitus Among Children Aged 10-18 Years in the United States (US) [128]**
 Dana Y Teltsch, Soulmaz Fazeli Farsani, Samuel Huse, Nicholas Sicignano, Kimberly G Brodovicz, Christina Cristaldi, Beth L Nordstrom. (United States)
15. **Gosh My HbA1c Is Too High [129]**
 Irene Petersen, Sia Kromann Nicolaisen, Reimar W Thomson, Lars Pedersen. (United Kingdom)
16. **Lower Limb Amputation: Cases Identification in Claims Data and Incidence Estimates in Patients With and Without Diabetes Mellitus [130]**
 Anouk Déruaz-Luyet, Christina Raabe, Hristo Iliev, Kimberly G. Brodovicz. (Germany)
17. **Increased Prevalence of Diabetes in the Netherlands Is Only Partly Explained by Changes in Age and Gender Over Time [131]**
 Jetty A Overbeek, Amber A van der Heijden, Ron M Herings, Giel Nijpels. (Netherlands)
18. **Incidence of Hyperglycemia in Diabetes Patient Population [132]**
 Katherine Tsai, Meera Kumar, Jane Thammakhoune, Daniel Gil, Chuntao Wu, Juhaeri Juhaeri. (United States)
19. **Time Trends in Diabetic Macular Edema Among Diabetic Adults in the UK [133]**
 Vidya Moorthy, Frank A Corvino, Matt McEnany, Monie Hussain, Pavel Napalkov. (United States)
20. **Potential Medication Triggers of Deteriorated Renal Function Among Patients with Type 2 Diabetes: Using Real World Data [134]**
 Elisabeth Smits, Eline Houben, Jetty A Overbeek, Peter A de Smet, Myrthe P van Herk-Sukel, Ron M Herings, Martina Teichert. (Netherlands)
21. **Type 1 and Type 2 Diabetes Mellitus Identification Using ICD-9-CM Codes within a Cohort of New Users of Drugs Labeled for Type 2 Diabetes Mellitus [135]**
 Laura Hou, Noelle Cocoros, Christian Hampp, Richard Swain, Judith C. Maro. (United States)
22. **Channeling in Users of Antiplatelet Agents and Consequences for Relative Risk and Relative Effectiveness Assessment [136]**
 Lamiae Grimaldi-Bensouda, Nicolas Danchin, Jean Dallongeville, Bruno Falissard, Jacques Bénichou, Lucien Abenheim. (France)
23. **Selection and Collider Bias in Electronic Health Databases for the Estimation of Drug Safety and Effectiveness [137]**
 Mireille E Schnitzer, Lucie Blais. (Canada)
24. **Missing Covariate Data in Electronic Health Records: Borrowing Information from Between Individuals or Within? [138]**
 Jenny W Sun, Jessica M Franklin, Joshua J Gagne. (United States)
25. **The Impact of Confounder Selection in Propensity Scores for Rare Events Data - with Applications to Birth Defects [139]**
 Ronghui Xu, Jue Hou, Christina Chambers. (United States)
26. **Methods for Time-Varying Exposure Related Problems in Pharmacoepidemiology: A Literature Overview [140]**
 Laura Pazzagli, Marie Linder, Mingliang Zhang, Emese Vago, Paul Stang, David Myers, Morten Andersen, Shahram Bahmanyar. (Sweden)
27. **The Search for Truth Amidst the Bias Addressing Unmeasured Confounding in Observational Studies Addressing Unmeasured Confounding in Observational Studies [141]**
 Hu Li, Xiang Zhang, Douglas E. Faries, James Stamey, Guido W. Imbens. (United States)
28. **Causal Mediation Analysis in Sibling Studies [142]**
 Mollie Wood, Hedvig Nordeng, Sonia Hernandez-Diaz. (Norway)
29. **The Risk of Acute Myocardial Infarction Associated with Non-Steroidal Anti-Inflammatory Drugs Users: Impact of Additional Confounding Control for Variables Collected from Self-Reported Data [143]**
 Mohammad Bakhriansyah, Patrick C Souverin, Anthonius deBoer, Olaf H Klungel. (Netherlands)
30. **Bias Due to Selective Inclusion of Variables, Not Related to the Exposure nor to the Outcome, into a Propensity Score Model - A Simulation Study [144]**
 Pär Karlsson, Marie Linder. (Sweden)
31. **Impact of Exposure Definition on Misclassification and Immortal Time Bias in Administrative Claims Databases [145]**
 Mareva Faure, Anne-Marie Castilloux, Agnès Lillo-Le-Louët, Yola Moride. (Canada)
32. **Immortal Time Bias in Pharmacoepidemiological Studies on Cancer Patient Survival: Empirical Illustration for Beta-Blocker Use in Four Cancers with Different Prognosis [146]**
 Janick Weberpals, Lina Jansen, Myrthe P. van Herk-Sukel, Josephina G. Kuiper, Mieke J. Aarts, Pauline A. Vissers, Hermann Brenner. (Germany)

Confounding/Bias



- 33. Examination on an Optimal Length of Exclusion Period for Identifying New Users for Pharmacoepidemiologic Study [147]**
Edward Chia-Cheng Lai, Chien-Hsun Li, Yea-Huei Kao Yang. (Taiwan)
- 34. Assessment of Potential Confounding Bias in Historical New Users of ACE Inhibitors (ACEIs) [148]**
David Smith, Eric Johnson, Alan Go, Kristi Reynolds, Andrea Cassidy-Bushrow, Ketan K Mane, Xuihai Yang, Jamie Thompson, Amanda Petrik, Sigrid Behr, Pritibha Singh, Raymond Schlienger. (United States)
- 35. Pharmacologically Pertinent Period of Effect (PPPE) [149]**
Melanie Suissa, Jacques Leloir. (Canada)
- 36. Observational Study or Low-Intervention Clinical Trial: It Is a Grey Area [150]**
Shreya Dave, Dimitri Bennett, Huifang Liang, Paul Dolin. (United Kingdom)
- 37. Investigating High Colorectal (CRC) Cancer Rates Shortly After Initiation in a New-User Study of Antidepressants (AD) and CRC [151]**
Monica E D'Arcy, Jennifer L Lund. (United States)
- 38. Machine Learning and Conventional Covariate Adjustment Methods for Control of Measured and Unmeasured Confounding [152]**
Syed S Islam, Raghava Danwada, Minoti Ganguli, William Finkle, Gregory Ridgeway. (United States)
- 39. Development and Evaluation of an Algorithm to Link Mothers and Children in Observational Data [153]**
James Weaver, Jill Hardin, Patrick Ryan. (United States)
- 40. Development of a Multi-Phase Claims-Based Algorithm for Pregnancy Research [154]**
Syd Phillips, Karin Johnson, Sophie W Shen, Kimberley J Woodcroft, Susan A. Oliveria, Teresa A Simon. (United States)
- 41. Importance and Challenges in Defining Condition Eras for Observational Database Research - An Orthopedic Example [155]**
Chantal E. Holy, Abhishek Chitnis, Jason Lerner. (United States)
- 42. Validation of Algorithm to Identify Adequate Intravesical Bacillus Calmette-Guerin Therapy in Non-Muscle-Invasive Bladder Cancer Patients in Administrative Claims [156]**
Ching-Yi Chuo, Kyle A Richard, Marko Zivkovic, Jingbo Yi, Thirupathi Pattipaka, Christina Derleth, Shih-Wen Lin. (United States)
- 43. Novel Linkage of Hospital Pharmacy Dispensing Database with Inpatient Diagnoses in England: Evaluation Using the Case of Antibiotics and Treatments for MRSA [157]**
Patrick Rockenschaub, David Ansell. (United Kingdom)
- 44. An Algorithm for Identifying and Representing Treatment Exposure Patterns [158]**
Eugene Chibrikov, John-Michael Gamble. (Canada)
- 45. Validation of Algorithms to Identify Perinatal Outcomes in Large Claims Databases [159]**
Mengdong He, Jennifer A Cottrall, Devan D Bartels, Sara Z Dejene, Helen Mogun, Krista F Huybrechts, Sonia Hernández-Díaz, Brian T Bateman. (United States)
- 46. Evaluation of Case-Finding Algorithm for Venous Thromboembolism Outcome [160]**
Megan E Reidy, Jill L de Jong, Lauren Zichittella, W. Katherine Yih. (United States)
- 47. Breaking News: Novel Design Methodology Combining a Registry with Claims Data to Study Fracture Non-Union [161]**
Christina Mack, Alessandra Pavesio, Kim Kelly, Tawana Wester, John T Jones, Greg Maislin, Debra Irwin, Emma Brinkley, Robert D Zura. (United States)
- 48. Can We Use Hospital Specific Billing Data for Longitudinal Studies? Example from Total Arthroplasty in IMS [162]**
Katherine Etter, David Wei, Andrew Yoo, Iftekhar Kalsekar. (United States)
- 49. Identifying Relapsing-Remitting Multiple Sclerosis (RRMS) in United States Integrated Delivery Network Healthcare Claims Data [163]**
Hoa V Le, Chi T Truong, Aaron W Kamauu, John R Holmén, Christopher L Fillmore, Monica G Kobayashi, Schiffo L Wong. (United States)
- 50. Proxies for Treatment Duration of Trastuzumab Emtrastine (T-DM1) Using Electronic Health Record (EHR) or Administrative Healthcare Claims Data [164]**
Thibaut Sanglier, Thirupathi Pattipaka, Christine Schuhmacher, Michael Taylor, Adrian Cassidy. (Switzerland)
- 51. A Review of Population- and Individual-Level Measures to Study Prescription Drug Misuse Based on Drug Dispensing Data [165]**
Micaela Tjäderborn, Lotte Rasmussen, Anton Pottegård. (Sweden)
- 52. Provider Details Are Smarter Than You Think: An Example of Antidepressant Initiators Within Claims Data [166]**
Greta A Bushnell, Til Stürmer, Christina Mack, Virginia Pate, Matthew Miller. (United States)
- 53. Measuring Breast Cancer Screening Rates in a US Administrative Claims Database [167]**
Karin E Johnson, Stacey Fedewa, Dawn Wiatrek, Jennifer Lombardo, Melissa Pirolli, Susan A Oliveria. (United States)
- 54. Impact of Different Assumptions on Incidence Estimates of Pediatric Diseases Derived from Healthcare Data: A Retrospective Cohort Study [168]**
Osemeke U. Osokogu, Alexandra Pacurariu, Mees Mosseveld, Peter Rijnbeek, Daniel Weibel, Katia Verhamme, Miriam Sturkenboom. (Netherlands)
- 55. Comparison of Approaches for Identifying Fatal Cardiovascular Disease in Medicare Using Administrative Data [169]**
Fenglong Xie, Lisandro D Colantonio, Jeffrey R Curtis, Meredith Kilgore, Emily B Levitan, Keri L Monda, Monika M Safford, Ben Taylor, Mark Woodward, Paul Muntner. (United States)

Data Algorithms for Pharmacoepidemiology

- 56. Does ICD10 Improve Our Ability to Separately Identify Diabetes Types I and II Cohorts In Claims and Electronic Health Record Data? [170]**
 Rebecca J Levin, Irene Cosmatos, Lee Kallenbach, Jamie Reifsnnyder, Dieck Gretchen. (United States)
- 57. To What Extent Do Data from Pharmaceutical Claims Under-Estimate Opioid Analgesic Utilisation in Australia? [171]**
 Natasa Gisev, Sallie-Anne Pearson, Emily A Karanges, Briony Larence, Nicholas A Buckley, Sarah Larney, Timothy Dobbins, Bianca Blanch, Louisa Degenhardt. (Australia)
- 58. Testing the Validity of Comparative Reproductive Tract Cancer Rates Combining Two Methods of Subject Identification in a Large Cohort Study of Rural Northern Vietnamese Women [172]**
 Arlene Tave, Judith Jones, Sharon Kardia. (United States)
- 59. Rehospitalization of Lung Cancer Patients Using EMR Data in China [173]**
 Wenhua Liang, Meng Shu, Jiangwei Sun, Hong Qiu, Jianxing He. (China)
- 60. Is Mirtazapine Addictive? What Can Big Data Reveal About Mirtazapine's Abuse Potential [174]**
 Dimitrios Spachos, Georgios Papazisis, Eirini Apostolidou, Dimitrios Kouvelas, Panagiotis Bamidis. (Greece)
- 61. Prevalence of Co-Administrations with Bexsero® in the UK: Comparison Between Post Marketing Spontaneous Reports Data and Electronic Health Care Records Observational Data [175]**
 Olivia B Mahaux, Emmanuel Aris, Lingling Yue, Vincent Bauchau. (Belgium)
- 62. Application of an Infusion Related Reactions Algorithm for US Claims Data [176]**
 Leo J Russo, Xiaofeng Zhou, Rongjun Shen. (United States)
- 63. Post-Marketing Safety Surveillance: Incorporation of a Test for Trends [177]**
 Nicole Kellier-Steele, E. Alan Thompson, Brenda Crowe, Kenneth Hornbuckle. (United States)

- 64. Identification of Inflammatory Bowel Disease Exacerbations and Multiple Sclerosis Relapses from Electronic Primary Health Care Records: Validation of Algorithms [178]**
 Gillian C Hall, M Yousuf Karim, Paul T Davies, Fiona Hill, Mendel D Haag. (United Kingdom)

Drug Utilization - Circulatory

- 65. Antihypertensive and Lipid-Lowering Drug Use Patterns in Patients with Ischaemic Stroke or Transient Ischaemic Attack [179]**
 Norazida Ab Rahman, Alfi Yasmina, Olaf H Klungel. (Netherlands)
- 66. Appropriateness of Ticagrelor Ambulatory Use in Quebec [180]**
 Jean-Pierre Grégoire, Paul Poirier, Norma Perez, Éric Demers, Jocelyne Moisan. (Canada)
- 67. Use of Statins in Primary Health Care - Brazil [181]**
 Renata C. Nascimento, Juliana Alvares, Augusto A. Junior, Francisco A Acurcio. (Brazil)
- 68. Geographic Variation in High-Intensity Statin Use in US Medicare Beneficiaries Following Myocardial Infarction [182]**
 Emily B Levitan, Paul Muntner, Yuling Dai, Mark Woodward, Matt Mefford, Lisandro D. Colantonio, Robert S. Rosenson, Keri L. Monda, Vera Bittner, Meredith L. Kilgore. (United States)
- 69. Early Users of Sacubitril/Valsartan in Ambulatory Care of Heart Failure [183]**
 Joseph Vasey, Patricia Russo, Alina Bogdanov, Jessica Ken. (United States)
- 70. Characteristics of Early Sacubitril/Valsartan Users in US Electronic Health Record Data [184]**
 Joshua J Gagne, Theodore Tsacogianis, Sara B Wirta, James R Rogers, Frederico Calado, Chun-Lan Chang, Stuart Turner, Bogdan Balas, Abdurrahman Abdurrob, Mehdi Najafzadeh, Shirley V Wang. (United States)
- 71. Antihypertensive Drug Treatment Prescribed for Essential Hypertension in a Private Hospital in South Sumatra, Indonesia [185]**
 Erna Kristin, Alfi Yasmina. (Indonesia)

- 72. NSAIDs Utilization in a Large Cohort of Italian Elderly in Secondary Prevention for Cerebro/ Cardiovascular Disease [186]**
 Giuseppe Roberto, Claudia Bartolini, Federico Rea, Arianna Ghirardi, Graziano Onder, Cristiana Vitale, Gianluca Trifiro, Ursula Kirchmayer, Alessandro Chinellato, Ersilia Lucenteforte, Giovanni Corrao, Alessandro Mugelli, Francesco Lapi, Rosa Gini. (Italy)
- 73. Use of Lipid-Lowering Treatments in Patients Infected with Human Immunodeficiency Virus [187]**
 Sampada K Gandhi, Meera Kumar, Chuntao Wu, Katarina Kralova, Juhaeri Juhaeri. (United States)

Drug Utilization - Cancer

- 74. Demographic and Clinical Characteristics of Lung Cancer Patients Receiving Target Treatment [188]**
 Lukas Löfling, Gunnar Wagenius, Shahram Bahmanyar. (Sweden)
- 75. Dosing Adequacy of Sunitinib in Taiwanese Patients with Renal Cell Carcinoma, a Nationwide Study [189]**
 Hsu-Chih Chien, Yea-Huei Kao Yang. (Taiwan)
- 76. Metastatic Castration-Resistant Prostate Cancer: Changes in Prescribing Patterns Since Abiraterone Approval in Quebec in 2012 [190]**
 Halima Lahcene, Armen Aprikian, Marie Vanhuysse, Franck Bladou, Noémie Prévost, Jason Hu, Fabio Cury, Wassim Kassouf, Sylvie Perreault, Alice Dragomir. (Canada)
- 77. Opportunities for Rapid Monitoring of New Cancer Treatments - Tyrosine Kinase Inhibitors in the Sentinel Database [191]**
 Anita K Wagner, Nicole Haug, Laura Hou, Emily C Welch, Christine Y Lu, Darren Toh. (United States)
- 78. Equity in Access to Tyrosine Kinase Inhibitors Among Veterans Diagnosed with Renal Cell Carcinoma [192]**
 Julie A Lynch, Kristine E Lynch, Brygida Berse, Donna Rivera, Ji won Chang, Daniel J Becker, Olga Efimonva, Scott L DuVall. (United States)

- 79. Treatment Pathways and Biomarker Testing in Malignant Melanoma: A Transformation in Treatment Regimens in European Countries [193]**
Dorothea von Bredow, Nikolaus Kolb, Birgit Ehlken, Nina Schmid. (Germany)
- 80. An Algorithm to Identify Somatostatin Analogue (SSA) Dose Escalations [194]**
Jessica J Jalbert, Jie Meng, Lauren K Brais, Trevor Dutton, Sonia J Pulgar, Anthony Berthon, Sylvie Gabriel, Jerome Dinot, Matthew H Kulke, Roman Casciano. (United States)
- 81. Treatment Patterns and Trends of Patients Dying of Prostate Cancer in Quebec: A Population-Based Study [195]**
Jason Hu, Alice Dragomir, Joice Rocha, Marie Vanhuysse, Wassim Kassouf, Fabio Cury, Armen Aprikian. (Canada)
- 82. Utilization and Patterns of Potentially Inappropriate Use of Phosphodiesterase Type 5 Inhibitors in the United Kingdom [196]**
Yi Lian, Hui Yin, Serge Carrier, Robert W. Platt, Samy Suissa, Laurent Azoulay. (Canada)
- 83. Assessment of Treatment Patterns in Ovarian Cancer Patients, Stratified by BRCA Testing and Platinum Sensitivity: A Study Using a United States Administrative Claims Database [197]**
William K Mountford, Tapashi Dalvi, Sudeep Karve, Caitlin Knox, Elise Kaufman, Jerzy E Tyczynski. (United States)
- 84. Use of Multiple Sources of Electronic Healthcare Record (EHR) Drug Data to Study Somatostatin Analogue (SSA) Dosing for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Treatment [198]**
Jessica J Jalbert, Jie Meng, Lauren K Brais, Trevor Dutton, Sonia J Pulgar, Anthony Berthon, Sylvie Gabriel, Jerome Dinot, Matthew H Kulke, Roman Casciano. (United States)

- 85. Oncoematologic Utilization of Rituximab: Linking Administrative with Hospital Pharmacy Data to Study Real World Utilization of Infusive Antineoplastics [199]**
Giuseppe Roberto, Valentino Moscatelli, Claudia Bartolini, Alessandro Barchielli, Davide Paoletti, Silvano Giorgi, Sandra Donnini, Rosa Gini. (Italy)
- 86. Use of SARI for Benign Prostatic Hypertrophy and Risk of High Grade Prostate Cancer: A Nested Matched Case-Control Study Within a Cohort on French Health Insurance Data Linked to Pathology Records in Brittany, France [200]**
Lucie-Marie Scailteux, Frédéric Balusson, Emmanuel Nowak, Sébastien Vincendeau, Nathalie Rioux-Leclercq, Emmanuel Oger. (France)

Drug Utilization - Diabetes

- 87. Understanding the Treatment Choice Between Insulin Glargine, Detemir and Human Insulin: Characteristics of Patients with Type 2 Diabetes Starting Insulin in Five European Countries [201]**
Marloes Bazelier, Nils Ekström, Øystein Karlstad, Peter Vestergaard, Jari Haukka, Frank de Vries, Kari Furu, Morten Andersen, Marie De Bruin. (Netherlands)
- 88. Use of Oral Glucocorticoids in Adults: A Population-Based Study [202]**
Antoine Pariente, Anne Bénard, Elodie Pambrun, Bernard Bégaud, Laurence Fardet, Pernelle Noize. (France)
- 89. Use of Empagliflozin and Other Non-Insulin Glucose Lowering Drugs (GLD) in the United Kingdom (UK) [203]**
Soulmaz Fazeli Farsani, Christina Raabe, Cynthia J. Girman, Will Spencer, Jyothis George, Patrice Verpillat, Kimberly G. Brodovicz. (Germany)
- 90. Impact of Hospitalization on Quality of Drug Use in Type 2 Diabetes Patients [204]**
Anara Richi Dossa, Jocelyne Moisan, Line Guénette, Sophie Lauzier, Jean-Pierre Grégoire. (Canada)
- 91. Availability of Essential Medicines for Diabetes and Cardiovascular Diseases in Health Facilities of Bangladesh: A Population Based Study [205]**
Md Jamal Uddin, Muhammed AB Chowdhury, Yaser T. Bazargani, Md Iqbal Hossain, Nasar U. Ahmed. (Bangladesh)
- 92. NPH Insulin Use by Patients with Type 2 Diabetes Mellitus in Minas Gerais, Brazil: Prevalence and Associated Factors [206]**
Michael Ruberson da Silva, Luísa Monteiro de Melo, Jéssica Barreto dos Santos, Leonardo Maurício Diniz, Juliana Alvares, Francisco de Assis Acurcio. (Brazil)
- 93. Prescribing Patterns and Characteristics of Patients with Type 2 Diabetes Mellitus Newly Initiated Sodium Glucose Co-Transporter 2 Inhibitors in Taiwan [207]**
Shih-Chieh Shao, Yuk-Ying Chan, Ming-Jui Hung, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- 94. Real Life Drug USAGE of New Glucose Lowering Drugs (GLD): Results of an Intensive Monitoring Study in Portugal [208]**
Carla M Torre, Jose Guerreiro, Patricia Longo, Helder Mota Filipe, Joao Filipe Raposo, Hubert Leufkens, Ana Paula Martins. (Portugal)
- 95. Characteristics of New Users of Dapagliflozin and Other Antidiabetic Drugs; United States (US), United Kingdom (UK), and the Netherlands [209]**
Lia Gutierrez, Daniel Beachler, Jetty Overbeek, Lisa McQuay, Ruihua Yin, Josine Kuiper, Leah McGrath, Jamileh Jemison, Eline Houben, Stephan Lanes, Alicia Gilsenan, Myrthe van Herk-Sukel. (Spain)
- 96. Characteristics of New Users of Dapagliflozin and Other Antidiabetic Drugs, United States and United Kingdom [210]**
Catherine Johannes, Daniel Beachler, Ryan Ziemiecki, Ruihua Yin, Leah McGrath, Jamileh Jemison, Stephan Lanes, Alicia Gilsenan. (United States)
- 97. Post-Authorisation Safety Study of Pioglitazone Use in Denmark Post Label Change [211]**
Javier Cid Ruzafa, Sinna P Ulrichsen, Dimitri Bennett, Vera Ehrenstein. (United Kingdom)

- 98. Examination of the Association Between Incident Type 2 Diabetes and Corticosteroid Exposure Among Commercially Insured COPD Patients in the US [212]**
 Cynthiya Ruban, Joseph Marino, William Saunders, Christopher Blanchette. (United States)
- 99. Characteristics of Patients Initiating Empagliflozin (EMPA) or Other Non-Insulin Glucose Lowering Drugs (GLDs) in the United Kingdom (UK) [213]**
 Soulmaz Fazeli Farsani, Christina Raabe, Cynthia J. Girman, Will Spencer, Jyothis George, Patrice Verpillat, Kimberly G. Brodovicz. (Germany)
- 100. Use of Dual Therapy for Treating Diabetes in the UK [214]**
 Samantha Wilkinson, Heide Stirnadel-Farrant, Laurie Tomlinson, Liam Smeeth, Ian Douglas. (United Kingdom)
- 101. Discontinuation of Oral Diabetes Regimens Among Patients with Reduced Renal Function [215]**
 Christianne L. Roumie, Jea Young Min, Amber Hackstadt, Johnathan Chipman, Robert Greevy, Adriana Hung, Carlos G. Grijalva, Marie R. Griffin. (United States)
- 102. Hypoglycemia in Portugal Study - Pharmacy (HIPOS-PHARMA) [216]**
 Carla Torre, Sónia Romano, José Guerreiro, Patrícia Longo, Ana Miranda, João Conceição, Sílvia Alão, Pedro Lares. (Portugal)
- Health Care Utilization & Costs**
- 103. Evaluating the Economic Burden and Health Care Utilization of Migraine in the US Department of Defense Population [217]**
 Neel Vaidya, Lin Xie, Yuexi Wang, Juan Du, Onur Baser. (United States)
- 104. Prevalence and Health Expenditure of Amyotrophic Lateral Sclerosis in Taiwan (2003-2014) [218]**
 Jason C. Hsu, Chih-Ho Chou. (Taiwan)
- 105. Epidemiology-Based Health Resource Allocation for Cancer Prevention and Treatment in Taiwan [219]**
 Jason C. Hsu, Peng-Chan Lin, Hone-Jay Chu. (Taiwan)
- 106. Assessing the Economic Burden and 30-Day Readmission Rates Among Patients with Heart Failure in the US Veteran Health Administration Population [220]**
 Shivani Pandya, Yiwen Cao, Li Wang, Onur Baser. (United States)
- 107. The Use of Hospital Care by People with Intellectual Disabilities in England [221]**
 Jessie O. Oyinlola, Gerald Tompkins, Rachael Williams, Gyles Glover. (United Kingdom)
- 108. Coverage of Treatments for Lower Back Pain: A Pilot Study [222]**
 Dora H. Lin, Irene B. Murimi, Jonathan Tierce, Christopher Jones, G. Caleb Alexander. (United States)
- 109. Medicine Use Profiles in Residential Aged Care: Can They Inform Policy and Guide Practice? [223]**
 Lisa G Pont, Magda Raban, Andrew Georgiou, Johanna Westbrook. (Australia)
- 110. Trends in Single Source Generic Product Availability [224]**
 Jodi B Segal, Aditi P Sen, Najlla Nassery, Jeromie Ballreich. (United States)
- 111. Impact of Non-Persistence to Subcutaneous TNF- α Inhibitors on Medical Resource Utilization and Costs [225]**
 Manon Belhassen, Florence Tubach, Christophe Hudry, Marie-Christine Woronoff, Laurie Levy-Bachelot, Liliane Lamezec, Eric Van Ganse, Bruno Fautrel. (France)
- 112. Health Care Utilization (HCU) and Costs of Systemic Lupus Erythematosus (SLE) in the United States: Systematic Review [226]**
 Edward Hammond, Irene B. Murimi, Dora H. Lin, Hong Kan, Jonathan Tierce, Xia Wang, Henk Nab, Barnabas Desta, G. Caleb Alexander. (United States)
- 113. The Impact of Rheumatoid Arthritis on Length of Stay and Health Care Costs Following Knee and Hip Replacements: A CPRD-HES Linked Study [227]**
 Edward Burn, Christopher J Edwards, David W Murray, Cyrus Cooper, Nigel K Arden, Rafael Pinedo-Villanueva, Daniel Prieto-Alhambra. (United Kingdom)
- 114. US Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016 [228]**
 Jing Luo, Aaron Kesselheim, Jerry Avorn. (United States)
- 115. Cost Analysis of Patients Undergoing Maintenance Hemodialysis - A Multicentric Patient Perspective Study [229]**
 Uday Venkat Mateti, Anantha Naik Nagappa, Ravindra Prabhu Attur. (India)
- 116. Abstract Withdrawn [230]**
- 117. Cost-Effectiveness of Human Papilloma Virus (HPV) Vaccination in Nigeria: A Decision Analysis Using Pragmatic Parameter Estimates For Cost and Programme Coverage Human Papilloma Virus (HPV) Vaccination in Nigeria: A Decision Analysis Using Pragmatic Parameter Estimates for Cost and Programme Coverage [231]**
 Obinna Ikechukwu Ekwunife, Stefan K Lhachimi. (Nigeria)
- 118. Additive Impact of Pneumococcal and Influenza Vaccination on Spending for Acute Respiratory Infection, Pneumonia and Influenza Among Medicare Beneficiaries [232]**
 Tham T Le, Julia Slejko, Eberchukwu Onukwugha. (United States)
- 119. Cost Analysis of Idiopathic Pulmonary Fibrosis: A Nintedanib Example [233]**
 Hristina Lebanova, Bogdan Kirilov, Evgeni Grigorov, Vessela Ninova, Ilko Getov. (Bulgaria)
- 120. Complications, Comorbidities and Associated Acute Care Utilization in Hyperuricemic Patients [234]**
 Kathy W Belk, Christopher W Craver. (United States)
- 121. Effects of Initiating Cardiac Rehabilitation After Myocardial Infarction on Subsequent Hospitalizations in Older Adults [235]**
 Montika Bush, Ross J Simpson, Anna Kucharska-Newton, Gang Fang, Til Stürmer, M. Alan Brookhart. (United States)

- 122. A Descriptive Analysis of the Health Care Utilization and Costs of Patients Diagnosed with Multiple Myeloma in the U.S. Medicare Population [236]**
Adesuwa Ogbomo, Allison Keshishian, Lin Xie, Yiyun Lin, Onur Baser. (United States)
- 123. Drug Related Hospital Admission: Predictors and Cost Implicated [237]**
Justin kurian, Savitha RS, Ann Kuruvilla, Manikanta Nalla, Sai Ashritha Allamaraju, Dalwin Wilson, Narahari MG. (India)

Heterogeneity and Generalizability

- 124. Can We Generalize? An Example of Older Adults with Metastatic Colorectal Cancer [238]**
Michael Webster-Clark, Hanna Sanoff, Til Stürmer, Jennifer L Lund. (United States)
- 125. Generalisability of Salford Lung Study: Comparing COPD Patients Enrolled in a Regional Effectiveness Trial with Matched COPD Patients Across England [239]**
Dr Matthew Sperrin, Tjeerd Van Staa, Mike Barrowman, Alexander Pate, Dave Webb, Jeanne M Pimenta, Rachael Williams, Kourtney Davis. (United Kingdom)
- 126. The Role of Gender as an Effect Measure Modifier in the Seek, Test, Treat, Retain (STTR) HIV Consortium: Evaluating the Relationship Between Antiretroviral Adherence and Poly-Substance Use [240]**
Maria E Perez Trejo, Lauren N Strand, Robin M Nance, Bridget Kruszka, Frederick L Altice, Curt G Beckwith, Redonna Chandler, Charles M Cleland, Heidi M Crane, Chinazo O Cunningham, William Cunningham, Mika Matsuzaki, Joseph A Delaney, Daniel J Feaster, Irene Kuo, Lisa Metsch, Elise Riley, Wendee Wechsberg, Shoshana Y Kahana, Sandra A Springer. (United States)
- 127. Is Patient Exposure a Determinant of Timing and Frequency of Safety Issues? [241]**
Alexandra Pacurariu, Christina Hoeve, Peter Arlett, Georgy Genov, Jim Slattery, Miriam Sturkenboom, Sabine Straus. (Netherlands)

Occult Outcomes

- 128. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration-Relationships [242]**
Morten Rix Hansen, Ida B Kuhlmann, Anton Pottegård, Per Damkier. (Denmark)
- 129. A Retrospective Cohort review of Time in the Therapeutic Range (TTR) for Patients on Warfarin at a Dedicated Tertiary and District Level INR Clinic in South Africa [243]**
Ismaeel Ebrahim. (South Africa)
- 130. The Use of Phthalate-Containing Drugs: A Danish Nationwide Study on Exposure Levels [244]**
Zandra Nymand Ennis, Anne Broe, Anton Pottegaard, Jesper Hallas, Thomas Ahern, Per Damkier. (Denmark)
- 131. Investigating Disparities in Rate of Immune Recovery Among Patients Living with HIV [245]**
Sabina O Nduaguba, Kentya H Ford, James Wilson, Kenneth Lawson. (United States)
- 132. Determination of Serum Carbamazepine Concentration Using Dried Blood Spot Specimens for Resource Limited Settings [246]**
Saibal Das, Denise H Fleming, Binu S Mathew, Blessed Winston A, Appaswamy T Prabhakar, Mathew Alexander. (India)

Patients of the World Unite! - HRQoL/PROs/Self Management

- 133. Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms [247]**
Martina Teichert, Tim W Schoenmakers, Michel Wensing, Peter A de Smet. (Netherlands)
- 134. Self-Management Practices in Type II Diabetic Patients; a Cross-Sectional Survey in Alexandria, Egypt [248]**
Reem Nagib, Maha Abdul-Latif, Laila AboulAtta, Mohamed A Mekkawy, Adel Abou-Ali. (Egypt)
- 135. Best Practices for the Design and Development of Patient Medication Information: A Systematic Review [249]**
Rebecca Mullen, James Duhig, Andrea Russell, Linda Scarazzini, Fabio Leviano, Michael Wolf. (United States)
- 136. Quality of Life of People Living with HIV/AIDS Initiating Antiretroviral Therapy in the Single Tablet Regimen Era [250]**
Juliana O Costa, Maria das Graças B Ceccato, Celline C Almeida-Brasil, Romara E Perdigão, Micheline R Silveira, Palmira F Bonolo, Francisco A Acurcio. (Brazil)
- 137. Self-Management Research of Asthma and Good Drug Use (SMARAGD Study): A Pilot Trial [251]**
Esther Kuipers, Michel Wensing, Peter de Smet, Martina Teichert. (Netherlands)
- 138. Patient Reported Symptoms as an Inducement for Medication Optimization [252]**
Martina Teichert, Tim W Schoenmakers, Michel Wensing, Peter A Smet. (Netherlands)
- 139. Reducing Antibiotic Self-Medication Practices in Lagos Southwest Nigeria: A Community-Based Intervention Study [253]**
Abdulwasiu A Busari, Ibrahim A Oreagba, O A Omotosho, Muhammed S Lawal. (Nigeria)
- 140. Medication Knowledge in Patients with Hypertension and Mellitus Diabetes [254]**
Pauline Bosco-Levy, Clément Prince, Pernelle Noize, Driss Berdaï. (France)
- 141. Mother's Understanding of Different Dosing Instructions for Oral Liquid Pediatric Medication [255]**
Anees Fathima, Kalpana Swain, Mounika Narla, Mada Harish, Sabiha Shaik, Varun Talla. (India)
- 142. Quantifying the Primary Worries of Patients with Acute Myeloid Leukemia to Promote Patient-Focused Drug Development: A Best-Worst Scaling [256]**
John Bridges, Jaein Seo, Allison Oakes, Ernest S Voyard, Bernadette O'Donoghue. (United States)



143. Association Between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument [257]

Daniel M Halperin, Lynn Huynh, Jennifer L Beaumont, Beilei Cai, Todor Totev, Rachel Bhak, Mei S Duh, Francis Vekeman, Maureen P Neary, David Cella. (United States)

144. Patient Preferences for Cholesterol Treatment Options: A Discrete Choice Experiment [258]

Jennifer Lewey, Niteesh K Choudhry, Joshua J Gagne, Jerry Avorn, Mehdi Najafzadeh. (United States)

145. Assessment of the Association Between the Burden of Carcinoid Syndrome Symptoms and the Quality of Life Among Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument [259]

Lynn Huynh, Todor Totev, Beilei Cai, Jennifer L Beaumont, Daniel M Halperin, Maureen P Neary, Rachel Bhak, Francis Vekeman, Mei S Duh, David Cella. (United States)

146. Value of Transfusion Independence in Severe Aplastic Anemia from Patients' Perspectives - A Discrete Choice Experiment [260]

A. Simon Pickard, Lynn Huynh, Jasmina I Ivanova, Todor Totev, Sophia Graham, Axel C Mühlbacher, Anuja Roy, Mei S Duh. (United States)

147. Describing Quality of Life and Disability of Fragility Fracture Patients in a Fracture Liaison Service in Quebec, Canada: A Prospective Cohort Study [261]

Andrea Senay, Sylvie Perreault, Josée Delisle, Clara Scattolin, Andreea Banica, Jean-Pierre Raynaud, Yves Troyanov, Pierre Beaumont, Mario Giroux, Alain Jodoin, G Yves Laflamme, Stephane Leduc, Jean-Marc MacThiong, Michel Malo, Gilles Maurais, Hai Nguyen, Stefan Parent, Pierre Ranger, Dominique Rouleau, Julio C Fernandes. (Canada)

148. Measurement Properties of Patient-Reported Outcome Instruments Evaluating Adherence to Inhaled Corticosteroids in Adults with Asthma: A Systematic Review [262]

Myriam Gagne, Louis-Philippe Boulet, Norma Perez, Jocelyne Moisan. (Canada)

149. Patient-Reported Outcome Instruments Used for Measurement of Adherence to Inhaled Corticosteroids in Adults with Asthma: A Systematic Scoping Review [263]

Myriam E. Gagne, Louis-Philippe Boulet, Norma Perez, Jocelyne Moisan. (Canada)

150. How Do Consumers Make Prescription Drug Decisions? An Evidence-Based Conceptual Model [264]

Douglas J Rupert, Olivia M Taylor, Vanessa Boudewyns, Sidney Holt, Helen W Sullivan, Kathryn J Aikin. (United States)

Pharmacoepidemiology in the Elderly

151. Mortality and Secondary Injury Following Traumatic Brain Injury in Older Medicare Statin Users [265]

Bilal R Khokhar, Linda Simoni-Wastila, Julia F. Slejko, Eleanor Perfetto, Min Zhan, Gordon S. Smith. (United States)

152. A Nationwide Study on Burden and Determinants of Anticholinergic Exposure in the French Elderly [266]

Annie Fourrier-Reglat, Marie Poiseuil, Julien Bezin, Paul de Boissieu, Pernelle Noize. (France)

153. Concurrent Use of Alcohol Interactive Medications and Alcohol in Older Adults: A Systematic Review of Prevalence and Associated Adverse Outcomes [267]

Alice Holton, Paul Gallagher, Tom Fahey, Gráinne Cousins. (Ireland)

154. Impact of Guideline-Concordant Medication Use on Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction [268]

Andrew R Zullo, Lori A Daiello, Yoojin Lee, David D Dore, Amal N Trivedi, W. John Boscardin, Sei J Lee, Michael A Steinman. (United States)

155. The Risk of Hip Fracture in Older People After Switching Between or Concurrently Using Mirtazapine and Other Antidepressants [269]

Michael J Leach, Nicole L Pratt, Elizabeth Roughead. (Australia)

156. Incidence of Adverse Drug Reactions Among Elderly Patients: A Systematic Review and Meta-Analysis [270]

Krishna Undela, Dhaval Joshi, Madhan Ramesh. (India)

157. Predictors of Transitioning from Adherent to Non-Adherent Among Elderly Patients with Diabetes [271]

Marsha A Raebel, Wendy Dyer, Gregory A Nichols, Julie A Schmittiel. (United States)

158. Proton Pump Inhibitor Use and Fracture Risk in Older Adults [272]

Barbara N Harding, Noel S Weiss, Sascha Dublin. (United States)

159. The Efficacy of a Clinical Pharmacist Intervention on Inappropriate Prescribing for Geriatric Inpatients in Saudi Arabia: A Pre- Post- Intervention Study [273]

Muath Fahmi Najjar, Syed Azhar Syed Sulaiman, Majed Al Jeraisy. (Saudi Arabia)

160. Anti-Osteoporotic Drug Use and Cardiovascular Risk in Elderly Patients with Previous Heart Disease [274]

Chiara Sorge, Ursula Kirchmayer, Nera Agabiti, Silvia Cascini, Gianluca Trifirò, Francesco Lapi, Graziano Onder, Danilo Fusco, Marina Davoli, on behalf of I-GrADE. (Italy)

161. Comparative Persistence of Antimuscarinic Agents in Older Adults [275]

Scott Martin Vouri, Mario Schootman, Seth A Strope, Stanley J. Birge, Margaret A. Olsen. (United States)

162. Describing Performance Status Changes in Older Adults During Adjuvant Chemotherapy [276]

Halei C Benefield, Hanna K Sanoff, Jennifer L Lund. (United States)

163. Abstract Withdrawn [277]

164. Patterns in Bladder Antimuscarinics Use in Medicare Nursing Homes [278]

Daniela C Moga, Quishan Wu, Pratik Doshi. (United States)

165. Pharmacotherapy Use in Older Patients with Heart Failure and Reduced Ejection Fraction Living in Skilled Nursing Facilities [279]

Lin Li, Bill M. Jesdale, Anne Hume, Giovanni Gambassi, Robert J. Goldberg, Kate L. Lapane. (United States)



- 166. Initiation of Medications Acting on the Central Nervous System (CNS) and Fall-Related Injuries [280]**
 Zachary Marcum, Eric Larson, Rod Walker, Negar Golchin, Dori Rosenberg, Paul Crane, Sascha Dublin, Shelly Gray. (United States)
- 167. Comparative Effectiveness Study of Selective and Non-Selective Bladder Antimuscarinics on Antipsychotic Initiation in Medicare Nursing Homes [281]**
 Pratik Doshi, Daniela C Moga, Quishan Wu, Li Chen, Candace Brancato. (United States)
- 168. Changing Patterns of Antipsychotic and Sedative-Hypnotic Use in US Nursing Homes: Is There a Substitution Effect? [282]**
 Stephen Crystal, Richard Hermida, Scott Bilder, Olga Jarrin. (United States)
- 169. Medical Treatment In Frail Elderly Heart Failure Patients [283]**
 Emma Nielsen, Maja S Brockhusen, Sidsel Arnspang, Jens-Ulrik Rosholm. (Denmark)
- 170. Findings from a Pharmacist-Led Medication Reconciliation for Cancer Patients Initiating a New Cycle of Chemotherapy [284]**
 Danielle S Chun, Jenny L Lund, Aimee M Faso. (United States)
- 171. The Association of Potentially Inappropriate Medication at Older Age with Cardiovascular Events and Overall Mortality: A Systematic Review and Meta-Analysis of Cohort Studies [285]**
 Dana Clarissa Muhlack, Liesa Katharina Hoppe, Janick Weberpals, Hermann Brenner, Ben Schöttker. (Germany)
- 172. Association Between Proton Pump Inhibitors Use and Dementia Incidence in Elderly People [286]**
 Jin-Won Kwon, Hyun-Jin Song, Hae-Young Park, Ji-Won Park, Hyun Soon Sohn. (Korea, Republic of)
- 173. Medicare Claims-Based Measures of Poor Physical Function and Associations with Treatment and Mortality in Older Colon Cancer Patients [287]**
 Sophie E Mayer, Hung-Jui Tan, Sharon Peacock Hinton, Laura L Hester, Til Stürmer, Keturah R. Faurot, Michele Jonsson Funk, Hanna K. Sanoff, Jennifer L. Lund. (United States)

- 174. Prevalence and Correlates of Receiving Tramadol with Adjuvant Gabapentin among Nursing Home Residents [288]**
 Christine M. Ulbricht, Jacob N. Hunnicutt, Anne Hume, Kate L. Lapane. (United States)

Pharmacovigilance - Cancer

- 175. The Association Between Diabetes Mellitus, Use of Glucose Lowering Agents and Cancer Incidence Among Medicare Patients [289]**
 Mansour Almetwazi, Ioana Popovici, Gabriel Suci, Catherine A Harrington, Jesus Sanchez, Manuel Carvajal. (Saudi Arabia)
- 176. Hormone Replacement Therapy and Risk of Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS) and MGUS Progression in the UK Clinical Practice Research Datalink [290]**
 Marie C Bradley, Charlene McShane, Carmel M Hughes, Ola Landgren, Liam Murray, Lesley A Anderson. (United States)
- 177. The Increased Risk of Dipeptidyl-Peptidase-4 Inhibitors (DPP-4i) Use on Cancer Is Not Yet Proven: A Systematic Review and Meta-Analysis [291]**
 Jetty A Overbeek, Marina Bakker, Amber A van der Heijden, Myrthe P van Herk-Sukel, Ron M Herings, Giel Nijpels. (Netherlands)
- 178. Statin Use and Mortality Among Ednomerial Cancer Patients: A Population-Wide Cohort Study [292]**
 Freija Verdoodt, Cecilie Dyg Sperling, Merete Kjær Hansen, Christian Dehlendorf, Søren Friis, Susanne K. Kjaer. (Denmark)
- 179. Pancreatic Cancer and Vildagliptin: Post-hoc Analysis of the Pan-European Non-Interventional Safety Study [293]**
 Rachael Williams, Carmen Serban, Sandra Lopez, Wolfgang Kothny, Raymond Schlienger. (United Kingdom)

Pharmacovigilance - Cardiovascular/Hematologic

- 180. Risk of Stroke and Myocardial Infarction in Users of Vasoconstrictor Drugs for Ear, Nose and Throat-Related Conditions [294]**
 Lamiae Grimaldi-Bensouda, Emmanuel Touzé, Jacques Bénichou, Yves Cottin, Elie Serrano, Bernard Bégaud, Lucien Abenhaim. (France)
- 181. Cardiotoxicity of Tyrosine Kinase Inhibitors Among Veterans Diagnosed with Renal Cell Carcinoma [295]**
 Kristine E Lynch, Julie A Lynch, Olga Efimova, Ji won Chang, Brygida Berse, Donna Rivera, Daniel J Becker, Scott L DuVall, Kelly K Filipksi. (United States)
- 182. Proton Pump Inhibitor Use Is Positively Associated with Incidence of Cardiovascular Disease [296]**
 Elizabeth J. Bell, Jennifer L St. Sauver, Aaron R. Folsom, Nicholas B. Larson, Hongfang Liu, Liwei Wang, Stephen Turner, Suzette J. Bielinski. (United States)
- 183. Statin Use and Venous Thromboembolism in Cancer: A Propensity Score Matched Cohort Study in the United States [297]**
 Joshua Brown, Sherif El-Refai, Val Adams, Penni Black, Jeffery Talbert. (United States)
- 184. Risk of a Combination of Amiodarone and Propafenone in Patients with Atrial Fibrillation: A 6-Year Population-Based Cohort Study [298]**
 Kai-Yu Liao, Pin-Hao Chen, Dan-Wei Choo, Yu-Wen Wang, Mu-Mei Hu, Po-Yu Chen, Wei Ho, Yi-Jung Wu, Zhen-Fang Lin. (Taiwan)
- 185. Incident Heart Failure Hospitalization Risk Associated with DPP-4 inhibitors Use in Type 2 Diabetes Following Metformin Treatment - A Novel Approach [299]**
 Chia-Hsui Chang, Yaa-Hui Dong, Li-Chiu Wu, Jing-Shiang Hwang. (Taiwan)
- 186. Long-Term Risk of Acute Myocardial Infarction, Stroke and Death with Outpatient Use of Clarithromycin: A Retrospective Cohort Study [300]**
 Andrew Mosholder, Joo-Yeon Lee, Esther Zhou, Elizabeth Kang, Mayurika Ghosh, Rima Izem, Jacqueline M. Puigbo, David J. Graham. (United States)

- 187. Incidence Rate of Rhabdomyolysis Compared Between Combined Statin and Fibrate Therapy or Monotherapy: Retrospective Cohort Study Using a Japanese Hospital Claims Database [301]**
 Kei Sagawa, Atsushi Takita, Shimpei Niwa, Goichi Tamura, Toru Sekine, Kaname Kawasugi, Chie Hasegawa, Hanako Saito, Masatoshi Tanigawa, Miyuki Arai, Yasushi Hasebe. (Japan)
- 188. Safety Signals for Major Adverse Cardiovascular Events as a Composite Outcome with Dipeptidyl Peptidase-4 Inhibitors in the FDA Adverse Event Reporting System [302]**
 Sheriza Baksh, Mara McAdams DeMarco, Jodi Segal, G. Caleb Alexander. (United States)
- 189. Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States [303]**
 Sandra Lopez Leon, Raymond G Schlienger, Jonathan R Korn, Elizabeth Wehler, Jason Yeaw. (United States)
- 190. Quality of Adverse Effect Reporting in the Use of Direct Oral Anticoagulants Against Warfarin in Atrial Fibrillation [304]**
 Fahad Saleh Alkhuzae, Hamdan Almalki, Shoeab Althubiani. (Saudi Arabia)
- 191. QTc-Prolongation When Using Two or More QTc-Prolonging Drugs: Prevalence and Associated Risk Factors [305]**
 Patricia M van den Bemt, Florine A Berger, Natasja M de Groot, I (Heleen) H van der Sijs, Teun van Gelder. (Netherlands)
- 192. Heat-Related Outcomes and Medication Use in Older Adults with Heart Failure [306]**
 J. Bradley Layton, Lily Wang, Wenhong Li, Jiacan Yuan, Soko Setoguchi. (United States)
- 193. Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS) [307]**
 Ahmed I. Fahmy, Mohamed A. Mekkawy, Adel Abou-Ali. (Egypt)
- 194. Statins for Primary Prevention and Rhabdomyolysis. A Nationwide Cohort Study in France [308]**
 Joel Coste, Cecile Billionnet, Annie Rudnichi, Rosemary Dray-Spira, Philippe Giral, Mahmoud Zureik. (France)
- 195. Association Between Medication-Related Adverse Events and Readmission in Acute Stroke [309]**
 James A. Crispo, Dylan P. Thibault, Yannick Fortin, Allison W. Willis. (Canada)
- 196. Risk of Severe Bleeding in Patients with Myocardial Infarction Receiving Clopidogrel - Nationwide Registry Study from Finland [310]**
 Tuire Prami, Houssein Khanfir, Pål Hasvold, Eeva Reissell, Juhani Airaksinen, Ville Kytö. (Finland)
- 197. QTc-prolongation When Using Two or More QTc-prolonging Drugs: A Retrospective Cohort Study [311]**
 Patricia M van den Bemt, Florine A Berger, Teun van Gelder, Matthijs L Becker. (Netherlands)
- 198. Initiation of Antihypertensive Monotherapy and Incident Fractures [312]**
 Jennifer L Hargrove, Yvonne M Golightly, Virginia Pate, Carri H Casteel, Laura R Loehr, Stephan W Marshall, Til Stürmer. (United States)
- 199. Adverse Effects in New Users of NOACs: A Symmetry Analysis Screening Study [313]**
 Maja Hellfritzsch, Lotte Rasmussen, Jesper Hallas, Anton Pottegård. (Denmark)
- 200. Novel Oral Antithrombotics and the Risk of Intraocular Bleeds [314]**
 Brian L. VanderBeek, Katherine E. Uyhazi, Wei Pan, Todd Miano. (United States)
- 201. No Evidence for an Association Between Renal Function and Bleeding Events in Patients on Coumarin Therapy: A Population-Based Study [315]**
 E Houben, E Smits, J.A. Overbeek, R.M.C. Herings, M.P.P. Van Herk-Sukel, M Teichert, P.A.G.M. De Smet. (Netherlands)
- 202. Bypassing Agents and Thromboembolic Events in Patients with Hemophilia and Inhibitors [316]**
 Katsiaryna Bykov, Rhonda L Bohn, Bruce M Ewenstein, John D Seeger, Jerry Avorn, Brian T Bateman. (United States)

Polypharmacy

- 203. The Use of Potentially Inappropriate Medications and Polypharmacy in Elderly Patients Receiving Long-Term Care Service [317]**
 Seung-Mi Lee, Hyen O La, Dong-churl Suh. (Korea, Republic of)
- 204. Polypharmacy and Mortality. New Insights from a Large Cohort of Older Adults by Detection of Effect Modification by Multi-Morbidity and Comprehensive Correction of Confounding by Indication [318]**
 Ben Schoettker, Kai Uwe Saum, Dana Clarissa Muhlack, Liesa Katharina Hoppe, Bernd Holleczek, Hermann Brenner. (Germany)
- 205. Polypharmacy in Older Adults - Individual and Community Determinants in Sao Paulo, Brazil [319]**
 Mariana Peixoto Socal, Gerard Anderson. (United States)
- 206. Sex Differences in Potentially Inappropriate Medication Use and Frailty at Nursing Home Transition: A Retrospective Cohort Study [320]**
 Laura C MacLagan, Colleen J Maxwell, Michael A Campitelli, Paula Rochon, David B Hogan, Kate L Lapane, Susan E Bronskill. (Canada)
- 207. The Effectiveness of Optimised Clinical Medication Reviews for Geriatric Patients: A Cluster Randomized Controlled Trial [321]**
 Jacqueline G Hugtenburg. (Netherlands)
- 208. Polypharmacy and Burden of Cardiovascular Medications in Older Adults with Heart Failure Near the End of Life [322]**
 Dr. Marie-Laure Laroche, Kristina Johnell, Johan Fastbom, Lucas Morin. (France)



- 209. Polypharmacy among Older and the Oldest People in Greece [323]**
Paraskevi Papaioannidou, Maria Michailidou. (Greece)
- 210. Prevalence of Polypharmacy Among Adults in Saudi Arabia [324]**
Bander Balkhi, Nasser Alqahtani, Mansour Almetwazi, Thamer Alshammari, Hisham Aljadhey. (Saudi Arabia)
- 211. Defining Pediatric Polypharmacy: A Scoping Review [325]**
Paul M Bakaki, Negar Golchin, Jennifer Staley, Alexis Horace, Hannah Johnson, Elia M Pestana Knight, Sharon B Meropol, Neal V Dawson, Almut G Winterstein, Lawrence C Kleinman, Shari Bolen. (United States)

Potpourri

- 212. Systematic Reviews in Ophthalmology: Methodological Considerations [326]**
Ana Penedones, Diogo Mendes, Carlos Alves, Francisco Batel Marques. (Portugal)
- 213. Knowledge About Patient Safety Policy by Health Professionals of a Public Hospital [327]**
Cristiane A Menezes de Padua, Gisele S Lemos, Ionara V Mota, Mário B Rosa, Edson Perini. (Brazil)
- 214. Abstract Selection Process for the 2017 International Society for Pharmacoepidemiology Mid-Year Meeting [328]**
Juan Hincapie-Castillo, Amelia Smith. (United States)
- 215. Knowledge and Practice on Safe Drug Use of Middle School Students in Beijing: a Cross-sectional Study [329]**
Yinchu Cheng, Yang Zhang, Yuting Pan, Yongping Pan, Jun Ma, Siyan Zhan. (China)
- 216. Prescription of Sedating H1-Antihistamines and the Risk of Road Traffic Crash: A Responsibility Study [330]**
Ludivine Orriols, Audrey Luxcey, Benjamin Contrand, Anne Bénard-Larivière, Antoine Pariente, Blandine Gadegbeku, Emmanuel Lagarde. (France)

- 217. The Association of Sedated Endoscopic Examination and Fatal Road Traffic Injuries [331]**
JoongYub Lee, Mi-Sook Kim, Bo Ram Yang, Kyoung-eun Kwon, Ye-jee Kim, Nam-Kyong Choi, Ju-Young Shin, Byung-Joo Park, Sun-Young Jung. (Korea, Republic of)
- 218. A Cumulative Meta-Analysis Evaluating the Risk of Cataracts Associated with Statins [332]**
Carlos Alves, Diogo Mendes, Francisco Batel Marques. (Portugal)
- 219. Pioglitazone and Risk of Bladder Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Studies [333]**
Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han. (United States)
- 220. Use of Phthalate Containing Medication and Sperm Quality Among Couples Referred to Assisted Reproduction [334]**
Anne Broe. (Denmark)
- 221. Can Lawyer Reports of Adverse Drug Events Affect Signal Detection in a Spontaneous Reporting Database? Investigation Through Simulation [335]**
Kristian Svendsen, Erika Olsson, Mollie Wood, Hedvig Nordeng. (Norway)

Risk Indices

- 222. Identifying Potentially Inappropriate Prescriptions in Whole Populations: Coding the Beers Criteria for Use with Large, Routinely Collected Population Datasets [336]**
Lise M. Bjerre, Timothy Ramsay, Catriona Cahir, Cristin Ryan, Roland Halil, Barbara Farrell, Kednapa Thavorn, Christina Catley, Steven Hawken, Robin Ducharme, Glenys Smith, Ulrika Gillespie, Douglas G Manuel. (Canada)
- 223. Identifying Potentially Inappropriate Prescriptions in Whole Populations: Coding the STOPP-START Criteria for Use with Large, Routinely Collected Population Datasets [337]**
Lise M Bjerre, Timothy Ramsay, Catriona Cahir, Cristin Ryan, Roland Halil, Barbara Farrell, Kednapa Thavorn, Christina Catley, Steven Hawken, Robin Ducharme, Glenys Smith, Ulrika Gillespie, Douglas G Manuel. (Canada)
- 224. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index [338]**
Dae Kim, Sebastian Schneeweiss, Robert Glynn, Lewis Lipsitz, Kenneth Rockwood, Jerry Avorn. (United States)
- 225. Electronic Medical Record Based Frailty Index to Predict Mortality [339]**
Dae H Kim, Abdurrahman Abdurrob. (United States)
- 226. Validation of Charlson Comorbidity Index in Japanese Hospital-Based Administrative Data [341]**
Tomomi Kimura, Takuya Nishimura, Toshifumi Sugitani. (Japan)
- 227. Development and Validation of an ICD-10 Version of the Combined Comorbidity Score [340]**
Jenny W Sun, James R Rogers, Qoua Her, Emily Welch, Tiffany S Woodworth, Catherine A Panozzo, Ting-Ying Jane Huang, Sengwee Toh, Joshua J. Gagne. (United States)
- 228. A Combined Comorbidity Indices of Charlson and Elixhauser Outperformed Both Measures Individually Across ICD-9 and ICD-10 Coding System [342]**
Marc Simard, Caroline Sirois, Bernard Candas. (Canada)
- 229. Predicting Disease Severity through Insights Gained from Electronic Medical Records: Case-Example of Alzheimer's Disease [343]**
Sandhya Mehta, William Mountford, Kathleen Lang. (United States)

End Session A



Spotlight Session - Adherence

- A. Observational Approaches for Comparing Treatment Continuation vs. Discontinuation [423]**
Alexis Krumme, Robert Glynn, Sebastian Schneeweiss, Niteesh Choudhry, Angela Tong, Joshua Gagne. (United States)
- B. Comparison of One-Year Non-Persistence Rates with Dabigatran or Rivaroxaban Versus Vitamin K Antagonists in Newly Treated Atrial Fibrillation Patients: A Competing Risk Analysis in the French Nationwide Healthcare Databases [424]**
Géric Maura, Antoine Pariente, François Alla, Joshua J. Gagne, Cécile Billionnet. (France)
- C. Adherence, Persistence, and Inpatient Utilization Among Adult Schizophrenia Patients Using Once-Monthly versus Twice-Monthly Long-Acting Antipsychotics [425]**
Matthew Alcusky, Dominic Pilon, Michael Durkin, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela Benson. (Canada)
- D. Opening the Black Box of the Trajectory Model-Building Process: An Example Using Real-World Statin Adherence Data [426]**
Ryan P Hickson, Izabela E Annis, Ley A Killea-Jones, Gang Fang. (United States)
- E. Trends in Adherence and Hip Fracture After Initiation of Bisphosphonates [427]**
Moa P Lee, Seoyoung C Kim, HoJin Shin, Gregory Brill, Joshua J Gagne. (United States)
- F. Predictors of Patient Reported Decision to Discontinue Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort [428]**
Vandana Ahluwalia, Mohammad Movahedi, Emmanouil Rampakakis, Angela Cesta, Xiuying Li, Sandra Couto, John Sampalis, Claire Bombardier and Other OBRI Investigators. (Canada)

- G. Adherence to Metformin Monotherapy as a Risk Factor for Hypoglycemia after Intensifying Treatment with a Sulfonylurea [429]**
Jea Young Min, Marie R Griffin, Robert A Greevy, Amber Hackstadt, Jonathan Chipman, Christianne L Roumie. (United States)
- H. Impact of Cancer Diagnosis on Persistence of Oral Antidiabetic Drugs [430]**
Louis Letinier, Yohann Mansiaux, Vanessa Labat, Antoine Pariente, Annie Fourier-Reglat. (France)

Spotlight Session - Molecular Epidemiology/Biomarkers/Pharmacogenetics

- I. CYP2B6 G516T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV Patients in Botswana [431]**
Marijana Vujkovic, Scarlett L Bellamy, Athena F Zuppa, Marc Gastonguay, Ganesh S Moorthy, Bakgaki R Ratshaa, Xiaoyan Han, Andrew P Steenhoff, Mosepele Mosepele, Brian L Strom, Richard Aplenc, Gregory P Bisson, Robert Gross. (United States)
- J. PPAR- α Genetic Variants Influence On-Treatment Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs and Undergoing Non-Urgent Percutaneous Coronary Intervention with Stent Implantation [432]**
Alfi Yasmina, Thomas O Bergmeijer, Paul W Janssen, Gerrit J Vos, Christian M Hackeng, Anthonius de Boer, Olaf H Klungel, Jurrien M ten Berg, Vera H Deneer. (Indonesia)
- K. Programmed Cell Death Receptor Ligand 1 (PD-L1) Expression; Epidermal Growth Factor Receptor (EGFR) and Kirsten RAS (KRAS) Mutations in Third-Line Therapy (3L) Non-Small Cell Lung Cancer (NSCLC) Patients: A Danish Cohort Study [433]**
Deirdre Cronin-Fenton, Tapashi Dalvi, Elizabeth Hedgeman, Mette Norgaard, Lars Pedersen, Hanh Hansen, Jon Fryzek, David Lawrence, Jill Walker, Anders Mellemegaard, Torben Rasmussen, Norah Shire, James Rigas, Danielle Potter, Stephen Hamilton-Dutoit, Henrik Sorensen. (Denmark)
- L. *In Silico* Integration of Epidemiologic and Genetic Evidence Reveals Candidate SNPs as Sex-Dependent Modifiers of Hip Arthroplasty Outcomes [434]**
Yelizaveta Torosyan, Stefan Dabic, Tigran Karapetyan, Yasameen Azarbaijani, Nilsa Loyo-Berrios, Vahan Simonyan, Terrie Kitchner, Murray Brilliant, Danica Marinac-Dabic. (United States)
- M. Communicating Genetic Research Results to Participants in Clinical Studies: Evidence and Strategies for Pharmacoepidemiology [435]**
Amalia M. Issa, David Pulford. (United States)
- N. Early HTA in Pharmacogenomics: A Case Example in Cardiovascular Drugs [436]**
Ekaterina V. Baranova, Joost W. Geenen, Folkert W. Asselbergs, Colin N. Palmer, Anthonius de Boer, Anke-Hilse Maitland - van der Zee, Anke M. Hövels. (Netherlands)
- O. Drug Interactions with Tamoxifen in a Danish Premenopausal Breast Cancer Cohort [437]**
Thomas P. Ahern, Timothy L. Lash, Anders Kjærsgaard, Per Damkier, Deirdre P. Cronin-Fenton. (United States)
- P. Pharmacoepidemiologic-Pharmacodynamic Method to Investigate the Mechanism of Adverse Drug Reaction (ADRs): Application to Movement Disorders ADRs of Antipsychotics [438]**
Dr. Francois Montastruc. (France)

Spotlight Session - Oncology

- Q. The Use of Incretin-Based Drugs and Colon Cancer Incidence in Patients with Type 2 Diabetes [439]**
Devin Abrahami, Hui Yin, Oriana H Yu, Michael Pollak, Laurent Azoulay. (Canada)
- R. A Population-Based Cohort Study to Assess the Potential Association Between Latanoprost Use and Primary Ocular Melanoma and Facial Cutaneous Melanoma [440]**
Prethibha George, Helle Kieler, Ingegård Berglind, Marie Linder, David Hägg, Wanning Xu, Qian Li, Duo Zhou, Ronald A. Schachar. (United States)



S. Identification of Staging for Bladder Cancer from Narrative Clinical Documents Using Natural Language Processing [441]

Jinghua He, Clint Cary, Anna Roberts, George Eckert, Fangqian Ouyang, David Haggstrom. (United States)

T. Effectiveness of Abiraterone in the Post-Docetaxel Setting on the Survival of Metastatic Castration-Resistant Prostate Cancer Patients in Quebec [442]

Jason Hu, Joice Rocha, Armen Aprikian, Marie Vanhuyse, Fabio Cury, Noemie Prevost, Alice Dragomir. (Canada)

U. Hb_{1c} Levels, Body Weight Change, and Risk of Pancreatic Cancer Among Patients with Long-Standing Diabetes Mellitus: A Case-Control Study [443]

Alexandra M. Mueller, Susan S. Jick, Christoph R. Meier, Cornelia Schneider. (Switzerland)

V. Blood Glucose Levels Prior to New-Onset Diabetes Mellitus Manifestation and Risk of Pancreatic Cancer: A Case-Control Study [444]

Alexandra M. Mueller, Susan S. Jick, Christoph R. Meier, Cornelia Schneider. (Switzerland)

W. Pre- and Post-Diagnostic Beta-Blocker Use and Lung Cancer Survival: A Population-Based Cohort Study [445]

Janick Weberpals, Lina Jansen, Walter E. Haefeli, Michael Hoffmeister, Martin Wolkewitz, Myrthe P. van Herk-Sukel, Pauline A. Vissers, Hermann Brenner. (Germany)

Spotlight Session - Pediatrics

X. Longitudinal Analysis of Psychotropic Medication Use in a Birth Cohort of Publicly-Insured U.S. Children: New Users and Cumulative Exposure [446]

Dinci Pennap, Mehmet Burcu, Julie M Zito. (United States)

Y. The Children Anticoagulation and Pharmacogenetics Study (CAPS): Developing a Dosing Algorithm for Acenocoumarol in Paediatric Patients [447]

Hedy Maagdenberg, Marc B Bierings, Anthonius de Boer, Anke H Maitland-van der Zee. (Netherlands)

Z. Rural and Appalachian Disparities in Neonatal Abstinence Syndrome Prevalence and Access to Opioid Abuse Treatment [448]

Amie Goodin, Jeffery Talbert, Joshua D Brown. (United States)

AA. Antibiotic Use in Children with Asthma [449]

Esmé J Baan, Hettie M Janssens, Tine Kerckaert, Johan C De Jongste, Miriam C Sturkenboom, Katia M Verhamme. (Netherlands)

BB. Physical Health Outcomes in Preschoolers with Prior Authorization for Antipsychotics [450]

Yu-Jung Wei, Xinyue Liu, Nikhil Rao, Marie McPherson, Mary Jones, Regina Bussing, Almut Winterstein. (United States)

CC. Early Life Antibiotic Use and the Risk of Asthma and Asthma Exacerbations in Children [451]

Fariba Ahmadizar. (Netherlands)

DD. Incidence of Bleeding and Thrombotic Events in Non-Institutionalized Paediatric Patients Using Warfarin in the United Kingdom [452]

Hedy Maagdenberg, Patrick C Souverein, Marc B. Bierings, Anthonius de Boer, Anke H. Maitland-van der Zee. (Netherlands)

EE. Preliminary Results of Cardiometabolic Risk Factors in Newly Diagnosed Individuals with Autism Spectrum Disorder (ASD) [453]

Caroline Croteau, Marc Dorais, Sylvie Perreault. (Canada)

Biologics, Molecular Pharmacoeconomics & Pharmacogenetics

1. A Study on Impact on G-CSF Prescription Patterns Following Guidance on Biosimilar Use [454]

Antonio Addis, Flavia Mayer, Alessandra Mecozzi, Laura Amato, Francesco Trotta. (Italy)

2. Chemotherapy-Induced Peripheral Neuropathy: Replication of the Results from Genome Wide Association Studies Within Multiple Myeloma Patients [455]

Seyed Hamidreza Mahmoudpour, Chiara Campo, Miguel I Da Silva Filho, Kari Hemminki, Hartmut Goldschmidt, Maximilian Merz, Asta Försti. (Germany)

3. Efficacy and Safety of Biosimilar Insulins Compared to Their Reference Products: A Systematic Review [456]

Carolyn Tieu, Mindi DePaola, Eleanor Lucas, Lori Rosman, Caleb Alexander. (United States)

4. Utilization of Biological Drugs for the Treatment of Rheumatoid Arthritis in Tuscany, Italy [457]

Giuseppe Roberto, Filippo Bardelli, Claudia Bartolini, Rosa Gini. (Italy)

5. Switching Between Epoetins Among Patients with Chronic Kidney Disease and Chemotherapy-Induced Anemia: An Italian Multi-Regional Population-Based Drug Utilization Study [458]

Valeria Belleudi, Francesco Giorgianni, Ylenia Ingrassiotta, Ilaria Marciànò, Francesco Trotta, Antonio Addis, Valentina Ientile, Alessandro Chinellato, Michele Tari, Rosa Gini, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Marina Davoli, Gianluca Trifirò, X Italian Biosimilar Network (ItaBioNet). (Italy)

6. Characteristics of Rheumatoid Arthritis Patients Initiating Therapy with Abatacept, Other Biologics, and Non-Biologic Disease-Modifying Anti-Rheumatic Drugs [459]

Veena Hoffman, Teresa A. Simon, Nan Liu, Nancy D. Lin. (United States)

Burden of Disease - Neurologic/Mental

7. Dementia and Alzheimer's Disease Among Older End-Stage Renal Disease Patients After Hemodialysis Initiation [460]

Matthew Daubresse, Mara McAdams Demarco, Sunjae Bae, Michelle Carlson, Alden Gross, Jeremy Walston, Dorry Segev. (United States)



- 8. The Burden of Medications with Depressions Side Effects in the US [461]**
Dima M Qato, Katharine Ozenberger, Mark Olsson. (United States)
- 9. Prevalence and Incidence of Autism Spectrum Disorders in Manitoba Preschoolers and Toddlers: 2004-2014 [462]**
Amani Hamad, I fan Kuo, Silvia Alessi-Severini, Salah Mahmud, Marni Brownell. (Canada)
- 10. The Prevalence and Severity of Low Back Pain among Adult North Indian population. A Cross Sectional Study [463]**
Dipika Bansal, Pushpendra Dhanuk, Babita Ghai. (India)
- 11. Comparison of Comorbid Conditions and Medication Utilization Among Patients with Multiple Sclerosis in the United States and England [464]**
Nicholas J Everage, Nydjie Payas, Denise Dietz, Madé Wenten. (United States)
- 12. Type and Risk of New Onset Seizures in Patients with/without Dementia [465]**
Ruby C Castilla-Puentes, Tatyana Falcone, Miguel Habeych. (United States)
- 13. Heat Stroke and Long-Term Clinical Neurological Outcomes: A Literature Review of Cases 2000-2016 [466]**
Emily M Lawton, Helen Pearce, Maud Taylor, Genevieve Gabb. (Australia)
- 14. Recent Age-Specific Prevalence and Incidence Time Trends of Autism Spectrum Disorder (ASD) in the United Kingdom (UK) Using the Clinical Practice Research Datalink (CPRD) [467]**
Mellissa Yong, Matthew McEnany, Jenny Chia, Christina Lorenz, Ulrike von Krosigk, Pavel Napalkov. (United States)
- 15. Understanding the Epidemiology of Chronic Lithium Use Leading to Renal Failure. The First Large Scale Study of 26,414 Incident Patients Starting Lithium, Using Data from the Health Improvement Network (THIN) in UK Primary Care [468]**
Ruben Hermans, Caroline J O'Leary, Sarah Rabhi, David Ansell. (United Kingdom)
- 16. Patient Profile of Trigeminal Neuralgia: A US Insurance Claims Database Study [469]**
Lisa C Vinikoor-Imler, Li Li, Susan Eaton, Anne Dilley. (United States)
- 17. Spinal Muscular Atrophy in Canada: Findings from the Canadian Neuromuscular Disease Registry [470]**
Victoria Hodgkinson, Josh Lounsberry, Pierre Bourque, Guy D'Anjou, Sue Dojeiji, Jean Mah, Laura McAdam, Anna McCormick, Hugh McMillan, Chantal Poulin, Kathryn Selby, Christen Shoemith, Louise Simard, Jiri Vajsar, Jodi Warman Chardon, Alex MacKenzie, Craig Campbell, Maryam Oskoui, Lawrence Korngut. (Canada)
- 18. Comorbid Conditions and Medication Utilization among Pediatric-Onset Multiple Sclerosis Patients in the United States and England [471]**
Nydjie Payas, Denise Dietz, Nicholas Everage, Satish Erlay, Madé Wenten. (United States)
- 19. Pain Sensitivity and Analgesic Use in 10,486 Adults: The Tromsø Study [472]**
Per-Jostein Samuelsen, Christopher Sivert Nielsen, Tom Wilsgaard, Audun Stubhaug, Kristian Svendsen, Anne Elise Eggen. (Norway)
- 20. Rare Disease Cohort Using Ambulatory Electronic Medical Record (AEMR) Data: Progressive Supranuclear Palsy (PSP) [473]**
Amanda Anderson, Deborah Casso, Susan A Oliveria, Tzuyung Douglas Kou. (United States)
- 21. Epidemiological Characteristics of Guillain-Barré Syndrome and Association with Preceding Infection: A Study Based on French Health Administrative Databases [474]**
Jeremie Rudant, Axelle Dupont, Alexandra Delannoy, Christophe Chaignot, Francis Bolgert, Yann Mikaeloff, Alain Weill. (France)
- 22. Identification of Rare Diseases Using Electronic Medical Records - Example of Allergic Bronchopulmonary Aspergillosis in UK Primary Care Data [475]**
Andrew Maguire, Michelle E Johnson, David W Denning, Germano LC Ferreira, Adrian Cassidy. (United Kingdom)
- 23. Causative Agent and Mortality Risk in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis [476]**
Megan H. Noe, Daniel B. Shin, Joel M. Gelfand, Misha Rosenbach, Robert G. Micheletti. (United States)
- 24. Assessment of Dietary Patterns and Physical Activity of Adolescent Students of Warangal [477]**
Vishwas Hunsure Nagendra, Varun Talla, Jhanavi Ramya, A Surekha, J Venkateshwar Rao. (India)
- 25. Incidence of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Results of 10 Years from the German Registry [478]**
David Nägele, Peggy Sekula, Maren Paulmann, Maja Mockenhaupt. (Germany)
- 26. The Descriptive Epidemiology of Cutaneous Lupus Erythematosus in Three Large U.S. Administrative Databases, 2010-2014 [479]**
Susan Audrey Hall, Li Li, Susan Eaton, Cristina Musselli, Anne B. Dilley. (United States)
- 27. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK [480]**
Noel Frey, Janine Jossi, Michael Bodmer, Andreas Bircher, Susan Jick, Christoph Meier, Julia Spoendlin. (Switzerland)
- 28. Rare Disease Cohort Using Ambulatory Electronic Medical Record (AEMR) Data: Duchenne Muscular Dystrophy (DMD) [481]**
Amanda Anderson, Deborah Casso, Susan A Oliveria, Tzuyung Douglas Kou. (United States)
- 29. Challenges in Accurate Diagnosis Determination: the Case of Idiopathic Normal Pressure Hydrocephalus [482]**
Chantal Holy, Andrew Yoo, Jason Lerner. (United States)

Burden of Disease - Other

- 30. Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Longitudinal Assessment of Severity, Progression, and Risk Factors [483]**
Beth Nordstrom, Jason Simeone, Byron J. Hoogwerf, Qian Li, Axel Haupt, Ayad K. Ali, Marilyn K. Boardman, Jay Bae. (United States)
- 31. Anti TNF- α Agents Usage as Second-Line Therapy in Inflammatory Bowel Disease: Based on Korean National Health Insurance Claims Data [484]**
Jung-Eun Ha, Eun Jin Jang, Jin-Won Kwon, Hyun Soon Sohn. (Korea, Republic of)
- 32. Cardiovascular Events in Hemodialysis [485]**
Kathy W Belk, Christopher Craver. (United States)
- 33. A Survey of Over-the-Counter Medication Use in Patients with Stevens - Johnson Syndrome, Toxic Epidermal Necrolysis, and Overlap Syndrome [486]**
Katherine Sullivan, Meghan Jeffres, Robert Dellavalle, Robert Valuck, Jonathan Campbell, Heather Anderson. (United States)
- Data - Detection, Validation and Accuracy**
- 34. Identification of Second Primary Malignancies (SPM) in Men with Castration-Resistant Prostate Cancer (CRPC) in SEER-Medicare Data [487]**
Catherine W Saltus, David H Harris, Brian Calingaert, Elizabeth B Andrews, Jihong Zong, Montse Soriano-Gabarro, Gunnar Persson Brobert, James A Kaye. (United States)
- 35. Issues in Assessment of Current Use of Warfarin Using Dispensation Data from Administrative Healthcare Databases: The Case of Anticoagulation in Atrial Fibrillation [488]**
Liliya Sinyavskaya, Alexis Matteau, Sarasa Johnson, Jacques Le Lorier, Madeleine Durand. (Canada)
- 36. Missing Prescriptions: Identifying Overlapping Monotherapy Regimens in EMR [489]**
Kristine E Lynch, Benjamin Viernes, Debbie Forbush, Carolyn Rochester, Linda Nici, Scott L DuVall. (United States)
- 37. Do Hospital Electronic Medical Records Reliably Register Pre-Admission Medications in Patients with Dementia? [490]**
Federica Edith Pisa, Francesca Palese, Federico Romanese, Fabio Barbone, Giancarlo Logroscino. (Germany)
- 38. Predictors of Discrepancies Between Electronic Medical Records Medication List and Dispensing Data in Elderly Inpatients with Dementia [491]**
Federica Edith Pisa, Federico Romanese, Francesca Palese, Fabio Barbone, Giancarlo Logroscino. (Germany)
- 39. Completeness of Medical Information Using Electronic Health Records for Secondary Use [492]**
Dr.Thamir Alshammari, Dr.Nasser AlQahtani, Dr.Mansour Almetwazi, Sondus Ata, Dr.Hisham Aljadhey. (Saudi Arabia)
- 40. Analysis of Pain Points in Life Science Pharmacoepidemiology Methods [493]**
Leemor Yuravlivker, Sharon Hensley Alford, Georgette Sullivan, Ramiro Galan, Sarah Miller. (United States)
- 41. Software for Prospective Near Real-Time Drug Safety Surveillance [494]**
Judith C. Maro, Ivair R. Silva, Laura Hou, Kirk Snyder, Martin Kuldorff. (United States)
- 42. Comparison of Privacy-Protecting Analytic and Data-Sharing Methods: A Simulation Study [495]**
Kazuki Yoshida, Susan Gruber, Lingling Li, Bruce H. Fireman, Sengwee Toh. (United States)
- 43. Linkage Between Claims and Biomarker Data for RA Patients to Study Outcomes Associated with Disease Activity [496]**
Jeffrey R Curtis, Fenglong Xie, Lang Chen, Huifeng Yun. (United States)
- 44. Validity of Danish Breast Cancer Group (DBCG) Registry Data Used in the Predictors of Breast Cancer Recurrence (ProbeCaRe) Premenopausal Breast Cancer Cohort Study [497]**
Deirdre Cronin-Fenton, Anders Kjaersgaard, Thomas P Ahern, Marco Mele, Marianne Ewertz, Stephen Hamilton-Dutoit, Peer Christiansen, Bent Ejlersen, Henrik T Sorensen, Timothy L Lash, Rebecca A Silliman. (Denmark)
- 45. ZIKA Virus: Implications for Pregnancy Exposure Registries [498]**
Deborah Covington, Rebecca Buus. (United States)
- 46. Agreement Between Medicaid Analytic eXtract Data and Birth Certificates on Neonatal Critical Conditions [499]**
Yasser Albogami, Yanmin Zhu, Xi Wang, Shannon Lyons, Almut Winterstein. (United States)
- 47. Estimation of Treatment Effects for Comparing Outcomes Among Multiple Drugs with the Same Indication [500]**
Elande Baro, Yuqin Wei, Mao Hu, Jiemin Liao, Yoganand Chillarige, Michael Wernecke, Rongmei Zhang, Rima Izem, Marsha E Reichman, Margie R Goulding, Onyekachukwu A Illoh, Chris Worrall, Jeffrey A Kelman, David J Graham. (United States)
- 48. The Accuracy of Death Dates Recorded in the Clinical Practice Research Datalink (CPRD) [501]**
Arlene M Gallagher, Frank de Vries. (United Kingdom)
- 49. Validation of Discharge Diagnosis Codes to Identify Hospitalizations for Serious Infections Among Older Adults in the Tennessee Medicaid Population [502]**
Andrew D. Wiese, Marie Griffin, C. Michael Stein, William Schaffner, Edward F. Mitchel, Carlos G. Grijalva. (United States)
- 50. Predicting Laterality of Oophorectomy in Administrative Data with Bundled CPT Codes [503]**
Elizabeth A Suarez, Kemi M Doll, Jennifer L Lund, Whitney R Robinson. (United States)

- 51. Usability of Medicaid Analytic eXtract Encounter Data for Comprehensive Managed Care from 2006 to 2010: An Exploratory Validation Study [504]**
Yan Li, Carl Henriksen, Almut G. Winterstein. (United States)
- 52. Validity of ICD-9-CM V-codes for Body Mass Index in Obesity Research [505]**
Stephen S Johnston, Mehmet Daskiran, Andrew Yoo. (United States)
- 53. Validation of Autism Spectrum Disorder Diagnoses in the Clinical Practice Research Datalink, 1990-2014 [506]**
Katrina Wilcox Hagberg, Susan S Jick. (United States)
- 54. Feasibility and Validity of the THIN Database to Characterize Small Cell Lung Cancer [507]**
Lucia Cea Soriano, Jihong Zong, Luis A Garcia Rodriguez. (Spain)
- 55. Mortality Ascertainment in a Medicare Advantage Population Using Health Plan Enrollment Data [508]**
Brandon Suehs, Andy Bowe, Cralen Davis, Su Bunniran, Claudia Uribe. (United States)
- 56. Systematic Review: Validation of Asthma Recording in Electronic Health Records [509]**
Francis Nissen, Jennifer Quint, Samantha Wilkinson, Liam Smeeth, Ian Douglas. (United Kingdom)
- 57. Examination of the Days Supply Field in Pharmacy Administrative Claims Data to Identify the Use of Blister Packaging of Medications [510]**
Lindsay N Baum, Jitender Sareen, William Leslie, Murray W Enns, James Bolton, Silvia Alessi-Severini, Laurence Katz, Carolyn Snider, Heather J Prior, Dan Chateau, Christine Leong. (Canada)
- 58. Detection and Validation of Postherpetic Neuralgia Cases for a Vaccine Effectiveness Study in an Integrated Healthcare System Database [511]**
Morgan Marks, John Hansen, Joan Bartlett, Edwin Lewis, Bruce Fireman, Laurie Aukes, Patricia Saddier, Nicola Klein, Roger Baxter. (United States)
- 59. Methodology to Assess Eligibility of Electronic Healthcare Databases to Conduct Vaccine Coverage, Risk and Benefits Studies in Europe-Contribution of the ADVANCE Project [512]**
Miriam Sturkenboom, Caitlin Dodd, Ana Correa, Hanne Dorthe-Emborg, Talita Duarte-Salles, Elisa Martin, Consuelo Huerta, Silvia Lucchi, Gino Picelli, Lara Tramontan, Lieke van der Aa, Daniel Weibel, Benedikt Becker, Guiseppe Roberto, Marius Gheorge, Rosa Gini. (Netherlands)
- 60. Validity of Claims-Based Definition of Acute Myocardial Infarction in Japan: A Single-Center Study [513]**
Kiyoshi Kubota, Takashi Ando, Nobuhiro Ooba, Mayumi Mochizuki, Daisuke Koide, Koichi Kimura, Seitetsu L Lee, Soko Setoguchi. (Japan)
- 61. Interrater Agreement of Two Adverse Drug Reaction Causality Assessment Methods: A Randomised Comparison [514]**
Johannes P Mouton, Ushma Mehta, Dawn Rossiter, Gary Maartens, Karen Cohen. (South Africa)
- 62. Medication Errors During Patient's Emergency Department Visits Compared to Those in Inpatient in an Academic Medical Center in Saudi Arabia [515]**
Eman N AlMutairi. (Saudi Arabia)
- 63. Design of a Multinational Post-Authorization Safety Study (PASS) of Crizotinib [516]**
Vera Ehrenstein, Kui Huang, Johnny Kahlert, Shahram Bahmanyar, Pär Karlsson, Lukas Löfling, Irene D Bezemer, Josine G Kuiper, Anthony P Nunes, Cheryl Enger, Fabian Hoti, Rosa Juuti, Pasi Korhonen, Jingping P Mo, Stephen Schachterle, Henrik T Sørensen. (Denmark)
- 64. Utilisation and Safety of Deferasirox (Exjade®) in Older Adults: Results form a Post Authorisation Safety Study (PASS) [517]**
Sandeep Dhanda, Deborah Layton, Vicki Osborne, Saad Shakir. (United Kingdom)
- 65. Usability Evaluation of Sentinel's Prospective Routine Observational Monitoring Program Tools (PROMPT) [518]**
Mitchell M Conover, Amy Lowman, Til Stürmer, J Bradley Layton, David Martin, Michele Jonsson Funk. (United States)
- 66. Post-Market Surveillance of Aflibercept for Macular Degeneration [519]**
Emmae Ramsay, Nicole Pratt, Lisa Kalisch Ellett, Sepehr Shakib, Gillian Caughey, Anna Kemp-Casey, Elizabeth Roughead. (Australia)
- 67. Study Update for a Postmarketing Case Series Study of Adult Osteosarcoma and Teriparatide in the US [520]**
David Harris, Kirk Midkiff, Alicia Gilsenan, Nicole Kellier-Steele, David McSorley, Elizabeth Andrews. (United States)
- 68. US Food and Drug Administration Systematic Review of Drug Exposure Registries [521]**
Yanling Zhao, Jacqueline M Major, David Moeny, Cunlin Wang. (United States)
- 69. Evaluation of Spontaneous Adverse Event Reports for Muscle Related Adverse Reactions Attributed to Daptomycin within the FDA Adverse Events Reporting System (FAERS) [522]**
Ola F Khedr, Hala Shokr, Mohamed A Mekkawy. (Egypt)
- 70. Hypothesis-Free Screening of Large Administrative Databases for Unknown Adverse Drug Effects: Output of a Comprehensive Symmetry Analysis [523]**
Jesper Hallas, Shirley V Wang, Joshua J Gagne, Sebastian Schneeweiss, Nicole Pratt, Anton Pottegård. (Denmark)
- 71. Exploring Patient Reported Information in Signal Detection within a Global Database [524]**
Sarah Watson, Henric Taavola, Rebecca Chandler, Linda Härmark, Florence van Hunsel, Alem Zekarias, Birgitta Grundmark, Kristina Star. (Sweden)

Data for Pharmacovigilance



- 72. Characteristics and Quality of Spontaneous ADR Reports Submitted via the WEB-RADR App [525]**
Henric Taavola, Ola Caster, Phil M Tregunno, Petar Mas, Ingrid Oosterhuis, Sara Gama, Linda Härmark. (Sweden)
- 73. Medication Error Reporting in European Regulatory Database EudraVigilance: A Descriptive Study [526]**
Christina E Hoeve, Sabine M Straus, Miriam C Sturkenboom. (Netherlands)
- 74. Analysis of Spontaneous Adverse Drug Reaction Reports in the Uganda Pharmacovigilance System (2008-2016) [527]**
Dan Kajungu, Victoria Nambasa, Helen Byomire Ndagije. (Uganda)
- 75. Quality Assessment of Individual Case Safety Reports in the Nigerian National Pharmacovigilance Centre Database [528]**
Anthony I Obieze, Ibrahim A Oreagba, Adeline I Osakwe, Azeef A Yusuf. (Nigeria)
- 76. Medicines' Packaging Components as a Risk-Minimization Measure: Focus on Ability to Drive and Use Machines [529]**
Violeta Getova, Hristina Lebanova, Assena Stoimenova, Stanislav Georgiev. (Bulgaria)
- 77. The Safety Concerns of Medicinal Products with Additional Risk Minimisation Measures [530]**
Remy D Francisca, Armando R Leyba, Inge M Zomerdijk, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)
- 78. Evaluation of the Pharmacovigilance Activities in the National Malaria, Tuberculosis and HIV/AIDS Control Programmes in Nigeria Using the WHO PV Indicators [531]**
Chioma S Ejekam, Ambrose Isah, Annie Fourier-Réglat. (Nigeria)
- 79. Incidence and Determinants of Serious Drug Related Problem in an Emergency Department [532]**
Matias Martinez, Luis Herrada, Ana Muñoz, Camila Chavez, Marcela Jiron. (Chile)
- 80. Adverse Drug Reactions as a Cause for Presentation to Two South African Emergency Units [533]**
Karen Cohen, Nicole Jobanputra, Ushma Mehta, Hannah Gunter, Christine Njuguna, Richard Court, Sa'ad Lahri, Johannes P Mouton. (South Africa)
- 81. Adverse Drug Reactions in Older Adults Hospitalized in a Teaching Hospital in Chile [534]**
Tamara Sandoval, Ricardo Bravo, Luis Calderón, Constanza Villagra, Matilde Lagos, Fabián Miranda, Elena Vega, Marcela Jirón. (Chile)
- 82. Prescription Trends Among Drug Pairs with a Known Serious Drug-Drug Interaction in UK Primary Care [535]**
Adrian Root, Ian Douglas. (United Kingdom)
- 83. Medication Errors and Associated Inevitable Risk Factors: Assessment of Risk Factors Associated with Reported Medication Errors in a Developing Nation's Scenario [536]**
Chalasanani Sri Harsha, Madhan Ramesh. (India)
- 84. An Evaluation of Drug-Ineffective Postmarketing Reports in Drug Safety Surveillance [537]**
Takashi Misu, Cindy Kortepeter, Monica Munoz, Eileen Wu, Haemy Chung, Gerald J Dal Pan. (United States)
- 85. Use of a Common Data Model Based Tool for Active Surveillance of Hepatic Decompensation in a Population Treated for Hepatitis C Infection [538]**
Denise Oleske, Raghava Danwada. (United States)
- 86. Early Post-Approval Surveillance of New Molecular Entity Uptake in the Sentinel Distributed Database [539]**
Nicole R Haug, Talia J. Menzin, Tiffany S. Woodworth, Judith C. Maro, Jeffery S. Brown, Michael D. Nguyen. (United States)
- 87. Poor Correlation Between Psoriasis Area and Severity Index and Quantity of Topical Agents Used in Six Preceding Months [540]**
David Hagg, Anders Sundström. (Sweden)
- 88. Patterns of Systemic Treatment for Psoriatic Arthritis in the United States [541]**
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim. (United States)
- 89. Sub-Groups of Anti-Osteoporosis Drug Users, and Associated Fracture Risk in Real World Primary Care Settings: A Data-Driven Cluster Analysis [542]**
Sara Khalid, M Sanni Ali, Alan Silman, Daniel Prieto-Alhambra. (United Kingdom)
- 90. Impact of Concomitant Use of Disease Modifying Antirheumatic Drugs and Methotrexate Administration Route on Durability of Biologic Treatment: Results from the Ontario Best Practice Research Initiative (OBRI) Cohort [543]**
Arthur Lau, Mohammad Movahedi, Carter Thorne, Angela Cesta, Xiuying Li, Sandra Couto, John Sampalis, Emmanouil Rampakakis, Claire Bombardier and other OBRI investigators. (Canada)
- Drug Utilization - Neurologic/ Mental Health**
- 91. Antipsychotic Utilization Patterns in a Cohort of 1.5 Million Schizophrenic Patients. A Cross-National Study [544]**
Dr. Gabriel Sanfelix-Gimeno, Gianluca Trifirò, Elisabetta Patorno, Francesco Giorgianni, Janet Sultana, Michele Tari, Zhigang Lu, Krista Huybrechts, Isabel Hurtado. (Spain)
- 92. Use of Psychotropics in Patients Newly Diagnosed with Cancer as Compared to New Diagnoses of Coronary Heart Diseases or Diabetes [545]**
Marie Tournier, Emilie Casarotto, Pierre Verger, Bernard Begaud, Elodie Pambrun, Annie Fourier-Reglat. (France)
- 93. Antipsychotics Are Forever? De-Prescribing of Antipsychotics in Residential Aged Care [546]**
Lisa G Pont, Magda Z Raban, Joyce Siette, Rebecca Mitchell, Andrew Georgiou, Johanna Westbrook. (Australia)
- Drug Utilization - Arthritis**
- 87. Poor Correlation Between Psoriasis Area and Severity Index and Quantity of Topical Agents Used in Six Preceding Months [540]**
David Hagg, Anders Sundström. (Sweden)

- 94. Antipsychotic Drug Use by Community Dwelling Older Persons and Adherence to STOPP Criteria After a Fall [547]**
Shanna C Trenaman, David Gardner, Barbara Hill-Taylor, Kara Matheson, Ingrid Sketris. (Canada)
- 95. Usage Patterns and Determinants of Hypnotics and Anxiolytics in Patients Newly Diagnosed with Cancer [548]**
Annie Fourrier-Reglat, Emilie Casarotto, Pierre Verger, Bernard Begaud, Elodie Pambrun, Marie Tournier. (France)
- 96. Assessing the Quality of Treatment with Attention-Deficit/Hyperactivity Disorder Medication in Denmark [549]**
Lotte Rasmussen, Helle Wallach-Kildemoes, Helga Zoëga, Niels Bilenberg, Jesper Hallas, Anton Pottegård. (Denmark)
- 97. Psychotropic Medication Use in Sudden Unexpected Death Victims [550]**
Mariya Husain, Greta Bushnell, Mitchell Conover, Jessica Ford, Zachariah Deyo, Ross Simpson. (United States)
- 98. Point Prevalence Survey of Benzodiazepine Use in Nova Scotia (Canada) Hospitals [551]**
Heather Neville, Mia Losier, Jennifer Pitman, Melissa Gehrig, Jennifer Isenor, Laura Minard, Ellen Penny, Susan Bowles. (Canada)
- 99. Utilization of Attention Deficit Hyperactivity Disorder Medications (ADHD) by Adults in 13 Countries [552]**
Sudha R Raman, Kenneth K Man, Shahram Bahmanyar, Greta Bushnell, Yea-Huei KaoYang, Øystein Karlstad, Kiyoshi Kubota, Edward Chia Cheng Lai, Jaana E Martikainen, Géric Maura, Dolores Montero, Anton Pottegård, Nicole Pratt, Elizabeth E Roughead, Til Stürmer, Chien-Chou Su, Helga Zoëga, Mariam C Sturkenboom, Ian C Wong. (United States)
- 100. Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults [553]**
Cody D Black, Lisa McCarthy, Tara Gomes, Muhammad Mamdani, David Jurlink, Mina Tadrous. (Canada)
- 101. Prevalence of Concomitant Use of Psychotropic Drugs with Severe or Major Drug-Drug Interactions in Children and Adults with Psychotropic Therapy [554]**
Xinyue Liu, Juan Hincapie Castillo, Yanmin Zhu, Regina Bussing, Almut Winterstein. (United States)
- 102. Variation in Antipsychotic Use in Hospitalized Older Adults After Cardiac Surgery [555]**
Dae Kim, Mufaddal Mahesri, Brian Bateman, Krista Huybrechts, Sharon Inouye, Edward Marcantonio, Shoshana Herzig, E. Wesley Ely, Pratik Pandharipande, Margaret Pisani, Jerry Avorn. (United States)
- 103. Body Weight and Gender Differences in Prescribing Antidepressants by Primary Care Providers [556]**
Svetlana Puzhko, Rachael Morkem, David Barber, Gillian Bartlett. (Canada)
- 104. International Patterns in Antipsychotic Medication Use: A Study of 16 countries, 2005 to 2014 [557]**
Oskar Halfdanarson, Helga Zoëga, Lise Aagaard, Miquel Bernardo, Lena Brandt, Anna Coma Fusté, Kari Furu, Falk Hoffmann, Krista F Huybrechts, Koji Kawakami, Helle Kieler, Takuya Kinoshita, Soffy C López, Jorge E Machado-Alba, Manuel E Machado-Duque, Mufaddal Mahesri, Prasad S Nishtala, Johan Reutfors, Leena K Saastamoinen, Izumi Sato, Yu-Chiau Shyu, Svetlana Skurtveit, Hélène Verdoux, Liang-Jen Wang, Christian J Bachmann. (Iceland)
- 105. Trends in Psychotropic Medication Use Among US Active Duty Members [558]**
Yingxin (Rachel) Hou, Jennifer G Naples, Suji Xie, Adrian Kress, James Masterson, Rosennie T Jean. (United States)
- 106. Antipsychotic Treatment Patterns in Veterans with Schizophrenia Prior to Initiation of Treatment with Once-Every-Three-Month Paliperidone Palmitate [559]**
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianna Brown, Marie-Hélène Lafeuille, Rachel Bhak, Jacquelyn McRae, Priyanka Bobbili, Michael Hellstern, Mei S Duh, Brian Shiner, Yinong Young-Xu. (United States)
- 107. Off-Label Use of Methylphenidate for Cognitive Enhancing Among Academic Students [560]**
Raissa C Cândido, Edson Perini, Cristiane A Menezes de Pádua, Joyce C de Faria, Daniela R Junqueira. (Brazil)
- 108. Exposure to Lamotrigine and Risk of Severe Cutaneous Adverse Drug Reactions (SCARs) Among Patients with Bipolar Disorder, Seizure, and Depression [561]**
Bon-Ki Koo, Haeyoung Lee, So Jeong Park, Eun Jin Kim, Sun-Young Jung, Soo-Youn Chung. (Korea, Republic of)
- 109. Five-Year Trajectories of Longitudinal Psychotropic Agents Use in The Elderly: A Population-Based Study [562]**
Shih-Tsung Huang, Kai-Hsin Liao, Chih-Wan Lin, Fei-Yuan Hsiao. ()
- 110. Cohort Study Evaluating Suicidal Behavior Associated with ADHD Stimulant Therapies [563]**
Csaba Siffel, William A Blumentals, William M Spalding, Matthew McEnany, Frank A Corvino. (United Kingdom)

Drug Utilization For Infections

- 111. Assessment of the Prescribed Daily Dose of Antibiotics in Outpatients from Mexico City [564]**
Ramiro Sanchez-Huesca, Claudia Lerma. (Mexico)
- 112. Drug Usage Patterns of Pylera in France Using the National Claims Database [565]**
Patrick Blin, Magali Rouyer, Estelle Guiard, Frank Zerbib, Bertrand Diquet, Francis Mégraud, François Tison, Abdelilah Abouelfath, Régis Lassalle, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 113. Antimicrobial Point Prevalence Survey in Nova Scotia (Canada) Acute Care Hospitals [566]**
Heather Neville, Emily Black, Mia Losier, Megan Harrison, Kim Abbass, Kathryn Slayter, Lynn Johnston, Ingrid Sketris. (Canada)



- 114. Outpatient Antibiotic Prescriptions with High Risk of Bacterial Resistance in France: A National Healthcare Insurance Database Analysis [567]**
Marie-Céline Casaurancq, Manuela Rueter, Bérangère Baricault, Emilie Patras de Campaigno, Mélanie Araujo, Maryse Lapeyre-Mestre, Agnes Sommet. (France)
- 115. A Comparison of Single versus Multiple-Tablet Regimens in HIV-Infected People Initiating Antiretroviral Therapy [568]**
Celline C Almeida-Brasil, Juliana O Costa, Elizabeth Nascimento, Romara E Perdigao, Micheline R Silveira, Palmira F Bonolo, Francisco A Acurcio, Maria das Graças B Ceccato. (Canada)
- 116. Adherence to Brazilian HIV-AIDS Treatment Guidelines: A 3-Year Retrospective Analysis of Dispensing Data [569]**
Cassia Cristina Mendicino, Leticia Penna Braga, Leonardo Vinicius Silva, Menezes de Pádua. (Brazil)
- 117. Assessment of Prescribing Ceftriaxone Sodium in Afghanistan's Secondary and Tertiary Hospitals [570]**
Mohammad Zafar Omari, Ahmad Seyar Samadi, Annie Fourrier-Réglat, Albert Figueras, Albert Figueras. (Afghanistan)
- 118. Dispensings of Influenza Antiviral Medications in the Sentinel System as a Source of Data for Influenza Surveillance [571]**
Noelle M Cocoros, Genna Panucci, Nicole Haug, Carmen Maher, Marsha Reichman, Darren Toh. (United States)
- 119. Antibiotic Prescribing Patterns for Acute Respiratory Infections in Military Treatment Facilities [572]**
Michelle J LaCour, Rosennie Thelus, James Masterson, Adrian Kress, Suji Xie, Trinka Coster. (United States)
- 120. Effectiveness of Second-Line Antiretroviral Therapy: The Impact of Drug Switches [573]**
Leticia P. Braga, Cássia C. Mendicino, Edna A. Reis, Ricardo A. Carmo, Cristiane A. Menezes de Pádua. (Brazil)
- 121. Association of the Number of Antibiotics Received and *Clostridium difficile* Infection Among Patients Admitted to the Intensive Care Unit [574]**
Carlos A Alvarez, Peia Lee, David Fike, Eric M Mortensen, Steven E Pass, Ronald G Hall. (United States)
- Informed Drug Policy**
- 122. Impact of Florida Pill Mill Legislation, PDMP Introduction and OxyContin Reformulation on Tablets Dispensed in Florida and California [575]**
Paul M Coplan, Angela DeVeaugh-Geiss, Venkatesh Harikrishnan, Anna Gyamarthy. (United States)
- 123. Effect of Increasing Generic Drug Use on Medical Prescription Plan Star Ratings [576]**
Jingjing Qian, Richard Hansen, Ilene Harris, Zippora Kiptanui, Jennifer Howard, Danial Surry. (United States)
- 124. International Comparison of Reimbursement Coverage Schemes of Antineoplastic and Immunomodulating Drugs: England, Australia, Canada and Taiwan [577]**
Yi-Ru Shin, Kai-Hsin Liao, Chih-Wan Lin, Fei-Yuan Hsiao. (Taiwan)
- 125. Change in the Utilization of Erythropoiesis-Stimulating Agents in Cancer Patients: A Policy Evaluation [578]**
Minghui Li, Richard Schulz, Kevin Lu. (United States)
- 126. Does Pay-for-Performance Influence Outcomes for People with Serious Mental Illness? [579]**
Rachael Williams, Panos Kasteridis, Christoph Kronenberg, Nils Gutacker, Tim Doran, Anne Mason, Nigel Rice, Hugh Gravelle, Maria Goddard, Tony Kendrick, Najma Siddiqi, Simon Gilbody, Ceri Owen, Lauren Aylott, Rowena Jacobs. (United Kingdom)
- 127. Impact of Diagnosis-Related Group (DRG)-Based Payment System on the Quality of Care for Elderly Patients with Hip Fracture in Taiwan [580]**
Hsien-Yeh Chuang, Li-Ning Peng, Chen-Yu Wang, Fei-Yuan Hsiao, Liang-Kung Chen. (Taiwan)
- 128. Reducing Prescription Drug Spending: A Review of Policy Options [581]**
G. Caleb Alexander, Jeromie Ballreich, Mariana P. Socal, Taruja Karmarkar, Antonio Trujillo, Jeremy Greene, Joshua M. Sharfstein, Gerard Anderson. (United States)
- 129. Cost-Utility of Burns Management in Nigeria: A Case-Study of National Orthopaedic Hospital, Enugu [582]**
Charles E. Okafor, BPharm, Ola Onunka, Nkechi Idoko. (Nigeria)
- 130. Health Care Resource Utilization Before and After Perampanel Initiation for the Treatment of Epilepsy in the United States [583]**
Edward Faught, François Laliberté, Zhixiao Wang, Victoria Barghout, Jiyeon Choi, Batool Haider, Dominique Lejeune, Guillaume Germain, Mei S Duh. (United States)
- 131. Cost Effectiveness Analysis of Broad Spectrum versus Narrow Spectrum Antibiotics for Prophylaxis of Surgical Site Infections [584]**
Shahenaz Sawmaa. (Egypt)
- 132. Framework for the Cost-Effectiveness of Secondary Prevention Strategies in Cardiovascular Diseases: A Canadian Theoretical Model-Based Analysis [585]**
Fiorella Fanton-Aita, Alexis Matteau, Dominic Mitchell, Brian J. Potter, Ange Christelle Iliza, Jason R. Guertin, Anick Dubois, Marie-Pierre Dubé, Jean-Claude Tardif, Jacques LeLorier. (Canada)
- 133. Trends in FDA Postmarketing Commitments and Requirements for Newly Approved Drugs, 2011-2016 [586]**
Jayashri Desai, Jessica Albano, Susan Sinclair, John P. McCormick. (United States)
- 134. The Safety Concerns of Medicinal Products Licensed in the European Union [587]**
Remy D Francisca, Armando R Leyba, Inge M Zomerdijk, Miriam C Sturkenboom, Sabine M Straus. (Netherlands)
- 135. Predictors of Health Plan Disenrollment Among Commercially-Insured Adults in the United States [588]**
Anne M. Butler, Jonathan V. Todd, M. Alan Brookhart. (United States)

136. Extent of Lack of Efficacy Reporting in the Canada Vigilance Database [589]

Marc F. Poitras, Papa Diogoye Sene, Alain Béliveau. (Canada)

137. Impact of a New Consumer-Friendly Form on Adverse Experience Reporting to the United States Food and Drug Administration [590]

Monica A Munoz, Almut G Winterstein, Chris Delcher, Cindy M Kortepeter, Yu-Jung Wei, Hong Xiao, Gerald Dal Pan. (United States)

Intended Effects of Medications - Real World Comparative Effectiveness**138. Bleeding-Related Hospital Admissions and 30-Day Readmissions with Dabigatran versus Warfarin in Patients with Nonvalvular Atrial Fibrillation [591]**

Esther W Chan, Wallis CY Lau, Xue Li, Ian CK Wong. (Hong Kong)

139. Non-Valvular Atrial Fibrillation, Anticoagulants and Stroke: The Stroke Prevention and Anticoagulants (SPA) Case-Control Study [592]

Lamia Grimaldi-Bensouda, Jean-Yves Le Heuzey, Jean Ferrières, Didier Leys, Jean-Marc Davy, Mikel Martinez, Didier Smadja, Emmanuel Ellie, Denis Sablot, Norbert Nighoghossian, Jacques Bénichou, Emmanuel Touzé, Lucien Abenham. (France)

140. Comparative Effectiveness of Cardioprotective Drugs in US Dialysis Patients [593]

Xuerong Wen, Rajesh Mohandas, David I. Weiner. (United States)

141. Comparative Effectiveness of Anesthesia Technique Among Older Patients After for Hip Fracture Surgery [594]

Takumi Nishi, Toshiki Maeda, Takuya Imatoh, Akira Babazono. (Japan)

142. Comparative Effectiveness of Vancomycin Monotherapy Compared to Combination Therapy in Methicillin-Resistant *Staphylococcus aureus* Bacteremia [595]

Aisling R Caffrey, Tristan T Timbrook, Megan K Luther, Vrishali V Lopes, Kerry L LaPlante. (United States)

143. Mortality and Cardiovascular Events Associated with DDP-4 Inhibitors: A Meta-Analysis of Observational Studies [596]

Carlos Alves, Diogo Mendes, Francisco Batel Marques. (Portugal)

144. Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Chronic Oral Glucocorticoid Users: A Population-Based Study [597]

Mohamed Amine Amiche, Linda E Lévesque, Tara Gomes, Jonathan D Adachi, Suzanne M Cadarette. (Canada)

145. A Meta-Analysis and Meta-Regression of the Effectiveness of Front-Line Treatment Combinations with Ponatinib versus 1st and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia [598]

Elias Jabbour, Maral DerSarkissian, Mei S Duh, Nora McCormick, Wendy Y Cheng, Lisa J McGarry, Ariadne Souroutzidis, Hui Huang, Hagop M Kantarjian. (United States)

146. Effectiveness of Ranibizumab Intravitreal Injections in Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion from the French BOREAL Cohorts [599]

Patrick Blin, Cécile Delcourt, Agnès Glacet-Bernard, Laetitia Finzi, Régis Lassalle, Anaïs Chartier, Marie-Agnès Bernard, Pauline Diez, Cécile Droz-Perroteau, Adeline Grolleau, Angela Grelaud, Nicholas Moore. (France)

147. Effectiveness of Ranibizumab Intravitreal Injections in Visual Impairment Due to Diabetic Macular Edema from the French BOREAL Cohort [600]

Patrick Blin, Cécile Delcourt, Pascale Massin, Pierre-Jean Guillausseau, Laetitia Finzi, Régis Lassalle, Anaïs Chartier, Marie-Agnès Bernard, Fatima Hamoud, Cécile Droz-Perroteau, Adeline Grolleau, Angela Grelaud, Nicholas Moore. (France)

148. Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval [601]

Derek R. Johnson, Antonio M. Omuro, Arlene Ravelo, Nicolas Sommer, Annie G Guerin, Raluca Ionescu-Iltu, Sherry Shi, Joon H. Uhm. (Canada)

149. Efficacy of Targeted Therapies in Metastatic Colorectal Cancer: Meta-Analysis [602]

Amandine Gouverneur, Mickaël Arnaud, Driss Berdai, Paul DeBoissieu, Annie Fourier-Réglat, Pernelle Noize, Francesco Salvo. (France)

150. Effectiveness of Antipsychotic Long-Acting Injections versus Oral Antipsychotics in Real-Life Prescribing Practice: A Community-Based Study [603]

Hélène Verdoux, Elodie Pambrun, Marie Tournier, Julien Bezin, Antoine Pariente. (France)

151. Outcomes in Post-Myocardial Infarction Patients Similar to Those of the PEGASUS-TIMI-54 Trial: A Cohort Study in the French National Claims Database Sample EGB [604]

Nicholas D Moore, Patrick Blin, Caroline Dureau-Pournin, Régis Lassalle, Jeremy Jove, Florence Thomas-Delecourt, Nicolas Danchin, Cecile Droz. (France)

152. Bisphosphate Use and Risk of Total Hip Replacement in Patients with Hip Osteoarthritis: A Nationwide Cohort Study [605]

Chen-Yu Wang, Shau-Huai Fu, Chih-Chien Hong, Chuan-Ching Huang, Chih-Wan Lin, Rong-Sen Yang, Fei-Yuan Hsiao. (Taiwan)

153. Unintended Pregnancies in Users of Different Combined Oral Contraceptives - Final Results from the INAS-SCORE Study [606]

Klaas Heinemann, Jürgen Dinger, Sabine Moehner, Thai Do Minh, Christian Franke. (Germany)

154. The Influence of Women's Educational Level on Unintended Pregnancy Rates Amongst Users of Combined Oral Contraceptives [607]

Anja Bauerfeind, Sabine Möhner, Thai Do Minh, Klaas Heinemann. (Germany)

155. Update on the Clinical Effect of Prophylactic Antibiotic Treatment for Acute Exacerbations in Patients with COPD: Systematic Review and Meta-Analysis [608]

Yuanyuan Wang, Tanja Zijp, Eelko Hak. (Netherlands)



- 156. Comparative Risks of Diabetes-Related Complications of Long versus Intermediate Acting Insulin in Type 1 Diabetes [609]**
Tsung-Ying Lee, Huang-Tz Ou, Ye-Fong Du, Chung-Yi Li. (Taiwan)
- 157. Risk of Diabetic Retinopathy in Type 2 Diabetes Patients Treated with DPP-4 Inhibitor and Metformin vs. Sulfonylurea and Metformin [610]**
Bo Ram Yang, Ye-jee Kim, Ju-Young Shin, Mi-Sook Kim, Byung-Joo Park, Joongyub Lee. (Korea, Republic of)
- 158. The Real World Evidence on Survival of Sunitinib Users with Metastatic Renal Cell Carcinoma in Taiwan [611]**
Hsu-Chih Chien, Yea-Huei Kao Yang. (Taiwan)
- 159. Trends in Statin Utilization and CVD Mortality at the Global, Regional and Country Level [612]**
Dima M Qato, Jenny Guadamuz, Andreas Seiter, Peter Stephens. (United States)
- 160. Ad-Hoc Analyses of Clinical Experience with Urinary Versus Recombinant Hormones for Ovarian Induction [613]**
Hristina Lebanova, Svetoslav Stoev, Emilia Naseva, Ilko Getov. (Bulgaria)

Medical Devices

- 161. Timing of Renal Replacement Therapy and Long-Term Risk of Chronic Kidney Disease and Death in Intensive Care Patients with Acute Kidney Injury [614]**
Søren Christiansen, Steffen Christensen, Lars Pedersen, Henrik Gammelager, Bradley Layton, M. Alan Brookhart, Christian F Christiansen. (Denmark)
- 162. Does Surgical Approach Impact Recurrence After Incisional Hernia Mesh Repair? [615]**
Andrew Yoo, Katherine Corso, Gary Chung, Rubin Sheng, Niels-Derrek Schmitz. (United States)
- 163. US Early Total Knee Arthroplasty Revision Rates in the Context of International Registries [616]**
Katherine Etter, John Leopold, Daniel Funk, Richard Beech, Andrew Yoo. (United States)

- 164. Anatomical Differences in the Incidence of Ventral Hernia Recurrence [617]**
Katherine A Corso, Niels-Derrek Schmitz, Gary Chung, Rubin Sheng, Andrew Yoo. (United States)
- 165. Delays in Radiotherapy Treatment Among Patients with Head and Neck Cancer: An Analysis of Medicare Claims Data [618]**
Joseph Menzin, Patrick McBee, Matthew Sussman. (United States)
- 166. Statin Treatment Is Not Associated with the Postoperative Risk of Cardiovascular Events or Death After Total Hip Arthroplasty Surgery. A Population-Based Study from the Danish Hip Arthroplasty Register [619]**
Alexander S Dastrup, Anton Pottegård, Søren Overgaard, Jesper Hallas. (Denmark)
- 167. Tranexamic Acid Does Not Increase the Postoperative Risk of Cardiovascular Events or Death After Total Hip Arthroplasty Surgery. A Population-Based Study from the Danish Hip Arthroplasty Register [620]**
Alexander S Dastrup, Anton Pottegård, Jesper Hallas, Søren Overgaard. (Denmark)
- 168. Safety and Efficacy of Intrauterine Devices: Baseline Characteristics of 26,053 Study Participants from the EURAS-LCS12 Study [621]**
Christine Hagemann, Klaas Heinemann, Sabine Moehner. (Germany)

Pharmacovigilance - Neurological/Mental

- 169. A Systematic Review on Neuropsychiatric Events Associated with Leukotriene-Modifying Agents [622]**
Sharon W Law, Angel Y Wong, Shweta Anand, Ian C Wong, Esther W Chan. (Hong Kong)
- 170. Impact of Adverse Drug Reactions on Daily Living of Patients on Anti-Psychotic Medications [623]**
Ramesh Madhan, Jisha M Lucca, Dushad Ram, Gurumurthy Parthasarathi, Himanshu Patel. (India)

- 171. Hepatotoxicity of Agomelatine and Other Antidepressants Versus Selective Serotonin Reuptake Inhibitors [624]**
Sophie Billiotti de Gage, Cédric Collin, Thien Le Tri, Antoine Pariente, Rosemary Dray-Spira, Mahmoud Zureik. (France)
- 172. Association Between Antipsychotics and Cataract Among Schizophrenia Patients with Metabolic-Related Diseases [625]**
Yu-Hsuan Joni Shao, Su-Chen Fang, Cheng-Yi Huang, Kitaw Demissie. (Taiwan)
- 173. Epidemiology of Drug Hypersensitivity Reactions Using 6-Year National Health Insurance Claim Data from Korea [626]**
Sukhyang Lee, JaeEun Han, Ye Young-Min. (Korea, Republic of)
- 174. Long-Term Safety Surveillance of Psychotropic Medications: A Five-Year Data from a Developing Country [627]**
Dr. Jisha Myalil Lucca, Madan Ramesh, Rajesh Raman, Dushad Ram. (India)

Pharmacovigilance - Other Therapeutic

- 175. Post-Marketing Safety of Deferasirox in Combo vs Monotherapy, a Comparative Assessment [628]**
Luis Velez-Nandayapa, Geoff Holder, Ritu Singal, Menon Kalidas, Annelore Cortoos, Michael Shi, Johannes Eisinger. (Switzerland)
- 176. Detection and Validation of Bullous Pemphigoid Associated with Dipeptidyl Peptidase IV Inhibitors Using a Hospital Database [629]**
Katsuhito Hori, Ayami Kato, Junichi Kawakami. (Japan)
- 177. Demographics and Prevalence of Comorbidities for Patients with Mild, Moderate, and Severe Psoriasis [630]**
Mohammadhossein Hajiebrahimi, Anders Sundström, David Hägg, Sean McElligott, Sverrir Valgardsson, Reginald Villacorta, Marie Linder. (Sweden)



- 178. The Risk of Infections and Serious Infections with Rituximab in Rheumatoid Arthritis. Results from an Updated Meta-Analysis of Randomised Clinical Trials [631]**
 Luis Velez-Nandayapa, Laura DeVore, Chahna Parikh. (Switzerland)
- 179. Alert Generation Using the Case-Population Approach in the French Claims Databases (ALCAPONE) [632]**
 Nicolas Thurin, Régis Lassalle, Patrick Blin, Marine Pénichon, Martijn Schuemie, Joshua J Gagne, Jeremy Rassen, Jacques Benichou, Alain Weill, Cécile Droz-Perroteau, Nicholas Moore. (France)
- 180. Dronedrone and Hepatic Toxicity? A Model for Evaluation of Post-Marketing Safety of Drugs in Routine Care [633]**
 Thomas Cars, Lars Lindhagen, Rickard E Malmström, Martin Neovius, Jonas Schwieler, Björn Wettermark, Johan Sundström. (Sweden)
- 181. Safety Profile of Intravitreal Anti-VEGF Drugs: An Analysis of the Italian Spontaneous Reporting System [634]**
 Ilaria Marciànò, Paola M Cutroneo, Claudia Giardina, Valentina Ientile, Simona Potenza, Laura Sottosanti, Carmen Ferrajolo, Costantino J Trombetta, Gianluca Trifirò. (Italy)
- 182. Substance Use Disorders and Overdose Events in Medicare Beneficiaries [635]**
 Aida Kuzucan, Linda Simoni-Wastila. (United States)
- 183. Correlation Between the Duration of Tuberculosis Treatment and the Level of Urea, Creatinine and GFR on the Adult Patients in Respira Hospital, Yogyakarta, Indonesia [636]**
 Leonardo Alfonsius Lalenoh, Jarir At Thobari, Heni Retnowulan, Uly Adhie, Dyah Aryani Perwitasari. (Indonesia)
- 184. COPD Exacerbations and Risk of Major Adverse Cardiac Events: A Danish Nationwide Register-Based Case-Crossover Study [637]**
 Mette Reilev, Anton Pottegård, Jesper Lykkegaard, Jens Søndergaard, Truls Sylvan Ingebrigtsen, Jesper Hallas. (Denmark)
- 185. Assessment of Transfusion-Related Acute Lung Injury after Red Blood Cell, Plasma and Platelet Administration: Initial Results in the Sentinel System [638]**
 Candace C Fuller, Craig Zinderman, Steven A Anderson, Carolyn Balsbaugh, Nicholas Bryant, Hayley Burgess, Howard Chazin, Pamela Clark, Lesley H Curtis, Richard Forshee, Jason Hickok, Stacey Honda, Richard M Kaufman, Mikhail Menis, Karla M Miller, Manette Niu, Joyce Obidi, Wendy Paul, Russell Poland, Robert Rosofsky, Azadeh Shoaibi, Caren Spencer-Smith, Jamie L Todd, Fang Zhang, Meghan A Baker. (United States)
- 186. Real-World Incidence of Malignancies, Infections and Auto-Immune Diseases in Persons with Rheumatoid Arthritis Treated with Biological vs. Non-Biological Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis [639]**
 Teresa A. Simon, Jacqueline Kostelec, Jacob Franek. (United States)
- 187. Allopurinol Use and Associated Cutaneous Adverse Reactions After Market Entry of Febuxostat: An Interrupted Time Series Study [640]**
 Chih-Wan Lin, Hsin-Chun Chou, Pi-Hui Chao, Wen-Wen Chen, Fei-Yuan Hsiao. (Taiwan)
- 188. Risk of Cutaneous Adverse Reactions Associated with Allopurinol or Febuxostat in Real-World Patients: a Nationwide Cohort Study [641]**
 Chih-Wan Lin, Hsin-Chun Chou, Pi-Hui Chao, Wen-Wen Chen, Fei-Yuan Hsiao. (Taiwan)
- 189. Social Impact of Adverse Drug Reactions in the Canada Vigilance Program [642]**
 Genaro Castillon, Yola Moride, Francesco Salvo. (Canada)
- 190. Adverse Drug Reactions to Thalidomide in Hansen's Disease Patients [643]**
 Cristiane A Menezes de Padua, Paula L Drummond, Roberta M Santos. (Brazil)
- 191. Agomelatine and Risk of Hospitalisation for Acute Liver Injury: Nested Case-Control Analysis in Three European Countries [644]**
 Manel Pladevall Vila, Jesper Hallas, Tania Schink, Rosa Morros, Beatriz Poblador, Joan Forns, Maja Hellfritzs, Tammo Reinders, Maria Giner-Soriano, Alexandra Prados-Torres, Miguel Cainzos-Achirica, Anton Pottegård, Bianca Kollhorst, Jordi Cortés, Jaume Aguado, Gabriel Perlemuter, Jordi Castellsagué, Emmanuelle Jacquot, Nicolas Deltour, Susana Perez-Gutthann. (Spain)
- 192. The Risk of Liver Injury Associated with Antibiotics Adjusting for Change of Treatment by Inverse Probability of Censoring Weighting [645]**
 Yoshinori Takeuchi, Tomohiro Shinozaki, Tatsuo Hiramatsu, Yutaka Matsuyama. (Japan)
- 193. Over-the-Counter (OTC) Weight Loss Nutraceuticals: Claim, Microbiological, Pharmaceutical Quality & Safety Assessments [646]**
 Nada Ahmed, Alaa AbouElfetouh, Amal H El-Kamel, Mohamed Ismail Nounou. (Egypt)
- 194. Disproportionality Analysis of Amoxicillin and Clavulanate Acid and Hepatotoxicity in FDA Adverse Event Reporting System [647]**
 Jung Lee. (United States)
- 195. Risk of Aortic Valve and Neuropsychiatric Disorders Following an Initial Prescription for Levofloxacin or Ciprofloxacin In The Elderly [648]**
 William D Finkle, Gregory Ridgeway, Sander Greenland, Debra E Irwin, Paul Juneau, Liisa Palmer. (United States)
- 196. Lupus Associated to TNF-Alpha Inhibitor in Children and Adults: A Disproportionality Analysis in the WHO Pharmacovigilance Database (Vigibase) [649]**
 Justine Bouton, Florence Moulis, Guillaume Moulis, Agnès Sommet, Vanessa Rousseau, Jean-Louis Montastruc, Genevieve Durrieu. (France)



197. Incidence of Upper and Lower Gastrointestinal Bleeds in New Users and Non-Users of Low-Dose Aspirin in the UK [650]

Lucia Cea Soriano, Montse Soriano-Gabarro, Angel Lanas, Luis A García Rodríguez. (Spain)

198. Drug-Induced Acute Liver Injury (ALI) in the French Claims Database: Description of Cases [651]

Adeline Grolleau, Vanessa Barbet, Nicolas Thurin, Régis Lassalle, Mai Duong, Cécile Droz-Perroteau, Nicholas Moore. (France)

199. Drug-Induced Acute Liver Injury (ALI) in the French Claims Database: Individual and Population Risks [652]

Adeline Grolleau, Vanessa Barbet, Régis Lassalle, Mai Duong, Nicolas Thurin, Cécile Droz-Perroteau, Nicholas Moore. (France)

200. Tuberculosis Drug-Induced Liver Injury: Cohort Monitoring in Health Facilities in Indonesia [653]

Dr Jarir At Thobari, DA Perwitasari. (Indonesia)

201. Drug-Drug Interactions and Clinical Significance of Frequently Prescribed Antibiotics for Treating Acute Exacerbation in COPD Patients with Other Co-Administered Agents: A Systematic Review [654]

Yuanyuan Wang, Anouk J Jansen, Eelko Hak. (Netherlands)

202. Evaluation of Spontaneous Adverse Event Reports for Osteonecrosis of the Jaw (ONJ) Attributed to Denosumab and Zoledronic Acid Within the FDA Adverse Events Reporting System (FAERS) [655]

Mohamed A Mekki, Kareem El-Fass, Reem Nagib Mohammad, Adel Abou-Ali. (Egypt)

203. A Safety and Pharmacokinetic Study in Real-Life Practice of Pylera in France: The SAPHARY Study [656]

Patrick Blin, Bénédicte Lelièvre, Magali Rouyer, Frank Zerbib, Bertrand Diquet, Francis Mégraud, François Tison, Estelle Guiard, Emmanuelle Bignon, Vanessa Barbet, Régis Lassalle, Cécile Droz-Perroteau, Nicholas Moore. (France)

Pharmacovigilance Diabetes-Ophthalmic

204. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Cancer in Patients with Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials [657]

Huilin Tang, Qi Dai, Weilong Shi, Suodi Zhai, Yiqing Song, Jiali Han. (United States)

205. Pancreatic Safety of Vildagliptin: Pan-European Non-Interventional Safety Study [658]

Rachael Williams, Carmen Serban, Sandra Lopez, Wolfgang Kothny, Raymond Schlienger. (United Kingdom)

206. TZD Anti-Diabetes Therapy and Bladder Cancer: Example of "Ripple Effect" in Pharmacovigilance [659]

Ayad K Ali. (United States)

207. Pioglitazone Use and Risk of Bladder Cancer: A Systematic Literature Review and Meta-Analysis of Observational Studies [660]

Fabian Hoti, Juha Mehtälä, Houssein Khanfir, Solomon Christopher, Dimitri Bennett, Yizhou Ye, Pasi Korhonen. (Finland)

208. SGLT-2 Inhibitors and Severe Ketoacidosis: A Disproportionality Analysis in the World Health Organization's Adverse Drug Reactions Database [661]

Jean-Luc Faillie, Abdel N Ado Moumouni, Perrine Robin, Virginie Bres, Dominique Hillaire-Buys. (France)

209. The Combination of Selective Serotonin Reuptake Inhibitors and Statins Increases the Risk of Hyperglycemia in Japanese Patients: A Case Cross-Over Study [662]

Takuya Imatoh, Kimie Sai, Katsuhito Hori, Katsunori Segawa, Junichi Kawakami, Michio Kimura, Yoshiro Saito. (Japan)

210. Evaluation of Spontaneous Pancreas Related Adverse Event Reports Attributed to Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Within the FDA Adverse Events Reporting System (FAERS) [663]

Ola Zaafan. (Egypt)

211. Risk Modification of New Onset Diabetes Mellitus After Transplantation by Immunosuppression Regimen Among Renal Allograft Recipients [664]

Chao Chen, Alfonso H. Santos, Xuerong Wen. (United States)

212. Testosterone Supplementation and Ocular Vascular Disease [665]

Brian L. VanderBeek, Vaidehi S. Dedania, Wei Pan, David N. Zacks. (United States)

213. Erythropoiesis Stimulating Agents and the Risk of Sight Threatening Diabetic Retinopathy [666]

Brian L. VanderBeek, Keirnan Willet, Jin Sha. (United States)

Pregnancy

214. Ability of a Cohort Study Based on the French Healthcare Databases to Detect Risks of Major Congenital Malformations Associated with Prenatal Exposure to Valproic Acid [667]

Pierre-Olivier Blotière, Fanny Raguideau, Alain Weill, Mahmoud Zureik, Joël Coste, Rosemary Dray-Spira. (France)

215. Patterns and Predictors of Hypothyroid Medication Use in Relation to Pregnancy: A Drug Utilization Study [668]

Anna-Simone Frank, Angela Lupattelli, Hedvig Nordeng. (Norway)

216. Existing Databases Useful for Pregnancy Exposure and Fetal Outcomes Research, Case Study in Multiple Sclerosis (MS) [669]

Whitney S. Krueger, Mary S. Anthony, Catherine W. Saltus, Andrea V. Margulis, Elena Rivero-Ferrer, Brigitta Monz, David Wormser, Elizabeth B. Andrews. (United States)

217. Drug and Vaccine Utilization Among Pregnant Women in the Iganga Mayuge Health and Demographic Surveillance Site (IMHDSS), Uganda [670]

James H. Stark, Edward Galiwango, Meaghan Chemelski, Grace Kim, Elizabeth Robinson, Lena Tran, Chinaka Ukachu, Eve Wool, Daniel Weibel, Wan-Ting Huang, Sonali Kochhar, Janet R. Hardy, Steven R. Bailey, Salima Darakjy, Doris Kwesiga, Joseph Akuze, Dan Kajungu. (United States)

- 218. The Comparative Safety of Types and Doses of Intrapartum Intravenous Fluids for Cesarean Delivery and Newborn Excess Weight Loss [671]**
 Sherif Eltonsy, Alain Blinn, Brigitte Sonier, Steven DeRoche, Aubin Mulaja, William Hynes, André Barrieau, Mathieu Bélanger. (Canada)
- 219. Paracetamol During Pregnancy and Risk of Neurodevelopmental Disorders: Systematic Review of Observational Studies and Methodological Considerations [672]**
 Daniel R Morales, Jean-Michel Dogné, Javier Sawchik, Jamila Hamdani, Isabelle Massat, Xavier Kurz, Laurence de Fays. (United Kingdom)
- 220. Antidepressant Use in Pregnancy and the Risk of Low Apgar Score [673]**
 Dr. Anna Cantarutti, Elisabetta Patorno, Giovanni Corrao, Luca Merlini, Sonia Hernandez - Diaz, Brian T. Bateman, Krista F. Huybrechts. (Italy)
- 221. Prenatal Exposure to Benzodiazepines or Z-Hypnotics and Behavioral Problems at 5 Years of Age: A Study from the Norwegian Mother and Child Cohort Study [674]**
 Lene Maria Sundbakk, Mollie Wood, Angela Lupattelli, Jon Michael Gran, Hedvig Nordeng. (Norway)
- 222. Acetaminophen Exposure in Pregnancy and Offspring ADHD: Familial Risk and Confounding by Indication [675]**
 Eivind Ystrom, Kristin Gustavson, Ragnhild E Brandlistuen, Gun Peggy Knudsen, Per Magnus, Ezra Susser, George Davey Smith, Camilla Stoltenberg, Pål Surén, Siri E Håberg, Mady Hornig, W. Ian Lipkin, Hedvig Nordeng, Ted Reichborn-Kjennerud. (Norway)
- 223. Antipsychotic Use in Pregnancy: Is Reproductive Safety Different According to the Indication? [676]**
 Dr. Francois Montastruc. (France)
- 224. Antiepileptic Drugs in Pregnancy: Searching for a Reference Drug for Comparative Safety [677]**
 Andrea V Margulis, Anna S Oberg, Sonia Hernandez-Diaz. (Spain)
- 225. Long-Acting Beta2-Agonists During Pregnancy and Risk of Hypertensive Disorders of Pregnancy [678]**
 Lucie Blais, Fatima Kettani, Amélie Forget, Marie-France Beauchesne, Catherine Lemièrre, Évelyne Rey. (Canada)
- 226. Safety of Trumenba Vaccine Among Pregnant Women in the United States: Planning and Design of a Large-Scale Multi-Site Observational Study [679]**
 Catherine A Panozzo, Brie Purcell, Susan Andrade, Marie R. Griffin, Kevin Haynes, Nancy D. Lin, Cheryl N. McMahon-Walraven, Allison Naleway, Jessica Young, Jeffrey S. Brown, James Stark. (United States)
- 227. Postnatal Depression and Pharmacological and Non-Pharmacological Treatment [680]**
 Irene Petersen, Tomi Peltola, Samuel Kaski, Kate Walters, Sarah Harwood. (United Kingdom)
- 228. Use of Prescribed Antibiotics and Female Fecundability [681]**
 Ellen M Mikkelsen, Anders H Riis, Elizabeth E Hatch, Kenneth J Rothman, Lauren A Wise, Kathryn A McInerney, Henrik T Sørensen. (Denmark)
- 229. Intentional Use of Medications During Completed and Terminated Pregnancies: A Population Based Study [682]**
 Colette B Raymond, Christine M Leong, Matthew Dahl, Alan Katz, Jamison Falk, Shawn C Bugden, Dan Chateau. (Canada)
- 230. Pattern of Psychotropic Drug Use Before, During, and After Pregnancy: A Population-Based Cohort Study (2001-2013) [683]**
 Christine M Leong, Dan Chateau, Matthew Dahl, Alan Katz, Jamison Falk, Shawn C Bugden, Colette B Raymond. (Canada)
- 231. Pregnancy Outcomes According to Long- and Short-Acting Beta-Agonist Use: The Asthma Medications in Pregnancy Surveillance System Cohort Arm [684]**
 Kristin Palmsten, Yunjun Luo, Diana L Johnson, Michael Schatz, Christina D Chambers. (United States)
- 232. Ritonavir Pre-Clinical Animal Studies Outcome of Cryptorchidism Not Supported by Real World Evidence in Humans [685]**
 Chris Schneiderman, Belen Tornesi-Solas. (United States)
- 233. Use and Avoidance of Medications in Pregnancy: An Italian Perspective [686]**
 Angela Lupattelli, Hedvig Nordeng. (Norway)
- 234. Trends of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccination During Pregnancy in the Sentinel System [687]**
 Genna Panucci, Kinnera Chada, Hector Izurieta, Azadeh Shoabi, Maria Said, Richard Forshee, Joyce Obidi, Andrew Petrone, Noelle Cocoros, Tiffany Woodworth, Alison Kawai. (United States)
- 235. Abstract Withdrawn [688]**
- 236. No Elevated Risk for Teratogenicity Found in Pregnancies Exposed to Leflunomide During 1st Trimester in Quebec Pregnancy Cohort [689]**
 Susan Colilla, Irene Shui, Stephanie Tcherny-Lessenot, Juhaeri Juhaeri, Jin-Ping Zhao, Anick Berard. (United States)
- 237. Assessment of Smoking Status Data in an Electronic Health Record-Based System for Use in Pregnancy Research [690]**
 Wendy J Carman, Kelesitse Phiri, Baevin S Feeser, C Robin Clifford, Nancy D Lin, Najat J Ziyadeh, Robert Gately, John D Seeger. (United States)
- 238. Drugs and Lactation: How to Measure Chaos in Package Information Leaflets? [691]**
 Aleksandr V Matveev, Nail S Yagya, Aleksandr Y Ezernitskiy, Natalya N Yarkova, Nikolay N Churilov, Gleb G Lykov, Natalya V Matveeva. (Russian Federation)
- 239. Estimating the Average Daily Dose of Teratogenic Medicines Dispensed to Women of Child-Bearing Age [692]**
 Smriti Raichand, Sallie A Pearson, Nicholas A Buckley, Alys Havard. (Australia)



240. Utilization of Acid-Suppressive Medication During Pregnancy in an Insured U.S. Population, 2001-2014 [693]

Suzanne N Landi, Michele Jonsson Funk. (United States)

241. Zidovudine Use in Pregnancy and Congenital Malformations: Bayesian Methods to Interpret New Data in the Context of Existing Evidence [694]

Kathryn Rough, Jenny Sun, George R. Seage, Paige L. Williams, Krista F. Huybrechts, Brian T. Bateman, Sonia Hernandez-Diaz. (United States)
Student Award Recipient – Third Best Abstract Submitted by a Student/ Post-Doc

242. SSRIs During Pregnancy and Risk of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: Systematic Review of Observational Studies and Methodological Considerations [695]

Daniel R Morales, Jim Slattery, Stephen Evans, Xavier Kurz. (United Kingdom)

Propensity Scores

243. The Use of Propensity Score Matching to Estimate the Association Between New Statin Use and Left Ventricular Structure: In the Multi-Ethnic Study of Atherosclerosis (MESA) [696]

Lauren N Strand, Alain G Bertoni, David A Bluemke, Joao A Lima, Bruce M Psaty, Susan R Heckbert, Joseph A Delaney, Robyn L McClelland. (United States)

244. Flagging of Disproportionality Scores Based on Frequency of Reporting Within a Therapeutic Class [697]

Scott Snyder, Jerzy E Tyczynski. (United States)

245. Use of a Multi-Level Propensity Score Matching Approach to Create a Treatment-Based Cohort Analysis Dataset from a Disease Registry [698]

Rajiv Mundayat, Michelle Stewart, Jose Alvir, Sarah A Short, Moh-Lim Ong, Denis Keohane, Denise Rill, Marla B Sultan. (United States)

246. Comparing Drug Effectiveness in Children Using Propensity Scores Based on Different Windows of Patient History: A Retrospective Cohort Study [699]

Osemeke Osokogu, Javeed Khan, Swabra Nakato, Daniel Weibel, Maria de Ridder, Miriam Sturkenboom, Katia Verhamme. (Netherlands)

247. Propensity Score Prediction for Electronic Healthcare Databases Using Super Learner and High-Dimensional Propensity Score Methods [700]

Cheng Ju, Mary Combs, Samuel D. Lendle, Jessica M. Franklin, Richard Wyss, Sebastian Schneeweiss, Mark van der Laan. (United States)

248. Propensity Score Matching to Balance Comparison Groups to Examine the Impact of CoOccurring Chronic Conditions in a US Medicare Population [701]

Daniel B Ng, Katherine Gooch, Eleanor Caplan, Ibrahim Abbass, Paul Abbott, Cindy Kirby, Brandon Suehs. (United States)

249. Balance on Unmeasured Socioeconomic Variables Obtained by Matching on Propensity Score in a Vaccine Study [702]

Kandace L Amend, Bruce Turnbull, Li Zhou, John D Seeger. (United States)

250. Evaluation of the Sentinel Propensity Score Matching Tool and a Commercial Cloud-Based Analytic Platform [703]

Jasmanda H Wu, Joshua J. Gagne, Shirley V. Wang, Stephen L. Lin, Meera Kumar, Juhaeri Juhaeri. (United States)

REMS and RMMs

251. Assessment Methods and Major Results of the 18-Month, 3-Year and 7-Year Assessments of Risk Evaluation and Mitigation Strategies (REMS) for Varenicline (Chantix®) [704]

Kandace L Amend, Muhammad Younus, Kenneth R Petronis, Jingping Mo, Xiangmei Gu, Cheryl Enger. (United States)

252. Evaluating the Effectiveness of Additional Risk Minimisation Measures (aRMM) for Voriconazole in 10 European Countries [705]

Joanna Lem, Muhammad Younus, Jalal Aram, Shahrzad Moosavi, Klaus Freivogel, Anne Lewis, Rachel E. Sobel. (United States)

253. Variability in Reporting Participation Data in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union [706]

Esther Artime, Pareen Vora, Alex Asiiimwe, Montse Soriano-Gabarro, Nawab Qizilbash. (Spain)

254. Sampling Methods Used and Country Selection in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union [707]

Esther Artime, Pareen Vora, Alex Asiiimwe, Montse Soriano-Gabarro, Nawab Qizilbash. (Spain)

255. How Post Authorisation Safety Studies (PASS) Are Used to Assess the Effectiveness of Risk Minimisation Measures (RMMs) [708]

Mariana Almas, Pierre Engel, Vasco Maria, Aaron Mendelsohn, Stella Blackburn. (United Kingdom)

256. A Review of Studies Utilizing Secondary Data to Evaluate the Effectiveness of Risk Minimisation Measures in European Union (EU) Using the EU Electronic Register of Post-Authorisation Studies (EU PAS Register) [709]

Pareen Vora, Esther Artime, Montse Soriano-Gabarro, Nawab Qizilbash, Alex Asiiimwe. (Germany)

257. REMS Survey Response Rate by Stakeholder Type, Mode of Invitation Delivery, and Method of Completion [710]

Kristin Velej, Deborah Covington, Samantha Sites, Robin Kinard. (United States)

258. Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey Among Health Care Professionals to Assess Their Knowledge and Attitudes on Prescribing Conditions of Instanyl® in France and the Netherlands [711]

Massoud Toussi, Isabelle Bardoulat, Anna Garofano. (France)





259. Impact of Risk Minimization Measures on the Use of Cilostazol in Europe [712]

Jordi Castellsague, Brian Calingaert, Beatriz Poblador-Plou, Maria Giner-Soriano, Marie Linder, Oliver Scholle, Alejandro Arana, Christine Bui, Clara Laguna, Alexandra Prados-Torres, Albert Roso-Llorach, Susana Perez-Gutthann. (Spain)

Trials & Tribulations

260. Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis [713]

Saibal Das, Jayanta Kumar Dey, Sumalya Sen, Rishav Mukherjee. (India)

261. Prophylactic Antibiotics for Children with Vesicoureteral Reflux: A Meta-Analysis [714]

Hyun Jin Choi, Kyoungsoon Park, Joongyub Lee, Byung-Joo Park. (Korea, Republic of)

262. Use of Health Administrative Claims Data in a Pragmatic Clinical Trial of Academic Detailing to Improve Prescribing [715]

Mina Tadrous, Kinwah Fung, Laura Desveaux, Monica Taljaard, Tara Gomes, Noah Ivers. (Canada)

263. The Benzodiazepine Discontinuation Study (BEDS): Non-Controlled Interventional Study [716]

Joana S Oliveira, Inês T Neves, Milene Fernandes, Osvaldo Santos, Vasco Maria. (Portugal)

264. Pharmacist-Led Intervention to Enhance Medication Adherence in Patients with Acute Coronary Syndrome in Vietnam: A Randomized Controlled Trial [717]

Thang Nguyen, Phu T Nguyen, Ha T Tran, Ngoc V Nguyen, Hoa Q Nguyen, Ban N Ha, Thao H Nguyen, Tam T Pham, Katja Taxis. (Viet Nam)

265. Large Streamlined Trials - What Works, and What Doesn't [718]

Amy Rogers, Thomas M MacDonald, Isla S Mackenzie, Alexander Doney. (United Kingdom)

266. Reporting of Interventions and Standard of Care Control Arms in Paediatric Clinical Trials; A Quantitative Analysis [719]

Dr. Lauren E Kelly, Ashley M Yu, Bannuya Balasubramaniam, Martin Offringa. (Canada)

267. Efficacy of Metformin Monotherapy on Glycemic Control, Weight and Serum Lipids in Drug-Naive Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials [720]

Jean-Luc Faillie, Carole Pietra-Mardemootoo, Béatrice Clarivet, Dominique Hillaire-Buys, Philippe Lambert. (France)

268. Discrepancies Between Protocols and Publications of Clinical Drug Trials [721]

Cornelis A van den Bogert, Patrick C Souverein, Cecile T Brekelmans, Susan W Janssen, Gerard Koëter, Hubert G Leufkens, Lex M Bouter. (Netherlands)

End Session B





Spotlight Session - BRACE

- A. Impact of Risk Minimisation Measures on the Use of Strontium Ranelate: A Multi-National Cohort Study in 5 EU Countries by the EU-ADR Alliance [799]**
Klara Berencsi, M Sanni Ali, Karine Marinier, Nicolas Deltour, Samuel Hawley, Lars Pedersen, Peter Rijnbeek, R G Duijnhoven, Johan Van der Lei, Francesco Lapi, Monica Simonetti, Cristina Reyes-Reyes, Miriam Sturkenboom, Daniel Prieto-Alhambra. (United Kingdom)
- B. Evaluation of Effectiveness of Risk Minimisation Measures Applied to the Use of Desmopressin by Elderly Patients in Denmark [800]**
Martin Erik Nyeland, Torbjörn Callréus. (Denmark)
- C. Qualitative Approaches to Testing Data Collection Instruments in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union [801]**
Esther Artime, Páireen Vora, Noelia Alfaro Oliver, Alex Asiimwe, Montse Soriano-Gabarro, Nawab Qizilbash. (Spain)
- D. Media Attention for Drug Safety Issues. A Survey of News Papers and Social Media in the Netherlands (2001 - 2015) [802]**
Peter G Mol, Taco B Monster, Sieta T de Vries, Jacqueline Hugtenburg. (Netherlands)
- E. Use of Geospatial Analysis to Examine Heterogeneity of Diabetes Risk Management Integration into Routine Healthcare for Adults Taking Antipsychotics [803]**
Randi K Johnson, Deborah Thomas, Elizabeth J Campagna, Elaine H Morrato. (United States)
- F. Application of the Number Needed to Treat (NNT) in Medical Literature: A Methodological Assessment [804]**
Diogo Mendes, Carlos Alves, Francisco Batel Marques. (Portugal)
- G. Is Prior Opioid Tolerance Associated with Safer Use of Extended-Release Opioids? [805]**
Jessica C Young, Jennifer L Lund, Nabarun Dasgupta, Michele Jonsson Funk. (United States)

- H. Assessment of the Effect of Minimization Measures of the Risk of Stroke with Antipsychotic Use in Elderly Persons: A Nested Case-Control Study [806]**
Janet Sultana, Francesco Giorgianni, Silvia Tillati, Miriam Sturkenboom, Gianluca Trifiro'. (Italy)

Spotlight Session - CER

- I. Clearer Answers, Superior Matching: Propensity Score Matching vs. Coarsened Exact Matching [807]**
Dan Busbridge, Tomass Bernots, Gwyn Jones. (United Kingdom)
- J. Adjusting for Unobserved Disease Severity Using Individuals as Their Own Controls - An Example from a Schizophrenia Study [808]**
Juha Mehtälä, Maila Majak, Heidi Taipale, Antti Tanskanen, Jari Tiihonen, Ellenor Mittendorfer-Rutz, Jan Sermon, Amy Leval, Fabian Hoti. (Finland)
- K. The Comparative Performance of Logistic Regression and Random Forest in Propensity Score Methods: a Simulation Study [809]**
M Sanni Ali, Sara Khalid, Gary S Collins, Daniel Prieto-Alhambra. (United Kingdom)
- L. Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccination Among Veterans Health Administration Patients: A Retrospective Observational Cohort Study [810]**
Yinong Young-Xu, Robertus van Aalst, Salah Mahmud, Ayman Chit. (United States)
- M. An Association Between the Use of a Selective or Non-Selective Bladder Antimuscarinic and the Risk of Fractures in a Medicare Nursing Home Population: A Comparative Effectiveness Study [811]**
Pratik Doshi, Daniela C Moga, Quishan Wu, Li Chen, Candace Brancato. (United States)

- N. Comparative Effectiveness and Safety of Antiplatelet Drug Regimens as Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack [812]**
Alfi Yasmina, Anthonius de Boer, Vera H. M. Deneer, Jurrien M. ten Berg, Rolf H. H. Groenwold, Patrick C. Souverein, Olaf H. Klungel. (Indonesia)
Recipient of the John Snow Award
- O. Comparative Bleeding Risk with Oral Anticoagulants: An Instrumental Variable Approach [813]**
Meijia Zhou, Ashkan Ertefaie, Todd E. Hecht, Sean Hennessy, Dylan S. Small. (United States)
- P. Performance of Confounder Summary Scores in Estimating Subgroup Effects in Comparative Effectiveness Research [814]**
Phyo Htoo, Mugdha Gokhale, Richard Wyss, Jennifer Lund, Virginia Pate, Michele Jonsson-Funk, John Buse, Til Stürmer. (United States)

Spotlight Session - Drug Utilization Research

- Q. Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults [815]**
Alex Secora, Morgan Grams, Caleb Alexander, Josef Coresh. (United States)
- R. Use of Attention-Deficit/Hyperactivity Disorder Medication Among Older Adults in Denmark [816]**
Lotte Rasmussen, Stina S Ormhøj, Christiane Gasse, Anton Pottegård. (Denmark)
- S. Patterns of Prescription Opioid Utilization Prior to Opioid Overdose in a Commercially Insured Population [817]**
Sara Z. Dejene, Kathryn Rough, Krista F. Huybrechts, Sonia Hernandez-Diaz, Raisa Levin, Rishi J. Desai, Elisabetta Paterno, Brian T. Bateman. (United States)
- T. The Impact of HIV Coinfection on Hepatitis C Virus (HCV) Treatment Initiation [818]**
Cassidy E Henegar, Robin Beckerman, Jennifer Fusco. (United States)

- U. Patterns of Antiplatelet Therapy in Patients with Ischaemic Stroke or Transient Ischaemic Attack [819]**
Norazida Ab Rahman, Alfi Yasmina, Anthonius de Boer, Vera H Deneer, Patrick C Souverein, Olaf H Klungel. (Netherlands)
- V. Trends in Use of Oral Anticoagulants as Stroke Prophylaxis in Norway - Direct-Acting Oral Anticoagulants Are Trendy! [820]**
Lars J Kjerpeseth, Hanne Ellekjær, Randi Selmer, Inger Ariansen, Kari Furu, Eva Skovlund. (Norway)
- W. Post-Stroke Antithrombotic Drug Treatment in People with Schizophrenia and Bipolar Disorder Regarding Treatment Choice and Intensity: A Danish Population-Based Study [821]**
Jeanette D Arnold Bik, Henriette Thisted Horsdal, Christiane Gasse. (Netherlands)
- X. Is Initial Therapy an Accurate Measure of Actual Treatment for Infectious Diseases? [822]**
Aisling R Caffrey, Zachary Babcock, Vrshali V Lopes, Tristan T Timbrook. (United States)

Spotlight Session - Medical Devices

- Y. Post-Approval Studies (PAS) for Medical Devices in the US 2012-2016: Characterization and Outcomes [823]**
Joan Largent, Aaron Mendelsohn. (United States)
- Z. Total Hip Arthroplasty with Metallic Bearing and Risk of Non-Hodgkin's Lymphoma [824]**
Anne Moulin, Sandrine Colas, Annie Rudnichi, Assia Allalou, Brigitte Heuls, Mahmoud Zureik, Rosemary Dray-Spira. (France)
- AA. Cardiotoxicity of Metallic Hip Implants [825]**
Marion Lassalle, Sandrine Colas, Annie Rudnichi, Mahmoud Zureik, Rosemary Dray-Spira. (France)
- BB. Causes of Readmission after Venous Thromboembolism with or without Vena Cava Filters in the United States: Nationwide Readmission Database 2013-2014 [826]**
Ming Chen, Joshua Brown. (United States)

- CC. Inferior Vena Cava Filter Retrieval Rates and Factors Associated with Retrieval in the United States [827]**
Joshua Brown, Val Adams, Jeffery Talbert. (United States)
- DD. Intrathecal Injections in a US Commercially Insured Database: Descriptive Characteristics, Medication Use and Comorbidities [828]**
Cynthia C. Jones, Susan Eaton, Anne Dilley, Suzanne F. Cook. (United States)
- EE. What Is the Prevalence of Self-Harm Risk Factors in Patients with Ventriculoperitoneal Shunts? [829]**
Andrew Yoo, Chantal Holy, Ruby Castilla. (United States)
- FF. Do Perioperative Complications and Readmissions After Incisional Hernia Mesh Repair Affect Recurrence Rates? [830]**
Andrew Yoo, Katherine Corso, Gary Chung, Rubin Sheng, Niels-Derrek Schmitz. (United States)

Spotlight Session - Medications in Pregnancy

- GG. ADHD Medication Use in Pregnancy and Risk of Preeclampsia and Small for Gestational Age Birth [831]**
Jacqueline M Cohen, Sonia Hernandez-Diaz, Brian T Bateman, Yoonyoung Park, Rishi Desai, Helen Mogun, Krista F Huybrechts. (United States)
- HH. Roxithromycin in Early Pregnancy and the Risk of Major Congenital Malformations: A Register Based Nationwide Cohort Study [832]**
Rasmus H Olsen, Henrik E Poulsen, Jon T Andersen. (Denmark)
- II. Teratogenic Risk of Macrolides During the First Trimester of Pregnancy: A Study with Two Complementary Approaches within the EFEMERIS Database [833]**
Agnes Sommet, Thuc Lê Nguyen, Mélanie Araujo, Caroline Hurault-Delarue, Isabelle Lacroix, Christine Damase-Michel. (France)
- JJ. Defects [834]**
Xi Wang, Yanmin Zhu, Yasser Albogalmi, Shannon Lyons, Almut Winterstein. (United States)

- KK. Patterns of Methadone Use and Perinatal Outcomes Among Pregnant Women in Ontario [835]**
Qi Guan, Beth Sproule, Simone N. Vigod, Suzanne M. Cadarette, Diana Martins, Simon Greaves, Tara Gomes. (Canada)
- LL. Agreement between Paternal Self-Reported Medication Use and Data from a National Prescription Database [836]**
Jacqueline M Cohen, Mollie E Wood, Sonia Hernandez-Diaz, Hedvig M Nordeng. (United States)
- MM. Anticonvulsants and Mood Stabilizers Prescribing During Pregnancy in France Between 2007 and 2014: A Study Based on the French Healthcare Databases [837]**
Pierre-Olivier Blotière, Fanny Raguideau, Carole Ehrhardt, Joël Coste, Mahmoud Zureik, Alain Weill, Rosemary Dray-Spira. (France)
- NN. Is the Use of Smoking Cessation Pharmacotherapies During Pregnancy Consistent with Clinical Guidelines? Findings from the Smoking MUMS (Maternal Use of Medications and Safety) Study [838]**
Alys Havard, Duong T Tran, David B Preen, Kristjana Einarsdottir, Louisa R Jorm. (Australia)

21st Century Pharmacoepidemiology

- Do Blogs Contain Data on Adverse Reactions to Japanese Drugs? A Comparison of English and Japanese News and Social Networking Websites [839]**
Minami Tomita. (Japan)
- Which Patients Are Interested In an APP for Reporting Adverse Drug Reactions and Receiving Drug Safety Information? [840]**
Peter Mol, Sieta de Vries, on behalf of IMI Web-RADR work package 3b Consortium. (Netherlands)
- Electronic Health Record-Based Medication Complete Communication (EMC²) Strategy: An Innovative Approach to Enhance Patient Safety and Adherence [841]**
Ken Hornbuckle, Karen Lockwood, Lori Hall, Emily Freeman, Stacy Cooper Bailey, Michael Wolf. (United States)

4. **Impact of Using an Electronic Platform for an Early-Access Program for Daratumumab in France: A System Utilisation and Satisfaction Study [842]**
Hubert Mechin, Claire Albrecht, Anna Dupuis Siraeva, Sophie Vernet, Jean Charles Tissier, Julien Thevenon. (France)
 5. **Eczema Information in the News Media - Myths or Facts [843]**
Cheong Hian Goh, Seow Koon Chua, Mui-Ling Tan, Wai-Ping Yau. (Singapore)
 6. **What Factors Relate to Patients Contributing Longitudinal Data Using Smartphone Technology? Findings from RA Patients Participating in ArthritisPower Registry [844]**
Huifeng Yun, Benjamin W. Nowell, James Willig, Jennifer Beaumont, Bernadette Johnson, Seth D. Ginsberg, Carole Wiedmeyer, Rachele Crow-Hercher, Britt J. Johnson, Shuo Yang, Jeffrey R. Curtis. (United States)
 7. **Survey of Physician-Mothers Facebook Group to Inform Pregnancy Registry Recruitment [845]**
Deborah Covington, Kristin Veley, Samantha Sites, Laura McKain. (United States)
 8. **Discussions About Medication and Vaccine Use During Pregnancy and Lactation on Pregnancy Related Social Media Sites [846]**
Lorrie Schifano, Marcy Powell, Linda Clayton, Arooj Akhtar, Jeffery Painter, Dean Jan, Greg Powell, Edgar P Simard. (United States)
 9. **Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation between PROMIS Instruments for PRO Data Capture [847]**
Huifeng Yun, Jennifer Beaumont, Shuo Yang, James Willig, Benjamin W. Nowell, Seth D. Ginsberg, Iris Navarro-Millan, Kelly V. Clayton, Shantana Hazel, Carole Wiedmeyer, Jeffrey R. Curtis. (United States)
 10. **Social Media Compared to FAERS and Administrative Claims for Pharmacovigilance [848]**
Brian Dreyfus, Carrie E Pierce. (United States)
 11. **Mining Events Appearing in Patient Narratives in Disease Blogs on the Internet: Social Pharmacovigilance [849]**
Shinichi Matsuda, Kotonari Aoki, Shiho Tomizawa, Masayoshi Sone, Riwa Tanaka, Hiroshi Kuriki, Yoichiro Takahashi. (Japan)
- Adherence**
12. **Determinants of 12-Months Persistence in Rheumatoid Arthritis Patients Initiating Subcutaneous TNF- α Inhibitors [850]**
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff, Najat Gouyette, Aurore Clément, Eric Van Ganse, Florence Tubach. (France)
 13. **Determinants of 12-Months Persistence in Ankylosing Spondylitis Patients Initiating Subcutaneous TNF- α Inhibitors [851]**
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff, Najat Gouyette, Aurore Clément, Eric Van Ganse, Florence Tubach. (France)
 14. **Determinants of 12-Months Persistence in Psoriatic Arthritis Patients Initiating Subcutaneous TNF- α Inhibitors [852]**
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff, Najat Gouyette, Aurore Clément, Eric Van Ganse, Florence Tubach. (France)
 15. **Treatment Efficacy and Adherence to Combined Enalapril and Nifedipine Compared to Conventional Treatment Among Hypertensive Patients in Primary Care from Mexico City [853]**
Claudia Lerma, Humberto Badillo, Abel Lerma. (Mexico)
 16. **Patient Compliance with Drug Storage Recommendations [854]**
Nicolaas D Vlieland, Bart J van den Bemt, Charlotte L Bekker, Marcel L Bouvy, Toine C Egberts, Helga Gardarsdottir. (Netherlands)
 17. **Long-Term Adherence to Metformin Is Associated with Better Survival: A Nested Case-Control Study in New Metformin Users [855]**
Sylvie Perreault, Patrice Simard, Nancy Presse, Louise Roy, Brian White-Guay, Agnès Rakel. (Canada)
 18. **Predictors of Non-Adherence to and Non-Persistence with Statin Therapy Among Patients on Oral Diabetes Medication in the Netherlands: A Retrospective Inception Cohort Study [856]**
Sofa Dewi Alfian, Pawida Worawutputtpong, Catharina CM Schuiling-Veninga, Jurjen van der Schans, Jens H Bos, Eelko Hak, Petra Denig. (Netherlands)
 19. **Compliance with New Pregnancy Prevention Recommendations in French Women of Childbearing Age Exposed to Acitretin (2007-2015) [857]**
Myriam Mezzarobba, Fanny Raguideau, Rosemary Dray-Spira, Mahmoud Zureik, Alain Weill, Joel Coste. (France)
 20. **Patients' Characteristics Associated with Trajectories of Benzodiazepine Use Leading to Non Adherence to Guidelines [858]**
Antoine Pariente, Sandy Maumus-Robert, Ana Jarne Munoz, Bernard Bégaud. (France)
 21. **Two-Year Statin Adherence Trajectories in Initiators of Combined Amlodipine-Atorvastatin Therapy: A Population-Based Study (2005-2015) [859]**
Andrea L Schaffer, Nicholas A Buckley, Sallie-Anne Pearson. (Australia)
 22. **Factors Associated with Antidiabetic Medication Non-Adherence in Patients with Incident Comorbid Depression [860]**
Carlotta Lunghi, Arsène Zongo, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
 23. **Computing an Individual-Level Disparity Ratio to Measure Racial Ethnic Disparities in Adherence to Cardiovascular Medications [861]**
Gang Fang, Izabela Annis, Delesha Carpenter, Christine Oramasionwu, Crystal Cene. (United States)
 24. **Association of Guideline Adherence and Clinical Outcomes in Management of *Clostridium Difficile* Infection [862]**
Hsing-Chun Hsieh, Chien-Ming Chen. (Taiwan)

- 25. The Relationship Between Medication Possession Ratio and Morisky Medication Adherence Scale-8 Among a Sample of Older Adults with Epilepsy [863]**
Yazed AlRuthia, Huda AlZahrani, Haya Almalq. (Saudi Arabia)
- 26. Influence of Medication Regimen Complexity on Adherence: A Systematic Review [864]**
Laís Lessa Pantuzza, Maria das Graças Braga Ceccato, Micheline Rosa Silveira, Luane Mendes Ribeiro Junqueira, Celline Cardoso Almeida-Brasil, Adriano Max Moreira Reis. (Brazil)
- 27. Reproducibility of Adherence Studies in Large Healthcare Databases [865]**
Shirley V Wang, Elizabeth M Garry, Patrice Verpillat, Amanda Patrick. (United States)
- 28. Adherence to Statin Therapy and the Use of Preventive Clinical Examinations: An Investigation Using Claims Database in Japan [866]**
Tsugumichi Sato, Motoyoshi Akiyama, Haruna Hasegawa, Moriya Ogino, Kiyoshi Kubota. (Japan)
- 29. Assessment of Impact of Pharmacist-Psychiatrist Collaborative Patient Education on Medication Adherence and Quality of Life in Patients with Bipolar Disorder [867]**
Ramesh Madha, Ambed Mishra, Kishor M, Justin Kurian, Tony D K, Saikrishna G, Sravani A. (India)
- Analytic Methods**
- 30. Multi-Level Modelling (MLM) in Specialist Cohort Event Monitoring (SCEM) Studies [868]**
Debabrata Roy, Deborah Layton, Sarah E Marley, Saad A Shakir. (United Kingdom)
- 31. Evaluation of Test Data in Distributed Research Networks: A Sentinel System Example [869]**
Emily C Welch, Tiffany S Woodworth, Talia J Menzin, Ting-Ying Jane Huang. (United States)
- 32. Distributed Regression Analysis in a Distributed Health Data Network [870]**
Jessica M. Malenfant, Qoua L. Her, Sarah Malek, Yury Vilik, Sengwee Toh. (United States)
- 33. Medication-Class Enrichment Analysis: A Novel Technique to Identify Pharmacologic Exposures Associated with Diseases [871]**
Ravy K Vajravelu, Ronac Mamtani, Frank I Scott, Hongzhe Li, James D Lewis. (United States)
- 34. Comparative Effectiveness Research in the Real World: A Bayesian Framework for Synthesising Evidence from RCT and Non-RCT Studies [872]**
C. Elizabeth McCarron, Hongbo Yuan. (Canada)
- 35. An Innovative Approach to Disproportionality to Characterize the Population within a Case Series [873]**
Scott Snyder, Jerzy E Tyczynski, Jeremy Jokinen. (United States)
- 36. Duration of Individual Prescriptions and Treatment Episodes in Users of Oral Glucocorticoids Using the Parametric Waiting Time Distribution [874]**
Kristina Laugesen, Henrik Støvring, Jens Otto Lunde Jørgensen, Henrik Toft Sørensen, Irene Petersen. (Denmark)
- 37. The Impact of Overfitting Logistic Propensity Score Models: A Simulation Study [875]**
Richard Wyss, Jessica M Franklin. (United States)
- 38. Scalable Collaborative Targeted Learning for Large Scale and High-Dimensional Data [876]**
Cheng Ju, Susan Gruber, Samuel D. Lendle, Jessica M Franklin, Richard Wyss, Sebastian Schneeweiss, Mark J. van der Laan. (United States)
- 39. Review of Methods for Propensity Score Matched Subgroup Analysis and Their Application in Peer Reviewed Research Studies [877]**
Shirley V Wang, Mengdong He, Yinzhu Jin, Richie Wyss, HoJin Shin, Yong Ma, Stephine Keeton, Bruce Fireman, Sara Karami, Jacqueline M Major, Sebastian Schneeweiss, Joshua J Gagne. (United States)
- 40. Propensity Score Trimming to Enhance Validity in Comparative Effectiveness Research [878]**
Richard Wyss, Til Stürmer, Joshua J. Gagne, Justin Bohn, Robert J. Glynn. (United States)
- 41. Reducing Unmeasured Confounding by Frailty Through Restriction When Estimating Influenza Vaccine Effectiveness in Older Adults [879]**
Henry T Zhang, Leah J McGrath, Alan R Ellis, Richard Wyss, Jennifer L Lund, Til Stürmer. (United States)
- 42. Using Internally Estimated Risk Scores to Evaluate Treatment Effect Heterogeneity in Comparative Safety and Effectiveness Research [880]**
Richard Wyss, Justin Bohn, Joshua J. Gagne. (United States)
- 43. The Impact of Differential Exposure Misclassification on Performance of Propensity Score Methods [881]**
Mollie Wood, Hedvig Nordeng, Stavroula Chrysanthopoulou, Kate Lapane. (Norway)
- 44. Comparison of Statistical Efficiency of Self-controlled Case Series and Case-Crossover Designs in Vaccine Safety [882]**
Javeed Khan, Maria de Ridder, Christel Faes, Miriam C Sturkenboom. (United Kingdom)
- 45. Abstract Withdrawn [883]**
- 46. The Use of Group-Based Trajectory Models to Characterize Longitudinal Patterns of Nonmotor Symptoms in Patients with Parkinson's Disease in Japan [884]**
Shih-Wei Chiu, Takuhiro Yamaguchi. (Japan)
- 47. Changepoint Analysis in Pharmacovigilance Signal Detection [885]**
Joep Scholl, Florence van Hunsel, Eugène van Puijenbroek. (Netherlands)
- 48. Evaluating Case-Crossover Design as a Screening Tool for Clinically Relevant Drug-Drug Interactions: Statins and Rhabdomyolysis [886]**
Katsiaryna Bykov, Sebastian Schneeweiss, Robert J Glynn, Murray A Mittleman, Joshua J Gagne. (United States)



Burden of Disease - Cardiovascular and Hematologic

- 49. Hip Fracture and Risk of Myocardial Infarction and Stroke in Denmark 1995-2015 [887]**
Alma B Pedersen, Vera Ehrenstein, Szimonetta Szépligeti, Henrik T Sorensen. (Denmark)
- 50. Excess Risk of Venous Thromboembolism in Hip Fracture Patients. A Danish Nationwide Study 1995-2015 [888]**
Alma B Pedersen, Vera Ehrenstein, Szimonetta Szepligeti, Henrik T Sørensen. (Denmark)
- 51. Migraine and Cardiovascular Disease. The Impact of Hormones, Anti-Thrombotic Medication and Comorbidity in Two Population-Based, Case-Control Studies [889]**
Merete Osler, Ida Wium-Andersen, Martin Balslev Jørgensen, Terese Jørgensen, Marie Wium-Andersen. (Denmark)
- 52. Investigating Eczema as a Risk Factor for Cardiovascular Disease Outcomes in a UK Adult Population [890]**
Sinead M Langan, Richard Silverwood, Harriet Forbes, Katrina Abuabara, Krishnan Bhaskaran, Morten Schmitt, Sigrun Schmitt, Liam Smeeth. (United Kingdom)
- 53. Long-Term Outcomes After Myocardial Infarction: A Cohort Study in the French National Claims Database [891]**
Nicholas Moore, Patrick Blin, Caroline Dureau-Pourmin, Regis Lassalle, Jeremy Jove, Nicolas Danchin, Cecile Droz-Perroteau. (France)
- 54. Outcomes in Patients with Heart Failure Treated in Hospitals with Varying Health Care Use: A Population-Based Cohort Study from 1997 to 2010 [892]**
Sylvie Perreault, Simon de Denus, Michel White, Brian White-Guay, Marc Dorais. (Canada)
- 55. Characterizing the Prevalence of Giant Cell Arteritis in the United Kingdom Using the Clinical Practice Research Datalink [893]**
Frank A. Corvino, Pavel Napalkov, Nengjun Zhao. (United States)

- 56. Clinical Features and Pharmacotherapy Use Among Older Patients with Heart Failure Living in Skilled Nursing Facilities [894]**
Lin Li, Bill M. Jesdale, Anne Hume, Giovanni Gambassi, Robert J. Goldberg, Kate L. Lapane. (United States)
- 57. Comparative Patterns of Use of Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Hemorrhage in Real Life. The Stroke Prevention and Anticoagulants (SPA) Study [895]**
Lamiae Grimaldi-Bensouda, Jean Yves Le Heuzey, Jean-Marc Davy, Emmanuel Touzé, Didier Leys, Jacques Bénichou, Jean Ferrières, Lucien Abenhaim. (France)

Burden of Disease - Infection

- 58. Incidence and Risk Factors of *Clostridium difficile* Infection in Patients with Ileal Pouch-Anal Anastomosis [896]**
Paula D Strassle, Jennifer Samples, Emily E Sickbert-Bennett, David J Weber, Timothy S Sadiq, Nicole Chaumont. (United States)
- 59. Global Risk Factors of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis [897]**
Ivan S. Pradipta, Lina Davies Forsman, Judith Bruchfeld, Eelko Hak, Jan-Willem Alffenaar. (Netherlands)
- 60. Estimation of Risk of Death Attributable to Acute Gastro-Enteritis Among Hospitalized Adults in England [898]**
Maria Alexandridou, Tom Cattaert, Germano Ferreira, Thomas Verstraeten. (Belgium)
- 61. Increased Episode Rate Of Medically-Attended Acute Gastroenteritis In Diabetics in England [899]**
Tom Cattaert, Germano Ferreira, Thomas Verstraeten. (Belgium)
- 62. Recent Trends in Hospital Acquired *Clostrum Difficile* in U.S. Hospitals [900]**
Christopher Craver, Kathy Belk. (United States)

- 63. Substance Use, Housing Stability, and HIV Infection: Study Context Is Everything [901]**
Bridget Kruszk, Bridget M Whitney, Mika Matsuzaki, Lauren Strand, Jennifer Lorvick, Gregory M Lucas, Wendee Wechsberg, Irene Kuo, William E Cunningham, Asa Clemenzi-Allen, Shoshana Kahana, Joseph A Delaney, Heidi M Crane. (United States)
- 64. Linkage to Care of Patients Living with HIV/AIDS in a Reference Hospital of Minas Gerais, Brazil [902]**
Romara E Perdigão, Juliana O Costa, Celline C Almeida-Brasil, Palmira F Bonolo, Francisco A Acurcio, Micheline R Silveira, Maria das Graças B Ceccato. (Brazil)

Burden of Disease - Respiratory

- 65. Tobacco Use and Associated Factors Among Adolescent Students in Bangladesh: A Cross Sectional Study [903]**
Muhammad Abdul Baker Chowdhury, Abdullah Al Islam, Bappi Kumar, Rana Mahmud, Shahin Mia, Jamal Uddin. (United States)
- 66. Comorbidities in Adults with Asthma: Population-Based Crosssectional Analysis of 1.4 Million UK Patients [904]**
Daniel R Morales, Bruce Guthrie, Stewart Mercer, Christopher Weatherburn. (United Kingdom)
- 67. The 12-Year Trend (2000-2011) of Prevalence of Chronic Obstructive Pulmonary Disease in Taiwan: A Population-Based Survey from National Health Insurance Research Database [905]**
Yu-Fen Huang, Chia-Lin Chou, Yueh-Ching Chou. (Taiwan)
- 68. Prevalence of Severe Asthma and Poorly Controlled Severe Asthma During 2009 - 2013 in the Netherlands [906]**
Elisabeth Smits, Jetty A Overbeek, Sverrir Valgardsson, Jan van Laer, Fernie Penning - van Beest. (Netherlands)

- 69. The Effect of Changing GOLD Severity Stage on Long-Term Mortality in COPD [907]**
Robert Flynn, Thomas MacDonald, Steve Morant, James Chalmers, Isla Mackenzie, Stuart Schembri. (United Kingdom)

Causal Relationships In Pharmacoepidemiology(?)

- 70. Use of Aspirin and Ovarian Cancer Mortality [908]**
Christian Dehlendorff, Freija Verdoodt, Merete K. Hansen, Susanne K. Kjaer, Søren Friis. (Denmark)
- 71. Bisphosphonate Use and Risk of Renal Cell Carcinoma: A Population Based Case-Control Study [909]**
Maja Hellfritsch, Benjamin I Chung, Sinna P Ulrichsen, Henrik T Sørensen, Vera Ehrenstein. (Denmark)
- 72. The Effect of Statin Use on Prostate Cancer Incidence - A Population-Based Nested Case-Control Study [910]**
David E Dawe, Xibiao Ye, Piotr Czaykowski, Davinder Jassal, Armen Aprikian, Eduardo Franco, Robert Platt, Harminder Singh, David Skarsgard, Jon Tonita, Salaheddin Mahmud. (Canada)
- 73. Nested Case-Control Studies to Assess the Association Between Pioglitazone Use and Bladder Cancer Risk in a Swedish Type 2 Diabetes Cohort [911]**
Elena Olmastroni, Shahram Bahmanyar, Marie Linder. (Italy)
- 74. Protective Effect of Inhaled Corticosteroids on Risk of Acute Myocardial Infarction in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study with Nested Case-Control Analysis from the National Health Insurance Research Database in Taiwan [912]**
Yu-Fen Huang, Chia-Lin Chou, Yueh-Ching Chou. (Taiwan)
- 75. Statins and Incident Disability in Community-Dwelling Older Adults - A Longitudinal Study [913]**
Ilan Matok, Amichai Perlman, Raj C. Shah, David A. Bennet, Aron S. Buchman. (Israel)
- 76. Association Of Antipsychotic Medications and All-Cause Mortality in Elderly Patients Affected By Cardio- and Cerebrovascular Diseases: A Nested Case-Control Study [914]**
Francesco Giorgianni, Janet Sultana, Alessandro Mugelli, Ersilia Lucenteforte, Niccolò Lombardi, Alfredo Vannacci, Graziano Onder, Ursula Kirchmayer, Cristina Vitale, Alessandro Chinellato, Rosa Gini, Giovanni Corrao, Gianluca Trifirò, on the behalf of I-GrADE. (Italy)
- 77. The Association Between Proton Pump Inhibitors and Myocardial Infarction: A Self-Controlled Case Series Study [915]**
Angel YS Wong, Celine SL Chui, Ian CK Wong, Wai K Leung, Esther W Chan. (China)
Recipient of the McAfee Award
- 78. Association of Chronic Hepatitis C Virus Infection and the Risk of Cardiovascular Disease in the U.S [916]**
Wei Wang, Chao Chen, Haesuk Park. (United States)
- 79. Statins Use and Risk of New-Onset Diabetes in Hypertensive Patients: A Population-Based Retrospective Cohort Study in China [917]**
Hailong Li, Siyan Zhan, Hongbo Lin, Peng Shen. (China)
- 80. Oral Contraceptive Use and Anterior Cruciate Ligament Injury: An Active Comparator New User Cohort Study [918]**
Mackenzie M Herzog, Jessica C Young, Stephen W Marshall, Christina D Mack, Virginia Pate, Jennifer L Lund. (United States)
- 81. Use of Beta-Blockers and Risk of Serious Upper Gastrointestinal Bleeding: A Population-Based Case-Control Study [919]**
Mette Reilev, Per Damkier, Lotte Rasmussen, Morten Olesen, Martin Thomsen Ernst, Rikke Mie Rishøj, Morten Rix Hansen, Anne Broe, Alexander Steenberg Dastrup, Maja Hellfritsch, Sidsel Arnspang, Anton Pottegård, Jesper Hallas. (Denmark)
- 82. Lipid-Lowering Drugs and Cataract [920]**
Julien Bezin, Yohann Mansiaux, Antoine Pariente. (France)
- 83. Incretin-Based Medications and the Risk of Cancer [921]**
Igor Karp, Linda Levesque, Sharifa Nasreen, Christopher Booth. (Canada)
- 84. Non-Insulin Glucose Lowering Drugs and Risk of Trauma: A Nested Case Control Study from French Health Insurance Database [922]**
Mickael Arnaud, Julien Bezin, Bernard Bégaud, Antoine Pariente, Francesco Salvo. (France)

Data Sources for Pharmacoepidemiology

- 85. The French National Health Insurance Claims Databases in France, SNIIRAM and EGB: A Whole-Country 66 Million Persons Resource for PharmacoEpidemiology [923]**
Nicholas D Moore, Patrick Blin, Mai Duong, Julien Bezin, Antoine Pariente, Regis Lassalle, Cecile Droz-Perroteau. (France)
- 86. Electronic Medical Record Databases from Chang Gung Medical Foundation of Taiwan - Data Characteristics and Representativeness [924]**
Shih-Chieh Shao, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. (Taiwan)
- 87. Data Variability Across Canadian Administrative Health Databases: Differences in Content, Coding, and Completeness [925]**
Carla M Doyle, Lisa M Lix, Brenda R Hemmelgarn, J. Michael Paterson, Christel Renoux. (Canada)
- 88. Mapping of Real-World Data Sources for Asthma in Europe [926]**
Danae Lemieux-Uresandi, Aurore Bergamasco, Yola Moride. (Canada)
- 89. Evaluating an Emerging Oncology EHR as a Resource for Safety Surveillance [927]**
Xiaofeng Zhou, Leo Russo, Rongjun Shen, Andrew Bate. (United States)
- 90. Use of an EHR-Based System to Understand Experiences of Patients with Major Depressive Disorder or Schizophrenia Treated with Atypical Antipsychotics [928]**
Anthony P Nunes, Siddhesh Kamat, Ann Hartry, Nancy D Lin. (United States)



- 91. Pilot Study of Natural Language Processing-Derived EHR Data vs. Full-Text EHR Data to Validate a Diagnostic Algorithm [929]**
Caihua Liang, Alexander M. Walker, Carla A. Green, Shannon L. Janoff, Nancy A. Perrin, Hantao Cheng, Paul Coplan, Angela DeVeauugh-Geiss, Cheryl Enger. (United States)
- 92. Optimizing Global Protocols for Local Implementation Using Real-World Data: A Multi-Country Approach in Ulcerative Colitis [930]**
Emma Brinkley, Yatesh Midha, Frank Lobeck, Nancy Dreyer, Kathy Lang, Jennifer B Christian. (United States)
- 93. Challenges and Solutions for Globally Establishing and Standardizing Population Healthcare Databases [931]**
Anokhi J Kapasi, Mariam Shokralla, Alexander N Dodoo, Katarina Ilic, Sharmila A Kamani, Judith K Jones. (United States)
- 94. Comparison of Real World Patient Data Sources: A Global Case Study [932]**
Dena H Jaffe, Tom Haskell, Jeffrey Bramlett, Carey Strader, Pankaj Patel, Becca Feldman, Asaf Bachrach, Ahn Hyunjung, Heiko Friedel, Marc Pignot. (Israel)
- 95. Testing the Robustness of the Outcome Measures Framework [933]**
Richard Gliklich, Michelle Leavy, Elise Berliner. (United States)
- 96. Existing Evidence in Published Literature for Drug-Condition Pairs [934]**
Erica A Voss, Martijn J Schuemie, Patrick B Ryan, Johan van der Lei, Peter R Rijnbeek. (United States)
- 97. Assessment of Medication Errors in the Emergency Department in a Developing Country's Tertiary Care Teaching Hospital [935]**
Chalasan Sri Harsha, Madhan Ramesh. (India)
- 98. Completeness of Reporting of Overnight Hospitalisations to a Psoriasis Pharmacovigilance Register and the National Health Service Wales Informatics Service [936]**
Kayleigh J Mason, Hassan Ali, Nick J Reynolds, Anthony D Burden, Catherine H Smith, Ian Evans, Kathleen McElhone, Oliver Steer, Saliha Tahir, Christopher E Griffiths, On behalf of the BADBIR Study Group. (United Kingdom)
- Drug Utilization - Hematologic**
- 99. NOACs Replace VKA as Preferred Oral Anticoagulant Among New Patients [937]**
Jan Maurik van den Heuvel, Anke M. Hövels, H.R. Büller, A.K. Mantel - Teeuwisse, A. De Boer, A.H. Maitland - van der Zee. (Netherlands)
- 100. Evaluation of Potential Off-Label Prescribing of Dabigatran Exelate in France, Denmark, and the United Kingdom and Associated Methodological Challenges [938]**
Miguel Cainzos-Achirica, Cristina Varas-Lorenzo, Anton Pottegård, Joelle Asmar, Estel Plana, Lotte Rasmussen, Geoffray Bizouard, Joan Forn, Maja Hellfritsch, Kristina Zint, Susana Perez-Gutthann, Manel Pladevall-Vila. (Spain)
- 101. Baseline Patient Characteristics Associated with Non-Adherence to Dabigatran and Rivaroxaban in Nonvalvular Atrial Fibrillation New Users. A French Nationwide Cohort Study [939]**
Géric Maura, Antoine Pariente, François Alla, Cécile Billionnet. (France)
- 102. Post-Authorization Safety Study of the Utilization of Apixaban in Sweden [940]**
Marie Linder, Stephen E. Schachterle, Quazi Ataher, Morten Andersen. (Sweden)
- 103. Management of Venous Thromboembolism in Taiwan, a Nationwide Descriptive Study [941]**
Hui-Min Lin, Yi-Chen Juan, Pareen Vora, K.Arnold Chan. (Taiwan)
- 104. Factors Associated with Antithrombotic Treatment Decisions for Stroke Prevention in Atrial Fibrillation in the Stockholm Region After the Introduction of NOACs [942]**
Joris Komen, Tomas Forslund, Paul Hjemedahl, Björn Wettermark. (Netherlands)
- 105. Prescription Trends of Novel Oral Anticoagulants in Patients with Atrial Fibrillation [943]**
Simone Y Loo, Sophie Dell'Aniello, Laetitia Huiart, Christel Renoux. (Canada)
- 106. Real World Evidence on Novel Oral Anticoagulant Use in Non-Valvular Atrial Fibrillation: An Italian Population-Based Study [944]**
Ylenia Ingrassiotta, Francesco Giorgianni, Giancristoforo Aliquò, Valentina Ientile, Giulia Scondotto, Pasquale Cananzi, Walter Sebastiano Pollina D'Addario, Salvatore Scondotto, Maurizio Pastorello, Michele Tari, Gianluca Trifirò. (Italy)
- 107. Variations in Prescribing of Oral Anticoagulants for Atrial Fibrillation in the Region of Valencia: A Multilevel Analysis with Real World Data [945]**
Gabriel Sanfelix-Gimeno, Anibal Garcia-Sempere, Daniel Bejarano Quisoboni, Julian Librero, Salvador Peiro-Moreno, Clara Rodriguez-Bernal. (Spain)
- 108. Regional Variation in the Use of ACEI/ARB RCT Target Doses Post Myocardial Infarction Among Elderly Medicare Patients [946]**
Izabela E Annis, Gang Fang. (United States)
- 109. Patterns of Anticoagulant Drug Use in the Military Health System [947]**
Dhritiman V. Mukherjee, Jennifer G. Naples, Adrian T. Kress, James N. Masterson, Suji Xie, Rosenie T. Jean. (United States)
- 110. Treatment Patterns in Primary Chronic Immune Thrombocytopenia Patients [948]**
Charlotta Ekstrand, Marie Linder, Honar Cherif, Helle Kieler, Shahram Bahmanyar. (Sweden)



- 111. Risk of Bleeding and Thromboembolism in Atrial Fibrillation Patients Who Switch Between Oral Anticoagulants: A Systematic Review [949]**
Maja Hellfritsch, Kasper Adelborg, Per Damkier, Søren P Johsen, Jesper Hallas, Anton Pottegård, Erik L Grove. (Denmark)

Drug Utilization - Respiratory

- 112. Evaluation of Algorithms for Severe Uncontrolled Asthma Patients in Commercial Claims [950]**
Melissa K. Van Dyke, Xuehua Ke, Gaurav Deshpande, Liya Wang, Debra Wertz, Matthew Lau, Richard Stanford, Keele E. Wurst. (United States)
- 113. How Often Do Asthma Patients Claim Prescribed Therapy? [951]**
Manon Belhassen, Marjorie Bérard, Alexandra Dima, Marine Ginoux, Eric Van Ganse. (France)
- 114. Therapeutic Ratios Predict Asthma Control in the ASTROLAB Cohort [952]**
Manon Belhassen, Alexandra Dima, Maeva Nolin, Nathalie Texier, Montse Ferrer, Marijn de Bruin, Eric Van Ganse, Astrolab Group. (France)
- 115. Considerations of Prescribers and Pharmacists for the Use of Non-Selective β -Blockers in Asthma and COPD Patients: An Explorative Study [953]**
Esther Kuipers, Michel Wensing, Peter de Smet, Martina Teichert. (Netherlands)
- 116. Oralair Real-Word Treatment Pattern from a French Cohort Study [954]**
Patrick Blin, Pascal Demoly, Martine Drouet, Séverine Lignot-Maleyran, Hélène Maizi, Simon Lorrain, Régis Lassalle, Cécile Droz-Perroteau, Nicholas Moore, Mathieu Molimard. (France)
- 117. Assessment of COPD Severity in the UK CPRD [955]**
Estel Plana, Cristina Rebordosa, Jaume Aguado, Steven Thomas, Esther Garcia-Gil, Susana Perez-Gutthann, Jordi Castellsague. (Spain)
- 118. Understanding Racial and Ethnic Differences in Primary Adherence with Controller Medications Among Patients with Asthma [956]**
Melissa G Butler, Elyse O Kharbanda, Vicki Fung, Stephen B Soumerai, William M Vollmer, Tracy A Lieu, Robert L Davis, Ann C Wu. (Bermuda)
- 119. Utilization of Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of U.S. Claims Data [957]**
Emma Viscidi, Nasha Wang, Susan Hall, Diana Gallagher, Susan Eaton, Anne Dilley. (United States)
- 120. Treatment Patterns Among Japanese Patients with Asthma: An Analysis of Medical Claims Data [958]**
Jordan A Menzin, Joseph Menzin, Kevin Stern, Jolyon Fairburn-Beech, Keiko Sato, John Logie. (United States)
- 121. Characteristics of COPD and Asthma Patients Receiving Inhaler Technique Assessment Service (ITAS) in Norwegian Pharmacies [959]**
Øystein Karlstad, Kari Furu. (Norway)
- 122. The Use of Domperidone for Insufficient Lactation in England Between 2002 and 2015: A Drug Utilization Study with Interrupted Time-Series Analysis [960]**
Azar Mehrabadi, Pauline Reynier, Adrian Root, Robert W Platt, Kristian B Filion. (Canada)
- 123. Ontario Pharmacy Smoking Cessation Program: More Pharmacies Need to Participate [961]**
Lindsay Wong, Giulia P. Consiglio, Lisa Dolovich, Zahava R. Rosenberg-Yunger, Beth A. Sproule, Michael Chaiton, Sara J. Guilcher, Suzanne M. Cadarette. (Canada)
- 124. Varenicline Utilization in the Canadian Province of Manitoba [962]**
Donica Janzen, Shelley Derksen, Silvia Alessi-Severini. (Canada)
- 125. Utilization Patterns of Denosumab and Bisphosphonates in Denmark, Norway and Sweden Between 2010 and 2015: A Descriptive Study Among Women Aged 50 Years and Above [963]**
Anna Westerlund, David Hägg, Astrid Lunde, Grethe Seppola Tell, Johnny Kahlert, Vera Ehrenstein, Helle Kieler, Anders Sundström. (Sweden)
- 126. Proton Pump Inhibitor Use Pattern in US and Japan: A Cross-National Drug Utilization Study [964]**
Yongjing Zhang, Ting Zhang, Minfu He, Hong Qiu. (China)
- 127. Relationship Between Non-Medical Use of Prescription Drugs and Drug Availability [965]**
Karilynn M Rockhill, K. Patrick May, Melanie D. Whittington, Nicolaia A. Eldred-Skemp, Colleen M. Haynes, Richard C. Dart, Jody L. Green. (United States)
- 128. Pattern of Use of Intravitreal Drugs with Antiangiogenic Properties for Age-related Macular Degeneration and Other Vascular Retinopathies [966]**
Rosa Gini, Giuseppe Roberto, Gianni Virgili, Francesco Attanasio, Andrea Spini, Valentino Moscatelli, Claudia Bartolini, Sabrina Trippoli, Marina Ziche, Andrea Messori, Andrea Vannucci, Claudio Marinai. (Italy)
- 129. Hormonal Treatment of Endometriosis: Comparative Data from the VIPOS Study [967]**
Klaas Heinemann, Sabine Moehner, Do Minh Thai. (Germany)

Drug Utilization - Various Conditions

Pharmacoepidemiology in Children

- 130. Clinical Factors Associated with Antipsychotic Initiation Among Youth: Implications for Therapeutic Management [968]**
O'Mareen Spence, Wendy Camelo Castillo, Susan dosReis. (United States)
- 131. Gender Specific Drug Use in Pediatrics: A Population-Based Study in Italy [969]**
Carmen Ferrajolo, Francesco Giorgianni, Giancristoforo Aliquo, Valentina Ientile, Michele Tari, Francesco Rossi, Annalisa Capuano, Gianluca Trifirò. (Italy)

- 132. Trends in Pediatric Acetaminophen Exposures Reported to the National Poison Data System in the United States [970]**
 Halei C Benefield, Meghan A Jobson, Katy Sims, Jason Fine, Richard J Chung, Michael C Beuhler, William F Pendergraft. (United States)
- 133. Serious Adverse Events in Children During On-Label versus Off-Label Use of Fentanyl or Azithromycin in Intensive Care Units [971]**
 Debbie Avant, Gerold T. Wharton, Ashley White, Renan Bonnel, Mary DeCelle, Edwin Doe, Mohammed H Al Jarwi, Sarah Donegan, Norman Fenn, Allison Lardieri, An Nguyen, Beena G. Sood, Carol Taketomo, Phuong Lieu, Lilly Yen, Kazeem Oshikoya, Sara L. Van Driest, Ann W. McMahon. (United States)
- 134. Time Trends in the Prevalence of Cardiovascular Risk Factors, Diseases and Medication Use in Children and Adolescents with Type 1 Diabetes [972]**
 Fariba Ahmadizar. (Netherlands)
- 135. Efficacy and Safety of Pulmonary Application of Corticosteroids in Preterm Infants with Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis [973]**
 Dr. Mahin Delara, Bhupendrasinh Chauhan, Mê-Linh Le, Ahmed M. Abou-Setta, Ryan Zarychanski, Geert 't Jong. (Canada)
- 136. Changing Patterns of Drug Utilization: From Childhood to Adulthood [974]**
 Richelle C. Kosse, Ellen S. Koster, Tjalling W. de Vries, Marcel L. Bouvy. (Netherlands)
- 137. Sibship and Asthma Medication Among Pre-School Children [975]**
 Elin Dahlen, Björn Wettermark, Sara Ekberg, Inger Kull, Cecilia Lundholm, Catarina Almqvist. (Sweden)
- 138. Safety Signals Concerning Asthma Drugs in Children [976]**
 Veronique A De Smet, Esmé Baan, Alexandra Pacurariu, Sabrina Commeyne, Miriam C Sturkenboom, Johan De Jongste, Hettie Janssens, Katia M Verhamme. (Belgium)
- 139. Utilization of Antibiotic Agents During Pre-school Stage in Preterm and Full-Term Children [977]**
 Ju-Ling Chen, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 140. A Prospective Cohort Study to Evaluate the Long Term Safety of Latanoprost Treatment in Pediatric Populations [978]**
 Muhammad Younus, Ronald A. Schachar, Min Zhang, Nandita Mukherjee. (United States)
- 141. Evaluation of Dystonia in Children and Adolescents Treated with Atomoxetine: A Retrospective Cohort Study [979]**
 Kristin J Meyers, Himanshu P Upadhyaya, Robert Goodloe, Ludmila A. Kryzhanowskaya, Marie A Liles-Burden, Nicole A Kellier-Steele, Michele Mancini. (United States)
- 142. Switching Between Antibiotics Among Danish Children Aged 0-4 Years: A Nationwide Drug Utilization Study [980]**
 Dr. Mette Reilev, Reimar Wernich Thomsen, Rune Aabenhus, Rikke Vognbjerg Sydenham, Jens Georg Hansen, Anton Pottegård. (Denmark)
- 143. Passive Enhanced Safety Surveillance in Children Receiving Fluenz® Tetra Vaccination in England During the Early 2016 Influenza Season [981]**
 Lorna Hazell, Saad Shakir, Andrew Finlay, Hannah Coulter, Robert S Brody, Dennis Brooks. (United Kingdom)
- 144. Evaluating Physician Knowledge of Safety Information for Eylea (Aflibercept) [982]**
 Kelly A Hollis, Elizabeth Andrews, Dan L Wolin, Brian Calingaert, Eric K Davenport, Paul Petraro, Zdravko Vassilev, Laurie J Zografos. (United States)
- 145. Anticoagulation Treatment and Management in Hemodialysis Patients with Atrial Fibrillation [983]**
 Sapna Rao, Abhijit V Kshirsagar, J Bradley Layton, M Alan Brookhart. (United States)
- 146. Is Guideline-adherent Prescribing Associated with Quality-of-Life in Patients with Type 2 Diabetes? [984]**
 Petra Denig, Kirsten P Smits, Grigory Sidorenkov, Gerjan Navis, Henk J Bilo. (Netherlands)
- 147. Physicians' Knowledge, Perceptions, Attitudes Toward Antibiotic Prescribing in Alexandria Fever Hospital, Egypt [985]**
 Hager A Saleh, Albert Figueras. (Saudi Arabia)
- 148. Overwrite or Over-Wrong: Drug Interactions and Oral Chemotherapy in Community Pharmacies [986]**
 Juliano Amador da Silva, Kevin Friesen, Silvia Alessi-Severini, Dan Chateau, Pat Trozzo, Shawn Bugden. (Canada)
- 149. Clinical Indications for Fluoroquinolones in Routine Care [987]**
 Daniel R Morales, Jim Slattery, Xavier Kurz, Luis Pinheiro, Karin Hedenmalm. (United Kingdom)
- 150. Drug Utilization Study on the Prescribing Indications for CPA/EE in 5 European Countries [988]**
 Karl Pauls, Klaas Heinemann. (Germany)
- 151. Medications Prescribed, Stopped and Modified at Hospital Discharge and Filled Medications in the Community: Predictors of Failure to Follow in-hospital Medication Changes 30-days Post Hospital Discharge in Patients with Multiple Chronic Conditions [989]**
 Daniala L Weir, Aude Motulsky, Robyn Tamblyn. (Canada)
- 152. The Impact of Pharmacists-Led Medicines Reconciliation on Healthcare Outcomes in Secondary Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [990]**
 Mahmoud M Mohamed, Amnah Kinsarah, Jomanah Alsiddik, Marwah Barnawi, Morojo Al-Muwallad, Shatha Abed, Mahmood Elraggal, Ejaz Cheema. (Saudi Arabia)
- 153. Impact of Discharge Counseling by Pharm.D. Candidates on Adverse Drug Events Risk Among Hospitalized Older Patients [991]**
 Mariam Algouzi, Tariq M Alhawassi, Khalid Alburikan, Mansour Adam, Hisham Aljadhey. (Saudi Arabia)
- 154. Effect of Clinical Pharmacist Interventions on Patient Satisfaction in the Emergency Department: A Randomized Controlled Trial [992]**
 Marcela Jiron, Matias Martinez, Tamara Sandoval, Luis Herrada. (Chile)

Prescribing and Dispensing

- 155. Physicians' Perception Towards Clinical Pharmacists' Service in Governmental Hospital, Egypt [993]**
 Hager A Saleh, Hoda Zaki. (Saudi Arabia)
- 156. Analysis of Medication Errors at Tertiary Care Hospital [994]**
 Sheraz Ali. (Saudi Arabia)
- 157. Physician & Pharmacist Perceptions of Generic Medicines in Addis Abab, an Urgent Call for Policy Makers [995]**
 Arebu I Bilal. (Ethiopia)
- 158. Impact of Medication Therapy Management Service Provided by Clinical Pharmacists on Drug Therapy of Patients Undergoing Hemodialysis [996]**
 Srikanth M S, Mahendra Kumar B.J, Himanshu Patel. (India)
- 159. Hospital Pharmacists' Perspectives About Pharmacovigilance in Malaysia [997]**
 Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari, Mohd Baidi Bahari. (Malaysia)
- 160. Abstract Withdrawn [998]**
- 161. Senior Pharmacy Students' Knowledge and Perceptions About Pharmacovigilance in Pakistan [999]**
 Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari, Mohd Baidi Bahari. (Malaysia)
- 162. What Encourages Community Pharmacists to Report Adverse Drug Reactions? [1000]**
 Ahmed Aldryihm, Abdulrahman Alomair, Meshari Alqahtani, Tariq Alhawassi, Mansour A Mahmoud, Bander Albalkhi, Hisham S Aljadhey. (Saudi Arabia)
- 163. Clinicians Attitudes and Concerns Toward Pioglitazone-Associated Bladder Malignancies [1001]**
 Dr. Nasser Alqahtani, Tariq Alhawassi, Adel Alharf, Yasser Albogami, Abdulaali Almuteri, Hisham Aljadhey. (Saudi Arabia)
- 164. Is Pharmacovigilance Concept Well-Known in Malaysia - An Insight from Community Pharmacists perspectives About Pharmacovigilance in Malaysia [1002]**
 Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari. (Malaysia)

- 165. Sensitizing Unqualified Rural Medical Practitioners About Rational Drug Use and Practicing Safety Pharmacology in India [1003]**
 Saibal Das, Soumyadip De, Somnath Mondal. (India)
- 166. Assessment of Romiplostim Self-Administration After Receipt of Home Administration Training (HAT) Materials: A Cross-Sectional Study of Patients with Immune Thrombocytopenic Purpura (ITP) and Caregivers [1004]**
 Martin R Schipperus, Georgia Kaiafa, Louise Taylor, Sally Wetten, James Bennett, Georg Kreuzbauer, Andy Boshier, Anouchka Seesaghur. (Netherlands)

Regulatory/Program Evaluation

- 167. Risk Factors Associated with Post-Marketing Changes in Specific Obligations of Conditionally Authorised Products in the EU [1005]**
 Lourens T. Bloem, Aukje K. Mantel-Teeuwisse, Hubert G. Leufkens, Marie L. De Bruin, Olaf. H. Klungel, Jarno Hoekman. (Netherlands)
- 168. Evaluation of a Disease Management Program for Asthmatic Patients: The French Sophia Asthme Program [1006]**
 Yann De Rycke, Fadia Dib, Alexandre Lafourcade, Sylvie Guillo, Florence Tubach. (France)
- 169. Post-Marketing Label Changes in Dosing Information of Biopharmaceuticals - Different from Small Molecules? [1007]**
 Lotte A Minnema, Thijs J Giezen, Helga Gardarsdottir, Toine C Egberts, Hubert G Leufkens, Aukje K Mantel-Teeuwisse. (Netherlands)
- 170. Pregnancy and Lactation Labeling Rule (PLLR) in Practice: More Human Data Needed [1008]**
 Keele E Wurst, Marianne Cunningham, Marcy Powell, Traci J Lee. (United States)

- 171. Consequences of FDA Modified Recommendations on Erythropoiesis-Stimulating Agent Use Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Truven MarketScan Database [1009]**
 Xinyue Liu, Wei Liu, Haesuk Park. (United States)
- 172. Dalhousie University's Academic Detailing Service Evaluation [1010]**
 Michelle Boudreau, Constance LeBlanc, Bronwen Jones, Ingrid Sketris. (Canada)
- 173. The Fragility of Osteoporosis Treatment in Manitoba, Canada [1011]**
 Shawn Bugden, Kevin J Friesen, Cole Lane, Juliano da Silva, Olasumbo Ojo, Jamie Falk. (Canada)
- 174. The Impact of FDA Risk-Communication on Health-Related Perceptions and Knowledge of Individuals in the United States [1012]**
 Divyan A Chopra, Naleen Raj Bhandari, Chenghui Li. (United States)
- 175. Pharmacovigilance of Drug Quality Deviation in the Public Health System [1013]**
 Cristiane A Menezes de Padua, Carolina R Bitencourt, Edson Perini. (Brazil)

Risk Prediction

- 176. Application of Risk Analysis Methodologies for Risk Management Planning [1014]**
 Michael Forstner. (Switzerland)
- 177. Development of a Prediction Model Including Modifiable Risk Factors for Uncontrolled Clostridium Difficile Infection Using Hospital Electronic Health Records [1015]**
 Nakyung Jeon, Ben Staley, Carl Henriksen, Gigi Lipori, Almut Gertrud Winterstein. (United States)
- 178. Geographic Risk Evaluation and Assessment Tool (GREAT): Model for Transfusion Transmitted Infectious Diseases [1016]**
 Kinnera Chada, Yin Huang, Cedric Lane, Guangfan Zhang, Mark Walderhaug, Hong Yang. (United States)



- 179. Risk Assessment for Transfusion-Transmission of ZIKA Virus (TTZIKV) in Puerto Rico [1017]**
Hong Yang, Kinnera Chada, Yin Huang, Richard Forshee, Steve Anderson. (United States)
- 180. Identification of Risk Factors Associated with drug-induced Hypotension Among Hospitalized Patients. A Predictive Model Using Electronic Medical Records [1018]**
Rene Soria-Saucedo. (United States)
- 181. Identification of Risk Factors Associated with Drug-Induced Severe Hypoglycemia Among Hospitalized Patients. A Predictive Model Using Electronic Medical Records [1019]**
Rene Soria-Saucedo. (United States)
- 182. Concordance Between Laboratory Sersus Non Laboratory Based Framingham Risk Scoring Engine Assessing Future Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus [1020]**
Azmeera Suman Naik, Dipika Bansal, Anil Bhansali. (India)
- 183. Comparing High Cardiovascular Disease Risk Among US Adults Using Multiple Risk Scores [1021]**
Rikki M Tanner, Lisandro D Colantonio, Michael E Farkouh, Luqin Deng, J Antonio López, Keri L Monda, Katherine Mues, Benjamin Taylor, Paul Muntner, Robert S Rosenson. (United States)
- 184. Predictors of Type 2 Diabetes Progression as Measured by the Diabetes Complications Severity Index [1022]**
Raymond A Harvey, Jenna M Collins, Ibrahim M Abbas, Edward S Kimball, Jonathan R Bouchard, Andrew M Renda, Tony DeLuzio, Elsie Allen. (United States)
- 185. Risk of Developing Guillain-Barré Syndrome Following Influenza Vaccinations in the US Veterans Population [1023]**
Kwan Hur, Fran Cunningham, Rongping Zhang, Bharat Thakkar, Cedric Salone, Michele Eskridge. (United States)
- 186. Non-Targeted Infectious Disease Hospitalizations Among U.S. Children Following Inactivated and Live Vaccines [1024]**
Frank DeStefano, Barbara Bardenheier, Michael McNeil, Patricia Wodi, Janet McNicholl. (United States)
- 187. Longitudinal Adherence to Influenza Vaccination and All-Cause Mortality Among the Elderly in Taiwan [1025]**
Yao-Chun Wen, Chih-Wan Lin, Kai-Hsin Liao, Fei-Yuan Hsiao. (Taiwan)
- 188. Reporting of Adverse Events Following Immunization in Ghana Using Disproportionality Analysis Ratios [1026]**
Daniel Ankrh. (Ghana)
- 189. Trends in the Incidence of Anogenital Warts (AGW) in Manitoba, Canada, Before and After the Introduction of the Quadrivalent HPV (QHPV) Vaccine [1027]**
Karla Willows, Christiaan Righolt, Erich Kliewer, Salaheddin Mahmud. (Canada)
- 190. Effectiveness of the Quadrivalent Vaccine (QHPV) Against Cervical Abnormalities in Manitoba, Canada [1028]**
Salaheddin Mahmud, Christiaan Righolt. (Canada)
- 191. Population-Based Evaluation of Safety Signals Related to Pneumococcal Conjugate Vaccination [1029]**
Miia Artama, Hanna Rinta-Kokko, Jukka Jokinen, Arto Palmu. (Finland)
- 192. Identifying GAIA Outcomes in Maternal Immunization Studies [1030]**
Charlotte Switzer, Julijana Dukanovic, Daniel Weibel, Miriam Sturkenboom. (Canada)
- 193. Public Willingness to Receive Vaccination in Community Pharmacies in Saudi Arabia [1031]**
Sara Alqahtani, Tariq Alhawassi, Bander Balkhi, Maha Alrasheed, Mansour Mahmoud, Hisham Aljadhey. (Saudi Arabia)
- 194. No Differences by Sex in Adverse Events Following Infant Vaccinations [1032]**
Jeanet M Kemmeren, Anna G Boef, Hester E de Melker, Mirjam J Knol. (Netherlands)
- 195. Safety of Currently Licensed Hepatitis B Vaccines in the United States, 2005-2015 [1033]**
Penina Haber, Pedro L Moro, Maria V Cano. (United States)
- 196. Patterns and Factors Associated with Immunization Among Adult Patients with Rheumatic Diseases in the US [1034]**
Huifeng Yun, Shuo Yang, Sofia Pedro, Jeffrey R. Curtis, Michaud Kaleb. (United States)
- 197. Epidemiology of Severe Varicella Infections in Taiwan, a Decade After Universal Vaccine Administration [1035]**
Chia-Hung Liu, Yi-Chen Juan, Yen-Yum Yang, Wan-Ting Huang, K. Arnold Chan. (Taiwan)
- 198. The Acceptability of Rotavirus Vaccine Among the Parents in Indonesia [1036]**
Dr Jarir At Thobari, Mei Neni Sitaresmi, Yati Soenarto. (Indonesia)
- 199. Understanding Cellular Kinetics of Squalene Based Oil-in-Water Emulsion Adjuvanted Influenza Vaccines: A Mathematical Approach [1037]**
Kinnera Chada, Hong Yang. (United States)
- 200. Missed Opportunities for Influenza and Pneumococcal Vaccinations in Adults in the United States [1038]**
Omotola O Olasupo, Joshua D Brown. (United States)
- 201. A Systematic Review of Methodological Approaches for Benefit-Risk Assessment of Vaccines [1039]**
Hugo Arlegui, Kaatje Bollaerts, Francesco Salvo, Vincent Bauchau, Gaëlle Nachbaur, Bernard Bégaud, Nicolas Praet. (France)
- 202. Methodology to Estimate the Health Burden of Adverse Events Following Immunization: A Contribution from the ADVANCE Project [1040]**
Scott A McDonald, Danielle Nijsten, Kaatje Bollaerts, Jorgen Bauwens, Tom De Smedt, Miriam Sturkenboom, Susan Hahné. (Netherlands)

Vaccines



What a Pain! Medications Use for Pain Management

- 203. Opioid Outpatient Prescription Claims among Pregnant Women, 2013 [1041]**
Jennifer N Lind, Elizabeth C Ailes, April L Dawson, Suzanne M Gilboa. (United States)
- 204. Household Availability of Prescription Opioids and Risk of Opioid Initiation in US Households [1042]**
Marissa J Seamans, Stephanie B Wheeler, Daniel J Westreich, Timothy S Carey, Stephen R Cole, M. Alan Brookhart. (United States)
- 205. Geographic Variation of Inappropriate Prescription Opioid Use Among Disabled Medicare Beneficiaries [1043]**
Weihsuan Lo-Ciganic, Walid F Gellad, Julie Donohue, Lili Zhou, Anne M Roubal, Lisa Hines, Jeremiah Lindemann, Jeannie Lee, Daniel C Malone, Sandipan Bhattacharjee, C. Kent Kwoh. (United States)
- 206. Changes in Prescription Opioid Use in a Medicaid Population [1044]**
Andrew D Wiese, Marie R Griffin, C. Michael Stein, Edward F Mitchel, Carlos G Grijalva. (United States)
- 207. Indications for Long-Term Extended-Release Opioid Therapy in Commercially-Insured Adults in the US, 2006-2014 [1045]**
Jessica C Young, Michele Jonsson Funk, Nabarun Dasgupta. (United States)
- 208. Trends in Concomitant Prescribing of Opioids and Benzodiazepines in Australia 2010-2015; a Cause for Concern? [1046]**
Gillian E Caughey, Svetla Gadzhanova, Sepehr Shakib, Elizabeth E Roughead. (Australia)
- 209. Utilization Patterns and Predictors of Opioid Use in Persons with Dementia [1047]**
GYeon Oh, Erin L. Abner, Daniela C. Moga. (United States)
- 210. Opioid Use in the Military [1048]**
Rosenie Thelus Jean, James N Masterson, Dhritiman V Mukherjee, Jennifer G Napples, Suji Xie, Adrian T Kress. (United States)
- 211. Prescription Opioid Utilization Among Medicare Beneficiaries with and without Recent Substance Abuse Disorder [1049]**
Aida Kuzucan, Linda Simoni-Wastila. (United States)
- 212. Black-White Disparities in Pain Management Among Nursing Home Residents with Cancer [1050]**
Deborah Mack, Jacob Hunnicutt, William Jesdale, Christine Ulbricht, Kate Lapane. (United States)
- 213. Differences in Chronic Pain, Pain Sites, and Analgesic Use by Body Mass Index Among U.S. Adults from NHANES [1051]**
Cheng Chen, Yu-Jung Wei. (United States)
- 214. Impact of Concomitant Use of Opioids and Benzodiazepines and Other Sedatives in Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease [1052]**
Bilal Khokhar, Michelle Choi, Tham Le, Linda Simoni-Wastila. (United States)
- 215. Opioid Risk Reduction Initiatives and Risk of Injuries in People Using Chronic Opioid Therapy [1053]**
Sascha Dublin, Rod L. Walker, Susan M. Shortreed, Kathleen Saunders, Evette J. Ludman, Ryan N. Hansen, Karen Sherman, Manu Thakral, Michael L. Parchman, Michael Von Korff. (United States)
- 216. The Attributable Risk of Opioid Overdose Fatalities from Opioid Analgesic Types in North Carolina in 2010 [1054]**
Paul M Coplan, Angela DeVeauugh-Geiss, Nabarun DasGupta. (United States)
- 217. Pain and Painkiller Use Among Multiple Sclerosis Patients in Sweden [1055]**
Sarah M Burkill, Scott Montgomery, Lukas Löfling, Ingrid Kockum, Fredrik Piehl, Pernilla Strid, Tomas Olsson, Jan Hillert, Lars Alfredsson, Shahram Bahmanyar. (Sweden)
- 218. Case Review of Opioid-Induced Thrombotic Thrombocytopenic Purpura (TTP) from Pharmacovigilance & Poison Centers [1056]**
Nabarun Dasgupta, John Schwarz, Rick C Dart. (United States)
- 219. A Systematic Review of Interventions and Programs Targeting Appropriate Prescribing of Opioids [1057]**
Yola Moride, Genaro Castillon, Danae Lemieux Uresandi, Sarah Gabrielle Beland, Cristiano Moura, Georges Wells, Louise Pilote, Sasha Bernartsky. (Canada)
- 220. Comparison of a Doctor/Pharmacy Shopping Measure for Opioid Analgesics Using Claims Data with Medical Chart Review to Identify Misuse, Diversion, Abuse and/or Addiction [1058]**
Jennifer Lyons, Soledad Cepeda, Paul Coplan, Ruihua Yin, Stephan Lanes, Daina Esposito. (United States)

End Session C

Pub. #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 28				
Control Yourself: Guidance for the Application and Reporting of Self-Controlled Study Designs in Pharmacoepidemiology				
1		10:30 AM	517CD	Symposia
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year				
2		10:30 AM	520AD	Symposia
The Non-Pharmacological Basis of Regulatory Decision-Making				
3		10:30 AM	520BE	Symposia
Conducting Pharmacoepidemiologic Research in the Nursing Home Population				
4		10:30 AM	520CF	Symposia
It Takes a Village: Raising a Global Community of Pharmacoepidemiologists Through High Quality Education				
5		10:30 AM	524AB	Symposia
Opening Doors to Data - Linkage or Comparison				
6		1:30 PM	517CD	Oral
7		1:45 PM	517CD	Oral
8		2:00 PM	517CD	Oral
9		2:15 PM	517CD	Oral
10		2:30 PM	517CD	Oral
11		2:45 PM	517CD	Oral
The "ACE" of BRACE				
12		1:30 PM	520AD	Oral
13		1:45 PM	520AD	Oral
14		2:00 PM	520AD	Oral
15		2:15 PM	520AD	Oral
16		2:30 PM	520AD	Oral
17		2:45 PM	520AD	Oral
Mapping the Epidemic of Opioids				
18		1:30 PM	520BE	Oral
19		1:45 PM	520BE	Oral
20		2:00 PM	520BE	Oral
21		2:15 PM	520BE	Oral
22		2:30 PM	520BE	Oral
23		2:45 PM	520BE	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Quality of Care: Provider and Policy Considerations				
24		1:30 PM	520CF	Oral
25		1:45 PM	520CF	Oral
26		2:00 PM	520CF	Oral
27		2:15 PM	520CF	Oral
28		2:30 PM	520CF	Oral
29		2:45 PM	520CF	Oral
Vaccines				
30		1:30 PM	524AB	Oral
31		1:45 PM	524AB	Oral
32		2:00 PM	524AB	Oral
33		2:15 PM	524AB	Oral
34		2:30 PM	524AB	Oral
35		2:45 PM	524AB	Oral
Pediatrics				
36		1:30 PM	524C	Oral
37		1:45 PM	524C	Oral
38		2:00 PM	524C	Oral
39		2:15 PM	524C	Oral
40		2:30 PM	524C	Oral
41		2:45 PM	524C	Oral
Fit-for-Purpose Non-Traditional RCTs. What Will It Take to Convince a Skeptical Community?				
42		3:30 PM	517CD	Symposia
Improving Screening of Adverse Drug Events in Large Electronic Healthcare Databases				
43		3:30 PM	520AD	Symposia
Therapeutic Monomania: Physician Preference-Based Instrumental Variables				
44		3:30 PM	520BE	Symposia
Medication Use and Criminality				
45		3:30 PM	520CF	Symposia
How to Measure the Impact of Pharmacovigilance Activities on Public Health?				
46		3:30 PM	524AB	Symposia
Design Tips for Observational and Final Data				
47		5:00 PM	517CD	Oral
48		5:15 PM	517CD	Oral
49		5:30 PM	517CD	Oral



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 28 (CON'T)				
50		5:45 PM	517CD	Oral
51		6:00 PM	517CD	Oral
52		6:15 PM	517CD	Oral
Using Natural Language Processing				
53		5:00 PM	520AD	Oral
54		5:15 PM	520AD	Oral
55		5:30 PM	520AD	Oral
56		5:45 PM	520AD	Oral
57		6:00 PM	520AD	Oral
58		6:15 PM	520AD	Oral
Is It Worth It: Cost Considerations in Medication Use				
59		5:00 PM	520BE	Oral
60		5:15 PM	520BE	Oral
61		5:30 PM	520BE	Oral
62		5:45 PM	520BE	Oral
63		6:00 PM	520BE	Oral
64		6:15 PM	520BE	Oral
Epidemiology of Respiratory Viruses, HIV, and Chronic Lung Disease				
65		5:00 PM	520CF	Oral
66		5:15 PM	520CF	Oral
67		5:30 PM	520CF	Oral
68		5:45 PM	520CF	Oral
69		6:00 PM	520CF	Oral
70		6:15 PM	520CF	Oral
(Cardio) Vascular Safety Outcomes				
71		5:00 PM	524AB	Oral
72		5:15 PM	524AB	Oral
73		5:30 PM	524AB	Oral
74		5:45 PM	524AB	Oral
75		6:00 PM	524AB	Oral
76		6:15 PM	524AB	Oral
Good & Bad of Diabetes Treatment				
77		5:00 PM	524AB	Oral
78		5:15 PM	524AB	Oral
79		5:30 PM	524AB	Oral
80		5:45 PM	524AB	Oral

Pub. #	Poster #	Presentation Time	Room	Format
81		6:00 PM	524AB	Oral
82		6:15 PM	524AB	Oral
Poster Session A: Spotlight Session - Asian Pharmacoepidemiology Network (AsPEN)				
83	A	12:15 PM – 1:15 PM	519	Poster
84	B	12:15 PM – 1:15 PM	519	Poster
85	C	12:15 PM – 1:15 PM	519	Poster
86	D	12:15 PM – 1:15 PM	519	Poster
87	E	12:15 PM – 1:15 PM	519	Poster
88	F	12:15 PM – 1:15 PM	519	Poster
89	G	12:15 PM – 1:15 PM	519	Poster
90	H	12:15 PM – 1:15 PM	519	Poster
Poster Session A: Spotlight Session - Biologics and Biosimilars				
91	I	12:15 PM – 1:15 PM	519	Poster
92	J	12:15 PM – 1:15 PM	519	Poster
93	K	12:15 PM – 1:15 PM	519	Poster
94	L	12:15 PM – 1:15 PM	Abstract Withdrawn	
95	M	12:15 PM – 1:15 PM	519	Poster
96	N	12:15 PM – 1:15 PM	519	Poster
97	O	12:15 PM – 1:15 PM	519	Poster
98	P	12:15 PM – 1:15 PM	519	Poster
Poster Session A: Spotlight Session - Databases				
99	Q	12:15 PM – 1:15 PM	519	Poster
100	R	12:15 PM – 1:15 PM	519	Poster
101	S	12:15 PM – 1:15 PM	519	Poster
102	T	12:15 PM – 1:15 PM	519	Poster
103	U	12:15 PM – 1:15 PM	519	Poster
104	V	12:15 PM – 1:15 PM	519	Poster
105	W	12:15 PM – 1:15 PM	519	Poster
106	X	12:15 PM – 1:15 PM	519	Poster
Poster Session A: Spotlight Session - Vaccines				
107	Y	12:15 PM – 1:15 PM	519	Poster
108	Z	12:15 PM – 1:15 PM	519	Poster
109	AA	12:15 PM – 1:15 PM	519	Poster
110	BB	12:15 PM – 1:15 PM	519	Poster
111	CC	12:15 PM – 1:15 PM	519	Poster
112	DD	12:15 PM – 1:15 PM	519	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 28 (CON'T)				
113	EE	12:15 PM – 1:15 PM	519	Poster
114	FF	12:15 PM – 1:15 PM	519	Poster
Poster Session A: Burden of Disease - Cancer				
115	1	8:00 AM – 6:00 PM	220BC	Poster
116	2	8:00 AM – 6:00 PM	220BC	Poster
117	3	8:00 AM – 6:00 PM	220BC	Poster
118	4	8:00 AM – 6:00 PM	220BC	Poster
119	5	8:00 AM – 6:00 PM	220BC	Poster
120	6	8:00 AM – 6:00 PM	220BC	Poster
121	7	8:00 AM – 6:00 PM	220BC	Poster
122	8	8:00 AM – 6:00 PM	220BC	Poster
Poster Session A: Burden of Disease - Diabetes				
123	9	8:00 AM – 6:00 PM	220BC	Poster
124	10	8:00 AM – 6:00 PM	220BC	Poster
125	11	8:00 AM – 6:00 PM	220BC	Poster
126	12	8:00 AM – 6:00 PM	220BC	Poster
127	13	8:00 AM – 6:00 PM	220BC	Poster
128	14	8:00 AM – 6:00 PM	220BC	Poster
129	15	8:00 AM – 6:00 PM	220BC	Poster
130	16	8:00 AM – 6:00 PM	220BC	Poster
131	17	8:00 AM – 6:00 PM	220BC	Poster
132	18	8:00 AM – 6:00 PM	220BC	Poster
133	19	8:00 AM – 6:00 PM	220BC	Poster
134	20	8:00 AM – 6:00 PM	220BC	Poster
135	21	8:00 AM – 6:00 PM	220BC	Poster
Poster Session A: Confounding/Bias				
136	22	8:00 AM – 6:00 PM	220BC	Poster
137	23	8:00 AM – 6:00 PM	220BC	Poster
138	24	8:00 AM – 6:00 PM	220BC	Poster
139	25	8:00 AM – 6:00 PM	220BC	Poster
140	26	8:00 AM – 6:00 PM	220BC	Poster
141	27	8:00 AM – 6:00 PM	220BC	Poster
142	28	8:00 AM – 6:00 PM	220BC	Poster
143	29	8:00 AM – 6:00 PM	220BC	Poster
144	30	8:00 AM – 6:00 PM	220BC	Poster
145	31	8:00 AM – 6:00 PM	220BC	Poster
146	32	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
147	33	8:00 AM – 6:00 PM	220BC	Poster
148	34	8:00 AM – 6:00 PM	220BC	Poster
149	35	8:00 AM – 6:00 PM	220BC	Poster
150	36	8:00 AM – 6:00 PM	220BC	Poster
151	37	8:00 AM – 6:00 PM	220BC	Poster
152	38	8:00 AM – 6:00 PM	220BC	Poster
Poster Session A: Data Algorithms for Pharmacoepidemiology				
153	39	8:00 AM – 6:00 PM	220BC	Poster
154	40	8:00 AM – 6:00 PM	220BC	Poster
155	41	8:00 AM – 6:00 PM	220BC	Poster
156	42	8:00 AM – 6:00 PM	220BC	Poster
157	43	8:00 AM – 6:00 PM	220BC	Poster
158	44	8:00 AM – 6:00 PM	220BC	Poster
159	45	8:00 AM – 6:00 PM	220BC	Poster
160	46	8:00 AM – 6:00 PM	220BC	Poster
161	47	8:00 AM – 6:00 PM	220BC	Poster
162	48	8:00 AM – 6:00 PM	220BC	Poster
163	49	8:00 AM – 6:00 PM	220BC	Poster
164	50	8:00 AM – 6:00 PM	220BC	Poster
165	51	8:00 AM – 6:00 PM	220BC	Poster
166	52	8:00 AM – 6:00 PM	220BC	Poster
167	53	8:00 AM – 6:00 PM	220BC	Poster
168	54	8:00 AM – 6:00 PM	220BC	Poster
169	55	8:00 AM – 6:00 PM	220BC	Poster
170	56	8:00 AM – 6:00 PM	220BC	Poster
171	57	8:00 AM – 6:00 PM	220BC	Poster
172	58	8:00 AM – 6:00 PM	220BC	Poster
173	59	8:00 AM – 6:00 PM	220BC	Poster
174	60	8:00 AM – 6:00 PM	220BC	Poster
175	61	8:00 AM – 6:00 PM	220BC	Poster
176	62	8:00 AM – 6:00 PM	220BC	Poster
177	63	8:00 AM – 6:00 PM	220BC	Poster
178	64	8:00 AM – 6:00 PM	220BC	Poster
Poster Session A: Drug Utilization - Circulatory				
179	65	8:00 AM – 6:00 PM	220BC	Poster
180	66	8:00 AM – 6:00 PM	220BC	Poster
181	67	8:00 AM – 6:00 PM	220BC	Poster
182	68	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

MONDAY, AUGUST 28 (CON'T)

183	69	8:00 AM – 6:00 PM	220BC	Poster
184	70	8:00 AM – 6:00 PM	220BC	Poster
185	71	8:00 AM – 6:00 PM	220BC	Poster
186	72	8:00 AM – 6:00 PM	220BC	Poster
187	73	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Drug Utilization - Cancer

188	74	8:00 AM – 6:00 PM	220BC	Poster
189	75	8:00 AM – 6:00 PM	220BC	Poster
190	76	8:00 AM – 6:00 PM	220BC	Poster
191	77	8:00 AM – 6:00 PM	220BC	Poster
192	78	8:00 AM – 6:00 PM	220BC	Poster
193	79	8:00 AM – 6:00 PM	220BC	Poster
194	80	8:00 AM – 6:00 PM	220BC	Poster
195	81	8:00 AM – 6:00 PM	220BC	Poster
196	82	8:00 AM – 6:00 PM	220BC	Poster
197	83	8:00 AM – 6:00 PM	220BC	Poster
198	84	8:00 AM – 6:00 PM	220BC	Poster
199	85	8:00 AM – 6:00 PM	220BC	Poster
200	86	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Drug Utilization - Diabetes

201	87	8:00 AM – 6:00 PM	220BC	Poster
202	88	8:00 AM – 6:00 PM	220BC	Poster
203	89	8:00 AM – 6:00 PM	220BC	Poster
204	90	8:00 AM – 6:00 PM	220BC	Poster
205	91	8:00 AM – 6:00 PM	220BC	Poster
206	92	8:00 AM – 6:00 PM	220BC	Poster
207	93	8:00 AM – 6:00 PM	220BC	Poster
208	94	8:00 AM – 6:00 PM	220BC	Poster
209	95	8:00 AM – 6:00 PM	220BC	Poster
210	96	8:00 AM – 6:00 PM	220BC	Poster
211	97	8:00 AM – 6:00 PM	220BC	Poster
212	98	8:00 AM – 6:00 PM	220BC	Poster
213	99	8:00 AM – 6:00 PM	220BC	Poster
214	100	8:00 AM – 6:00 PM	220BC	Poster
215	101	8:00 AM – 6:00 PM	220BC	Poster
216	102	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session A: Health Care Utilization & Costs

217	103	8:00 AM – 6:00 PM	220BC	Poster
218	104	8:00 AM – 6:00 PM	220BC	Poster
219	105	8:00 AM – 6:00 PM	220BC	Poster
220	106	8:00 AM – 6:00 PM	220BC	Poster
221	107	8:00 AM – 6:00 PM	220BC	Poster
222	108	8:00 AM – 6:00 PM	220BC	Poster
223	109	8:00 AM – 6:00 PM	220BC	Poster
224	110	8:00 AM – 6:00 PM	220BC	Poster
225	111	8:00 AM – 6:00 PM	220BC	Poster
226	112	8:00 AM – 6:00 PM	220BC	Poster
227	113	8:00 AM – 6:00 PM	220BC	Poster
228	114	8:00 AM – 6:00 PM	220BC	Poster
229	115	8:00 AM – 6:00 PM	220BC	Poster
230	116	8:00 AM – 6:00 PM	Abstract Withdrawn	
231	117	8:00 AM – 6:00 PM	220BC	Poster
232	118	8:00 AM – 6:00 PM	220BC	Poster
233	119	8:00 AM – 6:00 PM	220BC	Poster
234	120	8:00 AM – 6:00 PM	220BC	Poster
235	121	8:00 AM – 6:00 PM	220BC	Poster
236	122	8:00 AM – 6:00 PM	220BC	Poster
237	123	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Heterogeneity and Generalizability

238	124	8:00 AM – 6:00 PM	220BC	Poster
239	125	8:00 AM – 6:00 PM	220BC	Poster
240	126	8:00 AM – 6:00 PM	220BC	Poster
241	127	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Occult Outcomes

242	128	8:00 AM – 6:00 PM	220BC	Poster
243	129	8:00 AM – 6:00 PM	220BC	Poster
244	130	8:00 AM – 6:00 PM	220BC	Poster
245	131	8:00 AM – 6:00 PM	220BC	Poster
246	132	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Patients of the World Unite! - HRQoL/PROs/Self Management

247	133	8:00 AM – 6:00 PM	220BC	Poster
248	134	8:00 AM – 6:00 PM	220BC	Poster
249	135	8:00 AM – 6:00 PM	220BC	Poster
250	136	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

MONDAY, AUGUST 28 (CON'T)

251	137	8:00 AM – 6:00 PM	220BC	Poster
252	138	8:00 AM – 6:00 PM	220BC	Poster
253	139	8:00 AM – 6:00 PM	220BC	Poster
254	140	8:00 AM – 6:00 PM	220BC	Poster
255	141	8:00 AM – 6:00 PM	220BC	Poster
256	142	8:00 AM – 6:00 PM	220BC	Poster
257	143	8:00 AM – 6:00 PM	220BC	Poster
258	144	8:00 AM – 6:00 PM	220BC	Poster
259	145	8:00 AM – 6:00 PM	220BC	Poster
260	146	8:00 AM – 6:00 PM	220BC	Poster
261	147	8:00 AM – 6:00 PM	220BC	Poster
262	148	8:00 AM – 6:00 PM	220BC	Poster
263	149	8:00 AM – 6:00 PM	220BC	Poster
264	150	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Pharmacoeconomics in the Elderly

265	151	8:00 AM – 6:00 PM	220BC	Poster
266	152	8:00 AM – 6:00 PM	220BC	Poster
267	153	8:00 AM – 6:00 PM	220BC	Poster
268	154	8:00 AM – 6:00 PM	220BC	Poster
269	155	8:00 AM – 6:00 PM	220BC	Poster
270	156	8:00 AM – 6:00 PM	220BC	Poster
271	157	8:00 AM – 6:00 PM	220BC	Poster
272	158	8:00 AM – 6:00 PM	220BC	Poster
273	159	8:00 AM – 6:00 PM	220BC	Poster
274	160	8:00 AM – 6:00 PM	220BC	Poster
275	161	8:00 AM – 6:00 PM	220BC	Poster
276	162	8:00 AM – 6:00 PM	220BC	Poster
277	163	8:00 AM – 6:00 PM	Abstract Withdrawn	
278	164	8:00 AM – 6:00 PM	220BC	Poster
279	165	8:00 AM – 6:00 PM	220BC	Poster
280	166	8:00 AM – 6:00 PM	220BC	Poster
281	167	8:00 AM – 6:00 PM	220BC	Poster
282	168	8:00 AM – 6:00 PM	220BC	Poster
283	169	8:00 AM – 6:00 PM	220BC	Poster
284	170	8:00 AM – 6:00 PM	220BC	Poster
285	171	8:00 AM – 6:00 PM	220BC	Poster
286	172	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

287	173	8:00 AM – 6:00 PM	220BC	Poster
288	174	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Pharmacovigilance - Cancer

289	175	8:00 AM – 6:00 PM	220BC	Poster
290	176	8:00 AM – 6:00 PM	220BC	Poster
291	177	8:00 AM – 6:00 PM	220BC	Poster
292	178	8:00 AM – 6:00 PM	220BC	Poster
293	179	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Pharmacovigilance - Cardiovascular/Hematologic

294	180	8:00 AM – 6:00 PM	220BC	Poster
295	181	8:00 AM – 6:00 PM	220BC	Poster
296	182	8:00 AM – 6:00 PM	220BC	Poster
297	183	8:00 AM – 6:00 PM	220BC	Poster
298	184	8:00 AM – 6:00 PM	220BC	Poster
299	185	8:00 AM – 6:00 PM	220BC	Poster
300	186	8:00 AM – 6:00 PM	220BC	Poster
301	187	8:00 AM – 6:00 PM	220BC	Poster
302	188	8:00 AM – 6:00 PM	220BC	Poster
303	189	8:00 AM – 6:00 PM	220BC	Poster
304	190	8:00 AM – 6:00 PM	220BC	Poster
305	191	8:00 AM – 6:00 PM	220BC	Poster
306	192	8:00 AM – 6:00 PM	220BC	Poster
307	193	8:00 AM – 6:00 PM	220BC	Poster
308	194	8:00 AM – 6:00 PM	220BC	Poster
309	195	8:00 AM – 6:00 PM	220BC	Poster
310	196	8:00 AM – 6:00 PM	220BC	Poster
311	197	8:00 AM – 6:00 PM	220BC	Poster
312	198	8:00 AM – 6:00 PM	220BC	Poster
313	199	8:00 AM – 6:00 PM	220BC	Poster
314	200	8:00 AM – 6:00 PM	220BC	Poster
315	201	8:00 AM – 6:00 PM	220BC	Poster
316	202	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Polypharmacy

317	203	8:00 AM – 6:00 PM	220BC	Poster
318	204	8:00 AM – 6:00 PM	220BC	Poster
319	205	8:00 AM – 6:00 PM	220BC	Poster
320	206	8:00 AM – 6:00 PM	220BC	Poster
321	207	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
MONDAY, AUGUST 28 (CON'T)				
322	208	8:00 AM – 6:00 PM	220BC	Poster
323	209	8:00 AM – 6:00 PM	220BC	Poster
324	210	8:00 AM – 6:00 PM	220BC	Poster
325	211	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Potpourri

326	212	8:00 AM – 6:00 PM	220BC	Poster
327	213	8:00 AM – 6:00 PM	220BC	Poster
328	214	8:00 AM – 6:00 PM	220BC	Poster
329	215	8:00 AM – 6:00 PM	220BC	Poster
330	216	8:00 AM – 6:00 PM	220BC	Poster
331	217	8:00 AM – 6:00 PM	220BC	Poster
332	218	8:00 AM – 6:00 PM	220BC	Poster
333	219	8:00 AM – 6:00 PM	220BC	Poster
334	220	8:00 AM – 6:00 PM	220BC	Poster
335	221	8:00 AM – 6:00 PM	220BC	Poster

Poster Session A: Risk Indices

336	222	8:00 AM – 6:00 PM	220BC	Poster
337	223	8:00 AM – 6:00 PM	220BC	Poster
338	224	8:00 AM – 6:00 PM	220BC	Poster
339	225	8:00 AM – 6:00 PM	220BC	Poster
341	227	8:00 AM – 6:00 PM	220BC	Poster
340	226	8:00 AM – 6:00 PM	220BC	Poster
342	228	8:00 AM – 6:00 PM	220BC	Poster
343	229	8:00 AM – 6:00 PM	220BC	Poster

TUESDAY, AUGUST 29

Indices

344	8:00 AM	517CD	Oral
345	8:15 AM	517CD	Oral
346	8:30 AM	517CD	Oral
347	8:45 AM	517CD	Oral
348	9:00 AM	517CD	Oral
349	9:15 AM	517CD	Oral

Opioid Policy: Let's Put a Lid on It

350	8:00 AM	520AD	Oral
351	8:15 AM	520AD	Oral

Pub. #	Poster #	Presentation Time	Room	Format
352		8:30 AM	520AD	Oral
353		8:45 AM	520AD	Oral
354		9:00 AM	520AD	Oral
355		9:15 AM	520AD	Oral

Un mélange d'idées (A Mixture of Good Ideas)

356	8:00 AM	520BE	Oral
357	8:15 AM	520BE	Oral
358	8:30 AM	520BE	Oral
359	8:45 AM	520BE	Oral
360	9:00 AM	520BE	Oral
361	9:15 AM	520BE	Oral

Pregnancy General

362	8:00 AM	520CF	Oral
363	8:15 AM	520CF	Oral
364	8:30 AM	520CF	Oral
365	8:45 AM	520CF	Oral
366	9:00 AM	520CF	Oral
367	9:15 AM	520CF	Oral

Cancer 1

368	8:00 AM	524AB	Oral
369	8:15 AM	524AB	Oral
370	8:30 AM	524AB	Oral
371	8:45 AM	524AB	Oral
372	9:00 AM	524AB	Oral
373	9:15 AM	524AB	Oral

It's a Bloody Mess

374	8:00 AM	524C	Oral
375	8:15 AM	524C	Oral
376	8:30 AM	524C	Oral
377	8:45 AM	524C	Oral
378	9:00 AM	524C	Oral
379	9:15 AM	524C	Oral

Outsmarting Bias

380	1:00 PM	517CD	Oral
381	1:15 PM	517CD	Oral
382	1:30 PM	517CD	Oral
383	1:45 PM	517CD	Oral
384	2:00 PM	517CD	Oral



Pub. #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 29 (CON'T)				
385		2:15 PM	517CD	Oral
Seeing Beyond the Data Horizon				
386		1:00 PM	520AD	Oral
387		1:15 PM	520AD	Oral
388		1:30 PM	520AD	Oral
389		1:45 PM	520AD	Oral
390		2:00 PM	520AD	Oral
391		2:15 PM	520AD	Oral
Adherence				
392		1:00 PM	520BE	Oral
393		1:15 PM	520BE	Oral
394		1:30 PM	520BE	Oral
395		1:45 PM	520BE	Oral
396		2:00 PM	520BE	Oral
397		2:15 PM	520BE	Oral
Vaccines - Use and Effectiveness				
398		1:00 PM	520CF	Oral
399		1:15 PM	520CF	Oral
400		1:30 PM	520CF	Oral
401		1:45 PM	520CF	Oral
402		2:00 PM	520CF	Oral
403		2:15 PM	520CF	Oral
Macro- and Microvascular Outcomes in Diabetes...Mostly				
404		1:00 PM	524AB	Oral
405		1:15 PM	524AB	Oral
406		1:30 PM	524AB	Oral
407		1:45 PM	524AB	Oral
408		2:00 PM	524AB	Oral
409		2:15 PM	524AB	Oral
Strike Stroke Stricken -- Caridovascular Potpourri				
410		1:00 PM	524C	Oral
411		1:15 PM	524C	Oral
412		1:30 PM	524C	Oral
413		1:45 PM	524C	Oral
414		2:00 PM	524C	Oral
415		2:15 PM	524C	Oral

Pub. #	Poster #	Presentation Time	Room	Format
Annual Meeting of ISPE Members & Awards Ceremony				
416		2:35 PM	517CD	Oral
Comparative Safety and Effectiveness Evidence - What Do You Do When the Ideal Comparator Is Not Obtainable?				
417		4:00 PM	517CD	Symposia
Evidence Generation in Multimorbidity: A New Frontier in Drug Utilization				
418		4:00 PM	520AD	Symposia
TreeScan™: A Novel Data-Mining Tool for Medical Product Safety Surveillance				
419		4:00 PM	520BE	Symposia
Real-World Battles with Real-World Data				
420		4:00 PM	520CF	Symposia
A Practical Guide to Implementing Sequence Symmetry Analysis; a Tool for Conducting Studies in the Asian Pharmacoevidence Network (AsPEN)				
421		4:00 PM	524AB	Symposia
Listening to the Patient Voice in Pharmacoevidence Research: Opportunities for Innovation and Inclusion				
422		4:00 PM	524C	Symposia
Poster Session B: Spotlight Session - Adherence				
423	A	11:45 AM – 12:45 PM	519	Poster
424	B	11:45 AM – 12:45 PM	519	Poster
425	C	11:45 AM – 12:45 PM	519	Poster
426	D	11:45 AM – 12:45 PM	519	Poster
427	E	11:45 AM – 12:45 PM	519	Poster
428	F	11:45 AM – 12:45 PM	519	Poster
429	G	11:45 AM – 12:45 PM	519	Poster
430	H	11:45 AM – 12:45 PM	519	Poster
Poster Session B: Spotlight Session - Molecular Epidemiology/Biomarkers/Pharmacogenetics				
431	I	11:45 AM – 12:45 PM	519	Poster
432	J	11:45 AM – 12:45 PM	519	Poster
433	K	11:45 AM – 12:45 PM	519	Poster
434	L	11:45 AM – 12:45 PM	519	Poster
435	M	11:45 AM – 12:45 PM	519	Poster
436	N	11:45 AM – 12:45 PM	519	Poster



ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 29 (CON'T)				

437	O	11:45 AM – 12:45 PM	519	Poster
438	P	11:45 AM – 12:45 PM	519	Poster

Poster Session B: Spotlight Session - Oncology

439	Q	11:45 AM – 12:45 PM	519	Poster
440	R	11:45 AM – 12:45 PM	519	Poster
441	S	11:45 AM – 12:45 PM	519	Poster
442	T	11:45 AM – 12:45 PM	519	Poster
443	U	11:45 AM – 12:45 PM	519	Poster
444	V	11:45 AM – 12:45 PM	519	Poster
445	W	11:45 AM – 12:45 PM	519	Poster

Poster Session B: Spotlight Session - Pediatrics

446	X	11:45 AM – 12:45 PM	519	Poster
447	Y	11:45 AM – 12:45 PM	519	Poster
448	Z	11:45 AM – 12:45 PM	519	Poster
449	AA	11:45 AM – 12:45 PM	519	Poster
450	BB	11:45 AM – 12:45 PM	519	Poster
451	CC	11:45 AM – 12:45 PM	519	Poster
452	DD	11:45 AM – 12:45 PM	519	Poster
453	EE	11:45 AM – 12:45 PM	519	Poster

Poster Session B: Biologics, Molecular Pharmacopidemiology & Pharmacogenetics

454	1	8:00 AM – 6:00 PM	220BC	Poster
455	2	8:00 AM – 6:00 PM	220BC	Poster
456	3	8:00 AM – 6:00 PM	220BC	Poster
457	4	8:00 AM – 6:00 PM	220BC	Poster
458	5	8:00 AM – 6:00 PM	220BC	Poster
459	6	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Burden of Disease - Neurologic/Mental

460	7	8:00 AM – 6:00 PM	220BC	Poster
461	8	8:00 AM – 6:00 PM	220BC	Poster
462	9	8:00 AM – 6:00 PM	220BC	Poster
463	10	8:00 AM – 6:00 PM	220BC	Poster
464	11	8:00 AM – 6:00 PM	220BC	Poster
465	12	8:00 AM – 6:00 PM	220BC	Poster
466	13	8:00 AM – 6:00 PM	220BC	Poster
467	14	8:00 AM – 6:00 PM	220BC	Poster
468	15	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
469	16	8:00 AM – 6:00 PM	220BC	Poster
470	17	8:00 AM – 6:00 PM	220BC	Poster
471	18	8:00 AM – 6:00 PM	220BC	Poster
472	19	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Burden of Disease - Other

473	20	8:00 AM – 6:00 PM	220BC	Poster
474	21	8:00 AM – 6:00 PM	220BC	Poster
475	22	8:00 AM – 6:00 PM	220BC	Poster
476	23	8:00 AM – 6:00 PM	220BC	Poster
477	24	8:00 AM – 6:00 PM	220BC	Poster
478	25	8:00 AM – 6:00 PM	220BC	Poster
479	26	8:00 AM – 6:00 PM	220BC	Poster
480	27	8:00 AM – 6:00 PM	220BC	Poster
481	28	8:00 AM – 6:00 PM	220BC	Poster
482	29	8:00 AM – 6:00 PM	220BC	Poster
483	30	8:00 AM – 6:00 PM	220BC	Poster
484	31	8:00 AM – 6:00 PM	220BC	Poster
485	32	8:00 AM – 6:00 PM	220BC	Poster
486	33	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Data - Detection, Validation and Accuracy

487	34	8:00 AM – 6:00 PM	220BC	Poster
488	35	8:00 AM – 6:00 PM	220BC	Poster
489	36	8:00 AM – 6:00 PM	220BC	Poster
490	37	8:00 AM – 6:00 PM	220BC	Poster
491	38	8:00 AM – 6:00 PM	220BC	Poster
492	39	8:00 AM – 6:00 PM	220BC	Poster
493	40	8:00 AM – 6:00 PM	220BC	Poster
494	41	8:00 AM – 6:00 PM	220BC	Poster
495	42	8:00 AM – 6:00 PM	220BC	Poster
496	43	8:00 AM – 6:00 PM	220BC	Poster
497	44	8:00 AM – 6:00 PM	220BC	Poster
498	45	8:00 AM – 6:00 PM	220BC	Poster
499	46	8:00 AM – 6:00 PM	220BC	Poster
500	47	8:00 AM – 6:00 PM	220BC	Poster
501	48	8:00 AM – 6:00 PM	220BC	Poster
502	49	8:00 AM – 6:00 PM	220BC	Poster
503	50	8:00 AM – 6:00 PM	220BC	Poster
504	51	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

TUESDAY, AUGUST 29 (CON'T)

505	52	8:00 AM – 6:00 PM	220BC	Poster
506	53	8:00 AM – 6:00 PM	220BC	Poster
507	54	8:00 AM – 6:00 PM	220BC	Poster
508	55	8:00 AM – 6:00 PM	220BC	Poster
509	56	8:00 AM – 6:00 PM	220BC	Poster
510	57	8:00 AM – 6:00 PM	220BC	Poster
511	58	8:00 AM – 6:00 PM	220BC	Poster
512	59	8:00 AM – 6:00 PM	220BC	Poster
513	60	8:00 AM – 6:00 PM	220BC	Poster
514	61	8:00 AM – 6:00 PM	220BC	Poster
515	62	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Data for Pharmacovigilance

516	63	8:00 AM – 6:00 PM	220BC	Poster
517	64	8:00 AM – 6:00 PM	220BC	Poster
518	65	8:00 AM – 6:00 PM	220BC	Poster
519	66	8:00 AM – 6:00 PM	220BC	Poster
520	67	8:00 AM – 6:00 PM	220BC	Poster
521	68	8:00 AM – 6:00 PM	220BC	Poster
522	69	8:00 AM – 6:00 PM	220BC	Poster
523	70	8:00 AM – 6:00 PM	220BC	Poster
524	71	8:00 AM – 6:00 PM	220BC	Poster
525	72	8:00 AM – 6:00 PM	220BC	Poster
526	73	8:00 AM – 6:00 PM	220BC	Poster
527	74	8:00 AM – 6:00 PM	220BC	Poster
528	75	8:00 AM – 6:00 PM	220BC	Poster
529	76	8:00 AM – 6:00 PM	220BC	Poster
530	77	8:00 AM – 6:00 PM	220BC	Poster
531	78	8:00 AM – 6:00 PM	220BC	Poster
532	79	8:00 AM – 6:00 PM	220BC	Poster
533	80	8:00 AM – 6:00 PM	220BC	Poster
534	81	8:00 AM – 6:00 PM	220BC	Poster
535	82	8:00 AM – 6:00 PM	220BC	Poster
536	83	8:00 AM – 6:00 PM	220BC	Poster
537	84	8:00 AM – 6:00 PM	220BC	Poster
538	85	8:00 AM – 6:00 PM	220BC	Poster
539	86	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session B: Drug Utilization - Arthritis

540	87	8:00 AM – 6:00 PM	220BC	Poster
541	88	8:00 AM – 6:00 PM	220BC	Poster
542	89	8:00 AM – 6:00 PM	220BC	Poster
543	90	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Drug Utilization - Neurologic/ Mental Health

544	91	8:00 AM – 6:00 PM	220BC	Poster
545	92	8:00 AM – 6:00 PM	220BC	Poster
546	93	8:00 AM – 6:00 PM	220BC	Poster
547	94	8:00 AM – 6:00 PM	220BC	Poster
548	95	8:00 AM – 6:00 PM	220BC	Poster
549	96	8:00 AM – 6:00 PM	220BC	Poster
550	97	8:00 AM – 6:00 PM	220BC	Poster
551	98	8:00 AM – 6:00 PM	220BC	Poster
552	99	8:00 AM – 6:00 PM	220BC	Poster
553	100	8:00 AM – 6:00 PM	220BC	Poster
554	101	8:00 AM – 6:00 PM	220BC	Poster
555	102	8:00 AM – 6:00 PM	220BC	Poster
556	103	8:00 AM – 6:00 PM	220BC	Poster
557	104	8:00 AM – 6:00 PM	220BC	Poster
558	105	8:00 AM – 6:00 PM	220BC	Poster
559	106	8:00 AM – 6:00 PM	220BC	Poster
560	107	8:00 AM – 6:00 PM	220BC	Poster
561	108	8:00 AM – 6:00 PM	220BC	Poster
562	109	8:00 AM – 6:00 PM	220BC	Poster
563	110	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Drug Utilization For Infections

564	111	8:00 AM – 6:00 PM	220BC	Poster
565	112	8:00 AM – 6:00 PM	220BC	Poster
566	113	8:00 AM – 6:00 PM	220BC	Poster
567	114	8:00 AM – 6:00 PM	220BC	Poster
568	115	8:00 AM – 6:00 PM	220BC	Poster
569	116	8:00 AM – 6:00 PM	220BC	Poster
570	117	8:00 AM – 6:00 PM	220BC	Poster
571	118	8:00 AM – 6:00 PM	220BC	Poster
572	119	8:00 AM – 6:00 PM	220BC	Poster
573	120	8:00 AM – 6:00 PM	220BC	Poster
574	121	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

TUESDAY, AUGUST 29 (CON'T)

Poster Session B: Informed Drug Policy

575	122	8:00 AM – 6:00 PM	220BC	Poster
576	123	8:00 AM – 6:00 PM	220BC	Poster
577	124	8:00 AM – 6:00 PM	220BC	Poster
578	125	8:00 AM – 6:00 PM	220BC	Poster
579	126	8:00 AM – 6:00 PM	220BC	Poster
580	127	8:00 AM – 6:00 PM	220BC	Poster
581	128	8:00 AM – 6:00 PM	220BC	Poster
582	129	8:00 AM – 6:00 PM	220BC	Poster
583	130	8:00 AM – 6:00 PM	220BC	Poster
584	131	8:00 AM – 6:00 PM	220BC	Poster
585	132	8:00 AM – 6:00 PM	220BC	Poster
586	133	8:00 AM – 6:00 PM	220BC	Poster
587	134	8:00 AM – 6:00 PM	220BC	Poster
588	135	8:00 AM – 6:00 PM	220BC	Poster
589	136	8:00 AM – 6:00 PM	220BC	Poster
590	137	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Intended Effects of Medications - Real World Comparative Effectiveness

591	138	8:00 AM – 6:00 PM	220BC	Poster
592	139	8:00 AM – 6:00 PM	220BC	Poster
593	140	8:00 AM – 6:00 PM	220BC	Poster
594	141	8:00 AM – 6:00 PM	220BC	Poster
595	142	8:00 AM – 6:00 PM	220BC	Poster
596	143	8:00 AM – 6:00 PM	220BC	Poster
597	144	8:00 AM – 6:00 PM	220BC	Poster
598	145	8:00 AM – 6:00 PM	220BC	Poster
599	146	8:00 AM – 6:00 PM	220BC	Poster
600	147	8:00 AM – 6:00 PM	220BC	Poster
601	148	8:00 AM – 6:00 PM	220BC	Poster
602	149	8:00 AM – 6:00 PM	220BC	Poster
603	150	8:00 AM – 6:00 PM	220BC	Poster
604	151	8:00 AM – 6:00 PM	220BC	Poster
605	152	8:00 AM – 6:00 PM	220BC	Poster
606	153	8:00 AM – 6:00 PM	220BC	Poster
607	154	8:00 AM – 6:00 PM	220BC	Poster
608	155	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

609	156	8:00 AM – 6:00 PM	220BC	Poster
610	157	8:00 AM – 6:00 PM	220BC	Poster
611	158	8:00 AM – 6:00 PM	220BC	Poster
612	159	8:00 AM – 6:00 PM	220BC	Poster
613	160	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Medical Devices

614	161	8:00 AM – 6:00 PM	220BC	Poster
615	162	8:00 AM – 6:00 PM	220BC	Poster
616	163	8:00 AM – 6:00 PM	220BC	Poster
617	164	8:00 AM – 6:00 PM	220BC	Poster
618	165	8:00 AM – 6:00 PM	220BC	Poster
619	166	8:00 AM – 6:00 PM	220BC	Poster
620	167	8:00 AM – 6:00 PM	220BC	Poster
621	168	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Pharmacovigilance - Neurological/Mental

622	169	8:00 AM – 6:00 PM	220BC	Poster
623	170	8:00 AM – 6:00 PM	220BC	Poster
624	171	8:00 AM – 6:00 PM	220BC	Poster
625	172	8:00 AM – 6:00 PM	220BC	Poster
626	173	8:00 AM – 6:00 PM	220BC	Poster
627	174	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Pharmacovigilance - Other Therapeutic

628	175	8:00 AM – 6:00 PM	220BC	Poster
629	176	8:00 AM – 6:00 PM	220BC	Poster
630	177	8:00 AM – 6:00 PM	220BC	Poster
631	178	8:00 AM – 6:00 PM	220BC	Poster
632	179	8:00 AM – 6:00 PM	220BC	Poster
633	180	8:00 AM – 6:00 PM	220BC	Poster
634	181	8:00 AM – 6:00 PM	220BC	Poster
635	182	8:00 AM – 6:00 PM	220BC	Poster
636	183	8:00 AM – 6:00 PM	220BC	Poster
637	184	8:00 AM – 6:00 PM	220BC	Poster
638	185	8:00 AM – 6:00 PM	220BC	Poster
639	186	8:00 AM – 6:00 PM	220BC	Poster
640	187	8:00 AM – 6:00 PM	220BC	Poster
641	188	8:00 AM – 6:00 PM	220BC	Poster
642	189	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

TUESDAY, AUGUST 29 (CON'T)

643	190	8:00 AM – 6:00 PM	220BC	Poster
644	191	8:00 AM – 6:00 PM	220BC	Poster
645	192	8:00 AM – 6:00 PM	220BC	Poster
646	193	8:00 AM – 6:00 PM	220BC	Poster
647	194	8:00 AM – 6:00 PM	220BC	Poster
648	195	8:00 AM – 6:00 PM	220BC	Poster
649	196	8:00 AM – 6:00 PM	220BC	Poster
650	197	8:00 AM – 6:00 PM	220BC	Poster
651	198	8:00 AM – 6:00 PM	220BC	Poster
652	199	8:00 AM – 6:00 PM	220BC	Poster
653	200	8:00 AM – 6:00 PM	220BC	Poster
654	201	8:00 AM – 6:00 PM	220BC	Poster
655	202	8:00 AM – 6:00 PM	220BC	Poster
656	203	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Pharmacovigilance Diabetes-Ophthalmic

657	204	8:00 AM – 6:00 PM	220BC	Poster
658	205	8:00 AM – 6:00 PM	220BC	Poster
659	206	8:00 AM – 6:00 PM	220BC	Poster
660	207	8:00 AM – 6:00 PM	220BC	Poster
661	208	8:00 AM – 6:00 PM	220BC	Poster
662	209	8:00 AM – 6:00 PM	220BC	Poster
663	210	8:00 AM – 6:00 PM	220BC	Poster
664	211	8:00 AM – 6:00 PM	220BC	Poster
665	212	8:00 AM – 6:00 PM	220BC	Poster
666	213	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Pregnancy

667	214	8:00 AM – 6:00 PM	220BC	Poster
668	215	8:00 AM – 6:00 PM	220BC	Poster
669	216	8:00 AM – 6:00 PM	220BC	Poster
670	217	8:00 AM – 6:00 PM	220BC	Poster
671	218	8:00 AM – 6:00 PM	220BC	Poster
672	219	8:00 AM – 6:00 PM	220BC	Poster
673	220	8:00 AM – 6:00 PM	220BC	Poster
674	221	8:00 AM – 6:00 PM	220BC	Poster
675	222	8:00 AM – 6:00 PM	220BC	Poster
676	223	8:00 AM – 6:00 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

677	224	8:00 AM – 6:00 PM	220BC	Poster
678	225	8:00 AM – 6:00 PM	220BC	Poster
679	226	8:00 AM – 6:00 PM	220BC	Poster
680	227	8:00 AM – 6:00 PM	220BC	Poster
681	228	8:00 AM – 6:00 PM	220BC	Poster
682	229	8:00 AM – 6:00 PM	220BC	Poster
683	230	8:00 AM – 6:00 PM	220BC	Poster
684	231	8:00 AM – 6:00 PM	220BC	Poster
685	232	8:00 AM – 6:00 PM	220BC	Poster
686	233	8:00 AM – 6:00 PM	220BC	Poster
687	234	8:00 AM – 6:00 PM	220BC	Poster
688	235	8:00 AM – 6:00 PM	Abstract Withdrawn	
689	236	8:00 AM – 6:00 PM	220BC	Poster
690	237	8:00 AM – 6:00 PM	220BC	Poster
691	238	8:00 AM – 6:00 PM	220BC	Poster
692	239	8:00 AM – 6:00 PM	220BC	Poster
693	240	8:00 AM – 6:00 PM	220BC	Poster
694	241	8:00 AM – 6:00 PM	220BC	Poster
695	242	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: Propensity Scores

696	243	8:00 AM – 6:00 PM	220BC	Poster
697	244	8:00 AM – 6:00 PM	220BC	Poster
698	245	8:00 AM – 6:00 PM	220BC	Poster
699	246	8:00 AM – 6:00 PM	220BC	Poster
700	247	8:00 AM – 6:00 PM	220BC	Poster
701	248	8:00 AM – 6:00 PM	220BC	Poster
702	249	8:00 AM – 6:00 PM	220BC	Poster
703	250	8:00 AM – 6:00 PM	220BC	Poster

Poster Session B: REMS and RMMs

704	251	8:00 AM – 6:00 PM	220BC	Poster
705	252	8:00 AM – 6:00 PM	220BC	Poster
706	253	8:00 AM – 6:00 PM	220BC	Poster
707	254	8:00 AM – 6:00 PM	220BC	Poster
708	255	8:00 AM – 6:00 PM	220BC	Poster
709	256	8:00 AM – 6:00 PM	220BC	Poster
710	257	8:00 AM – 6:00 PM	220BC	Poster
711	258	8:00 AM – 6:00 PM	220BC	Poster
712	259	8:00 AM – 6:00 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
TUESDAY, AUGUST 29 (CON'T)				

Poster Session B: Trials & Tribulations

713	260	8:00 AM – 6:00 PM	220BC	Poster
714	261	8:00 AM – 6:00 PM	220BC	Poster
715	262	8:00 AM – 6:00 PM	220BC	Poster
716	263	8:00 AM – 6:00 PM	220BC	Poster
717	264	8:00 AM – 6:00 PM	220BC	Poster
718	265	8:00 AM – 6:00 PM	220BC	Poster
719	266	8:00 AM – 6:00 PM	220BC	Poster
720	267	8:00 AM – 6:00 PM	220BC	Poster
721	268	8:00 AM – 6:00 PM	220BC	Poster

WEDNESDAY, AUGUST 30

Pregnancy Methods

722		8:30 AM	517CD	Oral
723		8:45 AM	517CD	Oral
724		9:00 AM	517CD	Oral
725		9:15 AM	517CD	Oral
726		9:30 AM	517CD	Oral
727		9:45 AM	517CD	Oral

Better, Worse, or the Same?

728		8:30 AM	520AD	Oral
729		8:45 AM	520AD	Oral
730		9:00 AM	520AD	Oral
731		9:15 AM	520AD	Oral
732		9:30 AM	520AD	Oral
733		9:45 AM	520AD	Oral

It Is Nice to Know What You Are Talking About

734		8:30 AM	520BE	Oral
735		8:45 AM	520BE	Oral
736		9:00 AM	520BE	Oral
737		9:15 AM	520BE	Oral
738		9:30 AM	520BE	Oral
739		9:45 AM	520BE	Oral

Patient Centred Care

740		8:30 AM	520CF	Oral
741		8:45 AM	520CF	Oral
742		9:00 AM	520CF	Oral

Pub. #	Poster #	Presentation Time	Room	Format
743		9:15 AM	520CF	Oral
744		9:30 AM	520CF	Oral
745		9:45 AM	520CF	Oral

Evolution in Pharmacovigilance

746		8:30 AM	524AB	Oral
747		8:45 AM	524AB	Oral
748		9:00 AM	524AB	Oral
749		9:15 AM	524AB	Oral
750		9:30 AM	524AB	Oral
751		9:45 AM	524AB	Oral

Remember Not to Forget

752		8:30 AM	524C	Oral
753		8:45 AM	524C	Oral
754		9:00 AM	524C	Oral
755		9:15 AM	524C	Oral
756		9:30 AM	524C	Oral
757		9:45 AM	524C	Oral

Beyond Retrospective Studies, Using Electronic Health Records for Prospective Research

758		10:30 AM	517CD	Symposia
-----	--	----------	-------	----------

Real World Evidence and Precision Medicine in Cancer Research

759		10:30 AM	520AD	Symposia
-----	--	----------	-------	----------

Practical Points to Address Uncertainties in Risk Management Planning

760		10:30 AM	520BE	Symposia
-----	--	----------	-------	----------

Optimizing Design, Conduct and Interpretation of EHR-Enabled Randomised Clinical Trials: Case Examples Demonstrate the Critical Role of Epidemiology and Future Challenges

761		10:30 AM	520CF	Symposia
-----	--	----------	-------	----------

Promises and Perils of Machine Learning: A Real-World Evidence Fable

762		10:30 AM	524AB	Symposia
-----	--	----------	-------	----------

Coping with Imperfection

763		1:30 PM	517CD	Oral
764		1:45 PM	517CD	Oral
765		2:00 PM	517CD	Oral
766		2:15 PM	517CD	Oral
767		2:30 PM	517CD	Oral



Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

WEDNESDAY, AUGUST 30 (CON'T)

768		2:45 PM	517CD	Oral
-----	--	---------	-------	------

Drug Utilization Across the Board

769		1:30 PM	520AD	Oral
770		1:45 PM	520AD	Oral
771		2:00 PM	520AD	Oral
772		2:15 PM	520AD	Oral
773		2:30 PM	520AD	Oral
774		2:45 PM	520AD	Oral

Pregnancy Nerves

775		1:30 PM	520CF	Oral
776		1:45 PM	520CF	Oral
777		2:00 PM	520CF	Oral
778		2:15 PM	520CF	Oral
779		2:30 PM	520CF	Oral
780		2:45 PM	520CF	Oral

Cancer 2

781		1:30 PM	520BE	Oral
782		1:45 PM	520BE	Oral
783		2:00 PM	520BE	Oral
784		2:15 PM	520BE	Oral
785		2:30 PM	520BE	Oral
786		2:45 PM	520BE	Oral

Psych/Mental Health

787		1:30 PM	524AB	Oral
788		1:45 PM	524AB	Oral
789		2:00 PM	524AB	Oral
790		2:15 PM	524AB	Oral
791		2:30 PM	524AB	Oral
792		2:45 PM	524AB	Oral

Get the How Just Right

793		1:30 PM	524C	Oral
794		1:45 PM	524C	Oral
795		2:00 PM	524C	Oral
796		2:15 PM	524C	Oral
797		2:30 PM	524C	Oral
798		2:45 PM	524C	Oral

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

Poster Session C: Spotlight Session - BRACE

799	A	12:15 PM – 1:15 PM	519	Poster
800	B	12:15 PM – 1:15 PM	519	Poster
801	C	12:15 PM – 1:15 PM	519	Poster
802	D	12:15 PM – 1:15 PM	519	Poster
803	E	12:15 PM – 1:15 PM	519	Poster
804	F	12:15 PM – 1:15 PM	519	Poster
805	G	12:15 PM – 1:15 PM	519	Poster
806	H	12:15 PM – 1:15 PM	519	Poster

Poster Session C: Spotlight Session - CER

807	I	12:15 PM – 1:15 PM	519	Poster
808	J	12:15 PM – 1:15 PM	519	Poster
809	K	12:15 PM – 1:15 PM	519	Poster
810	L	12:15 PM – 1:15 PM	519	Poster
811	M	12:15 PM – 1:15 PM	519	Poster
812	N	12:15 PM – 1:15 PM	519	Poster
813	O	12:15 PM – 1:15 PM	519	Poster
814	P	12:15 PM – 1:15 PM	519	Poster

Poster Session C: Spotlight Session - Drug Utilization Research

815	Q	12:15 PM – 1:15 PM	519	Poster
816	R	12:15 PM – 1:15 PM	519	Poster
817	S	12:15 PM – 1:15 PM	519	Poster
818	T	12:15 PM – 1:15 PM	519	Poster
819	U	12:15 PM – 1:15 PM	519	Poster
820	V	12:15 PM – 1:15 PM	519	Poster
821	W	12:15 PM – 1:15 PM	519	Poster
822	X	12:15 PM – 1:15 PM	519	Poster

Poster Session C: Spotlight Session - Medical Devices

823	Y	12:15 PM – 1:15 PM	519	Poster
824	Z	12:15 PM – 1:15 PM	519	Poster
825	AA	12:15 PM – 1:15 PM	519	Poster
826	BB	12:15 PM – 1:15 PM	519	Poster
827	CC	12:15 PM – 1:15 PM	519	Poster
828	DD	12:15 PM – 1:15 PM	519	Poster
829	EE	12:15 PM – 1:15 PM	519	Poster
830	FF	12:15 PM – 1:15 PM	519	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

WEDNESDAY, AUGUST 30 (CON'T)

Poster Session C: Spotlight Session - Medications in Pregnancy

831	GG	12:15 PM – 1:15 PM	519	Poster
832	HH	12:15 PM – 1:15 PM	519	Poster
833	II	12:15 PM – 1:15 PM	519	Poster
834	JJ	12:15 PM – 1:15 PM	519	Poster
835	KK	12:15 PM – 1:15 PM	519	Poster
836	LL	12:15 PM – 1:15 PM	519	Poster
837	MM	12:15 PM – 1:15 PM	519	Poster
838	NN	12:15 PM – 1:15 PM	519	Poster

Poster Session C: 21st Century Pharmacoepidemiology

839	1	8:00 AM – 1:45 PM	220BC	Poster
840	2	8:00 AM – 1:45 PM	220BC	Poster
841	3	8:00 AM – 1:45 PM	220BC	Poster
842	4	8:00 AM – 1:45 PM	220BC	Poster
843	5	8:00 AM – 1:45 PM	220BC	Poster
844	6	8:00 AM – 1:45 PM	220BC	Poster
845	7	8:00 AM – 1:45 PM	220BC	Poster
846	8	8:00 AM – 1:45 PM	220BC	Poster
847	9	8:00 AM – 1:45 PM	220BC	Poster
848	10	8:00 AM – 1:45 PM	220BC	Poster
849	11	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Adherence

850	12	8:00 AM – 1:45 PM	220BC	Poster
851	13	8:00 AM – 1:45 PM	220BC	Poster
852	14	8:00 AM – 1:45 PM	220BC	Poster
853	15	8:00 AM – 1:45 PM	220BC	Poster
854	16	8:00 AM – 1:45 PM	220BC	Poster
855	17	8:00 AM – 1:45 PM	220BC	Poster
856	18	8:00 AM – 1:45 PM	220BC	Poster
857	19	8:00 AM – 1:45 PM	220BC	Poster
858	20	8:00 AM – 1:45 PM	220BC	Poster
859	21	8:00 AM – 1:45 PM	220BC	Poster
860	22	8:00 AM – 1:45 PM	220BC	Poster
861	23	8:00 AM – 1:45 PM	220BC	Poster
862	24	8:00 AM – 1:45 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

863	25	8:00 AM – 1:45 PM	220BC	Poster
864	26	8:00 AM – 1:45 PM	220BC	Poster
865	27	8:00 AM – 1:45 PM	220BC	Poster
866	28	8:00 AM – 1:45 PM	220BC	Poster
867	29	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Analytic Methods

868	30	8:00 AM – 1:45 PM	220BC	Poster
869	31	8:00 AM – 1:45 PM	220BC	Poster
870	32	8:00 AM – 1:45 PM	220BC	Poster
871	33	8:00 AM – 1:45 PM	220BC	Poster
872	34	8:00 AM – 1:45 PM	220BC	Poster
873	35	8:00 AM – 1:45 PM	220BC	Poster
874	36	8:00 AM – 1:45 PM	220BC	Poster
875	37	8:00 AM – 1:45 PM	220BC	Poster
876	38	8:00 AM – 1:45 PM	220BC	Poster
877	39	8:00 AM – 1:45 PM	220BC	Poster
878	40	8:00 AM – 1:45 PM	220BC	Poster
879	41	8:00 AM – 1:45 PM	220BC	Poster
880	42	8:00 AM – 1:45 PM	220BC	Poster
881	43	8:00 AM – 1:45 PM	220BC	Poster
882	44	8:00 AM – 1:45 PM	220BC	Poster
883	45	8:00 AM – 1:45 PM	Abstract Withdrawn	
884	46	8:00 AM – 1:45 PM	220BC	Poster
885	47	8:00 AM – 1:45 PM	220BC	Poster
886	48	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Burden of Disease - Cardiovascular and Hematologic

887	49	8:00 AM – 1:45 PM	220BC	Poster
888	50	8:00 AM – 1:45 PM	220BC	Poster
889	51	8:00 AM – 1:45 PM	220BC	Poster
890	52	8:00 AM – 1:45 PM	220BC	Poster
891	53	8:00 AM – 1:45 PM	220BC	Poster
892	54	8:00 AM – 1:45 PM	220BC	Poster
893	55	8:00 AM – 1:45 PM	220BC	Poster
894	56	8:00 AM – 1:45 PM	220BC	Poster
895	57	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Burden of Disease - Infection

896	58	8:00 AM – 1:45 PM	220BC	Poster
897	59	8:00 AM – 1:45 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

WEDNESDAY, AUGUST 30 (CON'T)

898	60	8:00 AM – 1:45 PM	220BC	Poster
899	61	8:00 AM – 1:45 PM	220BC	Poster
900	62	8:00 AM – 1:45 PM	220BC	Poster
901	63	8:00 AM – 1:45 PM	220BC	Poster
902	64	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Burden of Disease - Respiratory

903	65	8:00 AM – 1:45 PM	220BC	Poster
904	66	8:00 AM – 1:45 PM	220BC	Poster
905	67	8:00 AM – 1:45 PM	220BC	Poster
906	68	8:00 AM – 1:45 PM	220BC	Poster
907	69	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Causal Relationships In Pharmacoepidemiology(?)

908	70	8:00 AM – 1:45 PM	220BC	Poster
909	71	8:00 AM – 1:45 PM	220BC	Poster
910	72	8:00 AM – 1:45 PM	220BC	Poster
911	73	8:00 AM – 1:45 PM	220BC	Poster
912	74	8:00 AM – 1:45 PM	220BC	Poster
913	75	8:00 AM – 1:45 PM	220BC	Poster
914	76	8:00 AM – 1:45 PM	220BC	Poster
915	77	8:00 AM – 1:45 PM	220BC	Poster
916	78	8:00 AM – 1:45 PM	220BC	Poster
917	79	8:00 AM – 1:45 PM	220BC	Poster
918	80	8:00 AM – 1:45 PM	220BC	Poster
919	81	8:00 AM – 1:45 PM	220BC	Poster
920	82	8:00 AM – 1:45 PM	220BC	Poster
921	83	8:00 AM – 1:45 PM	220BC	Poster
922	84	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Data Sources for Pharmacoepidemiology

923	85	8:00 AM – 1:45 PM	220BC	Poster
924	86	8:00 AM – 1:45 PM	220BC	Poster
925	87	8:00 AM – 1:45 PM	220BC	Poster
926	88	8:00 AM – 1:45 PM	220BC	Poster
927	89	8:00 AM – 1:45 PM	220BC	Poster
928	90	8:00 AM – 1:45 PM	220BC	Poster
929	91	8:00 AM – 1:45 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

930	92	8:00 AM – 1:45 PM	220BC	Poster
931	93	8:00 AM – 1:45 PM	220BC	Poster
932	94	8:00 AM – 1:45 PM	220BC	Poster
933	95	8:00 AM – 1:45 PM	220BC	Poster
934	96	8:00 AM – 1:45 PM	220BC	Poster
935	97	8:00 AM – 1:45 PM	220BC	Poster
936	98	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Drug Utilization - Hematologic

937	99	8:00 AM – 1:45 PM	220BC	Poster
938	100	8:00 AM – 1:45 PM	220BC	Poster
939	101	8:00 AM – 1:45 PM	220BC	Poster
940	102	8:00 AM – 1:45 PM	220BC	Poster
941	103	8:00 AM – 1:45 PM	220BC	Poster
942	104	8:00 AM – 1:45 PM	220BC	Poster
943	105	8:00 AM – 1:45 PM	220BC	Poster
944	106	8:00 AM – 1:45 PM	220BC	Poster
945	107	8:00 AM – 1:45 PM	220BC	Poster
946	108	8:00 AM – 1:45 PM	220BC	Poster
947	109	8:00 AM – 1:45 PM	220BC	Poster
948	110	8:00 AM – 1:45 PM	220BC	Poster
949	111	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Drug Utilization - Respiratory

950	112	8:00 AM – 1:45 PM	220BC	Poster
951	113	8:00 AM – 1:45 PM	220BC	Poster
952	114	8:00 AM – 1:45 PM	220BC	Poster
953	115	8:00 AM – 1:45 PM	220BC	Poster
954	116	8:00 AM – 1:45 PM	220BC	Poster
955	117	8:00 AM – 1:45 PM	220BC	Poster
956	118	8:00 AM – 1:45 PM	220BC	Poster
957	119	8:00 AM – 1:45 PM	220BC	Poster
958	120	8:00 AM – 1:45 PM	220BC	Poster
959	121	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Drug Utilization - Various Conditions

960	122	8:00 AM – 1:45 PM	220BC	Poster
961	123	8:00 AM – 1:45 PM	220BC	Poster
962	124	8:00 AM – 1:45 PM	220BC	Poster
963	125	8:00 AM – 1:45 PM	220BC	Poster
964	126	8:00 AM – 1:45 PM	220BC	Poster
965	127	8:00 AM – 1:45 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 30 (CON'T)				
966	128	8:00 AM – 1:45 PM	220BC	Poster
967	129	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Pharmacoepidemiology in Children

968	130	8:00 AM – 1:45 PM	220BC	Poster
969	131	8:00 AM – 1:45 PM	220BC	Poster
970	132	8:00 AM – 1:45 PM	220BC	Poster
971	133	8:00 AM – 1:45 PM	220BC	Poster
972	134	8:00 AM – 1:45 PM	220BC	Poster
973	135	8:00 AM – 1:45 PM	220BC	Poster
974	136	8:00 AM – 1:45 PM	220BC	Poster
975	137	8:00 AM – 1:45 PM	220BC	Poster
976	138	8:00 AM – 1:45 PM	220BC	Poster
977	139	8:00 AM – 1:45 PM	220BC	Poster
978	140	8:00 AM – 1:45 PM	220BC	Poster
979	141	8:00 AM – 1:45 PM	220BC	Poster
980	142	8:00 AM – 1:45 PM	220BC	Poster
981	143	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Prescribing and Dispensing

982	144	8:00 AM – 1:45 PM	220BC	Poster
983	145	8:00 AM – 1:45 PM	220BC	Poster
984	146	8:00 AM – 1:45 PM	220BC	Poster
985	147	8:00 AM – 1:45 PM	220BC	Poster
986	148	8:00 AM – 1:45 PM	220BC	Poster
987	149	8:00 AM – 1:45 PM	220BC	Poster
988	150	8:00 AM – 1:45 PM	220BC	Poster
989	151	8:00 AM – 1:45 PM	220BC	Poster
990	152	8:00 AM – 1:45 PM	220BC	Poster
991	153	8:00 AM – 1:45 PM	220BC	Poster
992	154	8:00 AM – 1:45 PM	220BC	Poster
993	155	8:00 AM – 1:45 PM	220BC	Poster
994	156	8:00 AM – 1:45 PM	220BC	Poster
995	157	8:00 AM – 1:45 PM	220BC	Poster
996	158	8:00 AM – 1:45 PM	220BC	Poster
997	159	8:00 AM – 1:45 PM	220BC	Poster
998	160	8:00 AM – 1:45 PM	Abstract Withdrawn	
999	161	8:00 AM – 1:45 PM	220BC	Poster
1000	162	8:00 AM – 1:45 PM	220BC	Poster

Pub. #	Poster #	Presentation Time	Room	Format
1001	163	8:00 AM – 1:45 PM	220BC	Poster
1002	164	8:00 AM – 1:45 PM	220BC	Poster
1003	165	8:00 AM – 1:45 PM	220BC	Poster
1004	166	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Regulatory/Programme Evaluation

1005	167	8:00 AM – 1:45 PM	220BC	Poster
1006	168	8:00 AM – 1:45 PM	220BC	Poster
1007	169	8:00 AM – 1:45 PM	220BC	Poster
1008	170	8:00 AM – 1:45 PM	220BC	Poster
1009	171	8:00 AM – 1:45 PM	220BC	Poster
1010	172	8:00 AM – 1:45 PM	220BC	Poster
1011	173	8:00 AM – 1:45 PM	220BC	Poster
1012	174	8:00 AM – 1:45 PM	220BC	Poster
1013	175	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Risk Prediction

1014	176	8:00 AM – 1:45 PM	220BC	Poster
1015	177	8:00 AM – 1:45 PM	220BC	Poster
1016	178	8:00 AM – 1:45 PM	220BC	Poster
1017	179	8:00 AM – 1:45 PM	220BC	Poster
1018	180	8:00 AM – 1:45 PM	220BC	Poster
1019	181	8:00 AM – 1:45 PM	220BC	Poster
1020	182	8:00 AM – 1:45 PM	220BC	Poster
1021	183	8:00 AM – 1:45 PM	220BC	Poster
1022	184	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: Vaccines

1023	185	8:00 AM – 1:45 PM	220BC	Poster
1024	186	8:00 AM – 1:45 PM	220BC	Poster
1025	187	8:00 AM – 1:45 PM	220BC	Poster
1026	188	8:00 AM – 1:45 PM	220BC	Poster
1027	189	8:00 AM – 1:45 PM	220BC	Poster
1028	190	8:00 AM – 1:45 PM	220BC	Poster
1029	191	8:00 AM – 1:45 PM	220BC	Poster
1030	192	8:00 AM – 1:45 PM	220BC	Poster
1031	193	8:00 AM – 1:45 PM	220BC	Poster
1032	194	8:00 AM – 1:45 PM	220BC	Poster
1033	195	8:00 AM – 1:45 PM	220BC	Poster
1034	196	8:00 AM – 1:45 PM	220BC	Poster
1035	197	8:00 AM – 1:45 PM	220BC	Poster





ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
WEDNESDAY, AUGUST 30 (CON'T)				
1036	198	8:00 AM – 1:45 PM	220BC	Poster
1037	199	8:00 AM – 1:45 PM	220BC	Poster
1038	200	8:00 AM – 1:45 PM	220BC	Poster
1039	201	8:00 AM – 1:45 PM	220BC	Poster
1040	202	8:00 AM – 1:45 PM	220BC	Poster

Poster Session C: What a Pain! - Medications Use for Pain Management


1041	203	8:00 AM – 1:45 PM	220BC	Poster
1042	204	8:00 AM – 1:45 PM	220BC	Poster
1043	205	8:00 AM – 1:45 PM	220BC	Poster
1044	206	8:00 AM – 1:45 PM	220BC	Poster
1045	207	8:00 AM – 1:45 PM	220BC	Poster
1046	208	8:00 AM – 1:45 PM	220BC	Poster
1047	209	8:00 AM – 1:45 PM	220BC	Poster
1048	210	8:00 AM – 1:45 PM	220BC	Poster
1049	211	8:00 AM – 1:45 PM	220BC	Poster
1050	212	8:00 AM – 1:45 PM	220BC	Poster
1051	213	8:00 AM – 1:45 PM	220BC	Poster
1052	214	8:00 AM – 1:45 PM	220BC	Poster
1053	215	8:00 AM – 1:45 PM	220BC	Poster
1054	216	8:00 AM – 1:45 PM	220BC	Poster
1055	217	8:00 AM – 1:45 PM	220BC	Poster
1056	218	8:00 AM – 1:45 PM	220BC	Poster
1057	219	8:00 AM – 1:45 PM	220BC	Poster
1058	220	8:00 AM – 1:45 PM	220BC	Poster



ADVERTISER'S INDEX

◆ Action	17
◆ Analysis Group	58
◆ Bayer Pharma	33
◆ BHE Boston Health Economics	45
◆ Boehringer Ingelheim	60
◆ Department of Clinical Epidemiology, Aarhus University Hospital	41
◆ Department of Population Medicine	23
◆ Eli Lilly & Company	15
◆ EPID Research	30
◆ Evalytica	19
◆ Evidera	9
◆ HealthCore	13
◆ ICON	30
◆ Kantar Health	22
◆ Medical Data Vision	60
◆ Optum	49
◆ Pfizer	34
◆ RTI Health Solutions	25
◆ Takeda	38
◆ The Degge Group and DGI, LLC	25
◆ Truven Health Analytics	21
◆ Wiley Publications	121





Impact
Factor
2.552*

Official Journal of the International Society for Pharmacoepidemiology

Editor-In-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

Free online access for ISPE
members via the society website

*2016 Journal Citation Reports® (Thomson Reuters)

Congratulations to The Ronald D. Mann Best Article of 2016 Awards Winners

First Prize

Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke

James S. Floyd, Kerri L. Wiggins, Mark Christiansen, Sascha Dublin, William T. Longstreth, Nicholas L. Smith, Barbara McKnight, Susan R. Heckbert, Noel S. Weiss and Bruce M. Psaty

Volume 25, Issue 2, February 2016, Pages: 151 – 160

Honorable Mention:

Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort study

Maja Hellfritsch, Jette Rathe, Tore Bjerregaard Stage, Steffen Thirstrup, Erik L. Grove, Per Damkier and Anton Pottegård

Volume 25, Issue 3, March 2016, Pages: 336 – 343

Honorable Mention:

Trimethoprim-sulfonamide use during the first trimester of pregnancy and the risk of congenital anomalies

Craig Hansen, Susan E. Andrade, Heather Freiman, Sascha Dublin, Katie Haffenreffer, William O. Cooper, T. Craig Cheetham, Sengwee Toh, De-Kun Li, Marsha A. Raebel, Jennifer L. Kuntz, Nancy Perrin, A. Gabriela Rosales, Shelley Carter, Pamala A. Pawloski, Elizabeth M. Maloney, David J. Graham, Leyla Sahin, Pamela E. Scott, John Yap and Robert Davis

Volume 25, Issue 2, February 2016, Pages: 170 – 178

Honorable Mention:

Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes

Ahmed S. Abdelmoneim, Dean T. Eurich, Ambikaipakan Senthilselvan, Weiyu Qiu and Scot H. Simpson

Volume 25, Issue 10, October 2016, Pages: 1186 – 1195

For more information on these top papers and other journal features, please visit

www.pdsjournal.org

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2017 Volume: 26 • Frequency: Monthly

WILEY

MEETING INFO: PHARMACOPEI.ORG



ABSTRACT SUBMISSION DEADLINE: FEBRUARY 14, 2018

YOU ARE INVITED TO SUBMIT AN ABSTRACT

ISPE invites you to submit an abstract for an oral/poster presentation or a workshop/symposium at the 34th ICPE/Prague. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and experience Prague – a magical city of bridges, cathedrals, gold-tipped towers and church domes, that has been mirrored in the surface of the swan-filled Vltava River for more than ten centuries. Prague also is a modern and vibrant city full of energy, music, cultural art, and fine dining. (prague.eu).

GUIDELINES FOR SUBMISSIONS

The deadline for receipt of all abstracts is **February 14, 2018**. The online submission site will be operational by mid-December 2017 and will include submission guidelines.

Questions about abstract submissions should be directed to info@pharmacoepi.org. Note, submissions will not be accepted until the online submission site is open in December 2017. Late breaking abstracts will not be accepted.

REVIEWING/REGISTRATION

The ISPE Scientific Program Committee will review all abstracts in April 2018. All submitters will be notified by email in early June 2018. All presenters and panelists (workshop/symposia) must register to attend the 2018 ICPE.

SCHOLARSHIPS & STUDENT AWARDS

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The 2018 ICPE Scientific Program Committee oversees the selection of awards, which will be presented at the 2018 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

Scholarship
Submission Deadline:
MARCH 1, 2018

ISPE will award a limited number of scholarships to help defray conference expenses. Scholarship information will be posted on pharmacoepi.org. The ICPE 2018 scholarship submission deadline is **March 1, 2018**.

SPONSORSHIPS, EXHIBITS & ACADEMIC SHOWCASE

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on pharmacoepi.org/meetings/34ICPE.

SAVE THE DATES

August 22-26, 2018
Prague Congress Centre
Prague, Czech Republic

Please visit pharmacoepi.org/meetings/34ICPE for updated conference information.






PALAIS DES CONGRÈS DE MONTRÉAL

LEVEL 1

■ Les Galeries du Palais
 ■ Rental Space
 ■ Rental Space (Optional)
 ■ Common area
 ■ Restricted Area

Main entrances	Car entrances	Parking	ATM	Security Operations Centre (SOC)	Charging stations-Electric cars	Pedestrian Network
Entrances	Shuttle terminals	Freight elevators	Washrooms	Cloakroom	Metro station-Accessible to people with reduced mobility	Bixi - Bike Sharing System
Entrances pedestrians and people with reduced mobility	Truck waiting area	Elevators	Escalators	Phones		



Palais des Congrès de Montréal

Accredited with the AIPC Gold Quality Standards and shortlisted for the APEX award for World's Best Convention Centre, the Palais des congrès is the city of Montréal's leading host site for major international meetings.

We offer versatile and functional facilities, equipped with the latest state-of-the-art technology, and accessible to persons with reduced mobility in a building whose contemporary architecture abounds with natural light. Everything is ready for you to capitalize on your space and a wide range of services.

We offer you a centre with limitless possibilities.

33rd ICPE
 AUGUST 26-30, 2017
 PALAIS DES CONGRÈS DE MONTRÉAL
 MONTRÉAL, CANADA

International Conference on
Pharmacoeconomics &
Therapeutic Risk Management




LEVEL 2

Rental Space
 Rental Space (Optional)
 Ballroom
 Kitchen

Cloakroom
 Escalators
 Information
 Washrooms

Elevators
 Freight elevators
 Phones




LEVEL 5

Rental Space
 Rental Space (Optional)
 Ballroom
 Kitchen
 Official audiovisual supplier
 Urban Agriculture Lab of the Palais des congrès de Montréal

Elevators
 Escalators
 Freight elevators
 Phones
 Washrooms

Rooms 510 to 525



Easy to mingle

This level has been designed to integrate wide corridors and large public areas so attendees can easily circulate and congregate in a refined setting. Rooms are all equipped with the latest technology, including internet access, audiovisual systems, satellite transmission and adaptive technology for the hearing impaired.